

## Risk Factors Comparison 2025-03-31 to 2024-03-06 Form: 10-K

**Legend:** **New Text** ~~Removed Text~~ Unchanged Text **Moved Text Section**

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and are not required to provide the information specified under this item. Item 8. Financial Statements and Supplementary Data The financial statements required by this item are attached to this Form 10-K beginning with page F-1. Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure None. Item 9A. Controls and Procedures We maintain disclosure controls and procedures (as defined in Exchange Act Rule 13a-15 (e) and 15d-15 (e)) that are designed to ensure that information required to be disclosed in our reports under the ~~Securities Exchange Act of 1934, as amended, or the~~ Exchange Act, and the rules and regulations thereunder, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Evaluation of Disclosure Controls and Procedures We have carried out an evaluation, under the supervision, and with the participation, of management including our principal executive officer and principal financial officer, of our disclosure controls and procedures (as defined in Rule 13a-15 (e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of the end of the period covered by this Annual Report on Form 10-K. Based on the evaluation of our disclosure controls and procedures as of December 31, ~~2023~~ **2024**, our chief executive officer and chief financial officer have concluded that ~~subject to the limitations described below,~~ our disclosure controls and procedures were effective **at the reasonable assurance level** as of December 31, ~~2023~~ **2024**. Management's Annual Report on Internal Control over Financial Reporting The following report is provided by management in respect of Talphera's internal control over financial reporting (as defined in Rules 13a-15 (f) and 15d-15 (f) under the Exchange Act): 1. Talphera's management is responsible for establishing and maintaining adequate internal control over financial reporting. 2. Talphera's management has used the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, framework (2013 framework) to evaluate the effectiveness of internal control over financial reporting. Management believes that the COSO framework is a suitable framework for its evaluation of financial reporting because it is free from bias, permits reasonably consistent qualitative and quantitative measurements of Talphera's internal control over financial reporting, is sufficiently complete so that those relevant factors that would alter a conclusion about the effectiveness of Talphera's internal control over financial reporting are not omitted and is relevant to an evaluation of internal control over financial reporting. 3. Management has assessed the effectiveness of Talphera's internal control over financial reporting as of December 31, ~~2023~~ **2024**, and has concluded that such internal control over financial reporting was effective. This Annual Report on Form 10-K does not include an evaluation report of our registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by our registered public accounting firm pursuant to the rules of the Securities and Exchange Commission applicable to smaller reporting companies that permit us to provide only management's report in this Annual Report on Form 10-K. Changes in Internal Control over Financial Reporting There has been no change in our internal control over financial reporting as defined in Rules 13a-15 (f) and 15d-15 (f) that occurred during the quarter ended December 31, ~~2023~~ **2024**, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Limitations on the Effectiveness of Controls—A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures and our internal control over financial reporting are designed to provide reasonable, not absolute, assurance that the objectives of the control system are met. We continue to implement, improve and refine our disclosure controls and procedures and our internal control over financial reporting. Item 9B. Other Information Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. Not applicable. PART III Item 10. Directors, Executive Officers and Corporate Governance Information regarding our directors and executive officers set forth under the headings "Proposal No. 1—Election of Directors," "Information Regarding the Board of Directors and Corporate Governance," and "Executive Officers of the Registrant" of the ~~2024~~ **2025** Proxy Statement is incorporated herein by reference. Information regarding our Audit Committee, including the members of our Audit Committee, set forth under the heading "Information Regarding the Board of Directors and Corporate Governance—Audit Committee" of the ~~2024~~ **2025** Proxy Statement is incorporated herein by reference. Information regarding the procedures by which our shareholders may recommend nominees to our Board of Directors set forth under the heading "Information Regarding the Board of Directors and Corporate Governance—Nominating and Corporate Governance Committee" of the ~~2024~~ **2025** Proxy Statement is incorporated herein by reference. Information regarding our Code of Business Conduct and Ethics set forth under the heading "Information Regarding the Board of Directors and Corporate Governance—Code of Business Conduct and Ethics" of the ~~2024~~ **2025** Proxy Statement is incorporated herein by reference. ~~Item 11. Executive Compensation~~ Information regarding ~~executive compensation and director compensation~~ **our insider trading policy** is set forth under the headings ~~heading "Executive Compensation Information Regarding the Board of Directors and Corporate Governance—Insider Trading Policy" and "Director Compensation,"~~ respectively, of the ~~2024~~ **2025** Proxy Statement is incorporated herein by reference. ~~Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters~~ Information contained in ~~regarding executive compensation and director compensation set forth under the headings sections captioned "Executive Compensation Security Ownership of Certain Beneficial Owners and Management" and "Equity Director Compensation, Plan Information" respectively,~~ of the ~~2024~~ **2025** Proxy Statement is incorporated herein by reference. ~~Item 13. Certain Relationships and Related Transactions and Director Independence~~ Information contained in the ~~section sections~~ captioned **"Related Person Transactions Security Ownership of Certain Beneficial Owners and Indemnification Management" and "Equity Compensation Plan Information"** of the ~~2024~~ **2025** Proxy Statement is incorporated herein by reference. ~~Item 13. Certain Relationships and Related Transactions and Director Independence Information contained in the section captioned "Related Person Transactions and Indemnification" of the 2025 Proxy Statement is incorporated herein by reference.~~ Information regarding director independence set forth under the heading "Information Regarding the Board of Directors and Corporate Governance" of the ~~2024~~ **2025** Proxy Statement is incorporated herein by reference. Item 14. Principal Accounting Fees and Services Information regarding our independent auditor fees and services in the section captioned "Proposal No. 2—Ratification of Selection of Independent Registered Public Accounting Firm" of the ~~2024~~ **2025** Proxy Statement is incorporated herein by reference. PART IV Item 15. Exhibits and Financial Statement Schedules (a) The following documents are filed as part of this Form 10-K: 1. Financial Statements: See Index to Financial Statements in Item 8 of this Form 10-K. 2. Financial Statement Schedules: Reference is made to the financial statement schedules included under Item 8 of Part II hereof. All other schedules are omitted because they are not applicable, not required or the information is shown in the financial statements or the notes thereto. (b) Exhibits Incorporation by Reference Exhibit Number Exhibit Description Form SEC File No. Exhibit Filing ~~Date~~ **Date**. 1 § # Asset Purchase Agreement, between the Registrant and Vertical Pharmaceuticals, LLC, dated March 12, 2023. 10-Q 001-35068 2. 1 11/14/2023 3. 1 Amended and Restated Certificate of Incorporation of the Registrant. 8-K 001-35068 3. 1 02/18/2011 3. 2 Certificate of Amendment to the Amended and Restated Certificate of Incorporation, dated January 9, 2024 8-K 001-35068 3. 1 01/09/2024 3. 3 Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant. 8-K 001-35068 3. 1 06/25/2019 3. 4 Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant. 8-K 001-35068 3. 1 ~~10/25/2022~~ **3. 5 Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock of the Registrant. 8-K 001-35068 3. 1 08/04/2022** 3. 6 Certificate of Elimination of Series A Convertible Preferred Stock of the Registrant. 8-K 001-35068 3. 2 ~~10/25/2022~~ **3. 7 Amended and Restated Bylaws of the Registrant. 8-K 001-35068 3. 1 01/09/2024** 4. 1 Description of Capital Stock. 10-K 001-35068 4. 1 03/15/2021 4. 2 Reference is made to Exhibits 3. 1 through 3. 4. 4. 3 Specimen Common Stock Certificate of the Registrant. S-1 333-170594 4. 2 01/31/2011 4. 4 Form of **Common Warrant to Purchase (May 2019). 8-K 001-35068 4. 1 06/03/2019** 4. 5 Form of **Common Warrant (November 2021). 8-K 001-35068 4. 1 11/15/2021** 4. 6 Common Stock **Purchase of the Registrant, dated as of May 30, 2019. 8-K 001-35068 4. 1 06/03/2019** 4. 5 Form of Warrant **(to Purchase Common Stock of the Registrant, dated as of November 15, 2021. 8-K 001-35068 4. 1 11/15/2021** 4. 6 Warrant to Purchase Common Stock of the Registrant, dated as of August 3, 2022 ). 8-K 001-35068 4. 1 08/04/2022 4. 7 Form of Common Warrant (December 2022). 8-K 001-35068 4. 1 12/28/2022 4. 8 Form of Pre-Funded Warrant (December 2022). 8-K 001-35068 4. 2 12/28/2022 4. 9 Form of Common Warrant, as amended (November 2022). 8-K 001-35068 4. 3 12/28/2022 10. 1 Form of Indemnification Agreement between the Registrant and each of its directors and executive officers. S-1 333-170594 10. 1 01/07/2011 10. 2 2011 Equity Incentive Plan. S-8 333-172409 99. 3 02/24/2011 10. 3 Forms of Stock Option Grant Notice, Notice of Exercise and Option Agreement under 2011 Equity Incentive Plan. 10-K 001-35068 10. 5 03/30/2011 10. 4 Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under 2011 Equity Incentive Plan. 10-K 001-35068 10. 6 03/30/2011 **Incorporation By Reference Exhibit Number Exhibit Description Form SEC File No. Exhibit Filing Date** 10. 5 Amended and Restated 2020 Equity Incentive Plan. 8-K 001-35068 10. 1 06/17/24 ~~2021~~ **2024** 10. 6 Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the Amended and Restated 2020 Equity Incentive Plan. S-8 333-239213 99. 2 06/16/2020 10. 7 Forms of RSU Award Grant Notice and Award Agreement (RSU Award) under the Amended and Restated 2020 Equity Incentive Plan. S-8

333-239213 99. 3 06 / 16 / 2020 10. 8 Amended and Restated 2011 Employee Stock Purchase Plan. S- 8 333- 239213 99. 4 06 / 16-24, 2020-2024 10. 9 Amended and Restated Offer Letter between the Registrant and Badri (Anil) Dasu, dated December 30, 2010. S- 1 333- 170594 10. 15 01 / 07 / 2011 10. 10 Amended and Restated Offer Letter between the Registrant and Pamela Palmer, dated December 29, 2010. S- 1 333- 170594 10. 16 01 / 07 / 2011 10. 11 Offer Letter between the Registrant and **Shakil Aslam Vincent J. Angotti, dated May 13 effective as of March 6, 2017-2024, 10-Q 001-35068 10. 4 05 / 08 / 2017-10. 12** Offer Letter between the Registrant and **Vincent J. Angotti, effective as of March 6, 2017. 10-Q 001-35068 10. 4 05 / 08 / 2017 10. 13** Offer Letter between the Registrant and Raffi Asadorian, dated July 18, 2017. 8- K 001- 35068 10. 1 07 / 19 / 2017 10. **13-14** Amended and Restated Severance Benefit Plan effective as of February 7, 2017. 8- K 001- 35068 10. 2 02 / 09 / 2017 10. **14-15** # Commercial Supply Agreement, effective March 31, 2021 by and between the Registrant and Catalent Pharma Solutions, LLC. 10- Q 001- 35068 10. 1 08 / 16 / 2021 10. **15** # License and Commercialization Agreement (DZUVEO), dated July 14, 2021, between the Registrant and Laboratoire Aguettant. 10- Q 001- 35068 10. 1 11 / 15 / 2021 10. **16** # License and Commercialization Agreement ( PFS-DZUVEO ), dated July 14, 2021, between the Registrant and Laboratoire Aguettant. 10- Q 001- 35068 10. **1 11 / 15 / 2021 10. 17** # License and Commercialization Agreement (PFS), dated July 14, 2021, between the Registrant and Laboratoire Aguettant. 10- Q 001- 35068 10. **2 11 / 15 / 2021 10. 17-18** Contingent Value Rights Agreement, dated as of January 7, 2022, by and among the Registrant, James Wilkie, solely in his capacity as the representative of the Lowell stockholders and option holders, and Computershare Inc., and its wholly- owned subsidiary, Computershare Trust Company, N. A., a federally chartered trust company, collectively as Rights Agent. 8- K 001- 35068 10. 1 01 / 12 / 2022 10. **18** Controlled Equity Offering SM Sales Agreement between the Registrant and Cantor Fitzgerald & Co., dated as of June 21, 2016. 8- K 001- 35068 10. **1 06 / 21 / 2016 10- 19** Amendment No. 1 to the Controlled Equity Offering SM Sales Agreement between the Registrant and Cantor Fitzgerald & Co., dated as of August 29, 2020. S- 3 333- 239156 1- 3 06 / 12 / 2020 10- 20 Loan and Security Agreement between the Registrant and Oxford Finance, LLC, dated as of May 30, 2019. 8- K 001- 35068 10. 1 06 / 03 / 2019 10- 21 First Amendment to Loan and Security Agreement between the Registrant and Oxford Finance, LLC, dated as of May 5, 2021. 10- Q 001- 35068 10. 4 11 / 15 / 2021 10- 22 Second Amendment to Loan and Security Agreement between the Registrant and Oxford Finance, LLC, dated as of November 14, 2021. 10- K 001- 35068 10. 3 1 03 / 10 / 2022 10- 23 Registration Rights Agreement, between the Registrant and Lincoln Park Capital Fund, LLC, dated as of August 3, 2022. 8- K 001- 35068 10. 2 08 / 04 / 2022 10- 24 Form of Securities Purchase Agreement, by and among the Registrant and the Purchasers, dated as of July 17, 2023. 8- K 001- 35068 10. 1 07 / 21 / 2023 10- 25 Form of Registration Rights Agreement, by and among the Registrant and the Purchasers, dated as of July 17, 2023. 8- K 001- 35068 10. 2 07 / 21 / 2023 10- 26 Form of Series A common stock warrant (July 2023). 8- K 001- 35068 10. 3 07 / 21 / 2023 10- 27-**20** Form of Series B common stock warrant (July 2023). 8- K 001- 35068 10. 4 07 / 21 / 2023 10. **28-21** Form of Pre- Funded Warrant (July 2023). 8- K 001- 35068 10. 5 07 / 21 / 2023 10- 29-**22** Form of placement agent Series A common stock warrant (July 2023). 8- K 001- 35068 10. 6 07 / 21 / 2023 10- 30-**23** Form of placement agent Series B common stock warrant (July 2023). 8- K 001- 35068 10. 7 07 / 21 / 2023 **Incorporation By Reference Exhibit Number Exhibit Description Form SEC File No. Exhibit Filing Date** 10. **31-24** Form of Securities Purchase Agreement, by and among the Registrant and entities affiliated with Nantahala Management, LLC, dated as of January 17, 2024. 8- K 001- 35068 10. 1 01 / 22 / 2024 10. **32-25** Form of **Registration Rights Agreement, between the Registrant and the Purchasers, dated as of January 17, 2024. 8- K 001- 35068 10. 3 01 / 22 / 2024 10. 26** Form of Pre- Funded Warrant (January 2024). 8- K 001- 35068 10. 4 01 / 22 / 2024 10. **27** Form of Amendment No. 1 to Securities Purchase Agreement, dated September 30, 2024, by and among **Talpera the Registrant and Investor Company HF Rosalind Master Fund L.P., dated as of January 17, 2024. 8- K 001- 35068 10. 2 1 10 / 01 / 22 / 2024 Talpera 10- 33** Form of Registration Rights Agreement - **Inc** between the Registrant and the Purchasers, dated as of January 17, 2024. **Insider Trading Policy** 8- K 001- 35068 10. 3 01 / 22 / 2024 10- 34 Form of Pre- Funded Warrant (January 2024). 8- K 001- 35068 10. 4 01 / 22 / 2024 23. 1 Consent of BPM LLP, Independent Registered Public Accounting Firm. 23. 2 Consent of Withum Smith & Brown LLP, Independent Registered Public Accounting Firm. 24. 1 Power of Attorney (included in signature page). 31. 1 Certification of Principal Executive Officer pursuant to Rules 13a- 14 (a) and 15d- 14 (a) promulgated under the Securities Exchange Act of 1934, as amended. 31. 2 Certification of Principal Financial Officer pursuant to Rules 13a- 14 (a) and 15d- 14 (a) promulgated under the Securities Exchange Act of 1934, as amended. 32. 1 Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U. S. C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002. 97 Talpera, Inc. Incentive Compensation Recoupment Policy. **10- K 001- 35068 97 3 / 6 / 2024** 101. INS XBRL Instance Document- the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. 101. SCH Inline XBRL Taxonomy Schema Document 101. CAL Inline XBRL Taxonomy Calculation Linkbase Document 101. DEF Inline XBRL Taxonomy Definition Linkbase Document 101. LAB Inline XBRL Taxonomy Label Linkbase Document 101. PRE Inline XBRL Taxonomy Presentation Linkbase Document **Incorporation By Reference Exhibit Number Exhibit Description Form SEC File No. Exhibit Filing Date** Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101. INS, 101. SCH, 101. CAL, 101. DEF, 101. LAB, and 101. PRE). § Schedules omitted pursuant to Item 601 (a) (5) of Regulation S- K. The Registrant agrees to furnish supplementally a copy of any omitted schedule upon request by the SEC. Indicates management contract or compensatory plan. # Material in the exhibit marked with an “ [ \* ] ” has been omitted because it is confidential, not material, and would be competitively harmful if publicly disclosed. The certifications attached as Exhibit 32. 1 accompany this Annual Report on Form 10- K pursuant to 18 U. S. C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002, and shall not be deemed “ filed ” by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Item 16. Form 10- K Summary SIGNATURES Pursuant to the requirements of Section 13 or 15 (d) of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: March **6-31, 2024** **Talpera 2025 Talpera, Inc. (Registrant) / s / Vincent J. Angotti Vincent J. Angotti Chief Executive Officer and Director (Principal Executive Officer) / s / Raffi Asadorian Raffi Asadorian Chief Financial Officer (Principal Financial and Accounting Officer) POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Vincent J. Angotti and Raffi Asadorian, and each of them, as his or her true and lawful attorneys- in- fact and agents, with full power of substitution for him or her, and in his or her name in any and all capacities, to sign any and all amendments to this Annual Report on Form 10- K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys- in- fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys- in- fact and agents, and any of them, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated: **Signature Title Date Signature Title Date** / s / Vincent J. Angotti Chief Executive Officer and Director March **6-31, 2024** **Vincent 2025 Vincent J. Angotti (Principal Executive Officer) / s / Raffi Asadorian Chief Financial Officer March 6-31, 2024** **Raffi 2025 Raffi Asadorian (Principal Financial and Accounting Officer) / s / Adrian Adams Chairman March 6-31, 2024** **Adrian 2025 Adrian Adams / s / Marina Bozilenko Director March 6-31, 2024** **Marina 2025 Marina Bozilenko / s / Jill Broadfoot Director March 6-31, 2024** **Jill 2025 Jill Broadfoot / s / Stephen J. Hoffman, Ph. D., M. D. Director March 6-31, 2024** **Stephen 2025 Stephen J. Hoffman, Ph. D., M. D. / s / Abhinav Jain Director March 6-31, 2024** **Abhinav 2025 Abhinav Jain / s / Mark Wan Director March 6-31, 2024** **Mark 2025 Mark Wan TALPHERA, INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Page Report Report** of Independent Registered Public Accounting Firm (PCAOB ID Number 207) F- **2** Report of Independent Registered Public Accounting Firm (PCAOB ID Number 100) F- **Consolidated 2** Consolidated Balance Sheets at December 31, **2024 and 2023-2023F and 2022 F- 3** Consolidated Statements of Operations for the years ended December 31, **2024 and 2023-2023F and 2022 F- 4** Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) for the years ended December 31, **2024 and 2023-2023F and 2022 F- 5** Consolidated Statements of Cash Flows for the years ended December 31, **2024 and 2023-2023F and 2022 F- 6** Notes to Consolidated Financial Statements **Statements F- 7 F- 1** Report of Independent Registered Public Accounting Firm **REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM** To the Shareholders and Board of Directors of Talpera, Inc. Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheet sheets of Talpera, Inc. (the “ Company ”) as of December 31, **2024 and 2023**, and the related consolidated **statement statements** of operations, **changes in redeemable convertible preferred stock and stockholders' equity (deficit), and cash flow-flows** for **each of the two year-years in the period** ended December 31, **2023-2024**, and the related notes (collectively referred to as the “ consolidated financial statements ”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, **2024 and 2023**, and the results of its operations and its cash flows for **each of the two year-years in the period** ended December 31, **2023-2024**, in conformity with accounting principles generally accepted in the United States of America. Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring operating losses and negative cash flows from operating activities since inception and expects to continue to incur operating losses and negative cash flows in the future. These matters raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Basis for Opinion These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“ PCAOB”) and are required to be independent with respect to the Company in accordance with the U. S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.**

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

**Critical Audit Matters** Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.

/s/ BPM LLP We have served as the Company's auditor since 2023. Walnut Creek, California March 6, 2024

**2025 F-2 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

**The Board of Directors and Stockholders AcelRx Pharmaceuticals, Inc.: Opinion on the Consolidated Financial Statements** We have audited the accompanying consolidated balance sheet of AcelRx Pharmaceuticals, Inc. (the "Company") as of December 31, 2022, the related consolidated statement of operations, changes in redeemable convertible preferred stock and stockholders' equity (deficit), and cash flows for the year ended December 31, 2022, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022, and the results of its operations and its cash flows for the year ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.

**Going Concern** The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring operating losses and negative cash flows from operating activities since inception, and expects to continue incurring operating losses and negative cash flows in the future. These matters raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

**Basis for Opinion** These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.

**F-3 Critical Audit Matters** The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing a separate opinion on the critical audit matters or on the accounts or disclosures to which they relate.

**Product Revenue Allowances for Chargebacks, Government Rebates and Product Returns** Description of the Matter As described in Note 1 to the consolidated financial statements, revenue from product sales is recognized net of estimates for variable consideration consisting of chargebacks, government rebates, returns, distribution fees, GPO fees and product returns. This variable consideration is recorded in the same period that the related revenue is recognized and creates variability for the consideration that the Company expects to receive. Liabilities related to government rebates and rebate programs of managed healthcare organizations involve the use of significant assumptions and judgments that include consideration of legal interpretations of applicable laws and regulations, historical claims experience, the payer channel mix, current contract prices, unbilled claims, claims submission time lags, and inventory levels in the distribution channel. Estimates for product returns consider existing return policies with customers, historical sales and return rates, inventory levels in the distribution channel, and product shelf lives. Management's estimated allowance for chargebacks, government rebates, and product returns requires a high degree of judgment and is subject to change based on various quantitative and qualitative factors. Accordingly, extensive audit effort and a high degree of auditor judgment were needed to evaluate management's estimates and assumptions used in the determination of chargebacks, government rebates, and product returns.

**How We Addressed the Matter in Our Audit** We obtained an understanding of and evaluated the design of controls relating to the Company's processes for estimating chargebacks, government rebates, and product returns. We evaluated the significant accounting policies relating to chargebacks, government rebates, and product returns, as well as management's application of the policies, for appropriateness and reasonableness. To test management's estimates of chargebacks, rebates and returns, we obtained management's calculations for the respective estimates and performed one or more of the following procedures: clerically tested the calculation; agreed relevant inputs to the terms of relevant contracts; performed retrospective reviews; performed a sensitivity analysis on the inputs and assumptions used in the estimates and assessed subsequent events; evaluated the methodologies and assumptions used and the underlying data used by the Company; evaluated the assumptions used by management against historical trends; evaluated the change in estimated accruals from the prior periods; and assessed the historical accuracy of the Company's estimates against actual results.

/s/ WithumSmith+Brown, PC We began serving as the Company's auditor in 2015. We became the predecessor auditor in 2023. San Francisco, California March 31, 2023, except for the effects of the discontinued operations disclosed in Note 3, as to which the date is July 31, 2023

**PCAOB ID Number 100 F-4** (in thousands, except share data) December 31, 2023 2024 December 31, 2022 2023

**Assets** Current Assets: Cash and cash equivalents \$ 8,863 \$ 5,721 \$ 15,275 Restricted cash 5,000 Short-term investments 3,660 Prepaid expenses and other current assets 2,195 175 1,865 Assets of discontinued operations 1,921 Total current assets 9,417 11,576 556 24,566 In-process research and development asset 8,819 8,819 Other assets Assets of discontinued operations 13,936 Total assets \$ 18,236 \$ 20,395 \$ 47,487

**Liabilities and Stockholders' Equity** Current Liabilities: Accounts payable \$ 1,336 \$ 1,256 336 Accrued and other liabilities 1,254 2,445 Liabilities of discontinued operations 2,531 Long-term debt, current portion 5,363 Liabilities of discontinued operations, current portion 4,620 Total current liabilities 2,647 4,512 13,770 Warrant liability 1,061 1,778 Liability related 7,098 Other— the long-term liabilities sale of future payments 6,527 Liabilities of discontinued operations 3,995 Total liabilities 10,235 6,290 25,673

**Commitments and Contingencies** Stockholders' Equity: Common stock, \$ 0.001 par value 200,000,000 shares authorized as of December 31, 2024 and 2023 and 2022: 17,029,469 and 16,952,519 and 8,243,680 shares issued and outstanding as of December 31, 2024 and 2023 and 2022, respectively Additional paid-in capital 465,214 458,314 447,635 Accumulated deficit (457,230) (444,226) (425,829) Total stockholders' equity 8,001 14,105 21,814 Total Liabilities and Stockholders' Equity \$ 18,236 \$ 20,395 \$ 47,487

See notes to consolidated financial statements. (in thousands, except share and per share data) Year Ended December 31, 2023

**Revenue** \$ — Operating costs and expenses: Research and development 6,718 5,546 3,341 Selling, general and administrative 8,534 11,994 17,011 Impairment of property and equipment 4,948 Total operating costs and expenses 15,252 17,540 25,300 Loss from operations (15,252) (16,889) (25,300) Other income (expense): Interest expense (134) (1,116) Interest income and other income, net 6-1, 736 416 Gain on sale of future royalties 1,246 Gain on change in fair value of warrant liability 5,320 Non-cash interest income expense on liability related to the sale of future royalties payments (394) 1,136 Non-cash gain on extinguishment of liability related to the sale of future royalties 84,052 Total other income, net 2,248 6,602 84,438 Net (loss) income before income taxes (10,287) 59,125 Net loss from discontinued operations - See Note 3 (8,110) (11,370) Net (loss) income \$ (18,397) 47,755 Deemed dividends related to Series A Redeemable Convertible Preferred Stock (186) Income allocated to participating securities (5,240) Net (loss) income attributable to Common Shareholders, basic \$ (18,397) \$ 42,329 Net (loss) income attributable to Common Shareholders, diluted \$ (18,397) \$ 42,342 Net (loss) income per share attributable to stockholders: Basic and diluted, (loss) earnings per share (Loss) income from continuing operations \$ (0.50) \$ (0.72) Basic and diluted, \$ 7.27 Loss from discontinued operations \$ (0.00) \$ (0.57) Basic and diluted \$ (1.54) Net (loss) income per share \$ (0.50) \$ (1.29) \$ 5.73 Diluted (loss) earnings per share (Loss) income from continuing operations \$ (0.72) \$ 7.25 Loss from discontinued operations \$ (0.57) \$ (1.53) Net (loss) income per share \$ (1.29) \$ 5.72 Shares used in computing net (loss) income per share of common stock, basic and diluted - See Note 12 14,263,744 7,385,348 Shares used in computing net (loss) income per share of common stock, diluted - See Note 12 25,845,639 14,263,744 7,406,986 Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) Additional Total Series A Redeemable Paid-in Accumulated Stockholders' Convertible Preferred Stock Common Stock Capital Deficit Equity (Deficit) Shares Amount Shares Amount Balance as of December 31, 2021 2022 8 - \$ - 6,840 243,967 680 \$ 437 447,684 635 \$ (

473, 425, 584, 829) \$ 21 (35, 814, 893) Issuance of Series A Redeemable Convertible Preferred Stock and Warrants 3, 000 — Deemed dividends related to Series A Redeemable Convertible Preferred Stock (186) (186) Redemption of Series A Redeemable Convertible Preferred Stock and Warrants (3, 000) (315) — Stock-based compensation — 1, 729 1 — 2, 729 889 — 2, 889 Issuance of common stock in connection with asset purchase — 481, 026 5, 511 5, 511 Net proceeds from issuance of common stock and pre-funded warrants in connection with equity financings — 873, 074 Modification of equity-classified warrants — Issuance of common stock upon vesting of restricted stock units, net of shares withheld for employee taxes — 37, 672 (58) (58) Issuance of common stock upon ESPP purchase — 10, 941 Net income — 47, 755 47, 755 Balance as of December 31, 2022 — 8, 243, 680 447, 635 (425, 829) 21, 814 Stock-based compensation — 1, 729 — 1, 729 Issuance of common stock in connection with asset purchase — 69, 808 — Net proceeds from issuance of common stock and warrants..... Preferred Stock — (315) Proceeds from issuance of common stock, accompanying warrants and pre-funded warrants in July 2023 private placement offering 5, 340, 591 8, 851 — 8, 856 Exercise of pre-funded warrants 3, 228, 781 — Issuance of common stock upon vesting of restricted stock units, net of shares withheld for employee taxes 27, 450 — (22) — (22) Issuance of common stock upon ESPP purchase 42, 209 — Net loss — — (18, 397) Balance as of December 31, 2023 16, 952, 519 458, 314 (444, 226) 14, 105 Stock-based compensation — — Net Proceeds proceeds from issuance of common stock, accompanying warrants and pre-funded warrants in December-January 2022-2024 registered direct private placement offering — 7 — 5, 884 — 5, 884 Issuance of common stock upon vesting of restricted stock units, net of shares withheld for employee taxes — 27, 450 435 — (22-17) — (22-17) Issuance of common stock upon ESPP purchase 49 — 42, 209 515 — — Net loss — — (18, 13, 397-004) (18-13, 397-004) Balance as of December 31, 2023-2024 17 — \$ — 16, 952-029, 519-469 \$ \$ 458-465, 314 \$ (444, 226) \$ 14-214 \$ (457, 405-230) \$ 8, 001 (in thousands) Year Ended December 31, Cash flows from operating activities: Net (loss) \$ (13, 004) income \$ (18, 397) \$ 47, 755 Adjustments to reconcile net income (loss) to net cash used in operating activities: Non-cash interest income expense on liability related to the sale of future royalties payments — (1, 136) Depreciation and amortization 1, 647 — Net amortization of discount on short-term investments (121) (24) Non-cash interest expense related to debt financing Non-cash issuance costs for warrant liability — Revaluation of liability for Lowell holdback shares — (723) — Stock-based compensation 1, 729 Gain 2, 889 Non-on change in fair value — cash gain on extinguishment of liability related to the sale of future royalties — (84, 152) Impairment of property and equipment — 4, 948 Revaluation of warrant liability ( 717) ( 5, 320) — Impairment of net assets held for sale — 6, 853 — Impairment of fixed assets — 1, 065 — Gain on termination of lease liabilities — (1, 098) — Gain on extinguishment of debt liability — (400) — Other (24) (60) Changes in operating assets and liabilities: Accounts receivable (189) (149) Inventories — (107) Prepaid expenses and other current assets Other assets — 1, 641 Accounts payable ( 671) ( 575) Accrued liabilities (1, 194) (1, 132) (+1, 613) Operating lease liabilities — (147) (+285) Deferred revenue — (29) (86) Net cash used in operating activities ( 12, 683) ( 17, 492 ) (+28, 331) Cash flows from investing activities: Purchase of property and equipment — (100) Sale of the DSUVIA assets — 2, 723 Purchase of investments (4, 979) (3, 651) Proceeds from maturities of investments 8, 760 Net cash provided by (used in) investing activities 3, 781 ( 528 ) Cash flows from financing activities: Payment of long-term debt — (5, 416) Gross proceeds from sale of future payments 6, 654 — Issuance costs related to sale of future payments (521) — Net proceeds from issuance of common stock, accompanying warrants and pre-funded warrants in July 2023 private placement offering — 8, 856 Net proceeds from issuance of common stock in connection with exercise of pre-funded warrants — Net proceeds from issuance of common stock pre-funded warrants in January 2024 private placement offering 5, 884 connection with at-the-market sales agreement — Net proceeds from issuance of common stock through equity plans Payment of employee tax obligations related to vesting of restricted stock units (22) (58) Net cash provided by (used in) financing activities 12, 044 3, 466 (507) Net change in cash and cash equivalents and restricted cash 3, 142 (14, 554) 7, 612 Cash and cash equivalents and restricted cash — Beginning of period \$ 5, 721 20, 275 42, 663 Cash and cash equivalents and restricted cash — End of period \$ 8, 863 \$ 5, 721 \$ 20, 275 Supplemental Disclosures of Cash Flow Information: Cash paid for interest \$ — \$ Income taxes paid \$ — \$ Noncash Investing and Financing Activities: Purchase of property and equipment in accounts payable and accrued expenses \$ — \$ Equity issuance costs from warrant modification \$ of November 2021 Financing Warrants \$ — \$ Equity issuance costs in accounts payable and accrued expenses \$ — \$ (Settlement of) liability for held back shares issued in connection with asset acquisition \$ (77) \$ Issuance of common stock in connection with asset acquisition \$ — \$ (77) Offering costs in accounts payable \$ 5, 511 Establishment of right-of-use asset and lease liability \$ — \$ Fair value of warrants issued to placement agent \$ — \$ F-8 (In thousands, except where otherwise noted) 1.

Organization and Summary of Significant Accounting Policies Talphera, Inc., or the Company, or Talphera, was incorporated in Delaware on July 13, 2005, as SuRx, Inc. The Company subsequently changed its name to AcelRx Pharmaceuticals, Inc. and, on January 9, 2024, to Talphera, Inc. The Company's operations are based in San Mateo, California. Talphera is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. The Company's product development portfolio features Niyad™ (a regional anticoagulant for the dialysis circuit), two ready-to-use pre-filled syringe, or PFS, product candidates (Fedsyra and phenylephrine), and LTX-608 (a nafamostat formulation for direct IV infusion) that the Company intends to develop for one or more of the following indications: disseminated intravascular coagulation, or DIC, acute respiratory distress syndrome, or ARDS, acute pancreatitis, or as an anti-viral treatment, and two ready-to-use pre-filled syringe, or PFS, product candidates (Fedsyra and phenylephrine). On March 12, 2023, the Company entered into an Asset Purchase Agreement, or the DSUVIA Agreement, with Vertical Pharmaceuticals, LLC, a wholly owned subsidiary of Alora Pharmaceuticals, LLC, or Alora, pursuant to which Alora agreed to acquire certain assets and assume certain liabilities of the Company relating to its sufentanil sublingual tablet product referred to as DSUVIA or DZUVEO, or any other single-dose pharmaceutical product for use in medically supervised settings containing a sublingual tablet that includes sufentanil as the sole active ingredient, as a 30 mcg tablet or other dosage form or strength as reasonably necessary for lifecycle management, or the Product. The closing of the DSUVIA Agreement occurred on April 3, 2023 (see Note 3, "Discontinued Operations"). On January 7, 2022, the Company acquired Lowell Therapeutics, Inc., or Lowell, a privately held company (see Note 4, "Asset Acquisition" below) and, as a result acquired the Niyad™ developmental product, a regional anticoagulant for the dialysis circuit during continuous renal replacement therapy for acute kidney injury patients in the hospital, that the Company is plans to study studying under an investigational device exemption, or IDE, and for which it has received Breakthrough Device Designation status from the FDA. While not approved for commercial use in the United States, the active drug component of Niyad, nafamostat, has been approved in Japan and South Korea as a regional anticoagulant for the dialysis circuit, disseminated intravascular coagulation, and acute pancreatitis. Niyad is a lyophilized formulation of nafamostat, a broad-spectrum, synthetic serine protease inhibitor, with anticoagulant, anti-inflammatory, and potential anti-viral activities. The second intended indication for Niyad is as a regional anticoagulant for the dialysis circuit for chronic kidney disease patients undergoing intermittent hemodialysis in dialysis centers. In addition, the Company acquired LTX-608, a nafamostat formulation for direct IV infusion, that it intends to develop for the treatment of one or more of the following indications: ARDS, DIC, acute pancreatitis or as an anti-viral agent. On July 14, 2021, the Company entered into a License and Commercialization Agreement, or the PFS Agreement, with Laboratoire Aguettant, or Aguettant, pursuant to which the Company obtained the exclusive right to develop and, subject to FDA approval, commercialize in the United States an ephedrine pre-filled syringe for injection, and (ii) a phenylephrine PFS for injection. Aguettant will supply the Company with the products for use in commercialization, if they are approved in the U. S. F-9 Liquidity and Going Concern The consolidated financial statements for the year ended December 31, 2023-2024, were prepared on the basis of a going concern, which contemplates that the Company will be able to realize assets and discharge liabilities in the normal course of business. The termination of the Zalviso Royalty Monetization resulted in net income for the year ended December 31, 2022; however, prior to this, the Company had has incurred recurring operating losses and negative cash flows from operating activities since inception and expects to continue to incur operating losses and negative cash flows in the future. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Although, the Company raised additional capital in January 2024 (see Note 16, "Subsequent Events"), considering Considering the Company's current cash resources and its current and expected levels of operating expenses for the next twelve months, management expects to need additional capital to fund its planned operations prior to the 12-month anniversary of the date this Annual Report on Form 10-K is filed with the United States Securities and Exchange Commission, or the SEC. Management may seek to raise such additional capital through public or private equity offerings, including under the Controlled Equity Offering SM Sales Agreement, or the ATM Agreement, with Cantor Fitzgerald & Co., or Cantor, debt securities, a new debt facility, monetizing or securitizing certain assets, entering into product development, license or distribution agreements with third parties, or divesting any of the Company's remaining product candidates. While management believes its plans to raise additional funds will alleviate the conditions that raise substantial doubt about the Company's ability to continue as a going concern, these plans are not entirely within the Company's control and cannot be assessed as being probable of occurring. Additional funds may not be available when the Company needs them on terms that are acceptable to the Company, or at all. If adequate funds are not available, the Company may be required to further reduce its workforce, delay the ongoing clinical trial for Niyad, or delay the development of its regulatory filing plans for its product candidates in advance of the date on which the Company's cash resources are exhausted to ensure that the Company has sufficient capital to meet its obligations and continue on a path designed to preserve stockholder value. In addition, if additional funds are raised through collaborations, strategic alliances or licensing arrangements with third parties, the Company may have to relinquish rights to its technologies, future revenue streams or product candidates, or to grant licenses on terms that may not be favorable to the Company. Basis of Presentation The preparation of accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results could differ from those estimates. The Company's audited financial statements as of December 31, 2022, included in the Company's Annual Report on Form 10-K filed with the rules and regulations of the U. S. Securities and Exchange Commission, or SEC on March 31, 2023, were recast to reflect discontinued operations and filed with the

Company's Current Report on Form 8-K on August 1, 2023. See Note 3, "Discontinued operations" below. Reclassifications Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year's presentation. In particular, property and equipment, net and restricted cash, net of current portion have been reclassified as other assets, and operating lease liabilities, current portion, has been reclassified as accrued and other liabilities in the consolidated balance sheets. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. F-10 Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management believes its most significant accounting estimates relate to fair value of warrants, impairment liability related to the sale of future payments long-lived assets, accrued clinical trial liabilities and management's assessment of going concern, revenue recognition, liability for royalty monetization and accrued clinical trial liabilities. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.

**Reclassifications Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year's presentation. In particular, other assets has been reclassified as prepaid expenses and other current assets in the consolidated balance sheets, other has been reclassified as net amortization of discount on short-term investments, accounts receivable and other assets have been reclassified as prepaid expenses and other current assets, and payment of employee tax obligations related to vesting of restricted stock units has been reclassified to net proceeds from issuance of common stock through equity plans in the consolidated statement of cash flows and the portion of interest income and other income, net related to the revaluation of liability-classified warrants has been reclassified to change in fair value of warrants in the consolidated statements of operations. The Company has adopted Accounting Standards Update, or ASU, 2023-07, Improvements to Reportable Segment Disclosures, which requires the prior period to reflect the change in presentation. See Note 16, "Segment Reporting". These reclassifications did not affect the prior period's total assets, total liabilities, stockholders' equity, net loss or net cash used in operating activities. F-8 Cash and Cash Equivalents and Restricted Cash** The Company considers all highly liquid investments with an original maturity (at date of purchase) of three months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks. On May 30, 2019, the Company entered into a Loan Agreement with Oxford Finance LLC, or Oxford, or the Lender. The Loan Agreement requires that the Company always maintain unrestricted cash of not less than \$5.0 million in accounts subject to control agreements in favor of the Lender, tested monthly as of the last day of the month. The Company has classified these unrestricted funds as restricted cash on the consolidated balance sheets. On April 3, 2023, the Company repaid Oxford the full amount due under the loan, and the Loan Agreement was terminated with no further obligations by either party. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts in the consolidated statements of cash flows: Balance as of December 31, 2023 December 31, 2021 Cash and cash equivalents \$ 5,721 \$ 15,275 Restricted cash — 5,000 Total cash, cash equivalents, and restricted cash \$ 5,721 \$ 20,275 Short-Term Investments All marketable securities are classified as available for sale and consist of commercial paper and U. S. government sponsored enterprise debt securities. These securities are carried at estimated fair value, which is based on quoted market prices or observable market inputs of almost identical assets, with unrealized gains and losses included in accumulated other comprehensive income (loss). The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income or expense. The cost of securities sold is based on specific identification. When the fair value of an available-for-sale security falls below the amortized cost basis, it is evaluated to determine if any of the decline in value is attributable to credit loss. Decreases in fair value attributable to credit loss are recorded directly to the consolidated statement of operations with a corresponding allowance for credit losses, limited to the amount that the fair value is less than the amortized cost basis. If the credit quality subsequently improves, the allowance is reversed up to a maximum of the previously recorded credit losses. When the Company intends to sell an impaired available-for-sale security, or if it is more likely than not that the Company will be required to sell the security prior to recovering the amortized cost basis, the entire fair value adjustment will immediately be recognized in the consolidated statement of operations with no corresponding allowance for credit losses. F-11 Fair Value of Financial Instruments The Company measures and reports its cash equivalents, investments and financial liabilities at fair value. Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows: Level I — Unadjusted quoted prices in active markets for identical assets or liabilities; Level II — Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and Level III — Unobservable inputs that are supported by little or no market activity for the related assets or liabilities. The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Segment Information The Company operates in a single segment, the development and commercialization of innovative therapies for use in medically supervised settings. The Company's revenue relates to the Company's services performed to support sales of DSUVIA to the Department of Defense, or DoD, by Alora under the Marketing Agreement (as defined in Note 3, "Discontinued Operations" below). Concentration of Risk The Company invests cash that is currently not being used for operational purposes in accordance with its investment policy in debt securities of U. S. government sponsored agencies, commercial paper and overnight deposits. The Company is exposed to credit risk in the event of default by the institutions holding the cash equivalents and available-for-sale securities to the extent recorded on the consolidated balance sheets. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of \$250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows. F-9 The Company relies on a single contract manufacturer, or CMO, for the active pharmaceutical ingredient, or API, for Niyad™ and a second single contract manufacturer for the finished Niyad product. All revenue relates to the Company's services for fees earned on the sales of DSUVIA to the DoD by Alora. Impairment of Long-Lived Assets The Company periodically assesses the impairment of long-lived assets and, if indicators of asset impairment exist, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through an analysis of the undiscounted future expected operating cash flows. If impairment is indicated, the Company records the amount of such impairment for the excess of the carrying value of the asset over its estimated fair value. F-12 The Company realigned its cost structure from a focus on commercialization to a focus on advancing its late-stage development pipeline, namely the Niyad product candidates and the pre-filled syringes. As a result, the Company decided to not focus any development resources on Zalviso in the United States. In addition, due to the termination of the agreements with Grünenthal for Zalviso in Europe and the related withdrawal of the Marketing Authorization in Europe in July 2022, the Company did not expect any revenues from Zalviso in Europe in the foreseeable future. Accordingly, the Company determined that it was no longer probable that it would realize the future economic benefit associated with the costs of the Zalviso-related purchased equipment and manufacturing-related facility improvements the Company had made at its contract manufacturer and, therefore, recorded a non-cash impairment charge of \$4.9 million to the Zalviso-related assets for the year ended December 31, 2022. The impairment charge was recorded as operating expense in the consolidated statement of operations. Depreciation and amortization expense was immaterial for the year ended December 31, 2022. Acquisitions The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets. Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. For asset acquisitions, a cost accumulation model is used to determine the cost of an asset acquisition. Direct transaction costs are recognized as part of the cost of an asset acquisition. The Company also evaluates which elements of a transaction should be accounted for as a part of an asset acquisition and which should be accounted for separately. The cost of an asset acquisition, including transaction costs, is allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis. Goodwill is not recognized in an asset acquisition. Any difference between the cost of an asset acquisition and the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based on their relative fair values. When a transaction accounted for as an asset acquisition includes an in-process research and development, or IPR & D, asset, the IPR & D asset is only capitalized if it has an alternative future use other than in a particular research and development project. For an IPR & D asset to have an alternative future use (a) the Company must reasonably expect that it will use the asset acquired in the alternative manner and anticipate economic benefit from that alternative use, and (b) the Company's use of the asset acquired is not contingent on further development of the asset subsequent to the acquisition date (that is, the asset can be used in the alternative manner in the condition in which it existed at the acquisition date). Otherwise, amounts allocated to IPR & D that have no alternative use are expensed. Asset acquisitions may include contingent consideration arrangements that encompass obligations to make future payments to sellers contingent upon the achievement of

future financial targets. Contingent consideration is not recognized until all contingencies are resolved and the consideration is paid or probable of payment, at which point the consideration is allocated to the assets acquired on a relative fair value basis. **In-Process Research and Development In accordance with ASC Topic 350, Intangibles- Goodwill and Other, the acquired IPR & D has initially been accounted for as an indefinite-lived intangible asset and, therefore, not amortized. If the IPR & D asset achieves regulatory approval and the asset life is determined to be finite, the asset's useful life will be estimated, and the asset will be amortized over its remaining useful life. The IPR & D asset is reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. These events and changes can include significant current period operating losses or negative cash flows associated with the use of the IPR & D asset, such as the result of unfavorable data from any ongoing or future clinical trial, changes in assumptions that negatively impact projected cash flows, or because of any other information regarding the prospects of successfully developing or commercializing the Company's programs. When impairment indicators are present, the Company compares undiscounted future cash flows to the asset's carrying value to determine if the asset is recoverable. If the carrying values are in excess of undiscounted expected future cash flows, the Company measures any impairment by comparing the fair value of the asset to its carrying value.** F- 13-10 No impairment losses were recorded on the IPR & D asset during the years ended December 31, 2024 or 2023.

In accordance with ASC 205-20 Presentation of Financial Statements: Discontinued Operations, a disposal of a component of an entity or a group of components of an entity is required to be reported as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity's operations and financial results. In the period in which the component meets held-for-sale or discontinued operations criteria the major current assets, non-current assets, current liabilities, and non-current liabilities shall be reported as components of total assets and liabilities separate from those balances of the continuing operations. At the same time, the results of all discontinued operations, less applicable income taxes, shall be reported as components of net loss separate from the net income (loss) of continuing operations. The Company's DSUVIA business met the definition of a discontinued operation as of March 31, 2023. Accordingly, the Company has classified the results of the DSUVIA business as discontinued operations in its consolidated statements of operations for all periods presented. All assets and liabilities associated with the DSUVIA business were classified as assets and liabilities of discontinued operations in the consolidated balance sheets for the periods presented. All amounts included in the notes to the consolidated financial statements relate to continuing operations unless otherwise noted. (See Note 3, "Discontinued Operations").

**Revenue from Contracts with Customers** The Company follows the provisions of Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers. This guidance provides a unified model to determine how revenue is recognized. The Company recognizes revenue upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. Prior to the divestment of DSUVIA to Alora, the Company sold its products primarily through wholesale and specialty distributors. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company's revenue relates to the Company's services performed to support sales of DSUVIA to the Department of Defense, or DoD, by Alora under the Marketing Agreement (as defined in Note 3, "Discontinued Operations" below). The Company's performance obligation is to serve as the exclusive sales agent for selling DSUVIA to the DoD through the term of the Marketing Agreement. The non-creditable and non-refundable revenues are variable consideration based on 75% of net sales of DSUVIA to the DoD during the period subject to certain adjustments. The Company evaluates if it is a principal or an agent in a transaction to determine whether revenue should be recorded on a gross or net basis depending on if it obtains control over the goods and services before they are transferred to customers. The Company is acting as an agent in relation to DSUVIA sales to the DoD. The consideration in the Marketing Agreement reflects a variable amount, for which the Company estimates the amount of consideration to which it will be entitled by using the expected value method. The Company includes in the transaction price the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. Revenues are recognized when the DoD obtains control of the product, at which time the Company has an unconditional right to receive payment for such revenue earned.

Research and Development Expenses Research and development costs are charged to expense when incurred. Research and development expenses include salaries, employee benefits, including stock-based compensation, consultant fees, laboratory supplies, costs associated with clinical trials and manufacturing, including contract research organization fees, other professional services and allocations of corporate costs. The Company reviews and accrues clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of patient studies and other events. F-14 Stock-Based Compensation Compensation expense for all stock-based payment awards made to employees and directors, including employee stock options and restricted stock units related to the 2020 Equity Incentive Plan, or 2020 EIP, the 2011 Equity Incentive Plan, or 2011 EIP, and employee share purchases related to the Amended and Restated 2011 Employee Stock Purchase Plan, or ESPP, is based on estimated fair values at grant date. The Company determines the grant date fair value of the awards using the Black-Scholes option-pricing model and generally recognizes the fair value as stock-based compensation expense on a straight-line basis over the vesting period of the respective awards. The Company applies the graded-vesting attribution method to awards with market conditions that include graded-vesting features. Additionally, the Company uses the Monte Carlo Simulation model to evaluate the derived service period and fair value of awards with market conditions, including assumptions of historical volatility and risk-free interest rate commensurate with the vesting term. The Black-Scholes option pricing model requires inputs such as expected term, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. The expected term, which represents the period of time that options granted are expected to be outstanding, is derived by analyzing the historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior. Expected volatilities are estimated using the historical stock price performance over the expected term of the option, which are adjusted as necessary for any other factors which may reasonably affect the volatility of the Company's stock in the future. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for the expected term of the award. The Company recognizes forfeitures when they occur and does not anticipate paying dividends in the near future. F-11 Warrants Issued in Connection with Financings The Company accounts for issued warrants as either liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock. Under ASC 480-10, warrants are considered liability if they are mandatorily redeemable and they require settlement in cash or other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as liability or equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP. Equity classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.

**Restructuring Costs Sale of Future Payments On January 12, 2024, the Company entered into the Purchase Agreement with XOMA to monetize a portion of its future payments for commercial sales of DSUVIA and services performed by the Company to support sales of DSUVIA to the Department of Defense, or DoD, by Alora under the Marketing Agreement, and sales milestones under the DSUVIA Agreement. Refer to Note 7, "Sale of Future Payments" for further details on the Purchase Agreement. The Company recorded approximately \$ 6.1 million, net of \$ 0.5 million in issuance costs, of the \$ 8.0 million proceeds as a liability, as this portion of the proceeds represents a sale of future revenues under ASC 470 for which the Company has continuing involvement in the generation of cash flows. The Company recorded approximately \$ 1.2 million, net of \$ 0.2 million in issuance costs, of the \$ 8.0 million proceeds as other income, as this portion of proceeds represents the sale of all of the Company's interest in restructuring costs consist of employee termination benefit costs. Liabilities for costs associated with the cost reduction plan are recognized when the liability is incurred and are measured at fair value. One-time termination benefits are expensed at the date the Company notifies the employee, unless the employee must provide future payments service, in which case the benefits are expensed ratably over the future service period. F-15 In May 2022, the Company initiated a reorganization that eliminated approximately 40% of its employees, primarily within the commercial organization. For the year ended December 31, 2022, the Company incurred approximately \$ 0.5 million in employee termination benefits related to commercial sales this restructuring, all of DSUVIA for which the Company is no longer entitled to receive such payments and has no further been paid. This headcount reduction was completed in the second quarter of 2022. No additional expenses were incurred in connection with this cost reduction plan. Non-Cash Interest Income on Liability Related to Sale of Future Royalties In September 2015, the Company sold certain royalty and milestone payment rights from the sales of Zalviso in the European Union by Grünenthal to PDL for gross proceeds of \$ 65.0 million, or the Zalviso Royalty Monetization. Grünenthal terminated the Grünenthal Agreements effective November 13, 2020. The terms of the Grünenthal Agreements were extended to May 2021 to enable Grünenthal to sell down its Zalviso inventory. The rights to market and sell Zalviso in the Territory reverted back to the Company in May 2021. Under the Zalviso Royalty Monetization, the Company had a continuing obligation to use commercially reasonable efforts to negotiate a replacement license agreement, or New Arrangement. Under the relevant accounting guidance, because of the Company's significant continuing involvement, the Company utilized internal estimates to develop a cash flow model based on business assumptions to determine the**

Zalviso Royalty Monetization was accounted for allocation of the proceeds. The liability related to the sale of future payments is recorded as debt and will be a liability that is being amortized using under the effective interest rate method over the estimated life of the arrangement Purchase Agreement. The In-order to determine the amortization of the liability, the Company was required to estimate the effective interest rate based on its estimate of the total amount of future royalty and milestone payments to be received by KOMA under the Purchase Agreement. The Company reassesses these estimates at each reporting date and adjusts the effective interest rate and amortization of the liability on a prospective basis, as necessary. The Company records the payments to KOMA as a reduction of the liability when paid. As such payments are made to PDL-KOMA, the balance up to a capped amount of \$195.0 million, the liability will be effectively repaid over the life of the Purchase Agreement arrangement. The aggregate future estimated royalty and milestone payments (subject to the capped amount), less the \$61.2 million of net proceeds the Company received, was to be amortized as interest expense over the life of the liability. Consequently, the Company imputed interest on the unamortized portion of the liability and recorded interest expense, or interest income, as these estimates were updated and recorded non-cash royalty revenues and non-cash interest income (expense), net, within its consolidated statements of operations over the term of the Zalviso Royalty Monetization. When the expected payments under the Zalviso Royalty Monetization were lower than the gross proceeds of \$65.0 million received, the Company deferred recognition of any probable contingent gain until the Zalviso Royalty Monetization liability expired. See Note 7, "Liability Related to Sale of Future Royalties".

Income Taxes Deferred tax assets and liabilities are measured based on differences between the financial reporting and tax basis of assets and liabilities using enacted rates and laws that are expected to be in effect when the differences are expected to reverse. The Company records a valuation allowance for the full amount of deferred assets, which would otherwise be recorded for tax benefits relating to operating loss and tax credit carryforwards, as realization of such deferred tax assets cannot be determined to be more likely than not. F-12 Net Income (Loss) per Share of Common Stock Basic and diluted net income (loss) per common share, or EPS, are calculated in accordance with the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 260, Earnings per Share. The Company applies the two-class method to compute basic and, if more dilutive than other methods, diluted net income or loss per share. The two-class method is an earnings allocation formula that treats participating securities as having rights to earnings that would otherwise have been available to common stockholders (including pre-funded warrants). Shares of common stock into which the pre-funded warrants may be exercised are considered outstanding for the purposes of computing net loss per share because the shares may be issued for little or no consideration and are exercisable after the original issuance date. In addition, the Company is required to calculate diluted net income or loss per share under the two-class method if the effect is more dilutive than the application of another dilutive method of calculating diluted EPS (i.e., the treasury stock, if-converted, or contingently issuable share method). In periods where there is a net loss, no allocation of undistributed net loss to participating securities is performed if the holders of these securities are not contractually obligated to participate in the Company's losses. The Company's participating securities include the November 2021 Financing Warrants, December 2022 Common Stock Warrants, the July 2023 Series A Redeemable Convertible Preferred and Series B common stock warrants, and the placement agent July 2023 Series A and Series B Common common Stock stock Warrants warrants, the placement agent Series A and Series B Common Stock Warrants (see Note 9, "Stockholders' Equity" and Note 10, "Warrants" to the consolidated financial statements in this Annual Report on Form 10-K for additional information). F-16 For additional information regarding the net income (loss) per share, see Note 12, "Net Income (Loss) per Share of Common Stock".

Recently Adopted Accounting Pronouncements In June 2016 November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Standard Update, or ASU, 2016-2023 -13-07 Segment Reporting Financial Instruments Credit Losses (Topic 326-280): Measurement of Credit Losses on Financial Instruments Improvements to Reportable Segment Disclosures, or ASU 2023-07, which requires all public entities, including public entities with a single reportable segment, that financial assets measured at amortized cost be presented at the net amount expected to provide in interim and annual periods be collected. The measurement of expected credit losses is based on one or more measures historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. ASU 2016-13 also eliminates the concept of "segment profit or loss used by the chief operating decision maker to allocate resources and assess performance. Additionally, the standard requires disclosures of significant segment expenses and other segment items as - than temporary - impairment when evaluating available - for sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will well as incremental qualitative disclosures recognize an allowance for credit losses on available - for sale debt securities rather than an other - than temporary impairment that reduces the cost basis of the investment. The Company adopted annual requirements under ASU 2016-2023 -13-07 on January 1, 2024, and plans to adopt interim requirements under ASU 2023 -07 on January 1, using the modified 2025, on a retrospective basis approach, and no cumulative effect adjustment to accumulated deficit was needed as of the adoption date. Additionally, no prior period amounts were adjusted. The adoption of ASU 2016-2023 -13-07 only impacted the disclosures and did not have a material impact on the Company's consolidated financial statements. See Note 16, "Segment Information" for disclosures related to the adoption of ASU 2023-07.

Recently Issued Accounting Pronouncements On In November 2024, the FASB issued ASU 2024-03, Income Statement- Reporting Comprehensive Income- Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, or ASU 2024-03, which is intended to enhance transparency into the nature and function of expenses, primarily through additional disclosures on certain cost and expenses. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. The Company is in the process of evaluating the impact of this new guidance on its disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires companies to disclose, on an annual basis, specific categories in the effective tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. In addition, ASU 2023-09 requires companies to disclose additional information about income taxes paid. ASU 2023-09 will be effective for annual periods beginning January 1, 2025, and will be applied on a prospective basis with the option to apply the standard retrospectively. The Company is evaluating the disclosure impact of ASU 2023-09; however, the adoption of ASU 2023-09 will not have an a material impact on the Company's consolidated financial statements. F-13 The Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the consolidated financial statements.

2. Investments and Fair Value Measurement The Company classifies its marketable securities as available for sale and records its investments at fair value. Available- for- sale securities are carried at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income (loss). As of December 31, 2024 and 2023 and 2022, the contractual maturity of all investments held was less than one year. F-17 The tables below summarize the Company's cash, cash equivalents and short-term investments (in thousands):

	As of December 31, 2024	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value	Cash and cash equivalents
Cash \$	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —
Money market funds	2,632	—	2,632	—	5,867	—
U. S. government agency securities	5,867	—	5,867	—	8,863	—
As of December 31, 2023	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value	Cash and cash equivalents	
Cash \$	\$ 1,342	\$ —	\$ —	\$ 1,342	\$ —	
Money market funds	—	—	—	—	2,393	
U. S. government agency securities	1,896	—	1,896	—	3,660	
Commercial paper	2,362	—	2,362	—	5,721	
Total short-term investments	3,660	—	3,660	—	9,381	
Total cash, cash equivalents, and short-term investments	\$ 9,381	\$ —	\$ 9,381	\$ —	\$ 13,275	
As of December 31, 2022	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value	Cash, cash equivalents and restricted cash	
Cash \$	\$ 13,275	\$ —	\$ —	\$ 13,275	\$ —	
Money market funds	—	—	—	—	2,444	
U. S. government agency securities	2,444	—	2,444	—	4,235	
Commercial paper	4,235	—	4,235	—	20,275	
Total cash, cash equivalents and restricted cash	20,275	—	20,275	—	20,770	
Short-term investments: Commercial paper	—	—	—	—	20,770	
Total short-term investments	—	—	—	—	20,770	
Total cash, cash equivalents, restricted cash and short-term investments	\$ 20,770	\$ —	\$ 20,770	\$ —	\$ 20,770	

At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are the result of credit losses. Impairment is assessed at the individual security level. Factors considered in determining whether a loss resulted from a credit loss or other factors include the Company's intent and ability to hold the investment until the recovery of its amortized cost basis, the extent to which the fair value is less than the amortized cost basis, the length of time and extent to which fair value has been less than the cost basis, the financial condition of the issuer, any historical failure of the issuer to make scheduled interest or principal payments, any changes to the rating of the security by a rating agency, any adverse legal or regulatory events affecting the issuer or issuer's industry, any significant deterioration in economic conditions. There were no material realized or unrealized gains or losses on marketable securities for the years ended December 31, 2024 or 2023 or 2022. As such, we did not record a credit allowance for the year ended December 31, 2024 or 2023. F-18 The Company's financial instruments consist of Level I and II assets. Money market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments is readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level I of the fair value hierarchy. For Level II instruments, the Company estimates fair value by utilizing third-party pricing services in developing fair value measurements where fair value is based on valuation methodologies such as models using observable market inputs, including benchmark yields, reported trades, broker / dealer quotes, bids, offers and other reference data. Such Level II instruments typically include U. S. Treasury, U. S. government agency securities and commercial paper. As of December 31, 2023 2024 and December 31, 2022-2023, the Company held, in addition to Level II assets, a warrant liability related to the December 2022 Common Stock Warrants (see Note 10, "Warrants" below for further description). The fair value of the warrant liability was estimated using the Black Scholes Model which uses as inputs the following weighted average assumptions: dividend yield, expected term in years; equity volatility; and risk-free interest rate (see Note 10, "Warrants" below). The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period. The estimated

fair value of the warrant liability represents a Level III measurement. Changes to the estimated fair value of these liabilities are recorded in **interest income and other income, net change in fair value of warrant liability** in the consolidated statements of operations. The following tables set forth the fair value of the Company's financial assets by level within the fair value hierarchy (in thousands): **As of December 31, 2024 Fair Value Level I Level II Level III Assets Money market funds \$ 2, 632 \$ 2, 632 \$ — U. S. government agency securities 5, 867 — 5, 867 — Total assets measured at fair value \$ 8, 499 \$ 2, 632 \$ 5, 867 \$ — Liabilities Warrant liability \$ 1, 061 \$ — \$ — \$ 1, 061 Total liabilities measured at fair value \$ 1, 061 \$ — \$ — \$ 1, 061** As of December 31, 2023 Fair Value Level I Level II Level III Assets Money market funds \$ \$ \$ — U. S. government agency securities 5, 258 — 5, 258 — Commercial paper 2, 691 — 2, 691 — Total assets measured at fair value \$ 8, 039 \$ 7, 949 \$ — Liabilities Warrant liability \$ 1, 778 \$ — \$ — \$ 1, 778 Total liabilities measured at fair value \$ 1, 778 \$ — \$ — \$ 1, 778 **As of December 31, 2022 Fair Value Level I Level II Level III Assets Money market funds \$ — U. S. government agency securities 2, 444 — 2, 444 — Commercial paper 4, 730 — 4, 730 — Total assets measured at fair value \$ 7, 495 \$ 7, 174 \$ — Liabilities Warrant liability \$ 7, 098 \$ — \$ — \$ 7, 098 Total liabilities measured at fair value \$ 7, 098 \$ — \$ — \$ 7, 098** **F- 15** The following table sets forth a summary of the changes in the fair value of the Company's Level III warrant liability for the years ended December 31, **2024 and 2023 and 2022** (in thousands): Year Ended December 31, **2023-2024** Year Ended December 31, **2022-2023** Fair value — beginning of period \$ **1, 778** \$ **7, 098** — **Issuance Change in fair value** of December 2022 Common Stock Warrants **(717) (5, 320)** Fair value — **end 7, 098** **Change in fair value of period \$ 1, 061 \$ 1, 778** At December 31, 2024, the December 2022 Common Stock Warrants were (5, 320) — Fair value valued at approximately — **end of period \$ 1. 1 million** **778** using the Black-Scholes option pricing model as follows: exercise price of **\$ 7. 2. 07** per share, **098** stock price of **\$ 0. 5241** per share, expected life of 4 years, volatility of 100. 81 %, a risk-free rate of 4. 33 % and 0 % expected dividend yield. At December 31, 2023, the December 2022 Common Stock Warrants were valued at approximately **\$ 1. 8 million**, using the Black-Scholes option pricing model as follows: exercise price of **\$ 2. 07** per share, stock price of **\$ 0. 74** per share, expected life of 5 years, volatility of 94. 05 %, a risk-free rate of 3. 84 % and 0 % expected dividend yield. There were no transfers between Level I, Level II or Level III of the fair value hierarchy during the years ended December 31, **2024 or 2023 or 2022**.

3. Discontinued Operations On April 3, 2023, the Company, closed the transactions contemplated by the DSUVIA Agreement entered into on March 12, 2023, with Alora, pursuant to which Alora agreed to acquire certain assets and assume certain liabilities of the Company relating to its sufentanil sublingual tablet product referred to as DSUVIA or DZUVEO, or any other single-dose pharmaceutical product for use in medically supervised settings containing a sublingual tablet that includes sufentanil as the sole active ingredient, as a 30 mcg tablet or other dosage form or strength as reasonably necessary for lifecycle management, or the Product. The Product expressly excludes the pharmaceutical product referred to as Zalviso (sufentanil sublingual tablets, each 15 mcg), any other multi-dose administration system containing sufentanil sublingual tablets (whether as the sole active ingredient or in combination with other active ingredients), and any single-dose formulation of sufentanil for use outside of a medically supervised setting. **The With the closing of the transaction, the** Company is entitled to receive (a) up to \$ 116. 5 million in sales-based milestones, (b) quarterly payments in an amount equal to 15 % of net sales based on sales of the Product to all customers, other than sales to the United States DoD under the Marketing Agreement (as defined below), pursuant to which Alora will pay the Company 75 % of Product net sales to the DoD, and sales by or on behalf of Laboratoire Aguettant, or Aguettant, and (c) 20 % of any consideration, excluding royalty payments based on sales of the Product and subject to customary exclusions, received by Alora or its affiliates in connection with a grant to any third party of a license related to the Product, or by Alora or its affiliates or equity holders in connection with a sale or transfer to any third party of an ownership interest in any assets acquired by Alora under the DSUVIA Agreement. **F- 16** The DSUVIA Agreement contains customary representations, warranties, and covenants by each party. Alora agreed not to practice, license or otherwise exploit any of the intellectual property rights acquired by it under the DSUVIA Agreement to manufacture, develop or commercialize any product (other than the Product) that is or has been commercialized by the Company or its affiliate as of the date of the DSUVIA Agreement, or any product that is competitive with any such product. In addition, Alora will use commercially reasonable efforts to maintain regulatory approvals for and commercialize the Product in the United States. The DSUVIA Agreement also contains indemnification rights for each of the Company and Alora for breaches of representations, warranties, and covenants, as well as certain other matters, subject to certain specified limitations. **F- 20** The **Closing closing of the DSUVIA Agreement** included the execution of the Amended DZUVEO Agreement (as defined below) and the Amended and Restated Supply Agreement (as defined below) between the Company and Aguettant, as well as certain ancillary agreements between the Company and Alora. Such ancillary agreements include (a) an intellectual property agreement, pursuant to which Alora granted fully-paid, royalty-free and perpetual licenses to the Company under certain specified intellectual property rights acquired by Alora under the DSUVIA Agreement for, among other things, the development, manufacture, commercialization and exploitation of certain products, including Zalviso, (b) a transition services agreement, pursuant to which, during the period specified therein, the Company will be paid to provide certain services (including, manufacturing technology transfer, supply chain, regulatory, and medical affairs services) to Alora, and distribute, on behalf of Alora, certain inventory of the Product transferred to Alora under the DSUVIA Agreement, and (c) an ongoing marketing agreement, or the Marketing Agreement, pursuant to which the Company will have the exclusive right to market and offer the Product for sale to the DoD and Alora will pay to the Company 75 % of net sales of the Product sold to the DoD, subject to adjustment in certain circumstances. Amendments to Certain Agreements Between the Company and Aguettant The Company and Aguettant are parties to (a) the License and Commercialization Agreement, dated July 14, 2021, pursuant to which Aguettant obtained the exclusive right to develop and commercialize DZUVEO in certain European countries for the management of acute moderate to severe pain in adults in medically monitored settings, or the DZUVEO Agreement, and (b) the supply agreement, dated December 6, 2021, with respect to the manufacture and supply of DZUVEO in form of bulk product by the Company to Aguettant, or the Supply Agreement. Pursuant to the DSUVIA Agreement, the Company and Aguettant entered into an amendment to the DZUVEO Agreement, or the Amended DZUVEO Agreement, and an amendment and restatement to the Supply Agreement, or the Amended and Restated Supply Agreement. Pursuant to the Amended DZUVEO Agreement, (a) Aguettant's obligations to make sales-based milestone payments and to achieve certain levels of minimum sales terminated, (b) the Company agreed to manufacture and supply DZUVEO in the form of bulk products (i. e., products that are pre-packaged in labeled pouches and packed in bright stock cartons for shipment) to Aguettant or its affiliates or sublicensees, and Aguettant will be responsible for manufacturing finished products from bulk products, before Aguettant establishes a semi-automated packaging line for the Product, and (c) after Aguettant has established such semi-automated packaging line, the Company will cause DZUVEO to be manufactured and supplied in the form of bulk tablets (i. e., products in tablet forms supplied in bulk (not packaged) quantities) to Aguettant or its affiliates or sublicensees, and Aguettant will be responsible for manufacturing finished products from bulk tablets. The Amended and Restated Supply Agreement will govern the manufacture and supply of DZUVEO in the form of bulk products or bulk tablets, and contain customary terms, including those with respect to manufacturing requirements, forecast, delivery, and post-delivery inspection. Pursuant to the DSUVIA Agreement, the Company assigned the Amended DZUVEO Agreement and the Amended and Restated Supply Agreement to Alora. In addition, the Company and Aguettant amended the License and Commercialization Agreement, dated July 14, 2021, pursuant to which the Company obtained exclusive rights to develop and commercialize certain epinephrine pre-filled syringe and certain phenylephrine pre-filled syringe in the United States, or the PFS Agreement (see Note 5, "In-License Agreement" below). **F- 17** The Company's DSUVIA business met the definition of a discontinued operation as of March 31, 2023. Accordingly, the **assets and liabilities** associated with these operations have been classified as **assets and liabilities of discontinued operations** in the consolidated balance sheets at December 31, **2024 and 2023 and**. **There were no assets of discontinued operations at December 31, 2022-2024 or 2023**. The operations and cash flows of the DSUVIA business are presented as discontinued for all periods presented. **F- 21** The following table presents the results of the discontinued operations (in thousands): Year ended December 31, Total revenues \$ — \$ **1, 771** Cost of goods sold **1, 508** Selling, general and administrative expense **9, 744** Impairment of net assets held for sale **6, 853** Impairment of fixed assets **1, 065** Gain on termination of lease liabilities **(1, 098)** Research and development expenses **1, 852** Loss from discontinued operations **(8, 110) (11, 333)** Interest expense — Net loss from discontinued operations **\$ (8, 110) \$(11, 370)** The following table summarizes the carrying amounts of major classes of **assets and liabilities of discontinued operations** for each of the periods presented (in thousands). December 31, **2023-2024** December 31, **2022-2023** **Accrued liabilities** Accounts receivable, net \$ — \$ **Inventories** 1, 178 **Prepaid expenses and other current assets** — Total current **assets** **Liabilities** of discontinued operations **Net liabilities** — **1, 931** Property, plant and equipment, net — **10, 261** Operating lease right-of-use assets — **3, 499** Other assets — Total non-current **assets of discontinued operations** — **13, 936** Total **assets of discontinued operations** \$ — **(723)** \$ **15, 867** Accounts payable \$ **1, 720** Operating lease liabilities, current portion — **1, 601** Note payable, current portion — Deferred revenue, current portion — Total current **liabilities of discontinued operations** **4, 620** Operating lease liabilities, net of current portion — **2, 959** Deferred revenue, net of current portion — **1, 036** Total non-current **liabilities of discontinued operations** — **3, 995** Total **liabilities of discontinued operations** **8, 615** Net **assets (liabilities) of discontinued operations** \$ **(731) \$ 7, 252** **F- 22** The following table presents the significant non-cash items and purchases of property and equipment for the discontinued operations that are included in the consolidated statements of cash flows (in thousands): Year Ended December 31, Cash flows from operating activities: Depreciation and amortization \$ — \$ **1, 465** Stock-based compensation — Impairment of net assets held for sale — **6, 853** Impairment of fixed assets **1, 065** Gain on termination of lease liabilities **(1, 098)** Gain on extinguishment of debt **(400)** **Purchases of property and equipment** — **Purchases of property and equipment** **(100) (364)** The following table represents the loss on sale of discontinued operations for the year ended December 31, 2023: Year Ended December 31, 2023 Cash proceeds \$ 2, 723 Less: net assets transferred (8, 723) Less: disposal costs (853) Loss on sale of discontinued operations, before income taxes (6, 853) Income tax expense — Loss on sale of discontinued operations \$ (6, 853) **F- 18** In October 2024, Alora notified the Company that they are discontinuing their DSUVIA sales efforts on behalf of non-DoD customers. At this time, the Company is uncertain as to the impact of this decision on sales of DSUVIA to the DoD, but it expects to be able to continue to market DSUVIA to the DoD until all inventory is sold or Alora makes the

**decision to no longer provide the supply of DSUVIA to the DoD.** 4. Asset Acquisition On In January 7, 2022, the Company **acquired** closed its acquisition of Lowell **pursuant** and acquired the product nafamostat, and the associated patents and historical know-how. The acquisition was valued at approximately \$32.5 million plus cash acquired of \$3.5 million and certain other adjustments. All options to purchase capital stock and all shares of Lowell capital stock issued and outstanding immediately before the effective time of the merger **Merger** were cancelled **Agreement**, in exchange for the right to receive (i) 450,477 shares of the Company's common stock issued at a five day daily volume weighted average price of \$11.46 per share as of January 7, 2022, or the Acquisition Date, valued at \$5.2 million on closing, (ii) cash in the amount of \$3.5 million, (iii) 69,808 shares of the Company's common stock to be held back to satisfy any potential indemnification and other obligations of Lowell and its securityholders valued at \$0.8 million, (iv) \$0.5 million cash and stock paid for sellers' transaction **which includes** costs and (v) up to **approximately** \$26.0 million of contingent consideration payable in cash or stock at the Company's option, upon the achievement of regulatory and sales-based milestones. **In connection with** The shares issued in the merger **Merger Agreement** were issued in a private placement pursuant to the exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, or the Securities Act **Company acquired Niyad and LTX-608**, including Rule 506 of Regulation D promulgated under the Securities Act, or Regulation D, without general solicitation as a transaction not involving any public offering. The merger has been accounted for as an asset acquisition of a single IPR & D asset that has an alternative future use. The initial measurement **carrying value** of the IPR & D asset **is** purchased of \$8.8 million **at December 31** was based on the purchase cost of \$12.4 million including (i) \$6.0 million common stock fair value on the closing date (issued and held back on the acquisition date), **2024** (ii) \$0.5 million seller's costs paid by the Company, (iii) \$3.5 million cash and **2023** (iv) approximately \$2.5 million of transaction costs less purchase price allocated to cash acquired of \$3.5 million. Due to the nature of regulatory and sales-based milestones, the contingent **Contingent** consideration of up to \$26.0 million **associated with the Merger Agreement, payable in cash or stock at the Company's option**, was not included in the initial cost of the assets purchased as they **the are contingent consideration is** contingent upon events that are outside the Company's control, such as regulatory approvals and issuance of patents, **and which** are not considered probable until notification is received. However, upon achievement or anticipated achievement of each milestone, the Company shall recognize the related, appropriate payment as an additional cost of the acquired IPR & D asset. As of December 31, **2023-2024**, none of the contingent events have occurred. **F-23** The following table summarizes the total consideration for the acquisition and the value of the IPR & D asset acquired (in thousands):

Consideration Cash	\$3,536
Issuance of common stock to Lowell security holders in connection with asset acquisition	5,161
Issuance of common stock to settle Lowell's transaction costs in connection with asset acquisition	Liability for issuance of 69,808 hold back shares to Lowell securityholders
(1) Transaction costs	2,521
Total consideration	\$12,368
IPR & D Asset Acquired	Purchase price
\$12,368	Cash acquired (3,549)
Total IPR & D asset acquired	(2) \$8,819
(1) Recorded as	Other long-term liabilities in the consolidated balance sheets at December 31, 2022.
Shares were issued in the year ended	December 31, 2023 and, accordingly, the related liability was extinguished.
(2) Recorded as	In-process research and development asset in the consolidated balance sheets. The IPR & D asset has initially been accounted for as an indefinite-lived asset, and as a long-lived asset, it is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If the IPR & D asset achieves regulatory approval and the asset life is determined to be finite, the asset's useful life will be estimated, and the asset will be amortized over its remaining useful life. No impairment losses were recorded on the IPR & D asset during the years ended December 31, 2023 or 2022.

5. In-License Agreement On July 14, 2021, the Company entered into a License and Commercialization Agreement, or the PFS Agreement, with Aguettant pursuant to which the Company obtained the exclusive right to develop and, subject to FDA approval, commercialize in the United States (i) an ephedrine pre-filled syringe for injection, and (ii) a phenylephrine pre-filled syringe for injection. Aguettant will supply the Company with the products for use in commercialization if they are approved in the United States. The PFS Agreement has an initial term of ten (10) marketing years, with the first marketing year ending on December 31 of the calendar year after the first launch of a product (or December 31 of the same calendar year if the first launch of a product occurs between January 1 and April 30 of a calendar year). The term will automatically renew for successive five marketing year periods unless a party notifies the other party of its intention not to renew at least six (6) months prior to the expiration of the then-current term. **F-24** The Company will purchase each product from Aguettant at an agreed price, or the PFS Purchase Price, subject to adjustment. The Company will also make revenue share payments that, combined with the PFS Purchase Price, will range from 40% to 45% of net sales in the United States. The Company and Aguettant will agree on minimum sales obligations twelve (12) months prior to the launch of each product. The Company has the right to grant sublicenses to its affiliates or, with the prior approval of Aguettant, third parties, subject to certain limitations. In connection with the Company's and Aguettant's agreement to enter into the Amended DZUVEO Agreement and the Amended and Restated Supply Agreement, the parties entered into an amendment to the PFS Agreement, or the Amended PFS Agreement, pursuant to which, effective April 3, 2023, (a) Aguettant paid the Company a complementary payment in the amount of EUR 1,500,000, and (b) the Company's obligation to make a certain specified sales-milestone payment terminated such that the maximum amount in sales-based milestone payments that Aguettant is entitled to receive has been reduced from \$24.0 million to \$21.0 million. **F-19** As of December 31, **2023-2024**, there have been no payments by the Company to Aguettant under the PFS Agreement. 6. Long-Term Debt **Loan Agreement with Oxford** On May 30, 2019, the Company entered into the Loan Agreement with Oxford Finance LLC, or Oxford, as the Lender. Under the Loan Agreement, the Lender made a term loan to the Company in an aggregate principal amount of \$25.0 million, or the Loan, which was funded on May 30, 2019. As of December 31, 2022, the accrued balance due under the Loan Agreement with Oxford was \$5.4 million. Interest expense related to the Loan Agreement was \$0.1 million for the year ended December 31, 2023, \$0.1 million of which represented amortization of the debt discount. Interest expense related to the Loan Agreement was \$1.1 million, of which \$0.4 million represented amortization of the debt discount, and \$2.2 million for the year ended December 31, 2022 and the effective interest rate was approximately 13.6%. In connection with the closing of the divestment of DSUVIA to Alora, on April 3, 2023, the Company paid Oxford the remaining amount due of approximately \$3.4 million including accrued interest and fees under the Loan, and the Loan Agreement was terminated with no further obligations by either party. **Interest expense related to the Loan Agreement was \$0.1 million, which represented amortization of the debt discount, for the year ended December 31, 2023.** In connection with the Loan Agreement, on May 30, 2019, the Company issued warrants to the Lender and its affiliates, which are exercisable for an aggregate of 8,833 shares of the Company's common stock with a per share exercise price of \$56.60, or the **Loan Agreement Warrants** (The Warrants have been classified within stockholders' equity and accounted for as a discount to the loan by allocating the gross proceeds on a relative fair value basis. For further discussion, see Note 10, "Warrants"). 7. Liability-Related to Sale of Future **Payments In January 2024 Royalties** On September 18, 2015, the Company and XOMA entered into the **Purchase Agreement** Zalviso Royalty Monetization with PDL for which it received gross proceeds of the sale by the Company to XOMA, in exchange for \$65.8 million. Under the Zalviso Royalty Monetization, PDL was of the Company's right, title and interest in and to receive 75 certain amounts payable to the Company, or collectively, **the Purchased Receivables, pursuant to the DSUVIA Agreement in respect of net sales of the Product, excluding sales of the Product by Aguettant. The Purchased Receivables include:** (i) 100% of certain payments based on net sales of the European royalties under Product and potential sales-based milestone payments of up to \$116.5 million in respect of net sales of the Amended Product, in each case made on and after January 1, 2024 and excluding sales of the Product by Aguettant, and of certain associated **License license and acquisition payments relating to the Product, until XOMA has received a certain minimum amount \$20.0 million** of payments in respect of the foregoing, or the XOMA Threshold, or the Stepdown Date; and (ii) following the Stepdown Date, (A) 100% of **royalty** payments based on net sales of the Product other than net sales to the United States Department of Defense, or DoD and (B) 50% of each of the following: (a) payments based on net sales of the Product to the DoD, (b) potential sales-based milestone payments in respect of net sales of the Product, and (c) certain associated license and acquisition payments relating to the Product. The Company has retained its right, title and interest in and to, following the Stepdown Date, 50% of each of the following: (a) payments based on net sales of the Product to the DoD, (b) potential sales-based milestone payments in respect of net sales of the Product, and (c) of certain associated license and acquisition payments relating to the Product. **The Purchase Agreement contains customary representations, warranties and agreements Agreement with Grünenthal contains customary representations, as well as 80% warranties and agreements by the Company and XOMA, indemnification obligations of the parties and the other first obligations of the parties. The allocation of the consideration four- for the Purchase Agreement resulted in proceeds of \$1.4 million reduced by \$0.2 million of transaction costs being allocated to the sale of all future interest in payments related to commercial milestones worth sales of DSUVIA representing its fair value. As a result of the Company's loss of control, no further continuing involvement in, or rights to future payments related to commercial sales of DSUVIA, the Company recognized other income of \$35.1.2 million in January 2024. F-20** The Company evaluated the terms of the Purchase Agreement and concluded that the features of the Purchased Receivables are similar to those of a debt instrument. **Accordingly, the Company recorded the allocated proceeds of approximately \$6.6 million reduced by approximately (or 80% of) \$44.0.5 million) of transaction costs up as a liability. The Company accounts for the value of the debt at amortized cost. The amounts received by the Company will be accreted to a capped the total estimated amount of \$195.0 million over the life of payments necessary to extinguish the arrangement Company's obligation under the Purchase Agreement, which will be recognized as interest expense. F-25** The carrying value of the debt will decrease for payments made to XOMA. The Company periodically assessed assesses the expected royalty payments for services performed to support sales of DSUVIA to the DoD by Alora under the **Marketing Agreement** and milestone payments **under the DSUVIA Agreement** using a combination of historical results, internal projections, and forecasts from external sources. To the extent such payments were are greater or less than the Company's initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjusted-- adjust the amortization of the liability and the effective interest rate. **Grünenthal notified Due to the Company that it was terminating significant judgments and factors related to the Amended License estimates of future payments under the Purchase Agreement**

effective November 13, 2020 there are significant uncertainties surrounding the amount and timing of future payments. As the payments are remitted On August 31, 2020, PDL sold its royalty interest for Zalviso to XOMA SWK Funding, LLC, or SWK, under the liability will be effectively repaid over Zalviso Royalty Monetization. The terms of the Grünenthal life of the Agreements- agreement were extended. In order to May 12, 2021 to enable Grünenthal to sell down its Zalviso inventory. The rights to market and sell Zalviso in Europe reverted back to the Company on May 12, 2021. On May 31, 2022, the Company entered into a Termination Agreement with SWK to fully terminate— determine the Zalviso Royalty Monetization for which the Company paid cash consideration of \$ 0. 1 million, and neither PDL nor SWK retains any further interest in the Zalviso Royalty Monetization. Accordingly, effective May 31, 2022, the Zalviso Royalty Monetization is no longer reflected on the Company’s consolidated financial statements or other— the records as a sale of assets to PDL or SWK and all security interests and other liens of every type held by the parties to the Zalviso Royalty Monetization amortization have been terminated and automatically released without further action by any party. The \$ 84. 1 million gain on extinguishment of the liability related to the sale of future royalties payments, the Company is recognized in required to estimate the total amount of future payments to XOMA over the life of the Purchase Agreement. In October 2024, Alora notified the Company that the they consolidated statements of operations are discontinuing their DSUVIA sales efforts to non- DoD customers. At this time, the Company is uncertain as to other— the income impact of this decision on sales of DSUVIA to the DoD. The effective— As a result, the Company estimates that future payments under the Purchase Agreement will be less than the proceeds from the sale of such future payments. Accordingly, the Company will not recognize any related non- cash interest income rate for expense. When the expected payments under the sale of future payments are lower than the gross proceeds of \$ 6. 6 million received, the Company defers recognition of any probable contingent gain until the Company has met its obligations under the liability related to the sale of future payments. For the year ended December 31, 2022-2024 , the estimated effective interest rate under the agreement was approximately 0 3-2-% . The Company did not recognize any non- cash revenue and recognized non- cash interest expense of approximately \$ 0. 4 million for the year ended December 31, 2024. The interest and amortization of issuance costs are reflected as non- cash interest expense for the sale of future payments in the consolidated statements of operations. The following table shows the activity within the liability account during the year ended December 31, 2022-2024 , and the period from inception to December 31, 2024 (in thousands): Year ended December 31, 2022-2024 Period from inception to December 31, 2022-2024 Liability related to sale of future royalties payments — beginning balance \$ — 85; 288-\$ — Proceeds from sale of future royalties payments, net of issuance costs 6, 133 6, 133 Payments to XOMA — 61, 184 Non- cash royalty revenue — (1, 083) Non- cash interest (income) expense recognized (1, 136) 24, 051 Consideration paid for termination of Royalty Monetization (100) (100) Gain on extinguishment of liability related to sale of future royalties (84, 052) (84, 052) Liability related to sale of future royalties payments as of December 31, 2022-2024 \$ — 6, 527 \$ — 6, 527

**F- 21** 8. Commitments and Contingencies Litigation On June 8, 2021, a securities class action complaint was filed in the U. S. District Court for the Northern District of California against the Company and two of its officers. The plaintiff is a purported stockholder of the Company. The complaint alleged that defendants violated Sections 10 (b) and 20 (a) of the Exchange Act and SEC Rule 10b- 5 by making false and misleading statements and omissions of material fact about the Company’s disclosure controls and procedures with respect to its marketing of DSUVIA. The complaint sought unspecified damages, interest, attorneys’ fees, and other costs. On December 16, 2021, the Court appointed co- lead plaintiffs. Plaintiffs’ amended complaint was filed on March 7, 2022. The amended complaint named the Company and three of its officers and continued to allege that defendants violated Sections 10 (b) and 20 (a) of the Exchange Act and SEC Rule 10b- 5 by making false and misleading statements and omissions of material fact about the Company’s disclosure controls and procedures with respect to its marketing of DSUVIA. The amended complaint also asserted a violation of Section 20A of the Exchange Act against the individual defendants for alleged insider trading. The amended complaint sought unspecified damages, interest, attorneys’ fees, and other costs. The On September 1, 2022, the Court granted held oral hearings on the three Company’s motion motions to dismiss the amended plaintiffs’ complaint ; the first on September 28, 2022, the second on November 28, 2022, and the third, with prejudice that on May 7, 2024. Judgment was filed entered for defendants on July 21 plaintiffs’ claims on May 7, 2022-2024 . On June September 28, 2022, the Court issued a formal written opinion, or the First Opinion, dismissing all of the plaintiff’s claims against the Company and the named defendants with leave for plaintiffs to amend their complaint. On November 28, 2022 the plaintiffs filed their second amended complaint. On July 7, 2023, the Court issued a formal written opinion, or the Second Opinion, dismissing all of the plaintiff’s claims against the Company and the named defendants with leave for plaintiffs to amend their complaint in part and without leave to amend in part. On September 5, 2023-2024 , the plaintiffs filed a notice of appeal in third amended complaint. Defendants’ motion to dismiss the third amended complaint is fully briefed and United States Court of Appeals for the Ninth Circuit. Briefing on the appeal was complete on January 21, 2025. The Court has not yet scheduled a hearing on the appeal is scheduled for April 4, 2024. F- 26 On July 6, 2021, a purported shareholder derivative complaint was filed in the U. S. District Court for the Northern District of California. The complaint names ten of the Company’s officers and directors and asserts state and federal claims based on the same alleged misstatements as the securities class action complaint. On September 30, 2021, October 26, 2021, and November 17, 2021, three additional purported shareholder derivative complaints were filed in the U. S. District Court for the Northern District of California. The complaints name nine of the Company’s officers and directors and also assert state and federal claims based on the same alleged misstatements as the securities class action complaint. All four complaints seek unspecified damages, attorneys’ fees, and other costs. On December 6, 2021, the Court entered an order consolidating all four actions and staying the consolidated action pending the outcome of any motion to dismiss the securities class action. On February 16, 2024, another purported shareholder derivative complaint was filed in the Court of Chancery of the State of Delaware. The complaint names nine of the Company’s officers and directors and asserts asserting the same claims as those in the previously filed derivative actions. The Company case has not yet been served stayed pending the outcome of any motion to dismiss the securities class action. Please see “ Part I, Item 1A. Risk Factors — Risks of a General Nature — Litigation may substantially increase our costs and harm our business. ” The Company believes that these lawsuits are without merit and intends to vigorously defend against them. Given the uncertainty of litigation, the preliminary stage of the cases, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions. It is reasonably possible that this estimate may change in the near term. An adverse outcome regarding these matters could materially adversely affect the Company’s financial condition, results of operations, and cash flows. Termination Agreement and Mutual Release Between the Company and Catalent On March 12, 2023, the Company and Catalent Pharma Solutions, LCC, or Catalent, entered into a termination agreement and mutual release, or the Termination Agreement, to terminate the Site Readiness Agreement with an effective date of August 15, 2019 and as amended on September 24, 2020, the SRA Agreement, and the commercial supply agreement with an effective date of March 31, 2021, the CSA Agreement. Pursuant to the Termination Agreement, as of the date on which the Company has removed and transported certain equipment from Catalent’s site, the SRA Agreement and the CSA Agreement will terminate except with respect to certain specified provisions of such agreements. F- 22 9. Stockholders’ Equity The Company is authorized to issue two classes of stock to be designated, respectively, as “ Common Stock ” and “ Preferred Stock. ” The total number of shares which the Company is authorized to issue is 210, 000, 000 shares, and includes 200, 000, 000 shares of Common Stock, each having a par value of \$ 0. 001, and 10, 000, 000 shares of Preferred Stock, each having a par value of \$ 0. 001. Each outstanding share of Common Stock entitles the holder thereof to one vote on each matter properly submitted to the stockholders of the Company for their vote. The rights, preferences and privileges of the holders of Common Stock are subject to and may be adversely affected by the rights of the holders of shares of any series of Preferred Stock that we may designate in the future. As of December 31, 2023-2024 , there are no shares of Preferred Stock issued and outstanding. F- 27 Subject to the preferences that may be applicable to any outstanding shares of Preferred Stock, the holders of Common Stock are entitled to receive ratably such dividends, if any, as may be declared by the Company’s board of directors. No dividends have been declared to date. January 2024 Private Placement On August 3 January 17, 2022 2024 . These warrants expire in May 2029. January 2024 Private Placement On January 17, 2024 , the Company entered into a private placement with certain institutional investors, or the January 2024 Purchasers, for aggregate gross proceeds of \$ 6. 0 million upfront, an additional \$ 10. 0 million committed upon the announcement of positive clinical trial results for the Company’s NEPHRO CRRT study of Niyad, and an additional \$ 2. 0 million if Talphera stock trades above a specified price following the NEPHRO CRRT registration trial announcement, before deducting offering expenses payable by the Company us (see Note 16. “ Subsequent Events ” below or for additional information) the January 2024 Private Placement. The terms of the January 2024 Private Placement include: (i) the Company entered into a securities purchase agreement with LPC, or the Purchaser, pursuant to which the Company issued, in a private placement transaction, 3, 000 shares of Series A Redeemable Convertible Preferred Stock, par value \$ 0. 001 per share, with \$ 100 per share stated value, together with a warrant to purchase up to an aggregate of 81, 150 shares of common stock at an exercise price of \$ 4. 07 per share, for \$ 0. 3 million (see Note 10, “ Warrants ”). The transaction price of \$ 0. 3 million was allocated to the Series A Redeemable Convertible Preferred Stock and warrants based on their relative fair values. The Series A Redeemable Convertible Preferred Stock was initially recorded at \$ 0. 1 million separately from stockholders’ equity in the Company’s consolidated balance sheets due to the shares being redeemable based on contingent events outside of the Company’s control. The Series A Redeemable Convertible Preferred Stock was convertible, at the option of the holders, into shares of common stock at a conversion price of approximately \$ 3- 70 per share, subject to adjustment and beneficial ownership limitations set forth in the Certificate of Designation. The Company had the option to redeem the Series A Redeemable Convertible Preferred Stock for cash at 105% of the Stated Value on the date of and for 15 days following the Reverse Stock Split, subject to the Purchaser’s right to convert the shares prior to such redemption. The Purchaser had the right to require the Company to redeem the shares of Series A Redeemable Convertible Preferred Stock for cash at 110% of the Stated Value of such shares commencing after the Company’s right to redeem expired. The Series A Redeemable Convertible Preferred Stock was required to be redeemed for cash at 110% of the Stated Value upon a delisting event. As a result, the Series A Redeemable Convertible Preferred Stock was recorded separately from stockholders’ equity because it was redeemable upon

the occurrence of redemption events that were considered not solely within the Company's control. As such, during the year ended December 31, 2022, the Company recognized approximately \$ 0.2 million in deemed dividends related to the Series A Redeemable Convertible Preferred Stock in the consolidated statements of operations and the consolidated statements of changes in redeemable convertible preferred stock and stockholders' equity. The holders of the Series A Redeemable Convertible Preferred Stock were entitled to certain registration rights, rights for approval of increases in the authorized shares of such series, and to dividends paid on common stock on an as-if converted basis. The Series A Redeemable Convertible Preferred stock had no voting rights, other than the right to (i) vote exclusively on the Reverse Stock Split and any proposal to adjourn any meeting of stockholders called for the purpose of voting on the Reverse Stock Split and (ii) to 1,000,000 votes per each share of Series A Redeemable Convertible Preferred Stock, to vote together with the common stock, as a single class; to the extent cast on the Reverse Stock Split in the same proportion as shares of common stock. In addition, in the event of any liquidation, dissolution, or winding-up of the Company, the holders of the Series A Redeemable Convertible Preferred Stock were entitled to receive 110% the preferred stock's Stated Value plus any declared but unpaid dividends before any payment was made to holders of common stock. On October 11, 2022, the Company and LPC entered into the Securities Redemption Agreement whereby on October 12, 2022, the Company redeemed for cash at a price equal to 105% of the Stated Value per share all 3,000 outstanding shares of Series A Redeemable Convertible Preferred Stock for \$ 0.3 million. As a result, all shares of such series were retired and are no longer outstanding. On October 25, 2022, the Company filed a certificate of elimination to its amended and restated certificate of incorporation which (i) eliminated the previous designation of 3,000 shares of Series A Redeemable Convertible Preferred Stock from the Company's amended and restated certificate of incorporation and (ii) caused such shares of Series A Redeemable Convertible Preferred Stock to resume their status as authorized but unissued and non-designated shares of preferred stock. F-28 July 2023 Private Placement On July 17, 2023, the Company entered into a securities purchase agreement, or the Purchase Agreement, with several institutional investors, or the July 2023 Purchasers, relating to the issuance and sale to the July 2023 Purchasers in a private placement, or the July 2023 Private Placement, of 5,340,591 shares of common Common stock Stock - par value \$ 0.001 per share -, pre-funded warrants to purchase up to an aggregate of 2,012,356 shares of common Common stock Stock at an exercise price of \$ 0.001 per share, or the July 2023 Pre-Funded Warrants; July 2023 Series A common stock warrants to purchase up to an aggregate of 7,352,947 shares of common Common stock Stock at an exercise price of \$ 1.11 per share; and July 2023 Series B common stock warrants to purchase up to an aggregate of 7,352,947 shares of common Common stock Stock at an exercise price of \$ 1.11 per share. In connection with See Note 10, "Warrants" for additional information regarding the July-January 2023-2024 Private Placement Pre-Funded Warrants, and a portion of these July 2023 Series A common stock warrants and July 2023 Series B common stock warrants were restated and amended to reduce the exercise price thereunder from \$ 1. The private placement closed on July 20-11 to \$ 0.77 per share (see Note 10, 2023 "Warrants"). The combined offering price of the July 2023 Private Placement was \$ 1.36 per share of common Common stock Stock and accompanying July 2023 Series A common stock warrant and July 2023 Series B common stock warrant, or in the case of July 2023 Pre-Funded Warrants, \$ 1.359 per pre-funded warrant and accompanying July 2023 Series A common stock warrant and July 2023 Series B common stock warrant (which is the purchase price per share of common stock and accompanying warrants less \$ 0.001). The aggregate gross proceeds to the Company from the July 2023 private Private placement Placement were approximately \$ 10.0 million, before deducting placement agent fees and other expenses payable by the Company of approximately \$ 1.1 million, and excluding the proceeds, if any, from the exercise of the July 2023 Pre-Funded Warrants and July 2023 Series A and July 2023 Series B common stock warrants issued in the private placement. The potential gross proceeds from the July 2023 Private Placement Series A common stock warrants and July 2023 Series B common stock warrants, if fully exercised for cash, is approximately \$ 16.3 million. In May 2023, the Company engaged H. C. Wainwright & Co., LLC to act as placement agent in the private placement. As compensation, the Company paid the placement agent a cash fee equal to 5.25% of the aggregate gross proceeds generated from the private placement and reimbursed certain expenses of the placement agent in connection with the private placement totaling \$ 0.1 million. The placement agent will be entitled to an additional one-time payment of \$ 200,000 upon the exercise of the July 2023 Series A and Series B common stock warrants resulting in cumulative aggregate gross proceeds to the Company of at least \$ 9.5 million in cash. As of December 31, 2023, none of the July 2023 Series A or Series B common stock warrants were exercised. In addition, the Company issued to the placement agent fully vested July 2023 Series A common stock warrants, or placement agent July 2023 Series A common stock warrants, to purchase 183,824 shares of common stock and fully vested July 2023 Series B common stock warrants, or placement agent July 2023 Series B common stock warrants, to purchase 183,823 shares of common stock. See Note 10, "Warrants" for additional information regarding the July 2023 Series A and B warrants and the placement agent July 2023 Series A and Series B common stock warrants. December 2022 Registered Direct Offering On December 29, 2022, the Company completed the December 2022 Financing in which it issued (i) 748,744 shares of its common stock, par value \$ 0.001 per share, (ii) the December 2022 Pre-Funded Warrants to purchase 2,632,898 shares of common stock, and (iii) the December 2022 Common Stock Warrants, which accompany the common stock and December 2022 Pre-Funded Warrants, to purchase an aggregate of 4,227,052 shares of common stock (see Note 10, "Warrants"). The shares of common stock and accompanying December 2022 Warrants were sold at a combined offering price of \$ 2.22625 per share and accompanying common warrant, and the December 2022 Pre-Funded Warrants and accompanying December 2022 Common Stock Warrants were sold at a combined offering price of \$ 2.22615 per December 2022 Pre-Funded Warrant and accompanying December 2022 Common Stock Warrant. The December 2022 Financing resulted in aggregate gross proceeds of \$ 7.5 million, before \$ 1.7 million of transaction costs, \$ 0.8 million of which were non-cash issuance costs, excluding the proceeds, if any, from the exercise of the December 2022 Pre-Funded Warrants and the December 2022 Common Stock Warrants. The common stock was allocated \$ 0.1 million of the gross proceeds received based on its relative fair value to the other instruments issued (see Note 10, "Warrants"). F-29 January 2024 Private Placement On January 17, 2024, the Company entered into a private placement with certain institutional investors for aggregate gross proceeds of \$ 6.0 million upfront, an additional \$ 10.0 million committed upon the announcement of positive clinical trial results for the Company's NEPHRO study of Niyad, and an additional \$ 2.0 million if Talphera stock trades above a specified price following the NEPHRO registration trial announcement, before deducting offering expenses payable by us (see Note 16, "Subsequent Events" below for additional information). On June 21, 2016, the Company entered into a Controlled Equity Offering SM Sales Agreement, or the ATM Agreement, with Cantor Fitzgerald & Co., or Cantor, as agent, pursuant to which the Company may offer and sell, from time to time through Cantor, shares of the Company's common stock, or the Common Stock having an aggregate offering price of up to \$ 40.0 million, or the Shares. On May 9, 2019, the Company increased the aggregate offering price of shares of the Company's common stock which may be offered and sold under the ATM Agreement by \$ 40.0 million, for a total of \$ 80.0 million, or the Shares. The offering of Shares pursuant to the ATM Agreement will terminate upon the earlier of (a) the sale of all of the Shares subject to the ATM Agreement or (b) the termination of the ATM Agreement by Cantor or the Company, as permitted therein. The Company will pay Cantor a commission rate in the low single digits on the aggregate gross proceeds from each sale of Shares and has agreed to provide Cantor with customary indemnification and contribution rights. The Company issued and sold 124,241,330 shares of common stock pursuant to the ATM Agreement and received net proceeds of \$ 0.5 million, after deducting fees and expenses, during the year ended December 31, 2022. No shares were sold under the ATM Agreement in the year ended December 31, 2023. As of December 31, 2023, the Company had the ability to offer and sell shares of the Company's common stock having an aggregate offering price of up to \$ 35.6 million under the ATM Agreement. The Company's ability to sell shares under the ATM Agreement will be limited until the Company is no longer subject to the SEC's "baby shelf" limitations. Stock Plans In January 2011, the Board of Directors adopted, and the Company's stockholders approved, the 2011 Equity Incentive Plan, or 2011 EIP. The initial aggregate number of shares of the Company's common stock that were issuable pursuant to stock awards under the 2011 EIP was approximately 93,750 shares. The number of shares of common Common stock Stock reserved for issuance under the 2011 EIP automatically increased on January 1 of each year, starting on January 1, 2012 and continuing through January 1, 2020, by 4% of the total number of shares of the Company's common stock outstanding on December 31 of the preceding calendar year, or such lesser number of shares of common Common stock Stock as determined by the Board of Directors. As of June 16, 2020, no more awards may be granted under the 2011 Equity Incentive Plan, or the 2011 EIP, although all outstanding stock options and other stock awards previously granted under the 2011 EIP will continue to remain subject to the terms of the 2011 EIP. F-30 Amended and Restated 2020 Equity Incentive Plan On June 16, 2020, at the 2020 Annual Meeting of Stockholders of the Company, the Company's stockholders, upon the recommendation of the Company's Board of Directors, approved the Company's 2020 Equity Incentive Plan, or the 2020 EIP. The initial aggregate number of shares of the Company's common stock issuable pursuant to stock awards under the 2020 EIP was 275,000 shares. In addition, the share reserve will be increased by the number of returning shares, if any, as such shares become available from time to time under the 2011 EIP, for an additional number of shares not to exceed 744,608 shares. The term of any option granted under the 2020 EIP is determined on the date of grant but shall not be longer than 10 years. The Company issues new shares for settlement of vested restricted stock units and exercises of stock options. The Company does not have a policy of purchasing its shares relating to its stock-based programs. On October 10 June 24, 2023-2024, at the 2023-2024 Annual Meeting of Stockholders of the Company, upon the recommendation of the Company's Board of Directors, the Company's stockholders approved an amendment and restatement of the Company's 2020 Equity Incentive Plan, or the Amended 2020 Plan, to increase the number of authorized shares reserved for issuance thereunder by 1,500-171,000-395 shares, subject to adjustment for certain changes in the Company's capitalization. The aggregate number of shares of the Company's common stock that may be issued under the Amended 2020 Plan will not exceed the sum of: (i) +3,990-161,000-395 shares, and (ii) up to 744,608 shares subject to outstanding awards granted under the 2011 Equity Incentive Plan that may become available for issuance under the Amended 2020 Plan, as such shares become available from time to time. Additionally F-25 Inducement Grant In May 2024, the Company granted stock-based awards outside of the existing stock plans to one new employee, or the Inducement Grant. These awards were granted as a material inducement for accepting employment with the Company, in accordance with Nasdaq Listing Rule 5635 (c) (4). The inducement awards consisted of a total of

217,000 shares of the Company's common stock, which includes an aggregate of 185,000 shares of Common Stock issuable upon the exercise of inducement stock option grants and 32,000 shares of Common Stock issuable upon the vesting of restricted stock unit awards generally subject to the same terms and conditions as grants that are made under the Company's Amended 2020 Plan. On June 16, 2020, the Company's stockholders, upon the recommendation of the Company's Board of Directors, approved the Amended and Restated 2011 Employee Stock Purchase Plan, or the Amended ESPP, which increased the aggregate number of shares of the Company's common stock reserved for issuance under the 2011 Employee Stock Purchase Plan, or ESPP, to 245,000 shares, subject to adjustment for certain changes in the Company's capitalization, and removed the "evergreen" provision from the ESPP. ~~In On June 24, 2024, at the year 2024 Annual Meeting of Stockholders of the Company, upon the recommendation of the Company's Board of Directors, the Company's stockholders approved an amendment and restatement of the Company's 2011 Employee Stock Purchase Plan, or the ended Amended December 31 2011 ESPP. 2023, to increase there the number of authorized were 42,209 shares reserved for issuance thereunder by 100,000 shares, subject to adjustment for certain changes in the Company's capitalization. The aggregate number of shares of the Company's common stock that may now be issued under the Amended 2011 ESPP is 345.~~ The weighted average fair value of shares issued under the Amended ESPP in 2023 and 2022 was \$ 1.08 and \$ 6.82 per share, 000 respectively. As of December 31, 2023, there were 169,667 shares available for future grant under the Amended ESPP.

10. Warrants The activity related to warrants during the years ended December 31, 2024 and 2023 and 2022, is summarized as follows: Common Stock from Warrants Weighted- average Exercise Price (per share) Outstanding at December 31 January 1, 2021 2023 883-7, 824 833 \$ 5.15 Granted 6, 933 941, 100 \$ 1. 27-71 Granted 17, 085, 897 \$ 0.99 Exercised (3, 228, 781) \$ (0.0003) Outstanding at December 31, 2022 2023 7-21, 824 682, 933 049 \$ 1. 71-40 Granted 47-7, 085 792, 897 208 \$ 0. 001 99 Exercised (3, 228, 781) \$ (0.0003) Outstanding at December 31, 2023 2024 21-29, 682 474, 049 257 \$ +0. 40-96 Exercisable at December 31, 2023 2024 21-29, 682 474, 049 257 \$ +0. 96 40 F-31 At December 31, 2023 2024, the range of exercise prices for shares under warrants and the weighted- average remaining contractual life is as follows: Warrants Outstanding Warrants Exercisable Warrant Exercise Price Number of Warrants Weighted- Average Remaining Contractual Life (Years) Number of Warrants Weighted- Average Exercise Price \$ 0. 001 +9, 416 208, 473 681 Unlimited +9, 416 208, 473 681 \$ 0. 001 \$ 0. 77 5, 882, 356 3, 55 5, 882, 356 \$ 0. 77 \$ 1. 11 14 8, 787 904, 044 4 688 3, 62 14 55 8, 787 904, 044 688 \$ 1. 11 \$ 1. 70 367, 647 4 3, 62 55 367, 647 \$ 1. 70 \$ 2. 07 4, 977, 052 5 4, 07 00 4, 977, 052 \$ 2. 07 \$ 20. 00 125, 000 2 1, 92 87 125, 000 \$ 20. 00 \$ 56. 60 8, 833 5 4, 49 41 8, 833 \$ 56. 60 Total 21-29, 682 474, 049 5 257 3, 06 21 65 29, 682 474, 049 257 \$ +0. 40 96 F- 26 January 2024 Pre- Funded Warrants and Amendment of Prior Warrants On January 17, 2024, the Company issued the January 2024 Pre- Funded Warrants to purchase up to an aggregate of 7, 792, 208 shares of Common Stock in the first tranche of the two- tranche January 2024 Private Placement (see Note 9, " Stockholders' Equity "). The January 2024 Pre- Funded Warrants were exercisable immediately following the closing date of the first tranche of the January 2024 Private Placement, or January 22, 2024, and have an unlimited term and an exercise price of \$ 0. 001 per share. The January 2024 Pre- Funded Warrants were classified as a component of permanent equity in the Company's consolidated balance sheet as they are freestanding financial instruments that are immediately exercisable, do not embody an obligation for the Company to repurchase its own shares and permit the holders to receive a fixed number of shares of Common Stock upon exercise. All of the shares underlying the January 2024 Pre- Funded Warrants have been included in the weighted- average number of shares of Common Stock used to calculate net loss per share attributable to common stockholders because the shares may be issued for little or no consideration and are fully vested and are exercisable after their original issuance date. The January 2024 Pre- Funded Warrants may participate with common shareholders in dividends or other distributions. In July 2023, in connection with the July 2023 Private Placement Warrants (see below) " full review " by the SEC. Amendment of Prior Warrants On July 20, 2023, in connection with a prior private placement, the Company issued to certain of the July 2023 Purchasers (i) Series A common stock purchase warrants to purchase up to 3,676,473 shares of Common Stock and (ii) Series B common stock purchase warrants to purchase up to 3,676,473 shares of Common Stock, or collectively, the Prior Warrants. In connection with the current January 2024 Private Placement, the Company and the January 2024 Purchasers agreed to amend and restate a portion of the outstanding Prior Warrants, representing (i) Series A common stock purchase warrants to purchase up to 2,941,178 shares of each of the Series A common stock purchase warrants and (ii) Series B common stock purchase warrants outstanding to purchase up to 2, by reducing 941,178 shares of Common Stock, to reduce the exercise price thereunder from \$ 1.11 to \$ 0.77 per share. Pursuant to ASU 2021-04, the Company remeasured the fair value of the amended and restated Prior Warrants as of the modification date based on the modified terms and recorded the increase in fair value of \$ 0.3 million as equity. On July 20, 2023, the Company issued pre- funded warrants to purchase up to an aggregate of 2, 012, 356 shares of common Common stock Stock at an exercise price of \$ 0. 001 per share, or the July 2023 Pre- Funded Warrants, the July 2023 Series A Common common Stock stock Warrants warrants to purchase up to an aggregate of 7, 352, 947 shares of common Common stock Stock at an exercise price of \$ 1. 11 per share, and the July 2023 Series B Common common Stock stock Warrants warrants to purchase up to an aggregate of 7, 352, 947 shares of common Common stock Stock at an exercise price of \$ 1. 11 per share. The July 2023 Pre- Funded Warrants were exercisable immediately following the closing date of the July 2023 Private Placement, or July 20, 2023, and have an unlimited term and an exercise price of \$ 0. F- 27 001 per share. The July 2023 Series A and Series B common stock warrants were exercisable immediately following the closing date of July 20, 2023, and have a five- year term, unless certain milestone events are met which accelerate the expiration date to 45 days following such announcement. The July 2023 Series A and Series B Common common Stock stock Warrants warrants also include certain rights upon " fundamental transactions " as described in such warrants, including the right of the holders thereof to receive from the Company or a successor entity the same type or form of consideration (and in the same proportion) that is being offered and paid to the holders of common Common stock Stock in such fundamental transaction in the amount of the Black Scholes value (as described in such warrants) of the unexercised portion of the applicable warrants on the date of the consummation of such fundamental transaction. The Company evaluated the July 2023 Pre- Funded Warrants, and the July 2023 Series A and Series B Common common Stock stock Warrants warrants under ASC 815- 40 and determined that they did not require liability classification and met the requirements for instruments that are both indexed to an entity's own stock and classified in stockholders' equity. Accordingly, the proceeds were allocated between common Common stock Stock and the July 2023 Pre- Funded Warrants, Series A and Series B common stock warrants at their respective relative fair value basis to stockholders' equity and as a component of additional paid- in capital on the consolidated balance sheets. The fair value of the July 2023 Series A and Series B Common common Stock stock Warrants warrants was determined using a Black- Scholes option pricing model and the common Common stock Stock based on the closing date share price and were recorded in additional paid- in capital within stockholders' equity on the consolidated balance sheets. In connection with the January 2024 Private Placement, the Company and the purchasers agreed to amend and restate the Prior Warrants by reducing their exercise price from \$ 1. 11 to \$ 0. 77 per share (see " January 2024 Pre- Funded Warrants and Amendment of Prior Warrants " above). The placement agent July 2023 Series A and Series B Common Stock Warrants (see Note 9, " Stockholders' Equity ") have the same terms as the July 2023 Series A and Series B Common Stock Warrants to be issued to the purchasers, except such warrants do not have a Black Scholes provision in the event of a fundamental transaction and the exercise price of such warrants is \$ 1. 70 per share, which is 125 % of the combined offering price per share. The Company concluded that the placement agent July 2023 Series A and Series B Common Stock Warrants are freestanding equity- linked derivative instruments that met the criteria for equity classification. The placement agent July 2023 Series A and Series B Common Stock Warrants were valued at approximately \$ 0. 3 million, using the Black- Scholes option pricing model as follows: exercise price of \$ 1. 70 per share, stock price of \$ 1. 07 per share, expected life of 5 years, volatility of 94. 3 %, a risk- free rate of 4. 08 % and 0 % expected dividend yield. F- 32 As of December 31, 2023 2024, all none of the July 2023 Series A and Series B Common common Stock stock Warrants warrants and nor the placement agent July 2023 Series A and Series B Common common Stock stock Warrants warrants had not been exercised and all were still outstanding, while 595, 883 of the July 2023 Pre- Funded Warrants were exercised in the year ended December 31, 2023, and 1, 416, 473 remained outstanding as of December 31, 2023. On January 17, 2024, certain of these July 2023 Series A and Series B Common Stock Warrants were amended to reduce the exercise price to \$ 0. 77 per share in connection with the January 2024 Private Placement (see Note 16, " Subsequent Events " below for additional information). December 2022 Registered Direct Offering Warrants On December 29, 2022, the Company issued pre- funded warrants to purchase 2, 632, 898 shares of common Common stock Stock, or the December 2022 Pre- Funded Warrants, and common warrants to purchase an aggregate of 4, 227, 052 shares of common Common stock Stock, or the December 2022 Common Stock Warrants. The December 2022 Pre- Funded Warrants were exercisable immediately following the closing date of the December 2022 Registered Direct Offering, or December 29, 2022, had an unlimited term and an exercise price of \$ 0. 0001 per share. The December 2022 Common Stock Warrants were exercisable following the six- month anniversary of the closing date of December 29, 2022, have a six- year term and an exercise price of \$ 2. 07 per share. The 2022 Warrants included full ratchet anti- dilutive adjustment rights in the event the Company issued shares of common Common stock Stock or common stock equivalents in the future with a value less than the then effective exercise price of such common warrants subject to certain customary exceptions, and further subject to a minimum exercise price of \$ 1. 00 per share. On April 25, 2023, the December 2022 Common Stock Warrants were amended to remove these full ratchet anti- dilutive adjustment rights. F- 28 In the event of certain fundamental transactions involving the Company, the holder of the December 2022 Common Stock Warrants may require the Company to make a payment based on a Black- Scholes valuation, using specified inputs. The December 2022 Pre- Funded Warrants did not provide similar rights to the Purchaser. Therefore, the Company accounted for the December 2022 Common Stock Warrants as a liability, while the December 2022 Pre- Funded Warrants met the permanent equity criteria classification. The December 2022 Pre- Funded Warrants were classified as a component of permanent equity, or APIC, because they were freestanding financial instruments that are legally detachable and separately exercisable from the shares of common Common stock Stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common Common

stock **Stock** upon exercise. In addition, the December 2022 Pre-Funded Warrants did not provide any guarantee of value or return. **As** The December 2022 Common Stock Warrants were valued upon issuance at approximately \$ 7.1 million, using the Black-Scholes option pricing model as follows: exercise price of \$ 2.07 per share, stock price of \$ 2.13 per share, expected life of 6 years, volatility of 95.44%, a risk-free rate of 3.93% and 0% expected dividend yield. Accordingly, the Company allocated the fair value of \$ 7.1 million of the gross proceeds received to Warrant liability on its consolidated balance sheets. The aggregate remaining gross proceeds of \$ 0.4 million were allocated to the two remaining securities using the relative fair value method, resulting in the common stock and the December 2022 Pre-Funded Warrants being allocated values of \$ 0.1 million and \$ 0.3 million, respectively, and such amount being recorded to stockholders' equity. **F-33** At December 31, 2023 **2024**, the December 2022 Common Stock Warrants were valued at approximately \$ 1.8 million, using the Black-Scholes option pricing model as follows: exercise price of \$ 2.07 per share, stock price of \$ 0.74 per share, expected life of 5 years, volatility of 94.05%, a risk-free rate of 3.84% and 0% expected dividend yield. See Note 2, "Investments and Fair Value Measurement" above. As of December 31, 2023, none of the 4,227,052 December 2022 Common Stock Warrants had been exercised and **were still all remained** outstanding, while **all** the 2,632,898 December 2022 Pre-Funded Warrants were exercised in full in the year ended December 31, 2023 **and none remained outstanding at December 31, 2024**. August 2022 LPC Warrant The August 2022 LPC Warrant had an original exercise price of \$ 4.07 per share (subject to adjustment for stock splits, reverse stock splits and similar recapitalization events), became immediately exercisable and has a term ending on February 3, 2028. In addition, through August 3, 2023, if the Company issued or sold (or is deemed to have issued or sold) any **common Common stock Stock**, convertible securities or options (as defined in the August 2022 LPC Warrant), for a consideration per share, or the New Issuance Price, less than a price equal to the exercise price in effect immediately prior to such issue or sale or deemed issuance or sale, each of the foregoing, a dilutive issuance, then immediately after such dilutive issuance, the exercise price then in effect for the August 2022 LPC Warrant shall be reduced to an amount equal to the New Issuance Price, or the Down Round Feature. In December 2022, the Down Round Feature was triggered due to the price per share received from the issuance of **common Common stock Stock** and warrants in connection with the December 2022 Financing. In July 2023, the Down Round Feature was again triggered due to the price per share received from the issuance of **common Common stock Stock** and warrants in connection with the in connection with the July 2023 Private Placement. In each instance, the Company calculated the value of the effect of the Down Round Feature measured as the difference between the warrants' fair value, using the Black-Scholes option pricing model, before and after the Down Round Feature was triggered using the then current exercise price and the new exercise price. The difference in fair value of the effect of the Down Round Feature was immaterial in both instances and had no impact on net loss per share in the periods presented. This down round feature expired on August 3, 2023. The August 2022 LPC Warrant was originally valued at approximately \$ 0.3 million using the Black-Scholes option pricing model as follows: exercise price of \$ 4.07 per share, stock price of \$ 4.44 per share, expected life of 5.5 years, volatility of 89.94%, a risk-free rate of 2.86% and 0% expected dividend yield. The Series A Redeemable Convertible Preferred Stock and the August 2022 LPC Warrant were issued in a unit structure with the August 2022 LPC Warrant eligible to be classified in stockholders' equity, therefore the aggregate net proceeds of \$ 0.2 million were allocated to the two securities using the relative fair value method, resulting in the Series A Redeemable Convertible Preferred Stock and the August 2022 LPC Warrant being allocated values of \$ 0.1 million and \$ 0.1 million, respectively, and recorded to stockholders' equity. As of December 31, 2023 **2024**, the August 2022 LPC Warrant had not been exercised and was still outstanding. On November 15, 2021, the Company entered into a securities purchase agreement with certain investors pursuant to which the Company, in a registered direct offering, sold (i) an aggregate of 875,000 shares of the Company's common stock, and (ii) warrants to purchase up to an aggregate of 875,000 shares of **common Common stock Stock**, for an aggregate purchase price of \$ 14.0 million. The November 2021 Financing Warrants had an original exercise price of \$ 20.00 per share and became exercisable, if the holder's post-exercise beneficial ownership is less than or equal to 9.99%, 6 months after their issuance date and had a five-year term through November 15, 2026. **F-29** **34** The November 2021 Financing warrants were valued at approximately \$ 8.6 million using the Black-Scholes option pricing model as follows: exercise price of \$ 20.00 per share, stock price of \$ 14.92 per share, expected life of five years, volatility of 91.77%, a risk-free rate of 1.26% and 0% expected dividend yield. The common stock and warrants were issued in a unit structure; therefore, in accordance with ASC Topic 815, the aggregate gross proceeds of \$ 14.0 million were allocated to the two securities using the relative fair value method, resulting in the common stock and warrants being allocated values of \$ 8.4 million and \$ 5.6 million, respectively, and recorded to stockholders' equity. Upon the closing of the December 2022 Financing, 750,000 of the 875,000 November 2021 Financing Warrants were modified, to reduce the exercise price of the warrants from \$ 20.00 per share to \$ 2.07 per share and to extend the expiration date to December 29, 2028. The **modification of these November 2021 Financing Warrants..... 0% expected dividend yield.** The remaining warrants issued in the November 17, 2021, registered direct offering for 125,000 shares of the Company's common stock are currently exercisable at a price of \$ 20.00 per share and expire on November 15, 2026. As of December 31, 2023 **2024**, **none** all of the November 2021 Financing Warrants had **not** been exercised and **were still all remained** outstanding. **Loan Agreement Warrants** In connection with the Loan Agreement, on May 30, 2019, the Company issued warrants to the Lender and its affiliates, which are exercisable for an aggregate of 8,833 shares of the Company's common stock with a per share exercise price of \$ 56.60, or the Loan Agreement Warrants. The Loan Agreement Warrants may be exercised on a cashless basis. The Loan Agreement Warrants are exercisable for a term beginning on the date of issuance and ending on the earlier of ten years from the date of issuance or the consummation of certain acquisitions of the Company as set forth in the Loan Agreement Warrants. The number of shares for which the Loan Agreement Warrants are exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in the Loan Agreement Warrants. **The As of December 31, 2023, Loan Agreement Warrants have been classified within stockholders' equity and accounted for as a discount to purchase 8,833 shares of common stock issued to the Lender and its affiliates loan by allocating the gross proceeds on a relative fair value basis. As of December 31, 2024, none of the Loan Agreement Warrants had not been exercised and were still all remained** outstanding. **These warrants expire in May 2029..... additional information.** **F-35** 11. Stock-Based Compensation The Company recorded total stock-based compensation expense for stock options, stock awards and the Amended ESPP as follows (in thousands): **Year Ended** December 31, 2023 **December 31, 2022** Research and development \$ \$ Selling, general and administrative 1,212 **2,069** Discontinued operations — **Total** \$ **1,729** **In the year ended December 31, 2024, there were 49,515 shares issued under the Amended ESPP. The weighted average fair value of shares issued under the Amended ESPP in 2024 and 2023 was \$ 2.0, 889.88 and \$ 1.08 per share, respectively. As of December 31, 2024, there were 165,897 shares available for future grant under the Amended ESPP.** The following table summarizes restricted stock unit activity under the Company's Equity Incentive Plans: Weighted Number of Average Restricted Grant Date Stock Units Fair Value Restricted stock units outstanding, January 1, 2022 **2023** 88,711 **\$ 34.16** Granted 58,502 **7.75** Vested (44,744) **35.46** Forfeited (19,691) **25.00** Restricted stock units outstanding, December 31, 2022 **82,778** \$ 16.97 Granted 48,158 **1.67** Vested (40,356) **19.28** Forfeited (4,348) **12.56** Restricted stock units outstanding, December 31, 2023 **86,232** \$ 7.57 **Granted 176,768 1.03 Vested (42,525) 11.31 Forfeited (7,552) 2.03 Restricted stock units outstanding, December 31, 2024 212,923 \$ 1.59** **F-30** The following table summarizes stock option activity under the Company's Equity Incentive Plans: Number of Stock Options Outstanding Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (in thousands) **December 31 January 1, 2022-2023** 725,623 \$ 52.98 Granted 288,929 **1.67** Forfeited (14,673) **9.72** Expired (106,558) **83.88** **January 1** Exercised — **December 31, 2023-2024** 893,321 \$ 33.41 **Granted 1,053,612 1.03 Forfeited (41,156) 1.75 Expired (118,877) 71.96** **December 31, 2024 1,786,900 \$ 12.48** **7.6 -3-\$ —** Vested and exercisable options — **December 31, 2023-2024** 488,605 **725-249 \$ 53-34 69-28 4.3-8 \$ —** Vested and expected to vest — **December 31, 2023-2024** 893-1, **321-786,900 \$ 33-12. 41-48 7.6 -3-\$ —** As of December 31, 2023 **2024**, there were 1,631 **956 319-919** shares available for future grant under the 2020 EIP. **F-36** Additional information regarding the Company's stock options outstanding and vested and exercisable as of December 31, 2023 **2024**, is summarized below: Options Outstanding Options Vested and Exercisable Exercise Prices Number of Stock Options Outstanding Weighted-Average Remaining Contractual Life (Years) Weighted-Average Exercise Price per Share Shares Subject to Stock Options Weighted-Average Exercise Price per Share \$ 0.684 \$ 1.76 **281-03 859 505-701** 9.2 \$ 1.67 **01-24, 409 \$ 0.68-1.08-1.62 185,000 9.4 \$ 1.08 — \$ — 1.76-2.64 249,184 8.1 \$ 1.76 114,204 \$ 1.76 \$ 4.62-6.93 **15-10 350-8-850 7.5 \$ 5-4 21-12-62 10 818-850 4.93-62 \$ 8.03-12.045 86-84 817-8-703 7.1 \$ 8.08 40-60 123-199 \$ 8.09 08 \$ 14.40-21.60 **4-12 633-033 5.9-0 \$ 16.55-13-50 12 418-033 \$ 16.61-50 \$ 22.40-33.60 11,700 7-6 1 \$ 28.62 11,386-625 \$ 28.68-66 \$ 34.40-51.60 280-208 405-662-5-4 **1 \$ 41.01-208-92 206 326-605 \$ 42-41 23-96 \$ 57.40-86.10 169-163 213-2-274 1 7 \$ 64.86-169-92 163 213-274 \$ 64.86-92 \$ 94.60-141.90 17-2 371-050 0.9 \$ 94.60 2,050 \$ 94.60 **1 786,900 7 0-6 \$ 127-12 59-17-48 605 371-249 \$ 127-34 28 F 59 \$ 204-40-306.60 16,070 0.2 \$ 206.24-16,070 \$ 206.24 893-321-31 6.3-3-33.41 488,725 \$ 53-69** The weighted average grant-date fair value of options granted during the years ended December 31, **2024 and 2023**, and 2022 was \$ **0.84 and \$ 1.32 and \$ 5.80** per share, respectively. As of December 31, 2023 **2024**, total stock-based compensation expense related to unvested options to be recognized in future periods was \$ **1.0-9** million which is expected to be recognized over a weighted-average period of **2.1-5** years. The grant date fair value of options vested during the years ended December 31, **2024 and 2023**, and 2022 was \$ **2.0 million and \$ 0.9 million and \$ 1.7 million**, respectively. **The There were no total intrinsic value of options exercised during the years ended December 31, 2024 and 2023 and 2022 was \$ 0 and \$ 0, respectively.** The Company has granted **In addition, the performance-based stock options granted in March 2021 to certain of its the Company's executive officers remained**, which are included in the stock option tables and associated disclosures above. The Company uses the Monte Carlo Simulation model to evaluate the derived service period and fair value of awards with market conditions, including assumptions of historical volatility and risk-free interest rate commensurate with the vesting term. The performance-based stock options are eligible to vest subject to the satisfaction of the service-based vesting requirements and attainment of share price target goals, a market-based condition. No performance-based stock options vested **unvested and expired** during the years **year** ended December 31, 2023 **2024 and 2022**. The Company used the following assumptions to calculate the fair value of each time-based stock option: Year Ended December 31, **2024 2023 2022** Expected term (in********

years) 6. ~~3-5~~ 6.3 Risk-free interest rate ~~4.1%-4.5%~~ 3.9%-4.6% ~~1.6%-3.0%~~ Expected volatility ~~98%~~ 94%-88% Expected dividend rate 0% 0% 12. Net Income (Loss) per Share of Common Stock The Company applies the two-class method to compute basic net income (loss) per share by dividing the net income (loss) attributable to common shareholders by the weighted average number of shares of common stock outstanding for the period. The diluted net income (loss) per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the more dilutive of the 1) treasury stock method, if-converted method, or contingently issuable share method, as applicable, or 2) the two-class method. For purposes of this calculation, options to purchase common stock, RSUs, and warrants to purchase common stock were considered to be common stock equivalents. ~~F-37~~ The July 2023 Series A and Series B ~~Common-Common Stock-Stock Warrants-warrants~~, the placement agent July 2023 Series A and Series B ~~Common-Common Stock-Stock Warrants-warrants~~, the December 2022 Common Stock Warrants, the Series A Redeemable Convertible Preferred Stock and the November 2021 Financing Warrants are all participating securities which, by definition, entitle the holders thereof to participate in dividends and other distributions of assets by the Company to its holders of common shares as though the holder then held common shares; however, there is no contractual obligation on the part of the warrant holders to participate in the Company's losses. Given that the Company's participating securities do not have a contractual obligation to share in the Company's losses, net loss for the year years ended December 31, ~~2024 and 2023~~, was attributed entirely to common stockholders. ~~For the year ended December 31, 2022, the Company presented diluted EPS using the two-class method as it was more dilutive.~~ In periods with a reported net loss, common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is antidilutive. Potential common shares that are issuable for little or no cash consideration, such as the Company's ~~January 2024~~, July 2023 and December 2022 Pre-Funded Warrants issued with a de minimis exercise price prices of \$ 0.001, \$ 0.001 and \$ 0.001 per share, respectively, are considered outstanding common shares which are included in the calculation of basic and diluted net income (loss) per share in all circumstances. The following table sets forth the computation of the Company's basic and diluted net income (loss) per share of common stock during the years ended December 31, 2023 and 2022 (in thousands, except for share and per share amounts):

Year Ended December 31, (in thousands, except share and per share amounts)	2023	2022
Basic net income (loss) per common share: Net income (loss) from continuing operations	\$ (10,287) \$ 59,125	Less: deemed dividends related to Series A Redeemable Convertible Preferred Stock (186) Less: income allocated to participating securities (5,240)
Net income (loss) from continuing operations attributable to common shareholders, basic	(8,110) (11,370)	Net income (loss) from discontinued operations attributable to common shareholders, basic
Weighted average shares outstanding — basic	14,263,744	7,385,348
Income (loss) from continuing operations, basic	\$(0.72) \$ 7.27	Loss from discontinued operations, basic
Net income (loss) per share, basic	\$(1.29) \$ 5.73	Diluted net income (loss) per common share: Net income (loss) from continuing operations
Less: deemed dividends related to Series A Redeemable Convertible Preferred Stock	(186)	Less: income allocated to participating securities (5,227)
Net income (loss) from continuing operations attributable to common shareholders, diluted	(10,287) \$ 53,712	Net loss from discontinued operations attributable to common shareholders, diluted
Weighted average shares outstanding — diluted	14,263,744	7,406,986
Income (loss) from continuing operations, diluted	\$(0.72) \$ 7.25	Loss from discontinued operations, diluted
Net income (loss) per share, diluted	\$(1.29) \$ 5.72	F-38

The following outstanding shares of common stock equivalents were excluded from the computation of diluted net income (loss) per share of common stock for the periods presented because including them would have been antidilutive: Year Ended December 31, ~~2023 2024~~ 2022-ESPP, RSUs and stock options to purchase common stock ~~1,999,823~~ 979,553 ~~815,710~~ Common stock warrants ~~20,265,576~~ ~~433,203~~ ~~833,265,576~~ ~~F-32~~ In addition, the shares contingently issuable in connection with the Merger Agreement, as described in Note 4, "Asset Acquisition", have also been excluded from the computation of diluted net loss per share of common stock for the periods presented because the contingencies for issuance of these shares have not been met.

13. Accrued Liabilities Accrued liabilities consist of the following (in thousands): December 31, ~~2024 2023 2022~~ Accrued compensation and employee benefits \$ ~~2,005~~ ~~1,732~~ Accrued professional services Other accrued liabilities Total accrued liabilities \$ ~~2,144~~ ~~531~~ ~~445~~ 14. 401 (k) Plan The Company sponsors a 401 (k) plan that stipulates that eligible employees can elect to contribute to the 401 (k) plan, subject to certain limitations. Pursuant to the 401 (k) plan, the Company makes a matching contribution of up to 4% of the related compensation. Under the vesting schedule, employees have ownership in the matching employer contributions based on the number of years of vesting service completed. Company contributions were \$ 0.2 million and ~~\$ 0.3 million~~ for each of the years ended December 31, ~~2024 and 2023~~ and 2022, respectively.

15. Income Taxes The Company recorded a provision for income taxes of \$ 0 thousand and ~~\$ 13 thousand~~ for the years ended December 31, ~~2023 and 2022~~, respectively. ~~F-39~~ Net deferred tax assets as of December 31, ~~2024 and 2023~~, and 2022 consist of the following (in thousands): December 31, ~~2023 2024~~ December 31, ~~2022 2023~~ Deferred tax assets: Accruals and other \$ ~~1,347~~ ~~1,717~~ ~~3,790~~ Research credits ~~8,379~~ ~~7,839~~ ~~7,392~~ Net operating loss carryforward ~~90,142~~ ~~88,839~~ ~~84,325~~ Section 59 (e) R & D expenditures 1, ~~136~~ ~~1,937~~ ~~3,496~~ Section 174 R & D expenditures ~~2,446~~ ~~1,651~~ ~~XOMA royalty 1,371~~ Total deferred tax assets ~~104,821~~ ~~101,983~~ ~~99,984~~ Deferred tax liabilities: IP from Acquisition (1,852) (1,874) (2,052) Total deferred tax liabilities (1,852) (1,874) (2,052) Valuation allowance (102,969) (100,109) (97,932) Net deferred tax assets \$ — \$ — ~~F-33~~ Reconciliations of the statutory federal income tax to the Company's effective tax during the years ended December 31, ~~2024 and 2023~~ and 2022 are as follows (in thousands): Year Ended December 31, ~~2024 2023 2022~~ Tax at statutory federal rate \$ (2,731) \$ (3,862) \$ (10,031) State tax — net of federal benefit 2,495 Acquired assets — 1,728 Research credits (363) (292) Stock options Other (431) (139) Change in valuation allowance 2,860 2,177 (43,520) Revaluation of Put Option Liability (150) (1,117) (15) Provision for income taxes \$ — \$ — ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is "more likely than not." Realization of deferred tax assets is dependent on future taxable income, if any, the timing and the amount of which are uncertain. Accordingly, the deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by \$ 2.9 million and \$ 2 million and decreased by \$ 13.5 million during the years ended December 31, ~~2024 and 2023~~ and 2022, respectively. As of December 31, ~~2023 2024~~, the Company had federal net operating loss carryforwards of \$ 377,384. 7.8 million, of which \$ 114.9 million federal net operating losses generated before January 1, 2018, will begin to expire in 2029. Federal net operating losses of \$ 262,270. 8.0 million generated from 2018 to 2023, will carryforward indefinitely but are subject to the 80% taxable income limitation. As of December 31, ~~2023 2024~~, the Company had state net operating loss carryforwards of \$ 437,134. 4 million 7 million, which begin to expire in 2028. As of December 31, ~~2023 2024~~, the Company had federal research credit carryovers of \$ 7.05 million, which begin to expire in 2026. As of December 31, ~~2023 2024~~, the Company had state research credit carryovers of \$ 4.47 million, which will carryforward indefinitely. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an "ownership change," generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation's ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research credits, to offset its post-change income may be limited. Based on an analysis performed by the Company as of December 31, 2013, it was determined that two ownership changes have occurred since inception of the Company. The first ownership change occurred in 2006 at the time of the Series A financing and, as a result of the change, \$ 1.4 million in federal and state net operating loss carryforwards will expire unutilized. In addition, \$ 26 thousand in federal and state research and development credits will expire unutilized. The second ownership change occurred in July 2013 at the time of the underwritten public offering; however, the Company believes the resulting annual imposed limitation on use of pre-change tax attributes is sufficiently high that the limit itself will not result in unutilized pre-change tax attributes. ~~F-40 34~~ Uncertain Tax Positions A reconciliation of the beginning and ending balances of the unrecognized tax benefits during the years ended December 31, ~~2024 and 2023~~, and 2022 is as follows (in thousands): Year Ended December 31, ~~2024 2023 2022~~ Unrecognized benefit — beginning of period \$ 2,678,835 \$ 2,635,678 Gross increases — prior period tax positions — Gross increases — current period tax positions Unrecognized benefit — end of period \$ 2,31,835,031 \$ 2,678,835 The entire amount of the unrecognized tax benefits would not impact the Company's effective tax rate if recognized. There were no accrued interest or penalties related to unrecognized tax benefits in the years ended December 31, ~~2024 or 2023~~ and 2022. The Company files income tax returns in the United States, California, and other states. The tax years 2005 through 2014, and 2016 through ~~2023 2024~~, remain open in all jurisdictions. The Company is not currently under examination by income tax authorities in U. S. federal, state or foreign jurisdictions. The Company does not anticipate any significant changes within 12 months of this reporting date of its uncertain tax positions. In March 2020, the Coronavirus Aid, Relief and Economic Security, or CARES, Act was signed into law. The CARES Act included several tax changes as part of its economic package. These changes principally related to expanded net operating loss carryback periods, increases to interest deductibility limitations, and accelerated alternative minimum tax refunds. The Company has evaluated these items and determined that the items do not have a material effect on the Company's financial statements as of December 31, ~~2022 2023~~ or ~~2023 2024~~. Additionally, the CARES Act enacted the Employee Retention Credit, or ERC, to incentivize companies to retain employees, which was subsequently modified by extension of the CARES Act. Under the provisions of the CARES Act and its subsequent extension, the Company was eligible for ERCs, subject to certain criteria. Accordingly, the Company recorded a reduction in payroll taxes related to ERCs claimed for \$ 1.4 million in the year ended December 31, 2021. These credits were recorded in the consolidated statements of operations as an offset to the related payroll expenses in the respective operating costs and expenses line item and are disclosed within prepaid expenses and other current assets on the Company's consolidated balance sheets at December 31, 2023.

16. Segment Information The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company has one reportable segment, which is the development and commercialization of innovative therapies for use in medically supervised settings. The Company's chief operating decision maker, or CODM, which consists of its Chief Executive Officer and the Chief Financial Officer, reviews the Company's operating results on an aggregate basis and manages the Company's operations. The CODM



State of California without regard to its conflict of laws provision. We are all delighted to be able to extend you this offer and look forward to working with you. To indicate your acceptance of the Company's offer, please sign and date this letter in the space provided below and return it to me, along with a signed and dated copy of the Confidentiality Agreement and Arbitration Agreement. This offer will terminate if not accepted by you on or before May 16, 2024. Very truly yours, ACCEPTED AND AGREED: TALPHERA, INC. NAME Shakil Aslam By: /s/ Vincent Angotti /s/ Shakil Aslam Name: Vincent Angotti Signature Title: CEO Date 5/13/2024 Attachment A: Confidential Information and Invention Assignment Agreement Attachment B: Arbitration Agreement Exhibit 19 TALPHERA, INC. INSIDER TRADING POLICY (Approved on August 1, 2018) This Insider Trading Policy of Talphera, Inc. and its subsidiaries ("Talphera" or the "Company") outlines the restrictions and procedures that all Talphera personnel must follow. Failure to comply with these restrictions and procedures could result in a serious violation of the securities laws by you and / or Talphera and can involve both civil and criminal penalties. It is important that you review this policy carefully. The insider trading policy provides as follows: I. Definition of Insider: Reasons for Policy An "insider" is a person who possesses, has access to, or is aware of material information concerning Talphera or another publicly-traded company with which Talphera has business dealings (each, a "Third Party") that has not been fully disclosed to the public (see below for a definition of "material information"). Insiders may be subject to criminal prosecution and / or civil liability for trading (purchase or sale—sale—based-milestone-payments) in Talphera's or a Third Party's securities when they know material information concerning Talphera or such Third Party that has not been fully disclosed to the public ("Inside Information"). Persons found liable for insider trading could face penalties that include (i) imprisonment for up to 20 years; (ii) criminal fines of up to \$46.5 million and (iii) civil fines of up to three times the profit gained or loss avoided. If Talphera fails to take appropriate steps to prevent insider trading, Talphera may have "controlling person" liability for a trading violation, with civil penalties of up to the greater of \$1 million and three times the profit gained or loss avoided, as well as a criminal penalty of up to \$25 million. Such civil penalties can also extend personal liability to Talphera's directors, officers and other supervisory personnel if they fail to take appropriate steps to prevent insider trading. Finally, in addition to the potential criminal and civil liabilities mentioned above, in certain circumstances Talphera may be able to recover all profits made by an insider, plus collect other damages. Without regard to the penalties that may be imposed by others, willful violation of this policy constitutes grounds for dismissal from the Board of Directors or termination of your employment with Talphera or, with respect to net sales of the Product to Representatives (as defined below), termination of the contract. Insider trading proscriptions are not limited to trading by the insider alone; it is also illegal to advise others to trade on the basis of Inside Information. Liability in each such case can extend both to the "tippee" — the person to whom the insider disclosed Inside Information — and to the "tipper," the insider himself. Finally, insider trading can cause a substantial loss of confidence in Talphera and its securities on the part of the public and the securities markets. This could obviously have an adverse impact on Talphera and its stockholders. II. Applicability of Policy This policy applies to all transactions in Talphera's or a Third Party's securities by "insiders" (or where insiders provides Inside Information to enable others to make such transactions). As a rule of thumb, insiders are (1) members of the Board of Directors and officers of Talphera, (2) any employee of Talphera and its subsidiaries, and (3) any consultant, representative, or independent contractor ("Representative") who knows Inside Information. This policy also applies to the immediate families (defined as direct family members living in the same household) of such insiders, anyone else who lives in an insider's household, and any family members who do not live in an insider's household but whose transactions in the Company's securities are directed by, or subject to, the influence of control of an insider. In addition, this policy applies to any entities that an insider influences or controls, including any corporations, partnerships or trusts (collectively referred to as "Controlled Entities"), and transactions by these Controlled Entities should be treated for the purposes of this policy and applicable securities laws as if they were for the insider's own account. Finally, this policy shall continue to apply to transactions of Talphera securities by an insider even after January such insider has terminated his service or employment, if such person is in possession of Inside Information when the termination occurs. In that event, the insider may not trade in Talphera securities until such information has been publicly disclosed or is no longer material. Please contact the Chief Financial Officer or the General Counsel if you have any questions about the applicability of this policy to you. III. When Information is Considered Public Information that has not been disclosed to the public is generally considered to be nonpublic information. In order to establish that the information has been disclosed to the public, it may be necessary to demonstrate that the information has been widely disseminated. Information generally would be considered widely disseminated if it has been disclosed by a press release across a national wire service, broadcast on widely-available radio or television programs, published in a widely-available newspaper, magazine or news website, or disclosed in public disclosure documents filed with the Securities and Exchange Commission (the "SEC") that are available on the SEC's website. By contrast, information would not be considered widely disseminated if it is available only to the Company's employees, or if it is only available to a select group of analysts, brokers and institutional investors. Disclosure is considered widely disseminated when the securities markets have had the opportunity to digest the news. Generally, two full trading days after the announcement, publication or release to national wire services is regarded as sufficient. IV. Definition of Material Information It is not possible to define all categories of material information. In general, information should be regarded as material if there is a likelihood that it would be considered important by an investor in making a decision regarding the purchase or sale of Talphera or Third Party securities. Although it may be difficult under this standard to determine whether certain information is material, there are various categories of information that would almost always be regarded as material. Examples of such information include, but are not limited to: 1. Major corporate partnering transactions or proposed 2024 and excluding sales of the Product by Aguetant, and of certain associated license and acquisition acquisitions payments or divestitures; 2. Results or data relating to clinical trials or pre-clinical studies; 3. Communications and developments with government agencies, including the FDA; 4. Resignation, loss or hiring of directors, executive officers or key personnel; 5. Receipt, cancellation or deferral of significant contracts; 6. New project or Product-product announcements of a significant nature; 7. Planned stock splits, until XOMA reverse stock split or other recapitalization transactions; 8. Significant cybersecurity risks and incidents, including vulnerabilities and breaches; 9. New equity or debt offerings; 10. Pending or threatened significant litigation, or the resolution of such litigation; or 11. Financial and accounting information, including any changes in financial guidance or projection; and 12. A change in auditors or a notification that the Company can no longer rely on an auditor's report. If any insider has received questions as to the materiality of information, he or she should contact the Chief Financial Officer or the General Counsel for clarification. Further, any officer, director, employee or Representative who believes he or she would be regarded as an insider who is contemplating a transaction certain minimum amount of payments in respect of Talphera securities must contact the foregoing Chief Financial Officer or the XOMA Threshold, General Counsel prior to executing the transaction to determine if he or she should proceed. Officers and directors should be particularly careful following the Stepdown Date, since avoiding the appearance (A) 100% of royalty payments engaging in transactions on the basis of material undisclosed information can be as important as avoiding a transaction actually based on net such information. In addition to the requirement that employees not trade in the Company's securities when in possession of Inside Information, certain individuals are prohibited from trading during "blackout" period trading windows described below in "Specific Requirements." V. Specific Requirements I. Insiders may not discuss Inside Information about the Company or a Third Party with anyone outside the Company. This prohibition covers spouses, family members, friends, business associates, or persons with whom Talphera is doing business (except to the extent that such persons are covered by a non-disclosure agreement and the discussion is necessary to accomplish a business purpose of the Company). Insiders may not participate on Internet forums, message boards, social media sites, "chat rooms" or in other electronic discussions on the Internet concerning the activities of the Company or Third Parties, even if the insider does so anonymously. Any intention to disclose Inside Information requires the prior approval of the Chief Executive Officer, the Chief Financial Officer or the General Counsel, and must otherwise comply with the Company's policies, including the Company's Code of Business Conduct and Ethics and any Company communication policies. 2. Insiders may not engage in a transaction (purchase or sale) in Talphera or Third Party securities at any time between the date on which any insider becomes aware of the Inside Information and the close of business on the second trading day after such Inside Information is publicly disclosed. 3. In addition, no director or officer of Talphera, or any employee or other person who may have ongoing exposure to Inside Information because of the nature of their jobs, as specifically determined by the Chief Financial Officer or the General Counsel, may engage in a transaction (purchase or sale) in Talphera securities between the close of business on the day that is two weeks prior to the end of each fiscal quarter and the close of business on the second business day after the financial results of the Company's operations for such quarter are publicly announced (the "Quarterly Blackout Period"). Any employee, director or officer whose has terminated his or her service during any Quarterly Blackout Period will continue to be subject to such Quarterly Blackout Period until its expiration. 4. No officer, director or employee may engage in transactions in Talphera securities of a speculative nature at any time. All officers, directors and employees are prohibited from short-selling Talphera securities or engaging in transactions involving Talphera-based derivative securities. "Derivative Securities" are options, warrants, stock appreciation rights or similar rights whose value is derived from the value of an equity security, such as Talphera stock. This prohibition includes, but is not limited to, trading in Talphera-based put and call option contracts, transacting in straddles, and the like. However, as indicated below, holding and exercising options or other derivative securities granted under Talphera's employee stock option or equity incentive plans is not prohibited by this policy. 5. All directors and officers of Talphera, and any employees who may have ongoing exposure to Inside Information because of the nature of their jobs, as specifically determined by the Chief Financial Officer or the General Counsel, must inform the Chief Financial Officer or the General Counsel whenever they intend to

execute a trade in Talphera securities, including the placing of limit orders. At the time of executing a trade in Talphera securities, such individuals will be responsible for verifying that Talphera has not imposed any restrictions on their ability to engage in trades. If the individual has not completed the trade within three (3) business days of notification of the intention to trade, then the individual must re- confirm with the Chief Financial Officer or the General Counsel that they intend to execute a trade and the individual must re- verify the nonexistence of any restrictions on such trade. 6. The Chief Executive Officer, the Chief Financial Officer and the General Counsel have the authority to impose restrictions on trading in Talphera securities by appropriate individuals at any time, in addition to Quarterly Blackout Period imposed pursuant to paragraph 3 above, including any blackout periods imposed due to the occurrence or prospective occurrence of certain material events. In such event, Talphera management will notify the affected individuals, either personally or by email, to inform them of the restrictions. Any person made aware of the existence of such restrictions or event- specific blackout should not disclose its existence to any other person. The failure of management to designate a person as being subject to such restriction or event- specific blackout will not relieve that person of the obligation not to trade while aware of Inside Information. 7. Any individual who has placed a limit order or open instruction to buy or sell Talphera securities shall bear responsibility for cancelling such instructions immediately in the event restrictions are imposed on their ability to trade in accordance with either paragraphs 3 or 6 above. 8. Margin accounts or pledged securities are not permitted. Securities held in a margin account as collateral for a margin loan may be sold by the broker without the customer's consent if the customer fails to meet a margin call. Similarly, securities pledged (or hypothecated) as collateral for a loan may be sold in foreclosure if the borrower defaults on the loan. Because a margin sale or foreclosure sale may occur at a time when the pledgor is aware of Inside Information or otherwise is not permitted to trade in Talphera securities, directors, officers and other employees are prohibited from holding Talphera securities in a margin account or otherwise pledging Talphera securities as collateral for a loan. 9. Hedging transactions or short sales are not permitted. Hedging or monetization transactions can be accomplished through a number of possible mechanisms, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds. Such hedging transactions may permit a director, officer or employee to continue to own Talphera's securities obtained through employee benefit plans or otherwise, but without the full risks and rewards of ownership. When that occurs, the director, officer or employee may no longer have the same objectives as the Company's other Product shareholders. Therefore, directors, officers and employees are prohibited from engaging in any such transactions. Short sales of Talphera's securities (i. e., the sale of a security that the seller does not own) may evidence an expectation on the part of the seller that the securities will decline in value, and therefore have the potential to signal to the market that the seller lacks confidence in the Company's prospects. In addition, short sales may reduce a seller's incentive to seek to improve the Company's performance. For these reasons, short sales of Talphera securities by officers, directors and employees are also prohibited. 10. The only exceptions to the policy are set forth below. It does not matter that the insider may have decided to engage in a transaction before learning of the Inside Information or that delaying the transaction might result in economic loss. It is also irrelevant that publicly disclosed information about Talphera might, even aside from the Inside Information, provide a substantial basis for engaging in the transaction. You simply cannot trade in Talphera securities or a Third Party's securities while in possession of Inside Information about Talphera or such Third Party. The only exceptions to the policy are as follows: (a) Exercise of a stock option granted under Talphera's equity incentive plans or any successor plan (as amended, the " Stock Plans "). Note that this exception does not include a subsequent sale of the shares acquired pursuant to the exercise of the option under the Stock Plans. Thus, any sale of shares as part of a broker-assisted cashless exercise of an option (e. g., through Charles Schwab & Co.), or any other market sale for the purpose of generating the cash needed to pay the exercise price of an option and / or related withholding taxes, is not covered under this exception and all insiders must comply with all the provisions of this policy with respect to such sales. (b) Acquisition of shares under the Talphera Employee Stock Purchase Plan, but this exception does not apply to a subsequent sale of the acquired shares. (c) Any surrender of shares by the stockholder to Talphera to satisfy the stockholder's tax withholding obligations as a result of the issuance of shares upon vesting of restricted stock units or other equity awards granted under the Stock Plans. Note that this exception does not include a subsequent sale of the shares by the stockholder acquired upon vesting of restricted stock units granted under the Stock Plans, including any sale of the stock for the purpose of generating the cash needed to pay tax withholding taxes. This exception relates only to the surrender of shares directly to Talphera pursuant to the express terms of your equity award. (d) Bona fide gifts of securities are not deemed to be transactions for the purposes of this policy. Whether a gift is truly bona fide will depend on the facts and circumstances surrounding each gift. The more unrelated the donee is to the donor, the more likely the gift would be considered " bona fide " and not a " transaction. " For example, gifts to charities, churches and service organizations would clearly not be " transactions. " On the other hand, gifts to dependent children followed by a sale of the " gift " securities in close proximity to the time of the gift may imply some economic benefit to the donor and, therefore, make the gift not bona fide. (e) Any transaction specifically approved in writing in advance by the Chief Financial Officer or the General Counsel. (f) Sales made by an officer, director or employee pursuant to a qualified trading plan (a " Trading Plan ") that complies with and is approved in advance in accordance with the Company's Rule 10b5- 1 Trading Plan Policy (the " Trading Plan Policy ), a copy of which is attached hereto as Annex A) (it being understood that a Trading Plan implemented prior to the establishment of the Trading Plan Policy on August 1, 2018 shall be deemed to be in compliance with this Insider Trading Policy provided that it complied with this Insider Trading Policy in effect at the time of the implementation of such Trading Plan). Please consult with the Chief Financial Officer or the General Counsel to determine the requirements under the Trading Plan Policy. VI. Procedural and Other Requirements for Transactions by Officers and Directors The following procedures must be followed by Talphera officers and directors with respect to any purchase or sale of Talphera securities: (a) Despite the above provisions, there may be times when there exists a corporate basis for requesting that each officer or director refrain from trading in Talphera's securities even though such trading would otherwise be permitted under Section V. In order to comply with this restriction, all purchases and / or sales by officers or directors shall be approved beforehand with the Chief Financial Officer or the General Counsel. This restriction does not apply to stock purchases (but not subsequent sales of such purchased shares) under the Employee Stock Purchase Plan or to the exercise of stock options (but not subsequent sales of such purchased shares, including in connection with broker-assisted cashless exercise programs). (b) In connection with each transaction in Talphera securities, each officer and director is required to ensure (i) compliance with Rule 144, if required; and (ii) the preparation of the requisite Forms 3, 4 or 5 to be filed with SEC. The Company and its outside legal counsel may assist you in the preparation and filing of such forms. (c) In accordance with Regulation BTR under the Securities Exchange Act of 1934, as amended, no director or executive officer may, directly or indirectly, purchase, sell or otherwise acquire or transfer any equity security of Talphera ( other than net-an exempt security ) during any " blackout period " ( as defined in Regulation BTR ) with respect to such equity security, if such director or executive officer acquires or previously acquired such equity security in connection with his or her service or employment as a director or executive officer. This prohibition shall not apply to any transactions that are specifically exempted from Section 306 (a) (I) of the Sarbanes- Oxley Act of 2002 ( as set forth in Regulation BTR ), including but not limited to, purchases or sales of Talphera's securities made pursuant to the United States Department of Defense, and in compliance with, a Trading Plan established by a director or executive officer that meets the requirements DoD and (B) 50% of Rule 10b5- 1; compensatory grants or awards of equity securities pursuant to a plan that, by its terms, permits executive officers and directors to receive automatic grants or awards and specifies the terms of the grants and awards; or acquisitions or dispositions of equity securities involving a bona fide gift or by will or the laws of descent or pursuant to a domestic relations order. Talphera will notify each director and executive officer of any blackout periods in accordance with the following provisions of Regulation BTR. \* \* \* ACKNOWLEDGEMENT Please sign below acknowledging that you have read and agree to abide by Talphera's Insider Trading Policy. I received, reviewed and agree to be bound by Talphera's Insider Trading Policy. Dated: Signature Name: Title: RULE 10b5- 1 TRADING PLAN POLICY Purpose This policy ( the " Trading Plan Policy ") has been established by Talphera, Inc. ( the " Company ") to: • assist the Company's officers, directors and employees in meeting the requirements of the affirmative defense created by Rule 10b5- 1 ( " Rule 10b5- 1 ") of the Securities Exchange Act of 1934, as amended ( the " Exchange Act " ), in a ) payments manner that is consistent with the best interests of the Company; and • avoid the appearance of practices that might be viewed as abusive based on later developments net sales of the Product to the DoD, (b) potential sales- based milestone payments in respect of net sales of the Product and (c) certain associated license and acquisition payments relating to the Product. Scope This Trading Plan Policy defines procedures The Company has retained its right, title and guidelines for establishing interest in and to, following the Stepdown Date, 50 % of each of the following: ( a ) payments based on net sales of the Product to the DoD, (b) potential sales- based milestone payments in respect of net sales of the Product and (c) of certain associated license and acquisition payments relating to the Product. The Purchase Agreement contains customary representations, warranties and agreements by the Company and XOMA, indemnification obligations of the parties and other obligations of the parties. Securities Purchase Agreements On January 17, 2024, the Company entered into Securities Purchase Agreements, or the Securities Purchase Agreements, under exceptional and / with certain institutional investors, or the Purchasers limited circumstances, modifying relating to the issuance and sale of pre-terminating trading plans under Rule 10b5- 1 and provides funded warrants to the Purchasers in a two- tranche private placement, or for quantitative guidelines for selling the Private Placement, to purchase shares of the Company's common stock, par value \$ 0. Responsibility All persons 001 per share, or the Common..... is a conditional purchase by the Purchasers subject to either (a) the satisfaction or waiver of achieving a pivotal trial milestone event, or the Pivotal Trial Milestone, or (b) the satisfaction or waiver of the volume- weighted average price of the Common Stock for each of the immediately subsequent five (5) trading days following the Company's announcement Insider Trading Policy ( the " Insider Trading Policy ") who seek to establish

a Rule 10b5-1 trading plan relating to the Company's securities (a "Trading Plan") are required to adhere to this Trading Plan Policy. Eligibility All members of the Company's Board of Directors and its pivotal employees are eligible to adopt a Trading Plan. Rule 10b5-1 provides, subject to compliance with the applicable provisions of the rule, an affirmative defense for employees, officers, and directors against allegations of insider trading if the employee, officer or director's transactions occur under a previously established written contract, plan or instruction. 1. 10b5-1 Trading Plans 1.1 It shall not be a violation of the Insider Trading Policy for any person subject to any "blackout" period (as described in the Insider Trading Policy) to sell (or purchase) securities of the Company under Trading Plans that comply with Rule 10b5-1, applicable state laws and this Trading Plan Policy, and are pre-cleared in advance by the applicable Trading Compliance Officer. For purposes of this Trading Plan Policy, the "Trading Compliance Officer" shall be the Company's Chief Financial Officer and its General Counsel. 1.2 The Trading Plan must: (a) specify the amount, price and date of the transaction (s); or (b) include a written formula for determining amounts, prices and dates for the transaction (s). For the purposes of a Trading Plan, the following definitions apply: • "amount" means a specified number of shares of the Company's common stock or a specified dollar value of securities. • "price" means a market price on a particular date or a limit price, or a particular dollar price. • "date" means the day of the year when the order is to be executed, or as soon thereafter as is practical under ordinary principles of best execution. In case of a limit order, "date," means the day of the year when the order is in effect. 2. Procedures for Adopting, Modifying and Terminating Trading Plans 2.1 Any person wishing to establish a Trading Plan under this Trading Plan Policy must first obtain written preclearance from a Trading Compliance Officer. The Company reserves the right to preclear or not preclear any proposed Trading Plan (or modification or termination of any existing Trading Plan) in his or her, or the Company's, sole and absolute discretion and to require the termination or suspension of a Trading Plan at any time. In addition, to the extent that any proposed Trading Plan submitted for preclearance specifies the date or date (s) on which sales of the Company's common stock are to be effected, the Company reserves the right, as part of the preclearance procedure, to require modifications or changes to those dates in its sole and absolute discretion. 2.2 The Company's preclearance of a Trading Plan does not in any way constitute the rendering of financial, tax or legal advice to the person establishing a Trading Plan. Moreover, the Company's preclearance of a Trading Plan does not constitute a representation or warranty that the Trading Plan is valid under Rule 10b5-1. It is the responsibility of the person who adopts a Trading Plan to ensure compliance with Rule 10b5-1. 2.3 A proposed Trading Plan (or modification or termination of any existing Trading Plan) shall comply with and/or include the following elements, as well as such additional terms and conditions as the Company may require, in its sole and absolute discretion, in any particular circumstance: 2.3.1 All Trading Plans must be in writing. In addition, except as otherwise approved in advance by the Company's Chief Financial Officer or General Counsel, all Trading Plans must be entered into with Charles Schwab & Co. (or any successor thereto or affiliate thereof) ("Schwab") on Schwab's then standard form of Trading Plan, with any changes thereto as may be required by the Company in its sole and absolute discretion. 2.3.2 All Trading Plans must include or be accompanied by a written representation from the insider stating that the insider is not aware of any material non-public information at the time that the Trading Plan is established and that the insider intends for the Trading Plan to comply with, or that the Trading Plan is being entered into for the purpose of establishing a trading arrangement that complies with, the requirements of Rule 10b5-1. 2.3.3 The Company will assess whether there is material information that has not been publicly disclosed at the time that a person wishes to enter into a Trading Plan (or to modify or terminate a previously adopted Trading Plan) or whether it is otherwise in the best interest of the Company for a person to enter into a Trading Plan at the proposed time or on the proposed terms. If there is any such undisclosed information or other determination, the Company may delay its approval of the Trading Plan until the information has been disclosed or until such time as is determined to be in the Company's best interest. 2.3.4 No person may enter into, modify or terminate a Trading Plan during a blackout period in which the person is not permitted to purchase or sell pursuant to the Insider Trading Policy or when a person is aware of any material non-public information about the Company or its securities. 2.3.5 The Trading Plan must provide that the first trade under the Trading Plan shall not occur until at least 30 days after the date of adoption. 2.3.6 The Company may determine, and shall be entitled, to publicly disclose that a person has entered into a Trading Plan (by press release, web site posting, or the other Price-Milestone means of disclosure). 2.3.7 A Trading Plan should have a minimum term of at least six months and shall not have maximum term exceeding 24 months. 2.3.8 No person may (i) exercise any subsequent influence over how, which will result when, or whether to effect purchases or sales pursuant his or her Trading Plan or (ii) communicate any material nonpublic information to the broker managing the Trading Plan. After the establishment of the Trading Plan, there should be no communications between the broker and the person maintaining the Trading Plan other than the broker providing notice of trades under the Trading Plan to such person. 2.3.9 No person may have in additional aggregate gross proceeds effect at any time more than one Trading Plan covering any shares beneficially owned by that person, except in connection with any program specifically arranged by the Company related to the Company of approximately \$ equity compensation arrangements. 2.3.10 A person adopting a Trading Plan may not have entered into or altered a corresponding or hedging transaction or position with respect to the Pivotal Trial-Milestone securities subject to the Trading Plan and must agree not to enter into any such transaction while the Trading Plan is in effect. 2.3.11 No person may adopt a Trading Plan providing for the sale of shares of the Company's common stock to be purchased on a future date under the Company's Employee Stock Purchase Plan. 2.3.12 Although Rule 10b5-1 does not preclude terminating plans, committing to a Trading Plan structure and fully following through on the Trading Plan enhances the likelihood that the Rule 10b5-1's affirmative defense will be available should the Trading Plan transactions be challenged. Moreover, the voluntary termination of a Trading Plan can call into question the validity of a subsequently adopted Trading Plan. In addition, the effectiveness of the affirmative defense afforded by a Trading Plan could be put at risk as a result of Trading Plan modifications. Accordingly, voluntary plan terminations and modifications are strongly discouraged under this Trading Plan Policy. As a result, any person adopting a Trading Plan must be prepared to allow the Trading Plan to run its full course, with respect no expectation of any ability to voluntarily terminate or modify the Trading Plan. The Company recognizes, however, that there may be exceptional and/or limited circumstances under which a Trading Plan modification or termination may be necessary or appropriate. In such event, the Company's Chief Financial Officer or General Counsel may, in their sole and absolute discretion, approve in advance a Trading Plan modification or termination, with any such restrictions or conditions, including appropriate "cooling off" periods, as they may determine in Price-Milestone, excluding their proceeds sole and absolute discretion. 2.3.13 During the time period that a person has a Trading Plan in effect, such person should not trade in the Company's securities outside of the Trading Plan. Trading the Company's securities outside of a person's Trading Plan can in certain circumstances put the validity of a person's Trading Plan at risk. Notwithstanding the foregoing, if a person with a Trading Plan any, from the exercise of the Pre-Funded Warrants issued in such closing. In the first tranche effect desires to participate in a purchase and subsequent resale of shares of the Private Placement, the Company's issued Pre-Funded Warrants to purchase up to 7,792,208 shares of Common common Stock stock. In the second tranche of the Private Placement, the Company is expected to issue (i) in connection with achieving the Pivotal Trial-Milestone, Pre-Funded Warrants to purchase up to 12,987,013 shares of Common Stock, and (ii) in connection with achieving the Price-Milestone, Pre-Funded Warrants to purchase up to 2,597,402 shares of Common Stock. Any of the conditions in the second tranche can be waived by each Purchaser. The Securities Purchase Agreements contain customary representations, warranties and agreements by the Company and the Purchasers, indemnification rights and other obligations of the parties. F-42 In connection with the Private Placement, the Company entered into a registration rights agreement, dated January 17, 2024, with the Purchasers, or the Registration Rights Agreement, pursuant to which the Company's Employee Stock Purchase Plan ("ESPP Shares"), the person may effect a sale of ESPP Shares outside of the Trading Plan provided that (1) any such sale of ESPP shares is effected at a when the trading window is open and not during a blackout period), (2) the person is at the time of such sale not in possession of material non-public information of the Company, and (3) the sale of ESPP Shares has agreed been approved in advance by the Company's Chief Financial Officer or the General Counsel. 2.3.14 A Trading Plan must contain procedures to file one or more registration statements ensure prompt compliance with (1) any applicable reporting requirements under Section 16 of the Exchange Act, (2) Rule 144 under the Securities Act of 1933 as amended, relating to any sales under the Trading Plan and (3) any suspension of trading or the other Securities Act trading restrictions that the Company imposes on sales under an approved Trading Plan. Compliance with these rules is ultimately the responsibility of each person, not the Company. 2.3.15 Section 16, Form 4 and Form 144 filings by an insider with the Securities and Exchange Commission must expressly indicate when transactions are made pursuant, or the SEC, covering the resale of the shares of Common Stock underlying the Pre-Funded Warrants no later than 15 days following the date of each applicable closing of the Private Placement, and to use reasonable best efforts to have the registration statements declared effective as promptly as practical thereafter, and in any event no later than 90 days following the applicable closing date in the event of a Rule 10b5-1 Trading Plan "full review" by the SEC..... to \$ 0.77 per share. Exhibit 23.1 Consent of Independent Registered Public Accounting Firm We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-268396, 333-264326, 333-273589, and 333-275721) and Form S-8 (Nos. 333-275720, 333-258896, 333-239213, 333-230139, 333-223535, 333-216492, 333-202709, 333-194634, 333-187206, 333-237195, 333-209998, 333-180334, and 333-172409) of Talphera, Inc. of our report dated March 6-31, 2024-2025, which includes an explanatory paragraph relating to Talphera, Inc.'s ability to continue as a going concern, relating to the consolidated financial statements, which appears in this Form 10-K. Exhibit 23.2-CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-275721, 333-273589, 333-268396, and 333-264326) and Form S-8 (Nos. 333-275720, 333-258896, 333-239213, 333-230139, 333-223535, 333-216492, 333-202709, 333-194634, 333-187206, 333-237195, 333-

209998, 333-180334, and 333-172409) of Talphera, Inc. (formerly known as AcelRx Pharmaceuticals, Inc.) of our report dated March 31, 2023, except for the effects of the discontinued operations disclosed in Note 3, as to which the date is July 31, 2023, which includes an explanatory paragraph relating to Talphera, Inc.'s ability to continue as a going concern, relating to the consolidated financial statements which appear in this Annual Report on Form 10-K as of and for the years ended December 31, 2023 and 2022. Exhibit 31. 1 CERTIFICATIONS I, Vincent J. Angotti, certify that: 1. I have reviewed this annual report on Form 10-K of Talphera, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant's other certifying officer (s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 (e) and 15d-15 (e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15 (f) and 15d-15 (f)) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5. The registrant's other certifying officer (s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's Board of Directors (or persons performing the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. / s / Vincent J. Angotti Vincent J. Angotti Chief Executive Officer (Principal Executive Officer) Exhibit 31. 2 I, Raffi Asadorian, certify that: / s / Raffi Asadorian Raffi Asadorian Chief Financial Officer (Principal Financial Officer) Pursuant to the requirement set forth in Rule 13a-14 (b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U. S. C. § 1350), Vincent J. Angotti, Chief Executive Officer of Talphera, Inc. (the "Company"), and Raffi Asadorian, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge: 1. The Company's Annual Report on Form 10-K for the period ended December 31, 2023 2024, to which this Certification is attached as Exhibit 32. 1 (the "Annual Report") fully complies with the requirements of Section 13 (a) or Section 15 (d) of the Exchange Act, and 2. The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company. In Witness Whereof, the undersigned have set their hands hereto as of the 6th 31st day of March 2024 2025. / s / Vincent J. Angotti / s / Raffi Asadorian Vincent J. Angotti Chief Executive Officer Raffi Asadorian Chief Financial Officer " This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Talphera, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing. " Exhibit 97-1. Introduction The Compensation Committee (the "Compensation Committee") of the Board of Directors (the "Board") of Talphera, Inc., a Delaware corporation (the "Company"), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this "Policy") providing for the Company's recoupment of Recoverable Incentive Compensation that is received by Covered Officers of the Company under certain circumstances. Certain capitalized terms used in this Policy have the meanings given to such terms in Section 3 below. This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder ("Rule 10D-1") and Nasdaq Listing Rule 5608 (the "Listing Standards"). 2. Effective Date This Policy shall apply to all Incentive Compensation that is received by a Covered Officer on or after October 2, 2023 (the "Effective Date"). Incentive Compensation is deemed "received" in the Company's fiscal period in which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of such Incentive Compensation occurs after the end of that period. 3. Definitions "Accounting Restatement" means an accounting restatement that the Company is required to prepare due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period. "Accounting Restatement Date" means the earlier to occur of (a) the date that the Board, a committee of the Board authorized to take such action, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (b) the date that a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement. "Administrator" means the Compensation Committee or, in the absence of such committee, the Board. "Code" means the U. S. Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder. "Covered Officer" means each current and former Executive Officer. "Exchange" means The Nasdaq Stock Market LLC. "Exchange Act" means the U. S. Securities Exchange Act of 1934, as amended. "Executive Officer" means the Company's president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive officers of the Company's parent (s) or subsidiaries are deemed executive officers of the Company if they perform such policy-making functions for the Company. Policy-making function is not intended to include policy-making functions that are not significant. Identification of an executive officer for purposes of this Policy would include at a minimum executive officers identified pursuant to Item 401 (b) of Regulation S-K promulgated under the Exchange Act. "Financial Reporting Measures" means measures that are determined and presented in accordance with the accounting principles used in preparing the Company's financial statements, and any measures derived wholly or in part from such measures, including Company stock price and total stockholder return ("TSR"). A measure need not be presented in the Company's financial statements or included in a filing with the SEC in order to be a Financial Reporting Measure. "Incentive Compensation" means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure. "Lookback Period" means the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (resulting from a change in the Company's fiscal year) within or immediately following those three completed fiscal years (except that a transition period of at least nine months shall count as a completed fiscal year). Notwithstanding the foregoing, the Lookback Period shall not include fiscal years completed prior to the Effective Date. "Recoverable Incentive Compensation" means Incentive Compensation received by a Covered Officer during the Lookback Period that exceeds the amount of Incentive Compensation that would have been received had such amount been determined based on the Accounting Restatement, computed without regard to any taxes paid (i. e., on a gross basis without regard to tax withholdings and other deductions). For any compensation plans or programs that take into account Incentive Compensation, the amount of Recoverable Incentive Compensation for purposes of this Policy shall include, without limitation, the amount contributed to any notional account based on Recoverable Incentive Compensation and any earnings to date on that notional amount. For any Incentive Compensation that is based on stock price or TSR, where the Recoverable Incentive Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the Administrator will determine the amount of Recoverable Incentive Compensation based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or TSR upon which the Incentive Compensation was received. The Company shall maintain documentation of the determination of that reasonable estimate and provide such documentation to the Exchange in accordance with the Listing Standards. "SEC" means the U. S. Securities and Exchange Commission. 4. Recoupment (a) Applicability of Policy. This Policy applies to Incentive Compensation received by a Covered Officer (i) after beginning services as an Executive Officer, (ii) who served as an Executive Officer at any time during the performance period for such Incentive Compensation, (iii) while the Company had a class of securities listed on a national securities exchange or a national securities association, and (iv) during the Lookback Period. (b) Recoupment Generally. Pursuant to the provisions of this Policy, if there is an Accounting Restatement, the Company must reasonably promptly recoup the full amount of the Recoverable Incentive Compensation, unless the conditions of one or more subsections of Section 4 (c) of this Policy are met and the Compensation Committee, or, if such committee does not consist solely of independent directors, a majority of the independent directors serving on the Board, has made a determination that recoupment would be impracticable. Recoupment is required regardless of whether the Covered Officer engaged in any misconduct and regardless of fault, and the Company's obligation to recoup Recoverable Incentive Compensation is not dependent on whether or when any restated financial statements are filed. (c) Impracticability of Recovery. Recoupment may be determined to be impracticable if, and only if: (i) the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of the applicable Recoverable Incentive Compensation; provided that, before concluding that it would be impracticable to recover any amount of Recoverable Incentive Compensation based on expense of enforcement, the Company shall make a reasonable attempt to recover such

Recoverable Incentive Compensation, document such reasonable attempt (s) to recover, and provide that documentation to the Exchange in accordance with the Listing Standards; or (ii) recoupment of the applicable Recoverable Incentive Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Code Section 401 (a) (13) or Code Section 411 (a) and regulations thereunder. (d) Sources of Recoupment. To the extent permitted by applicable law, the Administrator shall, in its sole discretion, determine the timing and method for recouping Recoverable Incentive Compensation hereunder, provided that such recoupment is undertaken reasonably promptly. The Administrator may, in its discretion, seek recoupment from a Covered Officer from any of the following sources or a combination thereof, whether the applicable compensation was approved, awarded, granted, payable or paid to the Covered Officer prior to, on or after the Effective Date: (i) direct repayment of Recoverable Incentive Compensation previously paid to the Covered Officer; (ii) cancelling prior cash or equity-based awards (whether vested or unvested and whether paid or unpaid); (iii) cancelling or offsetting against any planned future cash or equity-based awards; (iv) forfeiture of deferred compensation, subject to compliance with Code Section 409A; and (v) any other method authorized by applicable law or contract. Subject to compliance with any applicable law, the Administrator may effectuate recoupment under this Policy from any amount otherwise payable to the Covered Officer, including amounts payable to such individual under any otherwise applicable Company plan or program, e.g., base salary, bonuses or commissions and compensation previously deferred by the Covered Officer. The Administrator need not utilize the same method of recovery for all Covered Officers or with respect to all types of Recoverable Incentive Compensation. (e) No Indemnification of Covered Officers. Notwithstanding any indemnification agreement, applicable insurance policy or any other agreement or provision of the Company's certificate of incorporation or bylaws to the contrary, no Covered Officer shall be entitled to indemnification or advancement of expenses in connection with any enforcement of this Policy by the Company, including paying or reimbursing such Covered Officer for insurance premiums to cover potential obligations to the Company under this Policy. (f) Indemnification of Administrator. Any members of the Administrator, and any other members of the Board who assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation made with respect to this Policy and shall be indemnified by the Company to the fullest extent under applicable law and Company policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the members of the Board under applicable law or Company policy. (g) No "Good Reason" for Covered Officers. Any action by the Company to recoup or any recoupment of Recoverable Incentive Compensation under this Policy from a Covered Officer shall not be deemed (i) "good reason" for resignation or to serve as a basis for a claim of constructive termination under any benefits or compensation arrangement applicable to such Covered Officer, or (ii) to constitute a breach of a contract or other arrangement to which such Covered Officer is party. 5. Administration Except as specifically set forth herein, this Policy shall be administered by the Administrator. The Administrator shall have full and final authority to make any and all determinations required under this Policy. Any determination by the Administrator with respect to this Policy shall be final, conclusive and binding on all interested parties and need not be uniform with respect to each individual covered by this Policy. In carrying out the administration of this Policy, the Administrator is authorized and directed to consult with the full Board or such other committees of the Board as may be necessary or appropriate as to matters within the scope of such other committee's responsibility and authority. Subject to applicable law, the Administrator may authorize and empower any officer or employee of the Company to take any and all actions that the Administrator, in its sole discretion, deems necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee). 6. Severability If any provision of this Policy or the application of any such provision to a Covered Officer shall be adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision or application enforceable. 7. No Impairment of Other Remedies Nothing contained in this Policy, and no recoupment or recovery as contemplated herein, shall limit any claims, damages or other legal remedies the Company or any of its affiliates may have against a Covered Officer arising out of or resulting from any actions or omissions by the Covered Officer. This Policy does not preclude the Company from taking any other action to enforce a Covered Officer's obligations to the Company, including, without limitation, termination of employment and / or institution of civil proceedings. This Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 ("SOX 304") that are applicable to the Company's Chief Executive Officer and Chief Financial Officer and to any other compensation recoupment policy and / or similar provisions in any employment, equity plan, equity award, or other individual agreement, to which the Company is a party or which the Company has adopted or may adopt and maintain from time to time; provided, however, that compensation recouped pursuant to this Policy shall not be duplicative of compensation recouped pursuant to SOX 304 or any such compensation recoupment policy and / or similar provisions in any such employment, equity plan, equity award, or other individual agreement except as may be required by law. 8. Amendment; Termination The Administrator may amend, terminate or replace this Policy or any portion of this Policy at any time and from time to time in its sole discretion. The Administrator shall amend this Policy as it deems necessary to comply with applicable law or any Listing Standard. 9. Successors This Policy shall be binding and enforceable against all Covered Officers and, to the extent required by Rule 10D-1 and / or the applicable Listing Standards, their beneficiaries, heirs, executors, administrators or other legal representatives. 10. Required Filings The Company shall make any disclosures and filings with respect to this Policy that are required by law, including as required by the SEC. \*\*\*\*\*v3 25 24-0-1 Document And Entity Information- USD (\$) \$ in Millions 12 Months Ended Dec. 31, 2023 Feb. 29, 2024 Mar. 17, 2025 Jun. 30, 2023 Document-2024 Document [ Information [ Line Items ] Document Type 10-K Document Annual Report true Document Period End Date Dec. 31, 2023-2024 Document Transition Report false Entity File Number 001- 35068 Entity Registrant Name TALPHERA, INC. Entity Incorporation, State or Country Code DE Entity Tax Identification Number 41- 2193603 Entity Address, Address Line One 1850 Gateway Drive, Suite 175 Entity Address, City or Town San Mateo Entity Address, State or Province CA Entity Address, Postal Zip Code City Area Code Local Phone Number 216- 3500 Title of 12 (b) Security Common Stock, \$ 0. 001 par value Trading Symbol TLPH Security Exchange Name NASDAQ Entity Well-known Seasoned Issuer No Entity Voluntary Filers No Entity Current Reporting Status Yes Entity Interactive Data Current Yes Entity Filer Category Non-accelerated Filer Entity Small Business true Entity Emerging Growth Company false ICFR Auditor Attestation Flag false Document Financial Statement Error Correction [ Flag ] false Entity Shell Company false Entity Public Float \$ 13, 12, 073, 654 Entity 2 Entity Common Stock, Shares Outstanding (in shares) 46-17, 969-098, 403-345 Auditor Firm ID Auditor Name BPM LLP Auditor Location Walnut Creek, California Entity Central Index Key Current Fiscal Year End Date-- 12- 31 Document Fiscal Year Focus Document Fiscal Period Focus FY Amendment Flag false X- Definition Boolean flag that is true when the XBRL content amends previously- filed or accepted submission. References No definition available. Details Name: dei\_AmendmentFlag Namespace Prefix: dei\_Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- Definition PCAOB issued Audit Firm Identifier References Reference 1: http:// www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 10- K- Number 249- Section 310 Reference 2: http:// www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 20- F- Number 249- Section 220- Subsection f Reference 3: http:// www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 40- F- Number 249- Section 240- Subsection f Details Name: dei\_AuditorFirmId Namespace Prefix: dei\_Data Type: dei: nonemptySequenceNumberItemType Balance Type: na Period Type: durationX- References Reference 1: http:// www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 10- K- Number 249- Section 310 Reference 2: http:// www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 20- F- Number 249- Section 220- Subsection f Reference 3: http:// www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 40- F- Number 249- Section 240- Subsection f Details Name: dei\_AuditorLocation Namespace Prefix: dei\_Data Type: dei: internationalNameItemType Balance Type: na Period Type: durationX- References Reference 1: http:// www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 10- K- Number 249- Section 310 Reference 2: http:// www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 20- F- Number 249- Section 220- Subsection f Reference 3: http:// www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 40- F- Number 249- Section 240- Subsection f Details Name: dei\_AuditorName Namespace Prefix: dei\_Data Type: dei: internationalNameItemType Balance Type: na Period Type: durationX- Definition Area code of city References No definition available. Details Name: dei\_CityAreaCode Namespace Prefix: dei\_Data Type: xbrli: normalizedStringItemType Balance Type: na Period Type: durationX- Definition End date of current fiscal year in the format-- MM- DD. References No definition available. Details Name: dei\_CurrentFiscalYearEndDate Namespace Prefix: dei\_Data Type: xbrli: gMonthDayItemType Balance Type: na Period Type: durationX- Definition Boolean flag that is true only for a form used as an annual report. References Reference 1: http:// www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 10- K- Number 249- Section 310 Reference 2: http:// www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 20- F- Number 249- Section 220- Subsection f Reference 3: http:// www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 40- F- Number 249- Section 240- Subsection f Details Name: dei\_DocumentAnnualReport Namespace Prefix: dei\_Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- Definition Indicates whether any of the financial statement period in the filing include a restatement due to error correction. References Reference 1: http:// www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Regulation S- K- Number 229- Section 402- Subsection w Reference 2: http:// www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 10- K- Number 249- Section 310 Reference 3: http:// www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 20- F- Number 249- Section 220- Subsection f Reference 4: http:// www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 40- F- Number 249- Section 240- Subsection f Details Name: dei\_DocumentFinStmntErrorCorrectionFlag Namespace Prefix: dei\_Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- Definition Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10- Q or 10- QT statements have value Q1, Q2, and Q3 respectively, with 10- K, 10- KT or other fiscal year statements having FY. References No definition available. Details Name: dei\_DocumentFiscalPeriodFocus Namespace Prefix: dei\_Data Type: dei: fiscalPeriodItemType Balance Type: na Period Type: durationX- Definition This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods,

fiscal 2006 should be given as the fiscal year focus. Example: 2006. ReferencesNo definition available. Details Name: dei\_DocumentFiscalYearFocus Namespace Prefix: dei\_Data Type: xbrli:gYearItemType Balance Type: na Period Type: durationX- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesNo definition available. Details Name: dei\_DocumentInformationLineItems Namespace Prefix: dei\_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. ReferencesNo definition available. Details Name: dei\_DocumentPeriodEndDate Namespace Prefix: dei\_Data Type: xbrli:dateItemType Balance Type: na Period Type: durationX- DefinitionBoolean flag that is true only for a form used as a transition report. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Forms 10-K, 10-Q, 20-F-Number 240-Section 13-Subsection a-1> Details Name: dei\_DocumentTransitionReport Namespace Prefix: dei\_Data Type: xbrli:booleanItemType Balance Type: na Period Type: durationX- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. ReferencesNo definition available. Details Name: dei\_DocumentType Namespace Prefix: dei\_Data Type: dei:submissionTypeItemType Balance Type: na Period Type: durationX- DefinitionAddress Line 1 such as Attn, Building Name, Street Name ReferencesNo definition available. Details Name: dei\_EntityAddressAddressLine1 Namespace Prefix: dei\_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: durationX- DefinitionName of the City or Town ReferencesNo definition available. Details Name: dei\_EntityAddressCityOrTown Namespace Prefix: dei\_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: durationX- DefinitionCode for the postal or zip code ReferencesNo definition available. Details Name: dei\_EntityAddressPostalZipCode Namespace Prefix: dei\_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: durationX- DefinitionName of the state or province. ReferencesNo definition available. Details Name: dei\_EntityAddressStateOrProvince Namespace Prefix: dei\_Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: durationX- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Exchange Act-Number 240-Section 12-Subsection b-2> Details Name: dei\_EntityCentralIndexKey Namespace Prefix: dei\_Data Type: dei:centerIndexKeyItemType Balance Type: na Period Type: durationX- DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class / interest by adding class of stock items such as Common Class A [ Member ], Common Class B [ Member ] or Partnership Interest [ Member ] onto the Instrument [ Domain ] of the Entity Listings, Instrument. ReferencesNo definition available. Details Name: dei\_EntityCommonStockSharesOutstanding Namespace Prefix: dei\_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX- DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. ReferencesNo definition available. Details Name: dei\_EntityCurrentReportingStatus Namespace Prefix: dei\_Data Type: dei:yesNoItem Balance Type: na Period Type: durationX- DefinitionIndicate if registrant meets the emerging growth company criteria. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Exchange Act-Number 240-Section 12-Subsection b-2> Details Name: dei\_EntityEmergingGrowthCompany Namespace Prefix: dei\_Data Type: xbrli:booleanItemType Balance Type: na Period Type: durationX- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. ReferencesNo definition available. Details Name: dei\_EntityFileNumber Namespace Prefix: dei\_Data Type: dei:fileNumberItemType Balance Type: na Period Type: durationX- DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Exchange Act-Number 240-Section 12-Subsection b-2> Details Name: dei\_EntityFilerCategory Namespace Prefix: dei\_Data Type: dei:filerCategoryItemType Balance Type: na Period Type: durationX- DefinitionTwo-character EDGAR code representing the state or country of incorporation. ReferencesNo definition available. Details Name: dei\_EntityIncorporationStateCountryCode Namespace Prefix: dei\_Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: durationX- DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Regulation S-T-Number 232-Section 405> Details Name: dei\_EntityInteractiveDataCurrent Namespace Prefix: dei\_Data Type: dei:yesNoItem Balance Type: na Period Type: durationX- DefinitionThe aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter. ReferencesNo definition available. Details Name: dei\_EntityPublicFloat Namespace Prefix: dei\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Exchange Act-Number 240-Section 12-Subsection b-2> Details Name: dei\_EntityRegistrantName Namespace Prefix: dei\_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: durationX- DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Exchange Act-Number 240-Section 12-Subsection b-2> Details Name: dei\_EntityShellCompany Namespace Prefix: dei\_Data Type: xbrli:booleanItemType Balance Type: na Period Type: durationX- DefinitionIndicates that the company is a Smaller Reporting Company (SRC). ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Exchange Act-Number 240-Section 12-Subsection b-2> Details Name: dei\_EntitySmallBusiness Namespace Prefix: dei\_Data Type: xbrli:booleanItemType Balance Type: na Period Type: durationX- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Exchange Act-Number 240-Section 12-Subsection b-2> Details Name: dei\_EntityTaxIdentificationNumber Namespace Prefix: dei\_Data Type: dei:employerIdItem Balance Type: na Period Type: durationX- DefinitionIndicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15 (d) of the Act. ReferencesNo definition available. Details Name: dei\_EntityVoluntaryFilers Namespace Prefix: dei\_Data Type: dei:yesNoItem Balance Type: na Period Type: durationX- DefinitionIndicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Securities Act-Number 230-Section 405> Details Name: dei\_EntityWellKnownSeasonedIssuer Namespace Prefix: dei\_Data Type: dei:yesNoItem Balance Type: na Period Type: durationX- ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Form 10-K-Number 249-Section 310> Reference 2: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Form 20-F-Number 249-Section 220-Subsection f> Reference 3: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Form 40-F-Number 249-Section 240-Subsection f> Details Name: dei\_IcfrAuditorAttestationFlag Namespace Prefix: dei\_Data Type: xbrli:booleanItemType Balance Type: na Period Type: durationX- DefinitionLocal phone number for entity. ReferencesNo definition available. Details Name: dei\_LocalPhoneNumber Namespace Prefix: dei\_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: durationX- DefinitionTitle of a 12 (b) registered security. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Exchange Act-Number 240-Section 12-Subsection b> Details Name: dei\_Security12bTitle Namespace Prefix: dei\_Data Type: dei:securityTitleItem Balance Type: na Period Type: durationX- DefinitionName of the Exchange on which a security is registered. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Exchange Act-Number 240-Section 12-Subsection d1-1> Details Name: dei\_SecurityExchangeName Namespace Prefix: dei\_Data Type: dei:edgarExchangeCodeItem Balance Type: na Period Type: durationX- DefinitionTrading symbol of an instrument as listed on an exchange. ReferencesNo definition available. Details Name: dei\_TradingSymbol Namespace Prefix: dei\_Data Type: dei:tradingSymbolItem Balance Type: na Period Type: duration Consolidated Balance Sheets- USD (\$) \$ in Thousands Dec. 31, 2023-2024 Dec. 31, 2022Current 2023Current Assets: Cash and cash equivalents \$ 8,863 \$ 5,721Short 721 \$ 15,275Restricted cash-5,000Short-term investments 3,660Prepaid expenses and other current assets 2,475 1,865Assets of discontinued operations 1,931Total 195Total current assets 9,417 11,556 24,566In- process research and development asset 8,819 8,819Other assetsAssets of discontinued operations 13,936Total 819Total assets 18,236 20,395Current 395 47,487Current Liabilities: Accounts payable 1,336 1,256Accrued 336Accrued and other liabilities 1,254 2,445 2,531Long-term debt, current portion 5,363Liabilities of discontinued operations, current portionTotal portion 4,620Total current liabilities 2,647 4,512Warrant 512 13,770Warrant liability 1,778 7,061 1,778Liability related the sale 098Other long-term liabilitiesLiabilities of discontinued operations 3 future payments 6,995Total 527Total liabilities 10,235 6,290 25,673Commitments 290Commitments and Contingencies us-gaap\_StockholdersEquityAbstract Stockholders' Equity: Common stock, \$ 0.001 par value -- 200,000,000 shares authorized as of December 31, 2024 and 2023 and 2022: 17,029,469 and 16,952,519 and 8,243,680 shares issued and outstanding as of December 31, 2024 and 2023 and 2022, respectivelyAdditional paid-in capital 465,214 458,314 447,635Accumulated 314Accumulated deficit (457,230) (444,226) (425,829) Total stockholders' equity 8,001 14,405 21,814Total 105Total Liabilities and

Stockholders' Equity \$ **18,236** \$ **20,395** \$ **47,487** -X - DefinitionAmount of liability related of the sale of future payments ReferencesNo definition available. Details Name: **tph\_LiabilitiesRelatedToTheSaleOfFuturePayments** Namespace Prefix: **tph\_** Data Type: **xbrli:monetaryItemType** Balance Type: **credit** Period Type: **instantX** - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). ReferencesReference 1: [http://www.fasb.org/xbrl/2003-us-gaap/role/exampleRef-ref/legacyRef-Topic852-210-SubTopic10-NameAccountingStandardsCodification-Section55-S99-Paragraph1-Subparagraph\(SX10-210-5-02\(19\)\(a\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481372-2147480566-210-10-S99-1Reference2:http://www.xbrl.org/2003/role/exampleRef-Topic852-SubTopic10-55-10Reference2:http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic210-Section55-SubTopicParagraph10-SectionS99-Paragraph1-Subparagraph\(SX210-5-02-19\(a\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566-2147481372-210-852-10-S99-55-10](http://www.fasb.org/xbrl/2003-us-gaap/role/exampleRef-ref/legacyRef-Topic852-210-SubTopic10-NameAccountingStandardsCodification-Section55-S99-Paragraph1-Subparagraph(SX10-210-5-02(19)(a))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481372-2147480566-210-10-S99-1Reference2:http://www.xbrl.org/2003/role/exampleRef-Topic852-SubTopic10-55-10Reference2:http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic210-Section55-SubTopicParagraph10-SectionS99-Paragraph1-Subparagraph(SX210-5-02-19(a))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566-2147481372-210-852-10-S99-55-10) Details Name: **us-gaap\_AccountsPayableCurrent** Namespace Prefix: **us-gaap\_** Data Type: **xbrli:monetaryItemType** Balance Type: **credit** Period Type: **instantX** - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). ReferencesReference 1:

Standards Codification- **Topic 740- SubTopic 10-** Section 50- Paragraph **7-3-** Subparagraph (a)- Publisher FASB- URI <https://asc.fasb.org/1943274/21474814042147482685/740-10-50-32147479853-2147478546> 942- 210- S99- 1 Details Name: us- gaap\_ Assets Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionSum- DefinitionAmount of the carrying amounts **asset recognized for present right to economic benefit, classified as current of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.** ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic810-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-Subparagraph\(bb\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic810-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-Subparagraph(bb)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.4-08\(g\)\(1\)\(ii\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic810-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph25-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic825-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph28-Subparagraph\(f\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic323-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-Subparagraph(c)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic210-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph1-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483467/210-10-45-1](http://www.xbrl.org/2003/role/exampleRef-Topic852-SubTopic10-NameAccountingStandardsCodification-Section55-Paragraph10-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481372/852-10-55-10)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(ii\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(9))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 10: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(iii\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(4)(ii))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(iii\)\(A\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(4)(iii)(A))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(iii\)\(A\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(4)(iv))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-02\(a\)\(4\)\(ii\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(5))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iii\)\(B\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(iii)(A))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(5\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(iv))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic852-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph7-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef-Topic852-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph7-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481404/852-10-50-7) Details Name: us- gaap\_ AssetsCurrent Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- ReferencesNo definition available. Details Name: us- gaap\_ AssetsCurrentAbstract Namespace Prefix: us- gaap\_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionAmount classified as **assets attributable to..... Type: debit Period Type: instantX-** DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic210-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph1-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483467/210-10-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(1))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic944-942-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.7-9-03\(17a\)\(19\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/21474794462147478546/944-942-210-S99-1](http://asc.fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic230-SubTopic10-Section45-Paragraph4-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482740/230-10-45-4)Reference 2: [http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic946-210-SubTopic210-10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.7-03\(a\)\(19\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic946-210-SubTopic210-10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.6-5-04-02(15-25))-PublisherFASB-URIhttps://asc.fasb.org/1943274/21474796172147480566/946-210-10-S99-1)Reference 4: [http://www.fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph\(SX210.5-6-02-25-04\(15\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/21474805662147479170/946-210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic942-946-SubTopic210-SectionS99-Paragraph1-Subparagraph(SX210.9-03-17)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479853/942-210-S99-1) Details Name: us- gaap\_ CommitmentsAndContingencies Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. ReferencesReference 1: [http://www.fasb.xbrl.org/2003/role/exampleRef-Topic852-SubTopic10-55-10](http://www.fasb.xbrl.org/2003-us-gaap/role/exampleRef-ref/legacyRef-Topic852-210-SubTopic10-NameAccountingStandardsCodification-Section55-S99-Paragraph1-Subparagraph(SX40-210.5-02(29))-PublisherFASB-URIhttps://asc.fasb.org/1943274/21474813722147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic210-NameAccountingStandardsCodification-SectionS99-55-Paragraph1-Subparagraph(SX210.10-7-03(a)(22))-PublisherFASB-URIhttps://asc.fasb.org/1943274/21474794402147481372/852-10-55-10)Reference 3: [http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-7-02-03\(29a\)\(22\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/21474805662147478777/944-210-10-S99-1](http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-7-02-03(29a)(22))-PublisherFASB-URIhttps://asc.fasb.org/1943274/21474805662147478777/944-210-10-S99-1) Details Name: us- gaap\_ CommonStockValue Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount ---- DefinitionSum classified of the carrying amounts of all intangible assets, excluding goodwill, as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle balance sheet date, if longer net of accumulated amortization and impairment charges. ReferencesReference 1: [http://www.fasb.org/2009-us-gaap/role/ref/legacyRef-commonPracticeRef-Topic350-SubTopic30-NameAccountingStandardsCodification-Section45-50-Paragraph40-2-SubTopic20-Topic205-Subparagraph\(a\)\(1\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/21474834752147482665/205-350-20-30-45-50-10](http://www.fasb.org/2009-us-gaap/role/ref/legacyRef-commonPracticeRef-Topic350-SubTopic30-NameAccountingStandardsCodification-Section45-50-Paragraph40-2-SubTopic20-Topic205-Subparagraph(a)(1)-PublisherFASB-URIhttps://asc.fasb.org/1943274/21474834752147482665/205-350-20-30-45-50-10)Reference 2: [http://www.fasb.org/2009-us-gaap/role/ref/legacyRef-commonPracticeRef-Topic350-SubTopic30-NameAccountingStandardsCodification-Section45-50-Paragraph41-2-Subparagraph\(b\)SubTopic10-Topic](http://www.fasb.org/2009-us-gaap/role/ref/legacyRef-commonPracticeRef-Topic350-SubTopic30-NameAccountingStandardsCodification-Section45-50-Paragraph41-2-Subparagraph(b)SubTopic10-Topic)

360 - Publisher FASB- URI [https://asc.fasb.org/#1943274/2147482130-2147482665\\_350-360-30\\_10-50-45-11Reference-2Reference-3](https://asc.fasb.org/#1943274/2147482130-2147482665_350-360-30_10-50-45-11Reference-2Reference-3): <http://www.xbrl.org/2003/role/disclosureRef-Topic-205-350-SubTopic-20-30-Name-Accounting-Standards-Codification-Section-50-45-Paragraph-7-1> - Publisher FASB- URI [https://asc.fasb.org/#1943274/2147482499-2147482686\\_205-20-50-350\\_7Reference-4-30-45-1-Details-Name-us-gaap-IntangibleAssetsNetExcludingGoodwillNamespace-Prefix-us-gaap-Data-Type-xbrli:monetaryItemType-Balance-Type-debitPeriod-Type-instantX-DefinitionAmount-of-liability-recognized-for-present-obligation-requiring-transfer-or-otherwise-providing-economic-benefit-to-others-ReferencesReference-1](https://asc.fasb.org/#1943274/2147482499-2147482686_205-20-50-350_7Reference-4-30-45-1-Details-Name-us-gaap-IntangibleAssetsNetExcludingGoodwillNamespace-Prefix-us-gaap-Data-Type-xbrli:monetaryItemType-Balance-Type-debitPeriod-Type-instantX-DefinitionAmount-of-liability-recognized-for-present-obligation-requiring-transfer-or-otherwise-providing-economic-benefit-to-others-ReferencesReference-1) : [http://www.fasb.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic-205-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-5C-1-Subparagraph-\(a\)-SX-210.5-02-\(2-22\)-SubTopic-10-Topic-210](http://www.fasb.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic-205-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-5C-1-Subparagraph-(a)-SX-210.5-02-(2-22)-SubTopic-10-Topic-210) - Publisher FASB- URI [https://asc.fasb.org/#1943274/2147483499-2147480566\\_205-20-210-50-10-S99-5CReference-1Reference-5-2](https://asc.fasb.org/#1943274/2147483499-2147480566_205-20-210-50-10-S99-5CReference-1Reference-5-2) : [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-205-210-SubTopic-20-10-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-5B-1-Subparagraph-\(e\)-SX-210.5-02-\(20\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-205-210-SubTopic-20-10-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-5B-1-Subparagraph-(e)-SX-210.5-02-(20)) - Publisher FASB- URI [https://asc.fasb.org/#1943274/2147483499-2147480566\\_205-20-210-50-10-S99-5BReference-1Reference-6-3](https://asc.fasb.org/#1943274/2147483499-2147480566_205-20-210-50-10-S99-5BReference-1Reference-6-3) : [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-360-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-3-1-Subparagraph-\(e\)-SX-210.5-02-\(24\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-360-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-3-1-Subparagraph-(e)-SX-210.5-02-(24)) - Publisher FASB- URI [https://asc.fasb.org/#1943274/2147482099-2147480566\\_360-210-10-50-S99-3Reference-1Reference-7-4](https://asc.fasb.org/#1943274/2147482099-2147480566_360-210-10-50-S99-3Reference-1Reference-7-4) : [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-205-210-SubTopic-20-10-Name-Accounting-Standards-Codification-Section-45-S99-Paragraph-1-1-Subparagraph-\(SX-210.5-02-\(19\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-205-210-SubTopic-20-10-Name-Accounting-Standards-Codification-Section-45-S99-Paragraph-1-1-Subparagraph-(SX-210.5-02-(19))) - Publisher FASB- URI [https://asc.fasb.org/#1943274/2147483475-2147480566\\_205-20-210-45-10\\_1-Details-Name-S99-1Reference-5](https://asc.fasb.org/#1943274/2147483475-2147480566_205-20-210-45-10_1-Details-Name-S99-1Reference-5) : <http://fasb.org/us-gaap-DisposalGroupIncludingDiscontinuedOperationAssetsNonecurrent-namespace-Prefix-us-gaap-Data-Type-xbrli:monetaryItemType-Balance-Type-debitPeriod-Type-instantX-DefinitionSum-of-the-carrying-amounts-of-all-intangible-assets-excluding-goodwill-as-of-the-balance-sheet-date-net-of-accumulated-amortization-and-impairment-charges-ReferencesReference-1> : [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-350-SubTopic-30-Section-50-S99-Paragraph-2-1-Subparagraph-\(SX-210.5-02-\(25-a\)\(1\)-\(b\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-350-SubTopic-30-Section-50-S99-Paragraph-2-1-Subparagraph-(SX-210.5-02-(25-a)(1)-(b))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482665-2147480566/350-210-30-10-50-S99-2Reference-1Reference-2-6> : [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-350-SubTopic-30-Section-45-S99-Paragraph-1-Subparagraph-\(SX-210.5-02-\(26\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-350-SubTopic-30-Section-45-S99-Paragraph-1-Subparagraph-(SX-210.5-02-(26))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482686-2147480566/350-210-30-10-45-S99-1Reference-7-1-Details-Name-us-gaap-IntangibleAssetsNetExcludingGoodwillNamespace-Prefix-us-gaap-gaap-Data-Type-xbrli:monetaryItemType-Balance-Type-debitPeriod-Type-instantX-DefinitionSum-of-the-carrying-amounts-as-of-the-balance-sheet-date-of-all-liabilities-that-are-recognized-Liabilities-are-probable-future-sacrifices-of-economic-benefits-arising-from-present-obligations-of-an-entity-to-transfer-assets-or-provide-services-to-other-entities-in-the-future-ReferencesReference-1> : [http://www.xbrl.org/2003/role/disclosureRef-ref/legacyRef-Topic-810-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-3-1-Subparagraph-\(e\)-SX-210.5-02-\(23\)](http://www.xbrl.org/2003/role/disclosureRef-ref/legacyRef-Topic-810-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-3-1-Subparagraph-(e)-SX-210.5-02-(23)) - Publisher FASB- URI [https://asc.fasb.org/#1943274/2147481203-2147480566\\_810-210-10-50-S99-3Reference-1Reference-2-8](https://asc.fasb.org/#1943274/2147481203-2147480566_810-210-10-50-S99-3Reference-1Reference-2-8) : [http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic-810-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-S99-Paragraph-25-1-Subparagraph-\(b\)-SX-210.5-02-\(21\)](http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic-810-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-S99-Paragraph-25-1-Subparagraph-(b)-SX-210.5-02-(21)) - Publisher FASB- URI [https://asc.fasb.org/#1943274/2147481231-2147480566\\_810-210-10-45-S99-25Reference-1Reference-3-9](https://asc.fasb.org/#1943274/2147481231-2147480566_810-210-10-45-S99-25Reference-1Reference-3-9) : [http://www.xbrl.org/2003/role/disclosureRef-Topic-810-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-\(bb-c\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-810-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-(bb-c)) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481203/810-10-50-3Reference-4-10> : [http://www.xbrl.org/2003/role/disclosureRef-Topic-235-810-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-45-Paragraph-1-25-Subparagraph-\(b\)-SX-210.4-08-\(g\)\(1\)\(ii\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-235-810-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-45-Paragraph-1-25-Subparagraph-(b)-SX-210.4-08-(g)(1)(ii)) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480678/235-810-10-S99-45-1Reference-25Reference-5-11> : [http://www.xbrl.org/2003/role/disclosureRef-Topic-323-810-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-\(e-bb\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-323-810-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-(e-bb)) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481687-2147481203/323-810-10-50-3Reference-6-12> : [http://www.xbrl.org/2003/role/disclosureRef-Topic-825-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-28-1-Subparagraph-\(f\)-SX-210.4-08-\(g\)\(1\)\(ii\)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147482907-2147480678/825-235-10-50-S99-28Reference-1Reference-7-13](http://www.xbrl.org/2003/role/disclosureRef-Topic-825-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-28-1-Subparagraph-(f)-SX-210.4-08-(g)(1)(ii)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147482907-2147480678/825-235-10-50-S99-28Reference-1Reference-7-13) : [http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic-946-323-SubTopic-830-10-Name-Accounting-Standards-Codification-Section-55-50-Paragraph-12-3-Subparagraph-\(c\)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147480167-2147481687/946-323-830-10-55-50-12Reference-3Reference-8-14](http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic-946-323-SubTopic-830-10-Name-Accounting-Standards-Codification-Section-55-50-Paragraph-12-3-Subparagraph-(c)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147480167-2147481687/946-323-830-10-55-50-12Reference-3Reference-8-14) : [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-825-SubTopic-210-10-Name-Accounting-Standards-Codification-Section-S99-50-Paragraph-1-28-Subparagraph-\(f\)-SX-210.6-04-\(14\)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147479617-2147482907/825-10-50-28Reference-15](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-825-SubTopic-210-10-Name-Accounting-Standards-Codification-Section-S99-50-Paragraph-1-28-Subparagraph-(f)-SX-210.6-04-(14)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147479617-2147482907/825-10-50-28Reference-15) : <http://www.xbrl.org/2003/role/exampleRef-Topic-946-210-S99-1Reference-9> : [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-55-Paragraph-12-1A-Subparagraph-\(SX-210.13-01\(a\)\(4\)\(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-55-Paragraph-12-1A-Subparagraph-(SX-210.13-01(a)(4)(i))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097-2147479168/470-946-10-830-S99-55-1AReference-12Reference-10-16> : [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic-470-946-SubTopic-10-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-1-Subparagraph-\(SX-210.13-6-01-04\\_14-a\)\(4\)\(ii\)\)](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic-470-946-SubTopic-10-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-1-Subparagraph-(SX-210.13-6-01-04_14-a)(4)(ii))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097-2147479168/470-946-10-210-S99-1AReference-1Reference-11-17> : [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210.13-01\(a\)\(4\)\(i-iii\)\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210.13-01(a)(4)(i-iii)(A))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097/470-10-S99-1AReference-12-18> : [http://www.xbrl.org/2009-2009/role/disclosureRef-commonPracticeRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210.13-01\(a\)\(4\)\(iv-ii\)\)](http://www.xbrl.org/2009-2009/role/disclosureRef-commonPracticeRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210.13-01(a)(4)(iv-ii))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097/470-10-S99-1AReference-14-20> : [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-\(SX-210.13-02\(a\)\(4\)\(iv-iii\)\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210.13-02(a)(4)(iv-iii)(A))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097/470-10-S99-1BReference-14-23> : [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-\(SX-210.13-02\(a\)\(5-4\)\(iii\)\(B\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210.13-02(a)(5-4)(iii)(B))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097/470-10-S99-1BReference-19-25> : [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic-852-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-7-1B-Subparagraph-\(SX-210.13-02\(a\)\(4\)\(iv\)\)](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic-852-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-7-1B-Subparagraph-(SX-210.13-02(a)(4)(iv))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481404-2147480097/852-470-10-50-S99-7Reference-1BReference-20-26> : [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic-852-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-7-1B-Subparagraph-\(b\)-SX-210.13-02\(a\)\(5\)\)](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic-852-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-7-1B-Subparagraph-(b)-SX-210.13-02(a)(5))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481404-2147480097/470-10-S99-1BReference-27> : <http://www.xbrl.org/2009/role/commonPracticeRef-Topic-852-10-50-7Reference-21> : [http://www.xbrl.org/2003/role/exampleRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-30-7-Subparagraph-\(d-a\)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147482810-2147481404/280-852-10-50-30Reference-7Reference-22-28](http://www.xbrl.org/2003/role/exampleRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-30-7-Subparagraph-(d-a)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147482810-2147481404/280-852-10-50-30Reference-7Reference-22-28) : [http://fasb-www.xbrl.org/2009-us-gaap/role/ref/legacyRef-commonPracticeRef-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-7-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference-29](http://fasb-www.xbrl.org/2009-us-gaap/role/ref/legacyRef-commonPracticeRef-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-7-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference-29) : [http://www.xbrl.org/2003/role/exampleRef-Topic-210-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-50-Paragraph-1-30-Subparagraph-\(d\)-SX-210.5-02-19-26](http://www.xbrl.org/2003/role/exampleRef-Topic-210-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-50-Paragraph-1-30-Subparagraph-(d)-SX-210.5-02-19-26) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480566-2147482810/210-280-10-S99-50-1-30-Details-Name-us-gaap-LiabilitiesNamespace-Prefix-us-gaap-Data-Type-xbrli:monetaryItemType-Balance-Type-creditPeriod-Type-instantX-DefinitionAmount-of-liabilities-and-equity-items-including-the-portion-of-equity-attributable-to-noncontrolling-interests-if-any-ReferencesReference-1> : <http://www.xbrl.org/2003/role/exampleRef-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-10-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147481372/852-10-55-10Reference-2> : [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.7-03\(a\)\(25\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.7-03(a)(25))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147479440-2147478777/944-210-S99-1Reference-3> : [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.4-08\(g\)\(1\)\(ii\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.4-08(g)(1)(ii))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480678/235-10-S99-1Reference-4> : [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-323-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-\(c\)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147481687/323-10-50-3Reference-5](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-323-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-(c)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147481687/323-10-50-3Reference-5) : [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-825-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-28-Subparagraph-\(f\)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147482907/825-10-50-28Reference-6](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-825-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-28-Subparagraph-(f)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147482907/825-10-50-28Reference-6) : [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-942-SubTopic-210-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-\(c\)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147481687/323-10-50-3Reference-5](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-942-SubTopic-210-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-(c)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147481687/323-10-50-3Reference-5) :



[www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 20-210-Name Accounting Standards Codification-Section 50-S99-Paragraph 11-1-Subparagraph \(SX 210. 7-03 \(a\) \(23\) \(a\) \(4\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 20-210-Name Accounting Standards Codification-Section 50-S99-Paragraph 11-1-Subparagraph (SX 210. 7-03 (a) (23) (a) (4))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480990-2147478777-944-210-S99-1Reference 7>: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-20-50-11Reference 5>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 7-6-03-04 \(17\) a\) \(23\) \(a\) \(4\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 7-6-03-04 (17) a) (23) (a) (4))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147479440-2147479170-944-946-210-S99-1Reference 6>: [http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 946-505-SubTopic 210-10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 6-3-04 \(17\)\)](http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 946-505-SubTopic 210-10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 6-3-04 (17))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147479617-2147480008-946-210-S99-1Reference 7>: [http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 5-9-02-03 \(8 4\)\)](http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 5-9-02-03 (8 4))) - Publisher FASB- URI [https://asc.fasb.org/#1943274/2147480566/210-10-S99-1Details Name: us-gaap\\_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap\\_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. ReferencesReference 1: http://www.fasb.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Topic 942-SubTopic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 5-9-02-03 \(8 4\)\)](https://asc.fasb.org/#1943274/2147480566/210-10-S99-1Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. ReferencesReference 1: http://www.fasb.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Topic 942-SubTopic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 5-9-02-03 (8 4))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480566-2147478546-942-210-10-S99-1Reference 2>: [http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 9-03 \(5\)\)](http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 9-03 (5))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147479853-2147478546-942-210-S99-1Reference 3>: [http://www.fasb.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Topic 942-210-SubTopic 210-10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 9-5-03-02 \(4 8\)\)](http://www.fasb.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Topic 942-210-SubTopic 210-10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 9-5-03-02 (4 8))) - Publisher FASB- URI [https://asc.fasb.org/#1943274/2147479853-2147480566-942-210-10-S99-1Details Name: us-gaap\\_ShortTermInvestments Namespace Prefix: us-gaap\\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of equity \(deficit\) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. ReferencesReference 1: http://www.fasb.org/2003-us-gaap/role/exampleRef-ref/legacyRef-Topic 852-210-SubTopic 10-Name Accounting Standards Codification-Section 55-S99-Paragraph 1-Subparagraph \(SX 210. 5-02 \(29\)\)](https://asc.fasb.org/#1943274/2147479853-2147480566-942-210-10-S99-1Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. ReferencesReference 1: http://www.fasb.org/2003-us-gaap/role/exampleRef-ref/legacyRef-Topic 852-210-SubTopic 10-Name Accounting Standards Codification-Section 55-S99-Paragraph 1-Subparagraph (SX 210. 5-02 (29))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480566-852-210-10-55-S99-1Reference-1Reference 2>: [http://www.fasb.org/2003-us-gaap/role/exampleRef-ref/legacyRef-Topic 946-210-SubTopic 830-10-Name Accounting Standards Codification-Section 55-S99-Paragraph 1-Subparagraph \(SX 210. 5-02 \(30\)\)](http://www.fasb.org/2003-us-gaap/role/exampleRef-ref/legacyRef-Topic 946-210-SubTopic 830-10-Name Accounting Standards Codification-Section 55-S99-Paragraph 1-Subparagraph (SX 210. 5-02 (30))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480167-2147480566-946-210-830-10-55-S99-1Reference-1Reference 3>: [http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 946-210-SubTopic 210-10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 6-5-04-02 \(19-31\)\)](http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 946-210-SubTopic 210-10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 6-5-04-02 (19-31))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147479617-2147480566-946-210-10-S99-1Reference 4>: [http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic 946-852-SubTopic 210-10-Name Accounting Standards Codification-Section S99-55-Paragraph 2-Subparagraph \(SX 210. 10-6-05 \(4\)\)](http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic 946-852-SubTopic 210-10-Name Accounting Standards Codification-Section S99-55-Paragraph 2-Subparagraph (SX 210. 10-6-05 (4))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147479617-2147481372-946-852-210-10-S99-55-2Reference-10Reference 5>: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-exampleRef-Topic 946-SubTopic 220-830-Name Accounting Standards Codification-Section S99-55-Paragraph 12-3-Subparagraph \(SX 210. 6-09 \(4\) \(b\)\)](http://www.xbrl.org/2009-2003/role/commonPracticeRef-exampleRef-Topic 946-SubTopic 220-830-Name Accounting Standards Codification-Section S99-55-Paragraph 12-3-Subparagraph (SX 210. 6-09 (4) (b))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147483575-2147479168-946-220-830-S99-55-3Reference-12Reference 6>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-1-Subparagraph \(SX 210. 6-09-04 \(6-19\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-1-Subparagraph (SX 210. 6-09-04 (6-19))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147483575-2147479170/946-220-210-S99-3Reference-1Reference 7>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-2-Subparagraph \(SX 210. 6-09-05 \(7-4\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-2-Subparagraph (SX 210. 6-09-05 (7-4))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147483575-2147479170/946-210-S99-2Reference 8>: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-S99-3Reference 8>: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-3-Subparagraph \(SX 210. 6-09 \(4\) \(08 \(g\) \(b\) \(ii\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-3-Subparagraph (SX 210. 6-09 (4) (08 (g) (b) (ii))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480678-2147479134-225-946-40-220-S99-1Reference-3Reference 9>: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 323-946-SubTopic 40-220-Name Accounting Standards Codification-Section 50-S99-Paragraph 3-Subparagraph \(e-SX 210. 6-09 \(6\)\)](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 323-946-SubTopic 40-220-Name Accounting Standards Codification-Section 50-S99-Paragraph 3-Subparagraph (e-SX 210. 6-09 (6))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481687-2147479134-323-946-40-220-50-S99-3Reference 10>: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 825-946-SubTopic 40-220-Name Accounting Standards Codification-Section 50-S99-Paragraph 28-3-Subparagraph \(e-SX 210. 6-09 \(7\)\)](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 825-946-SubTopic 40-220-Name Accounting Standards Codification-Section 50-S99-Paragraph 28-3-Subparagraph (e-SX 210. 6-09 (7))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482907-2147479134/825-946-40-220-50-S99-28Reference-3Reference 11>: [http://www.fasb.org/us-gaap/role/commonPracticeRef-ref/legacyRef-Topic 210-235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 5-4-02-08 \(29-g\) \(1\) \(ii\)\)](http://www.fasb.org/us-gaap/role/commonPracticeRef-ref/legacyRef-Topic 210-235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 5-4-02-08 (29-g) (1) (ii))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480566-2147480678-210-235-10-S99-1Reference 12>: [http://www.fasb.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Topic 210-323-SubTopic 10-Name Accounting Standards Codification-Section S99-50-Paragraph 1-3-Subparagraph \(e-SX 210. 5-02 \(31\)\)](http://www.fasb.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Topic 210-323-SubTopic 10-Name Accounting Standards Codification-Section S99-50-Paragraph 1-3-Subparagraph (e-SX 210. 5-02 (31))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480566-2147481687/210-323-10-S99-50-1Reference-3Reference 13>: [http://www.fasb.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Topic 210-825-SubTopic 10-Name Accounting Standards Codification-Section S99-50-Paragraph 1-28-Subparagraph \(e-SX 210. 5-02 \(30\)\)](http://www.fasb.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Topic 210-825-SubTopic 10-Name Accounting Standards Codification-Section S99-50-Paragraph 1-28-Subparagraph (e-SX 210. 5-02 (30))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480566-2147482907/210-825-10-S99-50-1Reference-28Reference 14>: [http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic 310-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SAB Topic 4. E\)\)](http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic 310-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SAB Topic 4. E))) - Publisher FASB- URI [https://asc.fasb.org/#1943274/2147480418/310-10-S99-2Details Name: us-gaap\\_StockholdersEquity Namespace Prefix: us-gaap\\_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- ReferencesNo definition available. Details Name: us-gaap\\_StockholdersEquityAbstract Namespace Prefix: us-gaap\\_Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities \(usually equity\) from the issuer at a specified price. ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(bbb\) \(2\) \(i\)-Publisher FASB-URI \[https://asc.fasb.org/1943274/2147482106/820-10-50-ReferencesNo-2Reference definition available 2: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 740-820-SubTopic 10-Name Accounting Standards Codification-Section S99-50-Paragraph 1-2-Subparagraph \\(bbb\\) \\(2\\) \\(SAB TOPIC 6.1.7\\)\\)\]\(https://asc.fasb.org/1943274/2147482106/820-10-50-ReferencesNo-2Reference definition available 2: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 740-820-SubTopic 10-Name Accounting Standards Codification-Section S99-50-Paragraph 1-2-Subparagraph \(bbb\) \(2\) \(SAB TOPIC 6.1.7\)\)\) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147479360-2147482106/740-820-10-S99-50-1Reference-2Reference 5-3>: \[http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 280-820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-2-Subparagraph \\(h-bbb\\) \\(1\\)\\)\]\(http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 280-820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-2-Subparagraph \(h-bbb\) \(1\)\)\) - Publisher FASB- URI \[https://asc.fasb.org/#1943274/2147482810-2147482106/280-820-10-50-2Details Name: us-gaap\\\_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap\\\_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instant Consolidated Balance Sheets \\(Parentheticals\\)- \\\$ / shares Dec. 31, 2023-2024 Dec. 31, 2022Common-2023Common Stock, Par or Stated Value Per Share \\(in dollars per share\\) \\\$ 0.001 \\\$ 0.001Common Stock, Shares Authorized \\(in shares\\) 200,000,000 200,000,000Common Stock, Shares, Issued \\(in shares\\) 17,029,469 16,952,519Common 519.8, 243,680Common Stock, Shares, Outstanding \\(in shares\\) 17,029,469 16,952,519 8,243,680-X- DefinitionFace amount or stated value per share of common stock. ReferencesReference 1: http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \\(SX 210. 5-02 \\(29\\)\\)\]\(https://asc.fasb.org/#1943274/2147482810-2147482106/280-820-10-50-2Details Name: us-gaap\_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instant Consolidated Balance Sheets \(Parentheticals\)- \$ / shares Dec. 31, 2023-2024 Dec. 31, 2022Common-2023Common Stock, Par or Stated Value Per Share \(in dollars per share\) \$ 0.001 \$ 0.001Common Stock, Shares Authorized \(in shares\) 200,000,000 200,000,000Common Stock, Shares, Issued \(in shares\) 17,029,469 16,952,519Common 519.8, 243,680Common Stock, Shares, Outstanding \(in shares\) 17,029,469 16,952,519 8,243,680-X- DefinitionFace amount or stated value per share of common stock. ReferencesReference 1: http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 5-02 \(29\)\)\) - Publisher FASB- URI \[https://asc.fasb.org/#1943274/2147480566/210-10-S99-1Details Name: us-gaap\\\_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap\\\_Data Type: dtr-types: perShareItemType Balance Type: na Period Type: instantX- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. ReferencesReference 1: http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 946-210-SubTopic 210-10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \\(SX 210. 6-5-04-02 \\(29-16\\) \\(a\\)\\)\]\(https://asc.fasb.org/#1943274/2147480566/210-10-S99-1Details Name: us-gaap\_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap\_Data Type: dtr-types: perShareItemType Balance Type: na Period Type: instantX- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. ReferencesReference 1: http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 946-210-SubTopic 210-10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 6-5-04-02 \(29-16\) \(a\)\)\) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147479617-2147480566-946-210-10-S99-1Reference 2>: \[http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 946-SubTopic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \\(SX 210. 5-6-02-04 \\(29-16\\) \\(a\\)\\)\]\(http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 946-SubTopic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 5-6-02-04 \(29-16\) \(a\)\)\) - Publisher FASB- URI \[https://asc.fasb.org/#1943274/2147479617-2147480566-2147479170/946-210-10-S99-1Details Name: us-gaap\\\_CommonStockSharesAuthorized Namespace Prefix: us-gaap\\\_Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantX- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders \\(includes common shares that were issued, repurchased and remain in the treasury\\). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. ReferencesReference 1: http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \\(SX 210. 5-02 \\(29\\)\\)\]\(https://asc.fasb.org/#1943274/2147480566-2147479170/946-210-10-S99-1Details Name: us-gaap\_CommonStockSharesAuthorized Namespace Prefix: us-gaap\_Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantX- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders \(includes common shares that were issued, repurchased and remain in the treasury\). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. ReferencesReference 1: http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 5-02 \(29\)\)\) - Publisher FASB- URI \[https://asc.fasb.org/#1943274/2147481112/505-10-50-2Reference 2: http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 946-210-SubTopic 210-10-Name Accounting Standards Codification-Section S99-Paragraph 2-1-Subparagraph \\(SX 210. 6-5-05-02 \\(4-29\\)\\)\]\(https://asc.fasb.org/#1943274/2147480566/210-10-S99-1Details Name: us-gaap\_CommonStockSharesIssued Namespace Prefix: us-gaap\_Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantX- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. ReferencesReference 1: http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic 946-210-SubTopic 210-10-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481112/505-10-50-2Reference 2: http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 946-210-SubTopic 210-10-Name Accounting Standards Codification-Section S99-Paragraph 2-1-Subparagraph \(SX 210. 6-5-05-02 \(4-29\)\)\) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147479617-2147480566-946-210-10-S99-2Reference-1Reference 3>: \[http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-2-Subparagraph \\(SX 210. 6-09-05 \\(7-4\\)\\)\]\(http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-2-Subparagraph \(SX 210. 6-09-05 \(7-4\)\)\) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480566-946-210-10-S99-2Reference-1Reference 3>: \[http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-2-Subparagraph \\(SX 210. 6-09-05 \\(7-4\\)\\)\]\(http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-2-Subparagraph \(SX 210. 6-09-05 \(7-4\)\)\) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480566-946-210-10-S99-2Reference-1Reference 3>: \[http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-2-Subparagraph \\(SX 210. 6-09-05 \\(7-4\\)\\)\]\(http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-2-Subparagraph \(SX 210. 6-09-05 \(7-4\)\)\) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480566-946-210-10-S99-2Reference-1Reference 3>: \[http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-2-Subparagraph \\(SX 210. 6-09-05 \\(7-4\\)\\)\]\(http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-2-Subparagraph \(SX 210. 6-09-05 \(7-4\)\)\) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480566-946-210-10-S99-2Reference-1Reference 3>: \[http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-2-Subparagraph \\(SX 210. 6-09-05 \\(7-4\\)\\)\]\(http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-2-Subparagraph \(SX 210. 6-09-05 \(7-4\)\)\) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480566-946-210-10-S99-2Reference-1Reference 3>: \[http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-2-Subparagraph \\(SX 210. 6-09-05 \\(7-4\\)\\)\]\(http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-2-Subparagraph \(SX 210. 6-09-05 \(7-4\)\)\) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480566-946-210-10-S99-2Reference-1Reference 3>: \[http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-2-Subparagraph \\(SX 210. 6-09-05 \\(7-4\\)\\)\]\(http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-2-Subparagraph \(SX 210. 6-09-05 \(7-4\)\)\) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480566-946-210-10-S99-2Reference-1Reference 3>: \[http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-2-Subparagraph \\(SX 210. 6-09-05 \\(7-4\\)\\)\]\(http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-2-Subparagraph \(SX 210. 6-09-05 \(7-4\)\)\) - Publisher FASB- URI](https://asc.fasb.org/#1943274/2147480418/310-10-S99-2Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- ReferencesNo definition available. Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (bbb) (2) (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-ReferencesNo-2Reference definition available 2: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 740-820-SubTopic 10-Name Accounting Standards Codification-Section S99-50-Paragraph 1-2-Subparagraph (bbb) (2) (SAB TOPIC 6.1.7)))

Subparagraph (SX 210. 6-09-05 (4)(b))- Publisher FASB- URI https://asc.fasb.org/1943274/2147483575-2147479170/946-220-210-S99-3Reference 2Reference 4: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 946-SubTopic 210-220-Name Accounting Standards Codification-Section S99-Paragraph 1-3-Subparagraph (SX 210. 6-04-09 (16-4)) (a-b))- Publisher FASB- URI https://asc.fasb.org/1943274/2147479617-2147479134/946-210-220-S99-1Reference 3Reference 5: http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-1-Subparagraph (SX 210. 6-09-04 (7-16) (a))- Publisher FASB- URI https://asc.fasb.org/1943274/2147483575-2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-S99-3Reference 6: http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-3-Subparagraph (SX 210. 5-6-02-09 (29-7))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480566-2147479134/210-946-40-220-S99-1-3-Details Name: us-gaap\_CommonStockSharesOutstanding Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant Consolidated Statements of Operations- USD (\$) in Thousands 12 Months Ended Dec. 31, 2023-2024 Dec. 31, 2023Revenue 2022Total revenue \$ 651.0 \$ 0us-gaap\_OperatingCostsAndExpensesAbstract 651Operating costs and expenses: Research and development 6,718 5,546 3,341Selling 546Selling , general and administrative 8,534 11,994 17,011Impairment of property and equipment 4,948Total 994Total operating costs and expenses 15,252 17,540Loss 540 25,300Loss from operations ( 15,252) ( 16,889) (25,300) Interest expense (134) (1,116) Interest income and other income, net 6-1, 736Non-416Gain on sale of future payments 1,246Gain on change in fair value of warrant liability 5,320Non-cash interest income expense on liability related to the sale of future payments (394) royalties 1,136Non-cash gain on extinguishment of liability related to the sale of future royalties 84,052Total --- Total other income, net 2,248 6,602Net 602 84,438Net income (loss) before provision for income taxes (10,287) 59,138Provision for income taxes (13) Net (loss) income from continuing operations ( 13,004) ( 10,287) Net 59,125Net loss from discontinued operations - See Note 3 (8,110) (11,370) Net income (loss) \$ (13,004) \$ (18,397) 47-75Deemed dividend related to Series A Redeemable Convertible Preferred Stock (186) Income allocated to participating securities (5,240) Net income (loss) per share attributable to stockholders: Common Shareholders, basic Basic and (18,397) 42,329Net income (loss) attributable to Common Shareholders, diluted \$ (18,397) \$ 42,342us-gaap\_EarningsPerShareBasicAbstract (Loss) income from continuing operations (in dollars per share) \$ (0.5) \$ (0.72) Basic and diluted, \$ -7.27Loss from discontinued operations (in dollars per share) (0.57) Basic and diluted (1.54) Net income (loss) per share of common stock, basic (in dollars per share) \$ (0.5) \$ (1.29) 5.73us-gaap\_EarningsPerShareDilutedAbstract (Loss) income from continuing operations (in dollars per share) (0.72) 7.25Loss from discontinued operations (in dollars per share) (0.57) (1.53) Net (loss) income per share (in dollars per share) \$ (1.29) \$ 5.72Shares -- Shares used in computing net (loss) income per share of common stock, basic and -- See Note 12 (in shares) 14,263,744 7,385,348Shares used in computing net (loss) income per share of common stock, diluted -- See Note 12 (in shares) 25,845,639 14,263,744 7,406,986-X- DefinitionThe DefinitionAmount of gain (loss) on the termination of liability related to sale of future royalties payments. ReferencesNo definition available. Details Name: tph\_GainOnTerminationOfLiabilityRelatedToSaleOfFutureRoyalties tph\_GainLossOnSaleOfFuturePayments Namespace Prefix: tph\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of non-cash DefinitionThe non-cash interest income expense expenses on the liability related to the sale of future royalties payments. ReferencesNo definition available. Details Name: tph\_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties ----- tph\_NoncashInterestExpenseOnLiabilitySaleOfFuturePayments Namespace Prefix: tph\_ Data Type: xbrli:monetaryItemType Balance Type: credit debit Period Type: durationX- DefinitionTotal costs of sales and operating expenses for the period. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210. 5-03)- Publisher FASB- URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Details Name: us-gaap\_CostsAndExpenses Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-6- Publisher FASB- URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6Reference 2: http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 45-52- Publisher FASB- URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference- 52Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-805-SubTopic 40-60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g e)(4)- Publisher FASB- URI https://asc.fasb.org/1943274/2147480175-2147476176-815-805-40-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-740-SubTopic 40-323-Name Accounting Standards Codification-Section 65-Paragraph 1-2-Subparagraph (f g)(3)- Publisher FASB- URI https://asc.fasb.org/1943274/2147480175-2147478666-815-40-740-323-65-1Reference-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-1-Subparagraph (a)- Publisher FASB- URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 3Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-260-SubTopic 10-Name Accounting Standards Codification-Section 50-55-Paragraph 15-1-Subparagraph (b)- Publisher FASB- URI https://asc.fasb.org/1943274/2147483443-2147482635/250-260-10-50-55-11Reference-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-815-SubTopic 10-40-Name Accounting Standards Codification-Section 50-65-Paragraph 7-1-Subparagraph (a e)(4)- Publisher FASB- URI https://asc.fasb.org/1943274/2147483443-2147480175/250-815-10-40-50-65-7Reference 1Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-815-SubTopic 10-40-Name Accounting Standards Codification-Section 45-65-Paragraph 2-1-Subparagraph (f)- Publisher FASB- URI https://asc.fasb.org/1943274/2147482689-2147480175/260-815-10-40-45-65-2Reference 1Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-250-SubTopic 10-Name Accounting Standards Codification-Section 45-50-Paragraph 60B-11-Subparagraph (d a)- Publisher FASB- URI https://asc.fasb.org/1943274/2147482689-2147483443/260-250-10-45-50-60BReference 11Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-11-Subparagraph (b)- Publisher FASB- URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 11Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-7-Subparagraph (a)- Publisher FASB- URI https://asc.fasb.org/1943274/2147482662-2147483443/260-250-10-50-11Reference-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 40-2- Publisher FASB- URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-260-SubTopic 10-Name Accounting Standards Codification-Section S99-45-Paragraph 2-60B-Subparagraph (d SX 210. 5-03 (25))- Publisher FASB- URI https://asc.fasb.org/1943274/2147482689/220-260-10-S99-45-2Reference 60BReference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 942-250-SubTopic 220-10-Name Accounting Standards Codification-Section S99-50-Paragraph 4-1-Subparagraph (a SX 210. 9-04 (27))- Publisher FASB- URI https://asc.fasb.org/1943274/2147483589-2147483443/942-250-220-10-S99-50-1Reference 4Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-260-SubTopic 220-10-Name Accounting Standards Codification-Section S99-50-Paragraph 1-Subparagraph (a SX 210. 7-04 (23))- Publisher FASB- URI https://asc.fasb.org/1943274/2147483586-2147482662/944-260-220-10-S99-50-1Reference 16: http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-45-Paragraph 52-10- Publisher FASB- URI https://asc.fasb.org/1943274/2147482635-2147482689/260-10-55-45-52Reference 10Reference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-2-Subparagraph (SX 210 SAB TOPIC 6. I-7-5-03 (25))- Publisher FASB- URI https://asc.fasb.org/1943274/2147479360-2147483621/740-220-10-S99-1Reference 2Reference 5-18 :http://www.xbrl.org/2003/role/disclosureRef-Topic 280-942-SubTopic 40-220-Name Accounting Standards Codification-Section 50-S99-Paragraph 22-1-Subparagraph (h SX 210.9-04 (27))- Publisher FASB- URI https://asc.fasb.org/1943274/2147482810-2147478524/280-942-40-220-50-S99-22Reference 1Reference 6-19 :http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04 (9-23))- Publisher FASB- URI https://asc.fasb.org/1943274/2147483586-2147477250/944-220-S99-1Reference 7-20 :http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Subparagraph (a 45-Paragraph 7- Publisher FASB- URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 Details Name: us-gaap\_EarningsPerShareBasic Namespace Prefix: us-gaap\_ Data Type: dti-types:perShareItemType Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap\_EarningsPerShareBasicAbstract Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- DefinitionAmount DefinitionThe amount of net expense (income (loss) related for the period available to adjustment each share of common stock or common unit outstanding during the reporting period and to fair value each share or unit that would have been outstanding assuming the issuance of warrant liability common shares or units for all dilutive potential common shares or units outstanding during the reporting period. ReferencesReference 1: http://www.fasb.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-45-Paragraph 3-28-Subparagraph (b)-SubTopic 10-Topic 230- Publisher FASB- URI https://asc.fasb.org/1943274/2147483443-2147482740/250-230-10-50-45-3Reference 28Reference 2: http://www.fasb.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-25-Paragraph 15-13-SubTopic 10-Topic 480- Publisher FASB- URI https://asc.fasb.org/1943274/2147482635-2147481766/260-480-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-25-Paragraph 15-13-SubTopic 10-Topic 480- Publisher FASB- URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 13 : http://www..... 260-10-45-7 Details Name: us-

gaap\_EarningsPerShareDiluted\_gaap\_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap\_Data Type: xbrli-dtr-types-perShareItemType  
monetaryItemType Balance Type: debit-na-Period Type: durationX-ReferencesNo definition available. Details Name: us-gaap\_EarningsPerShareDilutedAbstract  
Namespace Prefix: us-gaap\_Data Type: xbrli-stringItemType Balance Type: na-Period Type: durationX-Definition Amount after tax of income (loss) from continuing  
operations attributable to the parent. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards  
Codification-Section 50-Paragraph 3-6. Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6Reference 2: http://www.  
xbrl.org/2003/role/disclosureRef-Topic 250-805-SubTopic 40-60. Name Accounting Standards Codification-Section 50-65. Paragraph 1-1-Subparagraph (a-g  
)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443-2147476176/250-805-40-60-50-65-1Reference-1Reference 3: http://www.fasb.xbrl.  
org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Topic 250-220-SubTopic 10-Name Accounting Standards Codification-Section 50-S99-Paragraph 11-2-  
Subparagraph (b-SX 210.5-03(13))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443-2147483621/250-220-10-50-S99-1Reference  
2Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-3.  
Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 3Reference 5: http://www.xbrl.org/2003/role/disclosureRef-  
Topic 260-250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1  
943274/2147482662-2147483443/260-250-10-50-1Reference 1Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-250-SubTopic 10-  
Name Accounting Standards Codification-Section 45-50-Paragraph 60B-11-Subparagraph (a-b)-Publisher FASB-URI https://asc.fasb.org/1943274/  
2147482689-2147483443/260-250-10-45-50-60BReference 1Reference 7: http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-  
Topic 230-250-SubTopic 10-Name Accounting Standards Codification-Section 45-50-Paragraph 28-4-Publisher FASB-URI https://asc.fasb.org/1943274/  
2147482740-2147483443/230-250-10-45-50-28Reference 4Reference 8: http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef/disclosureRef-Topic  
260-SubTopic 10-Name Accounting Standards Codification-Topic 810-SubTopic 10-Section 45-50-Paragraph 18-1-Subparagraph (a)-Publisher FASB-URI  
https://asc.fasb.org/1943274/2147482662/810-260-10-45-50-18Reference-1Reference 9: http://fasb-www.xbrl.org/2003-us-gaap/role/  
disclosureRef/ref/legacyRef-Topic 220-260-SubTopic 10-Name Accounting Standards Codification-Section S99-45-Paragraph 2-60B-Subparagraph (a-SX 210-  
5-03-13)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621-2147482689/220-260-10-S99-45-60BReference 10-2-Details Name: http://  
fasb.org/us-gaap\_IncomeLossFromContinuingOperations Namespace Prefix: us-gaap\_gaap\_Data Type: xbrli-monetaryItemType Balance Type: credit-Period  
Type: durationX-Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income  
tax expense (benefit), and income (loss) attributable to noncontrolling interest. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef/ref/  
legacyRef-Topic 944-230-SubTopic 220-10-Name Accounting Standards Codification-Section S99-45-Paragraph 28-1-Subparagraph (SX 210.7-04(11))-  
Publisher FASB-URI https://asc.fasb.org/1943274/2147483586-2147482740/944-230-220-10-S99-45-1Reference 28Reference 2-11: http://www.fasb.  
xbrl.org/2003-us-gaap/role/ref/legacyRef/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Topic 810-SubTopic 10-Section  
50-45-Paragraph 22-18. Publisher FASB-URI https://asc.fasb.org/1943274/2147482810-2147481231/280-810-10-50-45-18-22Reference 3: http://.....  
942-220-S99-1-Details Name: us-gaap\_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest  
gaap\_IncomeLossFromContinuingOperations Namespace Prefix: us-gaap\_Data Type: xbrli-monetaryItemType Balance Type: credit-Period Type: durationX-  
Definition The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.  
ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph  
3-6. Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6Reference 2: http://www.xbrl.org/2003/role/  
disclosureRef-Topic 250-805-SubTopic 40-60-Name Accounting Standards Codification-Section 50-65-Paragraph 1-Subparagraph (g b)(2)-Publisher FASB-  
URI https://asc.fasb.org/1943274/2147483443-2147476176/250-805-40-60-50-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic  
815-740-SubTopic 40-323-Name Accounting Standards Codification-Section 65-Paragraph 1-2-Subparagraph (f g)(3)-Publisher FASB-URI https://asc.fasb.  
org/1943274/2147480175-2147478666/815-40-740-323-65-1Reference 2Reference 4: http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef/ref/  
legacyRef-Topic 250-220-SubTopic 10-Name Accounting Standards Codification-Section 50-S99-Paragraph 11-2-Subparagraph (a-SX 210.5-03(13))-  
Publisher FASB-URI https://asc.fasb.org/1943274/2147483443-2147483621/250-220-10-50-S99-1Reference 2Reference 5: http://www.xbrl.org/2003/  
role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-11-Subparagraph (b)-Publisher FASB-URI https://  
asc.fasb.org/1943274/2147483443/250-10-50-11Reference 3Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-250-SubTopic 10-  
Name Accounting Standards Codification-Section 45-50-Paragraph 1-Subparagraph (b)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/  
2147482689-2147483443/260-250-10-45-50-2Reference 1Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-815-SubTopic 40-40-  
Name Accounting Standards Codification-Section 45-65-Paragraph 60B-1-Subparagraph (d f)-Publisher FASB-URI https://asc.fasb.org/1943274/  
2147482689-2147480175/260-815-10-40-45-65-60BReference 1Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name  
Accounting Standards Codification-Section 50-Paragraph 4-11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-  
50-4Reference 11Reference 9: http://www.xbrl.org/2009-2003/role/commonPracticeRef/disclosureRef-Topic 944-250-SubTopic 220-10-Name Accounting  
Standards Codification-Section S99-50-Paragraph 1-11-Subparagraph (b SX 210.7-04(23))-Publisher FASB-URI https://asc.fasb.org/1943274/  
2147483586-2147483443/944-250-220-S99-1Reference 10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-260-SubTopic  
10-Name Accounting Standards Codification-Section S99-45-Paragraph 2-Subparagraph (SX 210.5-03(25))-Publisher FASB-URI https://asc.fasb.org/1  
943274/2147483621-2147482689/220-260-10-S99-45-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 942-260-SubTopic 220-10-  
Name Accounting Standards Codification-Section S99-45-Paragraph 1-60B-Subparagraph (d SX 210.9-04(27))-Publisher FASB-URI https://asc.fasb.org/1  
943274/2147483589-2147482689/942-260-220-10-S99-45-1Reference 60BReference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-250-  
SubTopic 10-Name Accounting Standards Codification-Section 45-50-Paragraph 7-4. Publisher FASB-URI https://asc.fasb.org/1943274/2147482689  
2147483443/260-250-10-45-50-7Reference 4Reference 13: http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef/ref/legacyRef-Topic 944-  
SubTopic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-7-03-04(13-23))-Publisher FASB-  
URI https://asc.fasb.org/1943274/2147483621-2147477250/944-220-10-S99-1Reference 14: http://fasb-www.xbrl.org/2003-us-gaap/role/  
disclosureRef/ref/legacyRef-Topic 942-220-SubTopic 220-10-Name Accounting Standards Codification-Section S99-Paragraph 1-2-Subparagraph (SX 210.9-5-  
04-03(20-25))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483589-2147483621/942-220-10-S99-1Reference 2Reference 15: http://fasb-www  
.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-  
Subparagraph (SX 210.7-9-04(19-27))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.  
org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://  
asc.fasb.org/1943274/2147483589-2147482689/260-10-45-7Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-  
Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(20))-Publisher FASB-URI https://asc.fasb.org/  
1943274/2147478524/942-220-S99-1-Details Name: us-gaap\_IncomeLossFromContinuingOperationsPerBasicShare Namespace Prefix: us-gaap\_Data..... Details  
Name: us-gaap\_IncomeLossFromContinuingOperationsPerDilutedShare Namespace Prefix: us-gaap\_Data Type: dtr-types-perShareItemType Balance Type: na  
Period Type: durationX-Definition Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income  
(loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and  
adjustments to a prior period gain (loss) on disposal. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 810-SubTopic 10-Name  
Accounting Standards Codification-Section 45-Paragraph 19-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2:  
http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 3A-Publisher FASB-URI  
https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205-SubTopic 20-Name  
Accounting Standards Codification-Section 50-Paragraph 5B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483499/205-20-50-  
5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 5C-  
Subparagraph (b)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 5: http://fasb.org/us-gaap/role/ref/  
legacyRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 3B-Publisher FASB-URI https://asc.fasb.org/1943274/  
2147483475/205-20-45-3BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-  
Section 45-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 7: http://fasb.org/us-gaap/role/ref/  
legacyRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.  
org/1943274/2147483499/205-20-50-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205-SubTopic 20-Name Accounting Standards  
Codification-Section 45-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483475/205-20-45-3-Details Name: us-  
gaap\_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity Namespace Prefix: us-gaap\_Data Type: xbrli-monetaryItemType Balance



S99- Paragraph **1B-1A** - Subparagraph (SX 210. 13- 02-01 (a) (4) (iv-iii) (A))- Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097/470-10-S99-1BReference-1AReference> 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02-01\(a\)\(5-4\)\(iii\)\(B\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02-01(a)(5-4)(iii)(B))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097/470-10-S99-1BReference-1AReference> 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iv-i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(iv-i))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097/470-10-S99-1BReference28>: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(5-4\)\(iii\)\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(5-4)(iii)(A))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097/470-10-S99-1BReference29>: [http://www.xbrl.org/2003/role/disclosureRef-Topic280-470-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph30-1B-Subparagraph\(b\)\(SX210.13-02\(a\)\(4\)\(iii\)\(B\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic280-470-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph30-1B-Subparagraph(b)(SX210.13-02(a)(4)(iii)(B))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810-2147480097/280-470-10-50-S99-30Reference-1BReference> 30: [http://www.xbrl.org/2003/role/disclosureRef-Topic280-470-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph32-1B-Subparagraph\(a\)\(SX210.13-02\(a\)\(4\)\(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic280-470-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph32-1B-Subparagraph(a)(SX210.13-02(a)(4)(iv))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810-2147480097/280-470-10-50-S99-32Reference-1BReference> 31: [http://www.xbrl.org/2003/role/disclosureRef-Topic260-470-SubTopic10-NameAccountingStandardsCodification-Section45-S99-Paragraph60B-1B-Subparagraph\(SX210.13-02\(a\)\(5\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic260-470-SubTopic10-NameAccountingStandardsCodification-Section45-S99-Paragraph60B-1B-Subparagraph(SX210.13-02(a)(5))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482689-2147480097/470-10-S99-1BReference32>: <http://www.xbrl.org/2003/role/disclosureRef-Topic260-10-45-60BReference32>: [http://www.xbrl.org/2003/role/exampleRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-45-Paragraph31-60B-Subparagraph\(a\)](http://www.xbrl.org/2003/role/exampleRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-45-Paragraph31-60B-Subparagraph(a)) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810-2147482689/280-260-10-50-45-31Reference-60BReference> 33: <http://www.xbrl.org/2003/role/disclosureRef-Topic280-205-SubTopic10-20-NameAccountingStandardsCodification-Section50-Paragraph7-28> - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810-2147483499/205-280-20-50-7Reference34>: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic230-SubTopic10-50-32Reference34>: <http://www.xbrl.org/2003/role/disclosureRef-Topic205-SubTopic10-20-NameAccountingStandardsCodification-Section50-45-Paragraph7-28> - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482740-205-20-230-50-10-45-7Reference28Reference> 35: [http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/legacyRef-Topic230-220-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph28-1A-Subparagraph\(a\)](http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/legacyRef-Topic230-220-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph28-1A-Subparagraph(a)) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482740-2147482790/230-220-10-45-28Reference-1AReference> 36: [http://www.xbrl.org/2003/role/disclosureRef-Topic220-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph1A-1B-Subparagraph\(a\)](http://www.xbrl.org/2003/role/disclosureRef-Topic220-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph1A-1B-Subparagraph(a)) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482790/220-10-45-1AReference-1BReference> 37: <http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef/legacyRef-Topic942-SubTopic220-SubTopic10-NameAccountingStandardsCodification-Section45-S99-Paragraph1B-1> - Subparagraph (a) (SX 210. 9- 04 (22)) - Publisher FASB- URI [https://asc.fasb.org/#1943274/2147478524-2147482790/220-10-45-942-220-S99-1DetailsName-us-gaap\\_NetIncomeLoss](https://asc.fasb.org/#1943274/2147478524-2147482790/220-10-45-942-220-S99-1DetailsName-us-gaap_NetIncomeLoss) Namespace Prefix: us-gaap\_ Data..... Details Name: us-gaap\_NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionThe aggregate amount of income or expense from ancillary business- related activities (that is to say, excluding major activities considered part of the normal operations of the business). ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic220-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph\(SX210.5-03-\(7\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic220-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph(SX210.5-03-(7))) - Publisher FASB- URI [https://asc.fasb.org/#1943274/2147483621/220-10-S99-2DetailsName-us-gaap\\_NonoperatingIncomeExpense](https://asc.fasb.org/#1943274/2147483621/220-10-S99-2DetailsName-us-gaap_NonoperatingIncomeExpense) Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap\_OperatingCostsAndExpensesAbstract Namespace Prefix: us-gaap\_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe net result for the period of deducting operating expenses from operating revenues. ReferencesReference 1: <http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph22> - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810/280-10-50-22Reference2>: <http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph30-32> - Subparagraph (b) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810/280-10-50-30Reference-32Reference> 3: <http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph32-30> - Subparagraph (b) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810/280-10-50-32Reference-30Reference> 4: [http://www.xbrl.org/2003-2009/role/exampleRef-commonPracticeRef-Topic280-270-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph31-1-Subparagraph\(i\) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810-2147482964/280-270-10-50-31Reference-1Reference> 5: \[http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph32-Subparagraph\\(e-e-e\\) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810/280-10-50-32Reference6> 32 Details Name: <http://fasb.org/us-gaap/OperatingIncomeLoss> Namespace Prefix: us-gaap\\\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionDividends paid to preferred stock holders that is redeemable solely at the option of the issuer. ReferencesReference 1: \\[http://fasb.org/us-gaap/role/ref/legacyRef-otherTransitionRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-32-Subparagraph\\\(c\\\)SubTopic10-Topic505\\]\\(http://fasb.org/us-gaap/role/ref/legacyRef-otherTransitionRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-32-Subparagraph\\(c\\)SubTopic10-Topic505\\) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481112-2147482810/505-280-10-50-2Reference-32Reference2-7>: \\[http://fasb-www.xbrl.org/2003-us-gaap/role/exampleRef-ref/legacyRef-Topic505-280-SubTopic10-NameAccountingStandardsCodification-SectionS99-50-Paragraph31-1-Subparagraph\\\(SX210.3-04\\\)\\]\\(http://fasb-www.xbrl.org/2003-us-gaap/role/exampleRef-ref/legacyRef-Topic505-280-SubTopic10-NameAccountingStandardsCodification-SectionS99-50-Paragraph31-1-Subparagraph\\(SX210.3-04\\)\\) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480008-2147482810/505-280-10-S99-50-1Reference3-31> Details Name: us-gaap\\\_OperatingIncomeLoss Namespace Prefix: us-gaap\\\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write- down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. ReferencesReference 1: <http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-exampleRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Topic260-SubTopic10-Section45-55-Paragraph44-48> - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482689-2147482785/260-280-10-45-55-48Reference> 11 Details Name: us-gaap\\\_RedeemablePreferredStockDividends Namespace Prefix: us-gaap\\\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe aggregate costs incurred \\(1\\) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or \\(2\\) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility; and costs allocated in accounting for a business combination to in- process projects deemed to have no alternative future use. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic730-985-SubTopic40-20-NameAccountingStandardsCodification-Section50-Paragraph1-2> - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482916-2147481283/985-20-50-2Reference3>: <http://www.xbrl.org/2003/role/disclosureRef-Topic730-SubTopic10-50-1Reference2>: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic912-SubTopic730-25-1Reference3>: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic912-SubTopic730-NameAccountingStandardsCodification-Section25-50-Paragraph1> - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482916/730-10-50-1Reference4>: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic912-SubTopic730-25-1Reference3>: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic985-SubTopic20-Section50-25-Paragraph1> - Publisher FASB- URI \\[https://asc.fasb.org/#1943274/2147481283-2147479532/985-912-20-730-50-25-1DetailsName-us-gaap\\\\_ResearchAndDevelopmentExpense\\]\\(https://asc.fasb.org/#1943274/2147481283-2147479532/985-912-20-730-50-25-1DetailsName-us-gaap\\_ResearchAndDevelopmentExpense\\) Namespace Prefix: us-gaap\\\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue- producing transaction, including, but not limited to, sales, use, value- added and excise. ReferencesReference 1: \\[http://www.xbrl.org/2003/role/disclosureRef-Topic924-280-SubTopic10-NameAccountingStandardsCodification-SectionS99-50-Paragraph1-41-Subparagraph\\\(a\\\)SAB-Topic11-1\\]\\(http://www.xbrl.org/2003/role/disclosureRef-Topic924-280-SubTopic10-NameAccountingStandardsCodification-SectionS99-50-Paragraph1-41-Subparagraph\\(a\\)SAB-Topic11-1\\) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147479941-2147482810/924-280-10-S99-50-1Reference41Reference2>: \\[http://www.xbrl.org/2003/role/disclosureRef-Topic606-270-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph5-1-Subparagraph\\\(i\\\) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147479806-2147482964/606-270-10-50-5Reference-1Reference3>: \\\[http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph30-32-Subparagraph\\\\(a-e-e\\\\)\\\]\\\(http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph30-32-Subparagraph\\\(a-e-e\\\)\\\) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810/280-10-50-30Reference-32Reference4>: \\\[http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef-ref/otherTransitionRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph42-32-Subparagraph\\\\(b\\\\) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810/280-10-50-42Reference-32Reference5>: \\\\[http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef-ref/otherTransitionRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph22-32-Subparagraph\\\\\(b-a\\\\\)\\\\]\\\\(http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef-ref/otherTransitionRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph22-32-Subparagraph\\\\(b-a\\\\)\\\\) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810/280-10-50-22Reference-32Reference6>: <http://www.xbrl.org/2003/role/disclosureRef-Topic280-924-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph32-1> -\\\]\\\(http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef-ref/otherTransitionRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph42-32-Subparagraph\\\(b\\\)\\\)\\]\\(http://www.xbrl.org/2003/role/disclosureRef-Topic606-270-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph5-1-Subparagraph\\(i\\)\\)\]\(http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph32-Subparagraph\(e-e-e\)\)](http://www.xbrl.org/2003-2009/role/exampleRef-commonPracticeRef-Topic280-270-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph31-1-Subparagraph(i))

Subparagraph (b-SAB Topic 11.L))- Publisher FASB- URI https://asc.fasb.org/1943274/2147482810-2147479941-280-924-10-50-S99-32Reference  
1Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 280-606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 40-5  
-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810-2147479806-280-606-10-50-40Reference-5Reference 8: http://www.xbrl.org/2003/role  
/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-30-Subparagraph (a)-Publisher FASB-URI https://  
asc.fasb.org/1943274/2147482810/280-10-50-22Reference-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name  
Accounting Standards Codification-Section 50-Paragraph 42-32-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-  
50-32Reference-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-  
Paragraph 41-22-Subparagraph (a-b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference-22Reference 11: http://  
www.xbrl.org/2003/role/disclosureRef-Topic 606-280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 40-4-Subparagraph (a)-  
Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-S99-50-1Reference-40Reference 5-12: http://www.xbrl.org/2003/role/  
disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph (h-a))-Publisher FASB-URI https://  
asc.fasb.org/1943274/2147482810/280-10-50-22Reference-6-13: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-606-SubTopic 220-10-Name  
Accounting Standards Codification-Section S99-50-Paragraph 1-4-Subparagraph (a) SX 210-7-04(9))-Publisher FASB-URI https://asc.fasb.org/1943274/  
2147479806/606-10-50-4-Details Name: us-gaap\_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap\_Data Type: xbrli:  
monetaryItemType Balance Type: credit Period Type: durationX-Definition The aggregate total costs related to selling a firm's product and services, as well as all other  
general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of  
specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and  
postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. ReferencesReference 1: http://fasb.org  
/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03-(4))-  
Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2-Details Name: us-gaap\_SellingGeneralAndAdministrativeExpense Namespace  
Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX-Definition The charge..... xbrli: sharesItemType Balance Type: na  
Period Type: durationX-Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed  
outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.  
ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph  
1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/  
disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/  
2147482689/260-10-45-10-Details Name: us-gaap\_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap\_Data Type: xbrli:  
sharesItemType Balance Type: na Period Type: duration Consolidated Statements of Stockholders' Deficit Equity - USD (\$) \$ in Thousands Preferred-Common Stock [Member]  
| July 2023 Private Placement Offering Redeemable Convertible Preferred Stock [Member] Preferred Stock [Member] Common Stock [Member]  
Redeemable Convertible Preferred Stock January 2024 Private Placement Offering [Member] Common Stock [Member] Additional Paid-in Capital [Member]  
Redeemable Convertible Preferred Stock July 2023 Private Placement Offering [Member] Additional Paid-in Capital [Member] January 2024 Private  
Placement Offering [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Redeemable Convertible Preferred Stock July 2023 Private  
Placement Offering [Member] Retained Earnings [Member] Redeemable Convertible Preferred Stock January 2024 Private Placement Offering [Member]  
Retained Earnings [Member] July 2023 Private Placement Offering [Member] January 2024 Private Placement Offering [Member] TotalBalance (in shares)  
at Dec. 31, 2021-2022 6-8, 840-243, 967-680 Balance at Dec. 31, 2021-2022 6-8 \$ 7,447,635 \$ 437 (425, 684-829) \$ 21 (473, 584) \$ (35,893) Issuance of Series A  
Redeemable Convertible Preferred Stock 814 Stock and Warrants (in shares) 3,000 Issuance of Series A Redeemable Convertible Preferred Stock and Warrants \$ 129 \$  
0 \$ 873,074 \$ 110 \$ 0 \$ 110 Deemed dividends related to Series A Redeemable Convertible Preferred Stock \$ 186 Deemed dividends related to Series A Redeemable  
Convertible Preferred Stock (186) (186) Redemption of Series A Redeemable Convertible Preferred Stock and Warrants (in shares) (3,000) Redemption of Series A  
Redeemable Convertible Preferred Stock and Warrants \$ (315) \$ 0 Stock-based compensation \$ 0 1 \$ 0-2, 889-2-729 1, 889 Issuance of common stock in  
connection with asset purchase (in shares) 481-69, 026-808 Issuance of common stock in connection with asset purchase \$ 0 Net proceeds from issuance of common  
stock, accompanying warrants and pre-funded warrants in July 2023 private placement offering (in shares) 5,340, 591 Net proceeds from issuance of  
common stock, accompanying warrants and pre-funded warrants in July 2023 private placement offering \$ 0-5 \$ 8, 851 511-5, 511 Modification of equity-  
classified warrants \$ 0 \$ 0-8, 856 Exercise of pre-funded warrants (in shares) 3,228, 781 Exercise of pre-funded warrants \$ 3 Issuance of common stock upon  
vesting of restricted stock units, net of shares withheld for employee taxes (in shares) 37-27, 672-450 Issuance of common stock upon vesting of restricted stock units,  
net of shares withheld for employee taxes \$ 0 \$ 0 (58-22) (58-22) Issuance of common stock upon ESPP purchase (in shares) 40-42, 941-209 Issuance of common  
stock upon ESPP purchase \$ 1 Net loss \$ 0 (18,397) (18,397) Balance (in shares) at Dec. 31, 2023 16,952, 519 Balance at Dec. 31, 2023 \$ 17,458, 314 (444, 226)  
14, 105 Stock-based compensation \$ 0 Net proceeds from issuance of common stock, accompanying warrants and pre-funded warrants in July 2023 private  
placement offering (in shares) Net proceeds from issuance of common stock, accompanying warrants and pre-funded warrants in July 2023 private placement  
offering \$ 0 \$ 5, 884 \$ 0 \$ 5, 884 Issuance of common stock upon vesting of restricted stock units, net of shares withheld for employee taxes (in shares) 27, 435  
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for employee taxes \$ 0 (17) (17) Issuance of common stock upon ESPP  
purchase (in shares) 49, 515 Issuance of common stock upon ESPP purchase \$ 0 Net loss \$ 0 Net income (13 loss) \$ 0 \$ 0-47, 755-47-004 (13, 004) 755 Balance  
--- Balance (in shares) at Dec. 31, 2022-2024 8-17, 243-029, 680-469 Balance at Dec. 31, 2022-2024 \$ 0 \$ 8,447,635 (425,829) 21,814 Stock-based compensation \$ 0 \$ 0  
0-1,729 1,729 Issuance of common stock in connection with asset purchase (in shares) 69,808 Issuance of common stock in connection with asset purchase \$ 0 \$ 0  
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for employee taxes (in shares) 27,450 Issuance of common stock upon vesting  
of restricted stock units, net of shares withheld for employee taxes \$ 0 \$ 0 (22) (22) Issuance of common stock upon ESPP purchase (in shares) 42,209 Issuance of  
common stock upon ESPP purchase \$ 0 \$ 1 Net income (loss) \$ 0 \$ 0 (18,397) (18,397) Net proceeds from issuance of common stock and warrants in connection with  
equity financings (in shares) 5,340,591 Net proceeds from issuance of common stock and warrants in connection with equity financings \$ 0 \$ 5,8,851 8,856 Exercise  
of pre-funded warrants (in shares) 3,228,781 Exercise of pre-funded warrants \$ 0 \$ 3 Balance (in shares) at Dec. 31, 2023 16,952,519 Balance at Dec. 31, 2023 \$ 0 \$  
17 \$ 458-465, 314-214 \$ (444-457, 226-230) \$ 14-8, 105-001 X-Definition Amount of increase (decrease)..... Type: na Period Type: durationX-Definition Number  
of shares issued during the period due to warrants exercised. ReferencesNo definition available. Details Name: t1ph\_StockIssuedDuringPeriodSharesWarrantsExercised  
Namespace Prefix: t1ph\_Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX-718-10-35-2Reference-6Reference 2: http://fasb.org/us-  
gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-740-SubTopic 20-10-Section 55-50-Paragraph 12-8-Publisher FASB-URI https://  
asc.fasb.org/1943274/2147481089-2147482685/718-740-20-10-55-50-13Reference-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Name  
Accounting Standards Codification-Topic 718-740-SubTopic 20-10-Section 55-50-Paragraph 12-3-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/  
1943274/2147481089-2147482685/718-740-20-10-55-50-12-3-Definition Equity impact of the value of new stock and warrants issued during the period. Includes  
shares issued in an initial public offering or a secondary public offering. ReferencesNo definition available. Details Name:  
t1ph\_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrants Namespace Prefix: t1ph\_Data Type: xbrli: monetaryItemType Balance Type: credit Period  
Type: durationX-Definition Value of stock issued during period because of warrants exercised. ReferencesNo definition available. Details Name:  
t1ph\_StockIssuedDuringPeriodValueWarrantsExercised Namespace Prefix: t1ph\_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX-  
Definition Amount of decrease (increase) in additional paid-in capital (APIC) for the increase in carrying amount of redeemable preferred stock. ReferencesReference 1:  
http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI  
https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-210-SubTopic 10-Name  
Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-5-04-02 (28))-Publisher FASB-URI https://asc.fasb.org/1943274/  
2147480008-2147480566/505-210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 480-210-SubTopic 10-Name Accounting  
Standards Codification-Section S99-Paragraph 2-1-Subparagraph (SX 210 SAB Topic 3-C-5-02 (29))-Publisher FASB-URI https://asc.fasb.org/1943274/  
2147480244-2147480566/480-210-10-S99-1Reference 4-2-Details Name: us-  
gaap\_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock Namespace Prefix: us-gaap\_Data Type: xbrli:  
monetaryItemType Balance Type: debit Period Type: durationX-Definition Amount of increase to additional paid-in capital (APIC) for recognition of cost for award  
under share-based payment arrangement. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic 718-946-SubTopic 40-830-  
Name Accounting Standards Codification-Section 35-55-Paragraph 2-11-Publisher FASB-URI https://asc.fasb.org/1943274/2147480483-2147479168/718-  
946-40-830-35-55-2Reference-11Reference 2-5: http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic 946-SubTopic 205-  
Name Accounting Standards Codification-Topic 718-SubTopic 20-Section 55-45-Paragraph 13-4-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/

/1943274/2147481089-2147478009/718-946-20-205-55-45-13Reference-4Reference-3-6: http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Topic 718-SubTopic 20-Section 55-50-Paragraph 12-2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481089-2147478009/718-946-20-55-505-50-12-Details Name: us-2Reference 7

gaap\_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 235-946-SubTopic 40-220-Name Accounting Standards Codification-Section S99-Paragraph 1-3-Subparagraph (SX 210. 6-09 (4 -08 (g) (b 1)(ii))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480678-2147479134/235-946-40-220-S99-1Reference-3Reference-2-8: http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 323-505-SubTopic 10-Name Accounting Standards Codification-Section 50-S99-Paragraph 1-Subparagraph (SX 210. 3-04-Subparagraph (e))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481687/323-10-50.....org/#1943274/2147480097-2147480008/470-10-S99-1AReference.....role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards.....//1943274/2147480566/210-10-S99-1 Details Name: us-gaap\_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-DefinitionValue of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 3-04)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480008/505-10-S99-1 Details Name: us-gaap\_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. ReferencesReference 1: http://www.fasb.xbrl.org/2003-us-gaap/role/exampleRef-ref/legacyRef-Topic 852-210-SubTopic 10-Name Accounting Standards Codification-Section 55-S99-Paragraph 1-Subparagraph (SX 40-210. 5-02 (29))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481372-2147480566/852-210-10-55-S99-10Reference-1Reference 2: http://www.fasb.xbrl.org/2003-us-gaap/role/exampleRef-ref/legacyRef-Topic 946-210-SubTopic 830-10-Name Accounting Standards Codification-Section 55-S99-Paragraph 12-1-Subparagraph (SX 210. 5-02 (30))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480167-2147480566/946-210-830-10-55-S99-12Reference-1Reference 3: http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 946-210-SubTopic 210-10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 6-5-04-02 (19-31))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147479617-2147480566/946-210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic 946-852-SubTopic 210-10-Name Accounting Standards Codification-Section S99-55-Paragraph 2-Subparagraph (SX 210-6-05 (4))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147479617-2147481372/946-852-210-10-S99-55-2Reference-10Reference 5: http://www.xbrl.org/2009-2003/role/commonPracticeRef-exampleRef-Topic 946-SubTopic 220-830-Name Accounting Standards Codification-Section S99-55-Paragraph 12-3-Subparagraph (SX 210. 6-09 (4) (b))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147483575-2147479168/946-220-830-S99-55-3Reference-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-1-Subparagraph (SX 210. 6-09-04 (6-19))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147483575-2147479170/946-220-210-S99-3Reference-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-2-Subparagraph (SX 210. 6-09-05 (7-4))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147483575-2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-S99-3Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-3-Subparagraph (SX 210. 6-09 (4 -08 (g) (b 1)(ii))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480678-2147479134/235-946-40-220-1Reference-3Reference 9: http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 323-946-SubTopic 40-220-Name Accounting Standards Codification-Section 50-S99-Paragraph 3-Subparagraph (e-SX 210. 6-09 (6))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481687-2147479134/323-946-40-220-50-S99-3Reference 10: http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 825-946-SubTopic 40-220-Name Accounting Standards Codification-Section 50-S99-Paragraph 28-3-Subparagraph (fSX 210. 6-09 (7))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482907-2147479134/825-946-40-220-50-S99-28Reference-3Reference 11: http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Topic 210-235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 5-4-02-08 (29-g) (1) (ii))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480566-2147480678/210-235-10-S99-1Reference 12: http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Topic 210-323-SubTopic 10-Name Accounting Standards Codification-Section S99-50-Paragraph 1-3-Subparagraph (c SX 210. 5-02 (31))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480566-2147481687/210-323-10-S99-50-1Reference-3Reference 13: http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Topic 210-825-SubTopic 10-Name Accounting Standards Codification-Section S99-50-Paragraph 1-28-Subparagraph (fSX 210. 5-02 (30))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480566-2147482907/210-825-10-S99-50-1Reference-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 310-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SAB Topic 4. E)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480418/310-10-S99-2 Details Name: us-gaap\_StockholdersEquity Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant Consolidated Statements of Cash Flows-USD (\$) \$ in Thousands 12 Months Ended Dec. 31, 2023-2024 Dec. 31, 2022Cash 2023Cash flows from operating activities: Net (loss) income \$ (13,004) \$ (18,397) \$ 47,755 Adjustments--- Adjustments to reconcile net income (loss) to net cash used in operating activities: Non-cash interest income on liability related to the sale of future royalties payments ( 0 1,136) Depreciation and amortizationNet amortization 1,647 Non of discount on short-term investments (121) (24) Non-cash interest expense related to debt financingRevaluation financingNon-cash issuance costs for warrant liabilityRevaluation of liability for Lowell holdback shares (723) Stock-based compensation 1,729 Gain 729 2,889 Non-cash gain on change in fair value extinguishment of liability related to the sale of future royalties (84,152) Impairment of property and equipment 4,948 Revaluation of warrant liability (717) (5,320) Impairment of net assets held for sale 6,853 Impairment of fixed assets 1,065 Gain on termination of lease liabilities (0) 1,098 Gain 098 (0) Gain on extinguishment of debt liability (0) Other (24) (60) Impairment of fixed assets 1,065 Changes--- Changes in operating assets and liabilities: Accounts receivable (189) (149) Inventories-Inventories Prepaid (107) Prepaid expenses and other assets Other assets Accounts current assets 1,641 Accounts payable (671) (575) Accrued liabilities (1,194) (1,132) (1,613) Operating lease liabilities (147) (285) Deferred revenue (29) (86) Net cash used in operating activities ( 12,683) (17,492) Cash flows from investing activities (28,331) CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment (100) (364) Purchase of investments (3,651) (7,861) Sale of the DSUVIA assets 2,723 Purchase 723 Cash paid for asset acquisition, net of investments cash acquired (14,687-979) (3,651) Proceeds from maturities of investments 46-8,362 Net 760 Net cash provided by (used in) investing activities 3,781 (528) Cash flows from financing activities 36,450 CASH FLOWS FROM FINANCING ACTIVITIES: Payment of long-term debt (5,416) Gross (8,433) Net proceeds from issuance sale of Series A Redeemable Convertible Preferred Stock and Warrants Redemption future payments 6,654 Issuance costs related to sale of future payments Series A Redeemable Convertible Preferred Stock ( 315-521 ) Net proceeds from issuance of common stock in connection with exercise of pre-funded warrants Net proceeds from issuance of common stock through equity plans Net plans Payment of employee tax obligations related to vesting of restricted stock units Net cash (used in) provided by financing activities 12,044 3,466 Net 466 (507) Net change in cash and cash equivalents and restricted cash 3,142 (14,554) Cash and 7,612 Cash-cash equivalents and restricted cash--- Beginning of period 5,721 20,275 Cash and 275 12,663 Cash-cash equivalents and restricted cash--- End of period 8,863 5,721 20,275 Supplemental 721 Supplemental Disclosures of Cash Flow Information: Cash paid for interest Income taxes paid Noncash Investing paid Cash-cash equivalents and Financing Activities: Equity restricted cash--- End of period Purchases of property and equipment in accounts payable and accrued expenses Equity issuance costs from modification warrant modification Settlement of November 2021 Financing Warrants Equity issuance costs in accounts payable and accrued expenses (Settlement) / liability for held back shares issued in connection with asset acquisition (77) Offering costs Issuance of common stock in accounts payable Fair connection with asset acquisition 5,511 Establishment of right-of-use asset and lease liability Fair value of warrants issued to placement agent July 2023 Private Placement Offering [ Member ] CASH FLOWS FROM FINANCING ACTIVITIES Cash flows from financing activities: Net Proceeds proceeds from issuance of common stock, accompanying warrants and pre-funded warrants in July 2023 private placement offering 8,856 December 856 January 2022-2024 Financing Private Placement Offering [ Member ] CASH FLOWS FROM FINANCING ACTIVITIES Cash flows from financing activities: Net Proceeds proceeds from issuance of common stock, accompanying warrants and pre-funded warrants in July January 2023-2024 private placement offering 7,528 ATM Agreement [ Member ] CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common stock, accompanying warrants and pre-funded warrants in July 2023 private placement offering \$ 5,884 \$ 0 \$ 458-X-DefinitionAmount Definition Represents the amount of amortization on short term investments discounts equity issuance costs in accounts payable and accrued expenses. ReferencesNo definition available. Details Name: t1ph\_Equity Issuance Costs Accounts Payable And Accrued Expenses t1ph\_Amortization Of Discount On Short Term Investments Namespace Prefix: t1ph\_Data Type: xbrli:monetaryItemType Balance Type: credit debit Period Type: durationX-Definition Represents the amount of modification of warrants for equity issuance costs.

ReferencesNo definition available. Details Name: t1ph\_EquityIssuanceCostsModificationOfWarrants Namespace Prefix: t1ph\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionThe cash inflow from gross proceeds related to the issuance sale of future payments common stock and exercise of warrants. ReferencesNo definition available. Details Name: t1ph\_NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants Namespace Prefix: t1ph\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionRepresents the issuance costs Amount of non-cash gain on termination of liability related to the sale of future payments royalties. ReferencesNo definition available. Details Name: t1ph\_NonCashGainOnTerminationOfLiabilityRelatedToSaleOfFutureRoyalties t1ph\_IssuanceCostsSaleOfFuturePayments Namespace Prefix: t1ph\_ Data Type: xbrli: monetaryItemType Balance Type: credit debit Period Type: durationX- DefinitionThe amount of non-cash interest expense recognized inflow from the issuance of common stock and exercise of warrants. ReferencesNo definition available. Details Name: t1ph\_NoncashInterestExpenseRecognized t1ph\_NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants Namespace Prefix: t1ph\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe amount of non-cash issuance costs for warrants interest expenses on the liability related to the sale of future payments. ReferencesNo definition available. Details Name: t1ph\_NoncashIssuanceCostsForWarrants t1ph\_NoncashInterestExpenseOnLiabilitySaleOfFuturePayments Namespace Prefix: t1ph\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionRepresents non-cash issuance of holdback shares. ReferencesNo definition available. Details Name: t1ph\_NoncashIssuanceOfHoldbackShares Namespace Prefix: t1ph\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe amount of common stock issued in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. ReferencesNo definition available. Details Name: t1ph\_NoncashOrPartNoncashAcquisitionCommonStockIssued Namespace Prefix: t1ph\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionThe noncash or part- noncash amount of liability for holdback shares under an acquisition. ReferencesNo definition available. Details Name: t1ph\_NoncashOrPartNoncashAcquisitionLiabilityForHoldbackShares Namespace Prefix: t1ph\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionRepresents purchases the value of offering costs yet to be paid property and equipment that were acquired through accounts payable. ReferencesNo definition available. Details Name: t1ph\_PurchasesOfPropertyAndEquipmentInAccountsPayable t1ph\_OfferingCostsYetToBePaid Namespace Prefix: t1ph\_ Data Type: xbrli: monetaryItemType Balance Type: credit debit Period Type: durationX- DefinitionRepresents the Revaluation of 2022 Warrants Liability. ReferencesNo definition available. Details Name: t1ph\_RevaluationOf2022WarrantsLiability Namespace Prefix: t1ph\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionRepresents the cash flow impact of warrants issued. ReferencesNo definition available. Details Name: t1ph\_WarrantsIssued1 Namespace Prefix: t1ph\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- ReferencesNo definition available. Details Name: us- gaap\_ AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities Abstract Namespace Prefix: us- gaap\_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph\(b\)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph(b)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482740/230-10-45-28) Reference 2: [http://www.fasb.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Topic470-SubTopic20-10-NameAccountingStandardsCodification-Section50S99-Paragraph4F-2-Subparagraph\(b\)SX210.5-03\(2-8\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/2147483621/220-10-S99-2](http://www.fasb.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Topic470-SubTopic20-10-NameAccountingStandardsCodification-Section50S99-Paragraph4F-2-Subparagraph(b)SX210.5-03(2-8)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/2147483621/220-10-S99-2) Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic20-50-1> Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph1F-Subparagraph\(b\)\(2\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/470-20-50-1F](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph1F-Subparagraph(b)(2)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/470-20-50-1F) Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic835-SubTopic30-Section45-Paragraph1A-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482925/835-30-45-1A> Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic220-SubTopic10-NameAccountingStandardsCodification-SectionS99-45-Paragraph3-2-Subparagraph\(SX210.5-03-8\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483621/2147482925/220-835-10-30-S99-45-2-3](http://fasb.org/us-gaap/role/ref/legacyRef-Topic220-SubTopic10-NameAccountingStandardsCodification-SectionS99-45-Paragraph3-2-Subparagraph(SX210.5-03-8)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483621/2147482925/220-835-10-30-S99-45-2-3) Details Name: us- gaap\_ AmortizationOfDebtDiscountPremium Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic230-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph8-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482913/230-10-50-8> Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic230-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph24-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482740/230-10-45-24> Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic230-SubTopic10-Section45-Paragraph4-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482740/230-10-45-4> Details Name: us- gaap\_ CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic230-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph24-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482740/230-10-45-24> Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph1-SubTopic230-Topic830-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481877/2147477401/830-230-45-1> Details Name: us- gaap\_ CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- ReferencesNo definition available. Details Name: us- gaap\_ CashFlowNoncashInvestingAndFinancingActivitiesDisclosure Abstract Namespace Prefix: us- gaap\_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph\(b\)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph(b)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482740/230-10-45-28) Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section40-55-48> Reference 3: <http://fasb.org/2003-us-gaap/role/ref/legacyRef-exampleRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Topic740-SubTopic10-Section55-50-Paragraph49-8> Reference 4: [http://fasb.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic270-SubTopic10-NameAccountingStandardsCodification-Topic740-SubTopic10-Section50-Paragraph4-3-Subparagraph\(i-a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482964-2147482685/270-740-10-50-3](http://fasb.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic270-SubTopic10-NameAccountingStandardsCodification-Topic740-SubTopic10-Section50-Paragraph4-3-Subparagraph(i-a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482964-2147482685/270-740-10-50-3) Reference 5: [http://fasb.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic270-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph22-Subparagraph\(e\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482810/280-10-50-22](http://fasb.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic270-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph22-Subparagraph(e)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482810/280-10-50-22) Details Name: us- gaap\_ DepreciationDepletionAndAmortization Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of gain expense (loss income) on termination related to adjustment to fair value of warrant liability lease before expiration of lease term. ReferencesReference 1: [http://www.fasb.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic842-SubTopic20-NameAccountingStandardsCodification-Section45-Paragraph2-28-Subparagraph\(a-b\)-SubTopic20-10-Topic740-230](http://www.fasb.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic842-SubTopic20-NameAccountingStandardsCodification-Section45-Paragraph2-28-Subparagraph(a-b)-SubTopic20-10-Topic740-230) Reference 2: [http://fasb.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-NameAccountingStandardsCodification-SectionS99-25-Paragraph13-1-Subparagraph\(SX210.4-08\(h\)\)-SubTopic10-Topic235-480](http://fasb.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-NameAccountingStandardsCodification-SectionS99-25-Paragraph13-1-Subparagraph(SX210.4-08(h))-SubTopic10-Topic235-480) Reference 3: <http://fasb.org/2003-us-gaap/role/disclosureRef-Topic842-SubTopic20-NameAccountingStandardsCodification-Section40-Paragraph1-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480678-2147481766/235-480-10-S99-25-1+13> Details Name: us- gaap\_ IncomeTaxExpenseBenefit Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of gain the difference between reported income tax expense (benefit loss) and on termination of lease before expiration of lease term. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic842-SubTopic20-NameAccountingStandardsCodification-Section40-Paragraph1-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479092/842-20-40-1> Details Name: us- gaap\_ GainLossOnTerminationOfLease Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph\(b\)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph(b)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482740/230-10-45-28) Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph\(b\)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph(b)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482740/230-10-45-28)

/ legacyRef- Name Accounting Standards Codification- Topic 470- SubTopic 50- Section 40- Paragraph 2- Publisher FASB- URI https://asc.fasb.org/#1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef- Name Accounting Standards Codification- Topic 470- SubTopic 50- Section 40- Paragraph 4- Publisher FASB- URI https://asc.fasb.org/#1943274/2147481303/470-50-40-4 Details Name: us-gaap\_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionFor the asset that is reclassified back to held and used from held- for- sale, the amount of impairment charge that is recognized on the reclassification date. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef- Name Accounting Standards Codification- Topic 360- SubTopic 10- Section 45- Paragraph 7- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482130/360-10-45-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef- Name Accounting Standards Codification- Topic 360- SubTopic 10- Section 35- Paragraph 44- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482190/360-10-35-44 Details Name: us-gaap\_ImpairmentChargeOnReclassifiedAssets Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe aggregate amount of write- downs for impairments recognized during the period for long lived assets held for use (including..... impairments recognized during the period for long lived assets held for abandonment, exchange or sale. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef- Name Accounting Standards Codification- Section 45- Paragraph 28- Subparagraph (b)- SubTopic 10- Topic 230- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef- Name Accounting Standards Codification- Section 55- Paragraph 100- Subparagraph (e)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef- Topic 360- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 15- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482130/360-10-45-15 Details Name: us-gaap\_ImpairmentOfLongLivedAssetsToBeDisposedOf Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe amount DefinitionAmount, after refund, of cash paid during the current period to foreign, federal, state, and local authorities jurisdictions as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes tax. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef- disclosureRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 8-2A- Publisher FASB- URI https://asc.fasb.org/#1943274/2147483443/2147482913/250-230-10-50-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef- Topic 250-740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 9-23- Publisher FASB- URI https://asc.fasb.org/#1943274/2147483443/2147482685/250-740-10-50-9Reference 23Reference 3: http://www.xbrl.org/2003/role/disclosureRef- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 10-22- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482685/740-10-50-10Reference 22Reference 4: http://fasb.org/us-gaap/role/disclosureRef- Topic 740- Name Accounting Standards Codification- SubTopic-Topic 230- SubTopic 10- Section 50- Paragraph 2- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482913/230-10-50-2 Details Name: us-gaap\_IncomeTaxesPaidNet Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef- Name Accounting Standards Codification- Section 45- Paragraph 28- Subparagraph (a)- SubTopic 10- Topic 230- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482740/230-10-45-28 Details Name: us-gaap\_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe increase..... xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef- Name Accounting Standards Codification- Section 45- Paragraph 28- Subparagraph (a)- SubTopic 10- Topic 230- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482740/230-10-45-28 Details Name: us-gaap\_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- Topic 912- SubTopic 310- Name Accounting Standards Codification- Section 45- Paragraph 11- Subparagraph (b)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482212/2147478345/912-310-45-11Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 28- Subparagraph (a)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482740/230-10-45-28 Details Name: us-gaap\_IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef- Name Accounting Standards Codification- Section 45- Paragraph 28- Subparagraph (a)- SubTopic 10- Topic 230- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482740/230-10-45-28 Details Name: us-gaap\_IncreaseDecreaseInInventories Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap\_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap\_Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionAmount of increase (decrease) in obligation for operating lease. ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 28- Subparagraph (a)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef- Name Accounting Standards Codification- Section 50- Paragraph 4- Subparagraph (g) (1)- SubTopic 20- Topic 842- Publisher FASB- URI https://asc.fasb.org/#1943274/2147478964/842-20-50-4 Details Name: us-gaap\_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of increase (decrease) in operating prepaid expenses, and assets classified as other. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef- Name Accounting Standards Codification- Section 45- Paragraph 28- Subparagraph (a)- SubTopic 10- Topic 230- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482740/230...../asc.fasb.org/#1943274/2147482740/230-10-45-28 Details Name: us-gaap\_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero- coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 17- Subparagraph (d)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 25- Subparagraph (e)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482913/230-10-50-2 Details Name: us-gaap\_InterestPaidNet Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long- term credit. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 24- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482740/230-10-45-24 Details Name: us-gaap\_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap\_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap\_Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 24- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482740/230-10-45-24 Details Name: us-gaap\_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap\_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap\_Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 28- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 24- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 25- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482740/230-10-45-25 Details Name:





for which it has received Breakthrough Device Designation status from the FDA. While not approved for commercial use in the United States, the active drug component of Niyad, nafamostat, has been approved in Japan and South Korea as a regional anticoagulant for the dialysis circuit, disseminated intravascular coagulation, and acute pancreatitis. Niyad is a lyophilized formulation of nafamostat, a broad-spectrum, synthetic serine protease inhibitor, with anticoagulant, anti-inflammatory, and potential anti-viral activities. The second intended indication for Niyad is as a regional anticoagulant for the dialysis circuit for chronic kidney disease patients undergoing intermittent hemodialysis in dialysis centers. In addition, the Company acquired LTX-608, a nafamostat formulation for direct IV infusion, that it intends to develop for the treatment of one or more of the following indications: ARDS, DIC, acute pancreatitis or as an anti-viral agent. On July 14, 2021, the Company entered into a License and Commercialization Agreement, or the PFS Agreement, with Laboratoire Aguettant, or Aguettant, pursuant to which the Company obtained the exclusive right to develop and, subject to FDA approval, commercialize in the United States an epinephrine pre-filled syringe for injection, and (ii) a phenylephrine PFS for injection. Aguettant will supply the Company with the products for use in commercialization, if they are approved in the U. S. Liquidity and Going Concern The consolidated financial statements for the year ended December 31, 2023-2024, were prepared on the basis of a going concern, which contemplates that the Company will be able to realize assets and discharge liabilities in the normal course of business. The termination of the Zalviso Royalty Monetization resulted in net income for the year ended December 31, 2022; however, prior to this, the Company had incurred recurring operating losses and negative cash flows from operating activities since inception and expects to continue to incur operating losses and negative cash flows in the future. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Although, the Company raised additional capital in January 2024 (see Note 16, "Subsequent Events"); considering the Company's current cash resources and its current and expected levels of operating expenses for the next twelve months, management expects to need additional capital to fund its planned operations prior to the 12-month anniversary of the date this Annual Report on Form 10-K is filed with the United States Securities and Exchange Commission, or the SEC. Management may seek to raise such additional capital through public or private equity offerings, including under the Controlled Equity Offering SM Sales Agreement, or the ATM Agreement, with Cantor Fitzgerald & Co., or Cantor, debt securities, a new debt facility, monetizing or securitizing certain assets, entering into product development, license or distribution agreements with third parties, or divesting any of the Company's remaining product candidates. While management believes its plans to raise additional funds will alleviate the conditions that raise substantial doubt about the Company's ability to continue as a going concern, these plans are not entirely within the Company's control and cannot be assessed as being probable of occurring. Additional funds may not be available when the Company needs them on terms that are acceptable to the Company, or at all. If adequate funds are not available, the Company may be required to further reduce its workforce, delay the ongoing clinical trial for Niyad, or delay the development of its regulatory filing plans for its product candidates in advance of the date on which the Company's cash resources are exhausted to ensure that the Company has sufficient capital to meet its obligations and continue on a path designed to preserve stockholder value. In addition, if additional funds are raised through collaborations, strategic alliances or licensing arrangements with third parties, the Company may have to relinquish rights to its technologies, future revenue streams or product candidates, or to grant licenses on terms that may not be favorable to the Company. Basis of Presentation The preparation of accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results could differ from those estimates. The Company's audited financial statements as of December 31, 2022, included in the Company's Annual Report on Form 10-K filed with the rules and regulations of the U. S. Securities and Exchange Commission, or SEC on March 31, 2023, were recast to reflect discontinued operations and filed with the Company's Current Report on Form 8-K on August 1, 2023. See Note 3, "Discontinued operations" below. Reclassifications Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year's presentation. In particular, property and equipment, net and restricted cash, net of current portion have been reclassified as other assets, and operating lease liabilities, current portion, has been reclassified as accrued and other liabilities in the consolidated balance sheets. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management believes its most significant accounting estimates relate to fair value of warrants, impairment liability related to the sale of future payments long-lived assets, accrued clinical trial liabilities and management's assessment of going concern, revenue recognition, liability for royalty monetization and accrued clinical trial liabilities. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Reclassifications Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year's presentation. In particular, other assets has been reclassified as prepaid expenses and other current assets in the consolidated balance sheets, other has been reclassified as net amortization of discount on short-term investments, accounts receivable and other assets have been reclassified as prepaid expenses and other current assets, and payment of employee tax obligations related to vesting of restricted stock units has been reclassified to net proceeds from issuance of common stock through equity plans in the consolidated statement of cash flows and the portion of interest income and other income, net related to the revaluation of liability-classified warrants has been reclassified to change in fair value of warrants in the consolidated statements of operations. The Company has adopted Accounting Standards Update, or ASU, 2023-07, Improvements to Reportable Segment Disclosures, which requires the prior period to reflect the change in presentation. See Note 16, "Segment Reporting". These reclassifications did not affect the prior period's total assets, total liabilities, stockholders' equity, net loss or net cash used in operating activities. Cash and Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with an original maturity (at date of purchase) of three months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks. On May 30, 2019, the Company entered into a Loan Agreement with Oxford Finance LLC, or Oxford, or the Lender. The Loan Agreement requires that the Company always maintain unrestricted cash of not less than \$ 5.0 million in accounts subject to control agreements in favor of the Lender, tested monthly as of the last day of the month. The Company has classified these unrestricted funds as restricted cash on the consolidated balance sheets. On April 3, 2023, the Company repaid Oxford the full amount due under the loan, and the Loan Agreement was terminated with no further obligations by either party. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts in the consolidated statements of cash flows: Balance as of December 31, 2023 December 31, 2021 Cash and cash equivalents \$ 5,721 \$ 15,275 Restricted cash — 5,000 Total cash, cash equivalents, and restricted cash \$ 5,721 \$ 20,275 Short-Term Investments All marketable securities are classified as available for sale and consist of commercial paper and U. S. government sponsored enterprise debt securities. These securities are carried at estimated fair value, which is based on quoted market prices or observable market inputs of almost identical assets, with unrealized gains and losses included in accumulated other comprehensive income (loss). The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income or expense. The cost of securities sold is based on specific identification. When the fair value of an available-for-sale security falls below the amortized cost basis, it is evaluated to determine if any of the decline in value is attributable to credit loss. Decreases in fair value attributable to credit loss are recorded directly to the consolidated statement of operations with a corresponding allowance for credit losses, limited to the amount that the fair value is less than the amortized cost basis. If the credit quality subsequently improves, the allowance is reversed up to a maximum of the previously recorded credit losses. When the Company intends to sell an impaired available-for-sale security, or if it is more likely than not that the Company will be required to sell the security prior to recovering the amortized cost basis, the entire fair value adjustment will immediately be recognized in the consolidated statement of operations with no corresponding allowance for credit losses. Fair Value of Financial Instruments The Company measures and reports its cash equivalents, investments and financial liabilities at fair value. Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows: Level I — Unadjusted quoted prices in active markets for identical assets or liabilities; Level II — Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and Level III — Unobservable inputs that are supported by little or no market activity for the related assets or liabilities. The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Segment Information The Company operates in a single segment, the development and commercialization of innovative therapies for use in medically supervised settings. The Company's revenue relates to the Company's services performed to support sales of DSUVIA to the Department of Defense, or DoD, by Alora under the Marketing Agreement (as defined in Note 3, "Discontinued Operations" below). Concentration of Risk The Company invests cash that is currently not being used for operational purposes in accordance with its investment policy in debt securities of U. S. government sponsored agencies, commercial paper and overnight deposits. The Company is exposed to credit risk in the event of default by the institutions holding the cash equivalents and available-for-sale securities to the extent recorded on the consolidated balance sheets. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of \$ 250,000. Any loss incurred or a lack of access to such funds could have a significant adverse

impact on the Company's financial condition, results of operations, and cash flows. The Company relies on a single contract manufacturer, or CMO, for the active pharmaceutical ingredient, or API, for Niyad™ and a second single contract manufacturer for the finished Niyad product. All revenue relates to the Company's services for fees earned on the sales of DSUVIA to the DoD by Alora. **Impairment of Long-Lived Assets** The Company periodically assesses the impairment of long-lived assets and, if indicators of asset impairment exist, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through an analysis of the undiscounted future expected operating cash flows. If impairment is indicated, the Company records the amount of such impairment for the excess of the carrying value of the asset over its estimated fair value. The Company realigned its cost structure from a focus on commercialization to a focus on advancing its late-stage development pipeline, namely the Niyad product candidates and the pre-filled syringes. As a result, the Company decided to not focus any development resources on Zalviso in the United States. In addition, due to the termination of the agreements with Grünenthal for Zalviso in Europe and the related withdrawal of the Marketing Authorization in Europe in July 2022, the Company did not expect any revenues from Zalviso in Europe in the foreseeable future. Accordingly, the Company determined that it was no longer probable that it would realize the future economic benefit associated with the costs of the Zalviso-related purchased equipment and manufacturing-related facility improvements the Company had made at its contract manufacturer and, therefore, recorded a non-cash impairment charge of \$ 4.9 million to the Zalviso-related assets for the year ended December 31, 2022. The impairment charge was recorded as operating expense in the consolidated statement of operations. Depreciation and amortization expense was immaterial for the year ended December 31, 2022.

**Acquisitions** The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets. Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. For asset acquisitions, a cost accumulation model is used to determine the cost of an asset acquisition. Direct transaction costs are recognized as part of the cost of an asset acquisition. The Company also evaluates which elements of a transaction should be accounted for as a part of an asset acquisition and which should be accounted for separately. The cost of an asset acquisition, including transaction costs, is allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis. Goodwill is not recognized in an asset acquisition. Any difference between the cost of an asset acquisition and the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based on their relative fair values. When a transaction accounted for as an asset acquisition includes an in-process research and development, or IPR & D, asset, the IPR & D asset is only capitalized if it has an alternative future use other than in a particular research and development project. For an IPR & D asset to have an alternative future use (a) the Company must reasonably expect that it will use the asset acquired in the alternative manner and anticipate economic benefit from that alternative use, and (b) the Company's use of the asset acquired is not contingent on further development of the asset subsequent to the acquisition date (that is, the asset can be used in the alternative manner in the condition in which it existed at the acquisition date). Otherwise, amounts allocated to IPR & D that have no alternative use are expensed. Asset acquisitions may include contingent consideration arrangements that encompass obligations to make future payments to sellers contingent upon the achievement of future financial targets. Contingent consideration is not recognized until all contingencies are resolved and the consideration is paid or probable of payment, at which point the consideration is allocated to the assets acquired on a relative fair value basis.

**In-Process Research and Development In accordance with ASC Topic 350, Intangibles- Goodwill and Other, the acquired IPR & D has initially been accounted for as an indefinite-lived intangible asset and, therefore, not amortized. If the IPR & D asset achieves regulatory approval and the asset life is determined to be finite, the asset's useful life will be estimated, and the asset will be amortized over its remaining useful life. The IPR & D asset is reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. These events and changes can include significant current period operating losses or negative cash flows associated with the use of the IPR & D asset, such as the result of unfavorable data from any ongoing or future clinical trial, changes in assumptions that negatively impact projected cash flows, or because of any other information regarding the prospects of successfully developing or commercializing the Company's programs. When impairment indicators are present, the Company compares undiscounted future cash flows to the asset's carrying value to determine if the asset is recoverable. If the carrying values are in excess of undiscounted expected future cash flows, the Company measures any impairment by comparing the fair value of the asset to its carrying value. No impairment losses were recorded on the IPR & D asset during the years ended December 31, 2024 or 2023.**

**Discontinued Operations** In accordance with ASC 205-20 Presentation of Financial Statements: Discontinued Operations, a disposal of a component of an entity or a group of components of the entity is required to be reported as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity's operations and financial results. In the period in which the component meets hold-for-sale or discontinued operations criteria the major current assets, non-current assets, current liabilities, and non-current liabilities shall be reported as components of total assets and liabilities separate from those balances of the continuing operations. At the same time, the results of all discontinued operations, less applicable income taxes, shall be reported as components of net loss separate from the net income (loss) of continuing operations. The Company's DSUVIA business met the definition of a discontinued operation as of March 31, 2023. Accordingly, the Company has classified the results of the DSUVIA business as discontinued operations in its consolidated statements of operations for all periods presented. All assets and liabilities associated with the DSUVIA business were classified as assets and liabilities of discontinued operations in the consolidated balance sheets for the periods presented. All amounts included in the notes to the consolidated financial statements relate to continuing operations unless otherwise noted. (See Note 3, "Discontinued Operations")

**Revenue from Contracts with Customers** The Company follows the provisions of Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers. This guidance provides a unified model to determine how revenue is recognized. The Company recognizes revenue upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. Prior to the divestment of DSUVIA to Alora, the Company sold its products primarily through wholesale and specialty distributors. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company's revenue relates to the Company's services performed to support sales of DSUVIA to the Department of Defense, or DoD, by Alora under the Marketing Agreement (as defined in Note 3, "Discontinued Operations" below). The Company's performance obligation is to serve as the exclusive sales agent for selling DSUVIA to the DoD through the term of the Marketing Agreement. The non-creditable and non-refundable revenues are variable consideration based on 75% of net sales of DSUVIA to the DoD during the period subject to certain adjustments. The Company evaluates if it is a principal or an agent in a transaction to determine whether revenue should be recorded on a gross or net basis depending on if it obtains control over the goods and services before they are transferred to customers. The Company is acting as an agent in relation to DSUVIA sales to the DoD. The consideration in the Marketing Agreement reflects a variable amount, for which the Company estimates the amount of consideration to which it will be entitled by using the expected value method. The Company includes in the transaction price the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. Revenues are recognized when the DoD obtains control of the product, at which time the Company has an unconditional right to receive payment for such revenue earned.

**Research and Development Expenses** Research and development costs are charged to expense when incurred. Research and development expenses include salaries, employee benefits, including stock-based compensation, consultant fees, laboratory supplies, costs associated with clinical trials and manufacturing, including contract research organization fees, other professional services and allocations of corporate costs. The Company reviews and accrues clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of patient studies and other events. **Stock-Based Compensation** Compensation expense for all stock-based payment awards made to employees and directors, including employee stock options and restricted stock units related to the 2020 Equity Incentive Plan, or 2020 EIP, the 2011 Equity Incentive Plan, or 2011 EIP, and employee share purchases related to the Amended and Restated 2011 Employee Stock Purchase Plan, or ESPP, is based on estimated fair values at grant date. The Company determines the grant date fair value of the awards using the Black-Scholes option-pricing model and generally recognizes the fair value as stock-based compensation expense on a straight-line basis over the vesting period of the respective awards. The Company applies the graded-vesting attribution method to awards with market conditions that include graded-vesting features. Additionally, the Company uses the Monte Carlo Simulation model to evaluate the derived service period and fair value of awards with market conditions, including assumptions of historical volatility and risk-free interest rate commensurate with the vesting term. The Black-Scholes option pricing model requires inputs such as expected term, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. The expected term, which represents the period of time that options granted are expected to be outstanding, is derived by analyzing the historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior. Expected volatilities are estimated using the historical stock price performance over the expected term of the option, which are adjusted as necessary

for any other factors which may reasonably affect the volatility of the Company's stock in the future. The risk-free interest rate is based on the U. S. Treasury yield in effect at the time of the grant for the expected term of the award. The Company recognizes forfeitures when they occur and does not anticipate paying dividends in the near future. Warrants Issued in Connection with Financings The Company accounts for issued warrants as either liability or equity in accordance with ASC 480- 10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, or ASC 815- 40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock. Under ASC 480- 10, warrants are considered liability if they are mandatorily redeemable and they require settlement in cash or other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480- 10, the Company considers the requirements of ASC 815- 40 to determine whether the warrants should be classified as liability or equity. Under ASC 815- 40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations. If warrants do not require liability classification under ASC 815- 40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815- 40 or other applicable GAAP. Equity classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.

**Restructuring Costs-Sale of Future Payments On January 12, 2024, the Company entered into the Purchase Agreement with XOMA to monetize a portion of its future payments for commercial sales of DSUVIA and services performed by the Company to support sales of DSUVIA to the Department of Defense, or DoD, by Alora under the Marketing Agreement, and sales milestones under the DSUVIA Agreement. Refer to Note 7, " Sale of Future Payments " for further details on the Purchase Agreement. The Company recorded approximately \$ 6. 1 million, net of \$ 0. 5 million in issuance costs, of the \$ 8. 0 million proceeds as a liability, as this portion of the proceeds represents a sale of future revenues under ASC 470 for which the Company has continuing involvement in the generation of cash flows. The Company recorded approximately \$ 1. 2 million, net of \$ 0. 2 million in issuance costs, of the \$ 8. 0 million proceeds as other income, as this portion of proceeds represents the sale of all of the Company's interest in restructuring costs consist of employee termination benefit costs. Liabilities for costs associated with the cost reduction plan are recognized when the liability is incurred and are measured at fair value. One-time termination benefits are expensed at the date the Company notifies the employee, unless the employee must provide future payments service, in which case the benefits are expensed ratably over the future service period. In May 2022, the Company initiated a reorganization that eliminated approximately 40% of its employees, primarily within the commercial organization. For the year ended December 31, 2022, the Company incurred approximately \$ 0. 5 million in employee termination benefits related to commercial sales this restructuring, all of DSUVIA for which the Company is no longer entitled to receive such payments and has no further been paid. This headcount reduction was completed in the second quarter of 2022. No additional expenses were incurred in connection with this cost reduction plan. Non-Cash Interest Income on Liability Related to Sale of Future Royalties In September 2015, the Company sold certain royalty and milestone payment rights from the sales of Zalviso in the European Union by Grünenthal to PDL for gross proceeds of \$ 65. 0 million, or the Zalviso Royalty Monetization. Grünenthal terminated the Grünenthal Agreements effective November 13, 2020. The terms of the Grünenthal Agreements were extended to May 2021 to enable Grünenthal to sell down its Zalviso inventory. The rights to market and sell Zalviso in the Territory reverted back to the Company in May 2021. Under the Zalviso Royalty Monetization, the Company had a continuing obligation to use commercially reasonable efforts to negotiate a replacement license agreement, or New Arrangement. Under the relevant accounting guidance, because of the Company's significant continuing involvement, the Company utilized internal estimates to develop a cash flow model based on business assumptions to determine the Zalviso Royalty Monetization was accounted for allocation of the proceeds. The liability related to the sale of future payments is recorded as debt and will be a liability that is being amortized using under the effective interest rate method over the estimated life of the arrangement. Purchase Agreement. The In order to determine the amortization of the liability, the Company was required to estimate the effective interest rate based on its estimate the of total amount of future royalty and milestone payments to be received by XOMA under the Purchase Agreement. The Company reassesses these estimates at each reporting date and adjusts the effective interest rate and amortization of the liability on a prospective basis, as necessary. The Company records the payments to XOMA as a reduction of the liability when paid. As such payments are made to PDL XOMA, the balance up to a capped amount of \$ 195. 0 million, the liability will be effectively repaid over the life of the Purchase Agreement arrangement. The aggregate future estimated royalty and milestone payments (subject to the capped amount), less the \$ 61. 2 million of net proceeds the Company received, was to be amortized as interest expense over the life of the liability. Consequently, the Company imputed interest on the unamortized portion of the liability and recorded interest expense, or interest income, as these estimates were updated and recorded non-cash royalty revenues and non-cash interest income (expense), net, within its consolidated statements of operations over the term of the Zalviso Royalty Monetization. When the expected payments under the Zalviso Royalty Monetization were lower than the gross proceeds of \$ 65. 0 million received, the Company deferred recognition of any probable contingent gain until the Zalviso Royalty Monetization liability expired. See Note 7, " Liability Related to Sale of Future Royalties ". Income Taxes Deferred tax assets and liabilities are measured based on differences between the financial reporting and tax basis of assets and liabilities using enacted rates and laws that are expected to be in effect when the differences are expected to reverse. The Company records a valuation allowance for the full amount of deferred assets, which would otherwise be recorded for tax benefits relating to operating loss and tax credit carryforwards, as realization of such deferred tax assets cannot be determined to be more likely than not. Net Income ( Loss ) per Share of Common Stock Basic and diluted net income (loss) per common share, or EPS, are calculated in accordance with the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 260, Earnings per Share. The Company applies the two-class method to compute basic and, if more dilutive than other methods, diluted net income or loss per share. The two-class method is an earnings allocation formula that treats participating securities as having rights to earnings that would otherwise have been available to common stockholders (including pre-funded warrants). Shares of common stock into which the pre-funded warrants may be exercised are considered outstanding for the purposes of computing net loss per share because the shares may be issued for little or no consideration and are exercisable after the original issuance date. In addition, the Company is required to calculate diluted net income or loss per share under the two-class method if the effect is more dilutive than the application of another dilutive method of calculating diluted EPS (i. e., the treasury stock, if-converted, or contingently issuable share method). In periods where there is a net loss, no allocation of undistributed net loss to participating securities is performed if the holders of these securities are not contractually obligated to participate in the Company's losses. The Company's participating securities include the November 2021 Financing Warrants, December 2022 Common Stock Warrants, the July 2023 Series A Redeemable Convertible Preferred and Series B common Stock-stock warrants, and the placement agent July 2023 Series A and Series B Common common Stock-stock Warrants warrants, the placement agent Series A and Series B Common Stock Warrants (see Note 9, " Stockholders' Equity " and Note 10, " Warrants " to the consolidated financial statements in this Annual Report on Form 10-K for additional information). For additional information regarding the net income (loss) per share, see Note 12, " Net Income (Loss) per Share of Common Stock ". Recently Adopted Accounting Pronouncements In June 2016 November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standards- Standard Update, or ASU, 2016-2023- 13-07, Segment Reporting Financial Instruments- Credit Losses (Topic 326-280): Measurement of Credit Losses on Financial Instruments Improvements to Reportable Segment Disclosures, or ASU 2023- 07, which requires all public entities, including public entities with a single reportable segment, that financial assets measured at amortized cost be presented at the net amount expected to provide in interim and annual periods be collected. The measurement of expected credit losses is based on one or more measures historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. ASU 2016- 13 also eliminates the concept of " segment profit or loss used by the chief operating decision maker to allocate resources and assess performance. Additionally, the standard requires disclosures of significant segment expenses and other segment items as -than-temporary " impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will well as incremental qualitative disclosures recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. The Company adopted annual requirements under ASU 2016-2023- 13-07 on January 1, 2024, and plans to adopt interim requirements under ASU 2023- 07 on January 1, using the modified-2025, on a retrospective basis approach, and no cumulative effect adjustment to accumulated deficit was needed as of the adoption date. Additionally, no prior period amounts were adjusted. The adoption of ASU 2016-2023- 13-07 only impacted the disclosures and did not have a material impact on the Company's consolidated financial statements. See Note 16, " Segment Information " for disclosures related to the adoption of ASU 2023- 07. Recently Issued Accounting Pronouncements On In November 2024, the FASB issued ASU 2024- 03, Income Statement- Reporting Comprehensive Income- Expense Disaggregation Disclosures (Subtopic 220- 40): Disaggregation of Income Statement Expenses, or ASU 2024- 03, which is intended to enhance transparency into the nature and function of expenses, primarily through additional disclosures on certain cost and expenses. ASU 2024- 03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. The Company is in the process of evaluating the impact of this new guidance on its disclosures. In December 2023, the FASB issued ASU 2023- 09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires companies to disclose, on an annual basis, specific categories in the effective tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. In addition, ASU 2023- 09 requires companies to disclose additional information about income taxes paid. ASU 2023- 09 will be effective for annual periods beginning January 1, 2025, and will be applied on a prospective basis with the option to apply the standard retrospectively. The Company is evaluating the disclosure**

impact of ASU 2023-09; however, the adoption of ASU 2023-09 will not have **an a material** impact on the Company's consolidated financial statements. The Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the consolidated financial statements. X- DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic-235-Name-Accounting-Standards-Codification-Publisher-FASB-URI-https://asc.fasb.org/#235/tableOfContent> Details Name: us-gaap\_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap\_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap\_DisclosureTextBlockAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration Note 2- Investments and Fair Value Measurement 12 Months Ended Dec. 31, **2023-2024** Notes to Financial Statements Investments and Fair Value Measurement Disclosure [Text Block] 2. Investments and Fair Value Measurement Investments The Company classifies its marketable securities as available for sale and records its investments at fair value. Available-for-sale securities are carried at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income (loss). As of December 31, **2024 and 2023 and 2022**, the contractual maturity of all investments held was less than one year. The tables below summarize the Company's cash, cash equivalents and **short-term investments** (in thousands): **As of December 31, 2024 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and cash equivalents: Cash \$ \$ — \$ — \$ Money market funds 2, 632 — 2, 632 U. S. government agency securities 5, 867 — 5, 867 Total cash and cash equivalents \$ 8, 863 \$ — \$ 8, 863** As of December 31, 2023 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and cash equivalents: Cash \$ 1, 342 \$ — \$ 1, 342 Money market funds — U. S. government agency securities 1, 896 — 1, 896 Commercial paper 2, 393 — 2, 393 Total cash and cash equivalents 5, 721 — 5, 721 Short-term investments: U. S. government agency securities 3, 362 — 3, 362 Commercial paper — Total short-term investments 3, 660 — 3, 660 Total cash, cash equivalents, and short-term investments \$ 9, 381 \$ — \$ 9, 381 **As of December 31, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash, cash equivalents and restricted cash: Cash \$ 13, 275 \$ — \$ 13, 275 Money market funds — U. S. government agency securities 2, 444 — 2, 444 Commercial paper 4, 235 — 4, 235 Total cash, cash equivalents and restricted cash 20, 275 — 20, 275 Short-term investments: Commercial paper — Total short-term investments — Total cash, cash equivalents, restricted cash and short-term investments \$ 20, 275 \$ — \$ 20, 275** At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are the result of credit losses. Impairment is assessed at the individual security level. Factors considered in determining whether a loss resulted from a credit loss or other factors include the Company's intent and ability to hold the investment until the recovery of its amortized cost basis, the extent to which the fair value is less than the amortized cost basis, the length of time and extent to which fair value has been less than the cost basis, the financial condition of the issuer, any historical failure of the issuer to make scheduled interest or principal payments, any changes to the rating of the security by a rating agency, any adverse legal or regulatory events affecting the issuer or issuer's industry, any significant deterioration in economic conditions. There were no material realized or unrealized gains or losses on marketable securities for the years ended December 31, **2024 or 2023 or 2022**. As such, we did not record a credit allowance for the year ended December 31, **2024 or 2023**. Fair Value Measurement The Company's financial instruments consist of Level I and II assets. Money market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments is readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy. For Level II instruments, the Company estimates fair value by utilizing third-party pricing services in developing fair value measurements where fair value is based on valuation methodologies such as models using observable market inputs, including benchmark yields, reported trades, broker/dealer quotes, bids, offers and other reference data. Such Level II instruments typically include U. S. Treasury, U. S. government agency securities and commercial paper. As of December 31, **2023-2024** and December 31, **2022-2023**, the Company held, in addition to Level II assets, a warrant liability related to the December 2022 Common Stock Warrants (see Note 10, "Warrants" below for further description). The fair value of the warrant liability was estimated using the Black Scholes Model which uses as inputs the following weighted average assumptions: dividend yield, expected term in years; equity volatility; and risk-free interest rate (see Note 10, "Warrants" below). The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period. The estimated fair value of the warrant liability represents a Level III measurement. Changes to the estimated fair value of these liabilities are recorded in **interest income and other income, net change in fair value of warrant liability** in the consolidated statements of operations. The following tables set forth the fair value of the Company's financial assets by level within the fair value hierarchy (in thousands): **As of December 31, 2024 Fair Value Level I Level II Level III Assets Money market funds \$ 2, 632 \$ 2, 632 \$ — \$ — U. S. government agency securities 5, 867 — 5, 867 — Total assets measured at fair value \$ 8, 499 \$ 2, 632 \$ 5, 867 \$ — Liabilities Warrant liability \$ 1, 061 \$ — \$ — \$ 1, 061 Total liabilities measured at fair value \$ 1, 061 \$ — \$ — \$ 1, 061** As of December 31, 2023 Fair Value Level I Level II Level III Assets Money market funds \$ \$ — \$ — U. S. government agency securities 5, 258 — 5, 258 — Commercial paper 2, 691 — 2, 691 — Total assets measured at fair value \$ 8, 039 \$ 7, 949 \$ — Liabilities Warrant liability \$ — \$ — \$ 1, 778 Total liabilities measured at fair value \$ 1, 778 \$ — \$ — \$ 1, 778 **As of December 31, 2022 Fair Value Level I Level II Level III Assets Money market funds \$ — U. S. government agency securities 2, 444 — 2, 444 — Commercial paper 4, 730 — 4, 730 — Total assets measured at fair value \$ 7, 495 \$ 7, 174 \$ — Liabilities Warrant liability \$ 7, 098 \$ — \$ 7, 098 Total liabilities measured at fair value \$ 7, 098 \$ — \$ 7, 098** The following table sets forth a summary of the changes in the fair value of the Company's Level III warrant liability for the years ended December 31, **2024 and 2023 and 2022** (in thousands): Year Ended December 31, **2023-2024** Year Ended December 31, **2022-2023** Fair value — beginning of period \$ **1, 778 \$ 7, 098** — Issuance **Change in fair value** of December 2022 Common Stock Warrants **(717) (5, 320)** Fair value — end **7, 098** Change in fair value of period \$ **1, 061 \$ 1, 778** At December 31, 2024, the December 2022 Common Stock Warrants **were (5, 320) — Fair value valued at approximately — end of period \$ 1. 1 million. 778 using the Black-Scholes option pricing model as follows: exercise price of \$ 7. 27 per share. 098 stock price of \$ 0. 5241 per share, expected life of 4 years, volatility of 100. 81 %, a risk-free rate of 4. 33 % and 0 % expected dividend yield. At December 31, 2023, the December 2022 Common Stock Warrants were valued at approximately \$ 1. 8 million, using the Black-Scholes option pricing model as follows: exercise price of \$ 2. 07 per share, stock price of \$ 0. 74 per share, expected life of 5 years, volatility of 94. 05 %, a risk-free rate of 3. 84 % and 0 % expected dividend yield.** There were no transfers between Level I, Level II or Level III of the fair value hierarchy during the years ended December 31, **2024 or 2023 or 2022**. X- DefinitionThe disclosure of investments and fair value measurement. ReferencesNo definition available. Details Name: t1ph\_InvestmentsAndFairValueMeasurementDisclosureTextBlock Namespace Prefix: t1ph\_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap\_DisclosureTextBlockAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration Note 3- Discontinued Operations 12 Months Ended Dec. 31, **2023-2024** Notes to Financial Statements Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] 3. Discontinued Operations **DSUVIA Asset Purchase** Agreement On April 3, 2023, the Company, closed the transactions contemplated by the DSUVIA Agreement entered into on March 12, 2023, with Alora, pursuant to which Alora agreed to acquire certain assets and assume certain liabilities of the Company relating to its sufentanil sublingual tablet product referred to as DSUVIA or DZUVEO, or any other single-dose pharmaceutical product for use in medically supervised settings containing a sublingual tablet that includes sufentanil as the sole active ingredient, as a 30 mcg tablet or other dosage form or strength as reasonably necessary for lifecycle management, or the Product. The Product expressly excludes the pharmaceutical product referred to as Zalviso (sufentanil sublingual tablets, each 15 mcg), any other multi-dose administration system containing sufentanil sublingual tablets (whether as the sole active ingredient or in combination with other active ingredients), and any single-dose formulation of sufentanil for use outside of a medically supervised setting. **The With the closing of the transaction, the** Company is entitled to receive (a) up to \$ 116. 5 million in sales-based milestones, (b) quarterly payments in an amount equal to 15 % of net sales based on sales of the Product to all customers, other than sales to the United States DoD under the Marketing Agreement (as defined below), pursuant to which Alora will pay the Company 75 % of Product net sales to the DoD, and sales by or on behalf of Laboratoire Aguettant, or Aguettant, and (c) 20 % of any consideration, excluding royalty payments based on sales of the Product and subject to customary exclusions, received by Alora or its affiliates in connection with a grant to any third party of a license related to the Product, or by Alora or its affiliates or equity holders in connection with a sale or transfer to any third party of an ownership interest in any assets acquired by Alora under the DSUVIA Agreement. The DSUVIA Agreement contains customary representations, warranties, and covenants by each party. Alora agreed not to practice, license or otherwise exploit any of the intellectual property rights acquired by it under the DSUVIA Agreement to manufacture, develop or commercialize any product (other than the Product) that is or has been commercialized by the Company or its affiliate as of the date of the DSUVIA Agreement, or any product that is competitive with any such product. In addition, Alora will use commercially reasonable efforts to maintain regulatory approvals for and commercialize the Product in the United States. The DSUVIA Agreement also contains indemnification rights for each of the Company and Alora for breaches of representations, warranties, and covenants, as well as certain other matters, subject to certain specified limitations. **The Closing closing of the DSUVIA Agreement** included the execution of the Amended DZUVEO Agreement (as defined below) and the Amended and Restated Supply Agreement (as defined below) between the Company and Aguettant, as well as certain ancillary agreements between the Company and Alora. Such ancillary agreements include (a) an intellectual property agreement, pursuant to which Alora granted fully-paid, royalty-free and perpetual licenses to the Company under certain specified intellectual property rights acquired by Alora under the DSUVIA Agreement for, among other things, the development, manufacture, commercialization and exploitation of certain products,

including Zalviso, (b) a transition services agreement, pursuant to which, during the period specified therein, the Company will be paid to provide certain services (including, manufacturing technology transfer, supply chain, regulatory, and medical affairs services) to Alora, and distribute, on behalf of Alora, certain inventory of the Product transferred to Alora under the DSUVIA Agreement, and (c) an ongoing marketing agreement, or the Marketing Agreement, pursuant to which the Company will have the exclusive right to market and offer the Product for sale to the DoD and Alora will pay to the Company 75 % of net sales of the Product sold to the DoD, subject to adjustment in certain circumstances. Amendments to Certain Agreements Between the Company and Aguettant The Company and Aguettant are parties to (a) the License and Commercialization Agreement, dated July 14, 2021, pursuant to which Aguettant obtained the exclusive right to develop and commercialize DZUVEO in certain European countries for the management of acute moderate to severe pain in adults in medically monitored settings, or the DZUVEO Agreement, and (b) the supply agreement, dated December 6, 2021, with respect to the manufacture and supply of DZUVEO in form of bulk product by the Company to Aguettant, or the Supply Agreement. Pursuant to the DSUVIA Agreement, the Company and Aguettant entered into an amendment to the DZUVEO Agreement, or the Amended DZUVEO Agreement, and an amendment and restatement to the Supply Agreement, or the Amended and Restated Supply Agreement. Pursuant to the Amended DZUVEO Agreement, (a) Aguettant's obligations to make sales-based milestone payments and to achieve certain levels of minimum sales terminated, (b) the Company agreed to manufacture and supply DZUVEO in the form of bulk products (i. e., products that are pre-packaged in labeled pouches and packed in bright stock cartons for shipment) to Aguettant or its affiliates or sublicensees, and Aguettant will be responsible for manufacturing finished products from bulk products, before Aguettant establishes a semi-automated packaging line for the Product, and (c) after Aguettant has established such semi-automated packaging line, the Company will cause DZUVEO to be manufactured and supplied in the form of bulk tablets (i. e., products in tablet forms supplied in bulk (not packaged) quantities) to Aguettant or its affiliates or sublicensees, and Aguettant will be responsible for manufacturing finished products from bulk tablets. The Amended and Restated Supply Agreement will govern the manufacture and supply of DZUVEO in the form of bulk products or bulk tablets, and contain customary terms, including those with respect to manufacturing requirements, forecast, delivery, and post-delivery inspection. Pursuant to the DSUVIA Agreement, the Company assigned the Amended DZUVEO Agreement and the Amended and Restated Supply Agreement to Alora. In addition, the Company and Aguettant amended the License and Commercialization Agreement, dated July 14, 2021, pursuant to which the Company obtained exclusive rights to develop and commercialize certain ephedrine pre-filled syringe and certain phenylephrine pre-filled syringe in the United States, or the PFS Agreement (see Note 5, "In-License Agreement" below). The Company's DSUVIA business met the definition of a discontinued operation as of March 31, 2023. Accordingly, the assets and liabilities associated with these operations have been classified as assets and liabilities of discontinued operations in the consolidated balance sheets at December 31, 2024 and 2023 and. **There were no assets of discontinued operations at December 31, 2022-2024 or 2023.** The operations and cash flows of the DSUVIA business are presented as discontinued for all periods presented. The following table presents the results of the discontinued operations (in thousands): Year ended December 31, Total revenues \$ 1,771-Cost of goods sold 1,508-Selling, general and administrative expense 9,744-Impairment of net assets held for sale 6,853-Impairment of fixed assets 1,065-Gain on termination of lease liabilities (1,098)-Research and development expenses 1,852-Loss from discontinued operations (8,110) (11,333) Interest expense - Net loss from discontinued operations \$ (8,110) \$(11,370) The following table summarizes the carrying amounts of major classes of assets and liabilities of discontinued operations for each of the periods presented (in thousands). December 31, 2023-2024 December 31, 2022-2023 **Accrued liabilities** Accounts receivable, net \$ - Inventories 1,178 **Prepaid expenses and other current assets** Total current assets-liabilities of discontinued operations **Net liabilities** 1,931 Property, plant and equipment, net 10,261 Operating lease right-of-use assets 3,499 Other assets Total non-current assets of discontinued operations 13,936 Total assets of discontinued operations \$ (723) \$ 15,867 Accounts payable \$ 1,720 Operating lease liabilities, current portion 1,601 Note payable, current portion - Deferred revenue, current portion - Total current liabilities of discontinued operations 4,620 Operating lease liabilities, net of current portion 2,959 Deferred revenue, net of current portion 1,036 Total non-current liabilities of discontinued operations 3,995 Total liabilities of discontinued operations 8,615 Net assets (liabilities) of discontinued operations \$ (731) \$ 7,252 The following table presents the significant non-cash items and purchases of property and equipment for the discontinued operations that are included in the consolidated statements of cash flows (in thousands): Year Ended December 31, Cash flows from operating activities: Depreciation and amortization \$ 1,465 Stock-based compensation - Impairment of net assets held for sale 6,853 - Impairment of fixed assets 1,065 - Gain on termination of lease liabilities (1,098) - Gain on extinguishment of debt (400) **Purchases of property and equipment** - Purchases of property and equipment (100) (364) The following table represents the loss on sale of discontinued operations for the year ended December 31, 2023: Year Ended December 31, 2023 Cash proceeds \$ 2,723 Less: net assets transferred (8,723) Loss: disposal costs (853) Loss on sale of discontinued operations, before income taxes (6,853) Income tax expense - Loss on sale of discontinued operations \$ (6,853) **In October 2024, Alora notified the Company that they are discontinuing their DSUVIA sales efforts on behalf of non-DoD customers. At this time, the Company is uncertain as to the impact of this decision on sales of DSUVIA to the DoD, but it expects to be able to continue to market DSUVIA to the DoD until all inventory is sold or Alora makes the decision to no longer provide the supply of DSUVIA to the DoD.** X-ReferencesNo definition available. Details Name: us-gaap\_DisclosureTextBlockAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na:Period Type: durationX-DefinitionThe entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/#205-20/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 360-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/#360/tableOfContentDetails Name: us-gaap\_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock Namespace Prefix: us-gaap\_Data Type: dtr-types:textBlockItemType Balance Type: na:Period Type: duration Note 4-Asset Acquisition 12 Months Ended Dec. 31, 2023-2024 Notes to Financial Statements Business Combination Disclosure [Text Block] 4. Asset Acquisition On January 7, 2022, the Company **acquired** closed its acquisition of Lowell **pursuant** and **acquired** the product nafamostat, and the associated patents and historical know-how. The acquisition was valued at approximately \$ 32.5 million plus cash acquired of \$ 3.5 million and certain other adjustments. All options to purchase capital stock and all shares of Lowell capital stock issued and outstanding immediately before the effective time of the merger **Merger** were cancelled. **Agreement**, in exchange for the right to receive (i) 450,477 shares of the Company's common stock issued at a five-day daily volume-weighted average price of \$ 11.46 per share as of January 7, 2022, or the Acquisition Date, valued at \$ 5.2 million on closing, (ii) cash in the amount of \$ 3.5 million, (iii) 69,808 shares of the Company's common stock to be held back to satisfy any potential indemnification and other obligations of Lowell and its securityholders valued at \$ 0.8 million, (iv) \$ 0.5 million cash and stock paid for sellers' transaction **which includes** costs and (v) up to **approximately** \$ 26.0 million of contingent consideration payable in cash or stock at the Company's option, upon the achievement of regulatory and sales-based milestones. **In connection with** The shares issued in the merger **Merger Agreement** were issued in a private placement pursuant to the exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, or the Securities Act **Company acquired Niyad and LTX-608**, including Rule 506 of Regulation D promulgated under the Securities Act, or Regulation D, without general solicitation as a transaction not involving any public offering. The merger has been accounted for as an asset acquisition of a single IPR & D asset that has an alternative future use. The initial measurement **carrying value** of the **IPR & D** asset **is** purchased of \$ 8.8 million **at December 31** was based on the purchase cost of \$ 12.4 million including (i) \$ 6.0 million common stock fair value on the closing date (issued and held back on the acquisition date), 2024 (ii) \$ 0.5 million seller's costs paid by the Company, (iii) \$ 3.5 million cash and 2023 (iv) approximately \$ 2.5 million of transaction costs less purchase price allocated to cash acquired of \$ 3.5 million. Due to the nature of regulatory and sales-based milestones, the contingent **Contingent** consideration of up to \$ 26.0 million **associated with the Merger Agreement, payable in cash or stock at the Company's option**, was not included in the initial cost of the assets purchased as they **the are contingent consideration is** contingent upon events that are outside the Company's control, such as regulatory approvals and issuance of patents, **and which** are not considered probable until notification is received. However, upon achievement or anticipated achievement of each milestone, the Company shall recognize the related, appropriate payment as an additional cost of the acquired IPR & D asset. As of December 31, 2023-2024, none of the contingent events have occurred. The following table summarizes the total consideration for the acquisition and the value of the IPR & D asset acquired (in thousands): Consideration Cash \$ 3,536 Issuance of common stock to Lowell security holders in connection with asset acquisition 5,161 Issuance of common stock to settle Lowell's transaction costs in connection with asset acquisition Liability for issuance of 69,808 hold back shares to Lowell securityholders (1) Transaction costs 2,521 Total consideration \$ 12,368 IPR & D Asset Acquired Purchase price \$ 12,368 Cash acquired (3,549) Total IPR & D asset acquired (2) \$ 8,819 (1) Recorded as Other long-term liabilities in the consolidated balance sheets at December 31, 2022. Shares were issued in the year ended December 31, 2023 and, accordingly, the related liability was extinguished. (2) Recorded as in-process research and development asset in the consolidated balance sheets. The IPR & D asset has initially been accounted for as an indefinite-lived asset, and as a long-lived asset, it is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If the IPR & D asset achieves regulatory approval and the asset life is determined to be finite, the asset's useful life will be estimated, and the asset will be amortized over its remaining useful life. No impairment losses were recorded on the IPR & D asset during the years ended December 31, 2023 or 2022. X-DefinitionThe entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 5-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147479907/805-20-50-5Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 805-Name

Accounting Standards Codification- Publisher FASB- URI https://asc.fasb.org/805/tableOfContent Details Name: us-gaap\_BusinessCombinationDisclosureTextBlock Namespace Prefix: us-gaap\_Data Type: dt- types: textBlockItemType Balance Type: na Period Type: durationX-ReferencesNo definition available. Details Name: us-gaap\_DisclosureTextBlockAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration Note 5- In- license Agreement 12 Months Ended Dec. 31, 2023-2024 Notes to Financial Statements In- license Agreement [ Text Block ] 5. In-License Agreement On July 14, 2021, the Company entered into a License and Commercialization Agreement, or the PFS Agreement, with Aguettant pursuant to which the Company obtained the exclusive right to develop and, subject to FDA approval, commercialize in the United States (i) an ephedrine pre- filled syringe for injection, and (ii) a phenylephrine pre- filled syringe for injection. Aguettant will supply the Company with the products for use in commercialization if they are approved in the United States. The PFS Agreement has an initial term of ten (10) marketing years, with the first marketing year ending on December 31 of the calendar year after the first launch of a product (or December 31 of the same calendar year if the first launch of a product occurs between January 1 and April 30 of a calendar year). The term will automatically renew for successive five marketing year periods unless a party notifies the other party of its intention not to renew at least six (6) months prior to the expiration of the then- current term. The Company will purchase each product from Aguettant at an agreed price, or the PFS Purchase Price, subject to adjustment. The Company will also make revenue share payments that, combined with the PFS Purchase Price, will range from 40 % to 45 % of net sales in the United States. The Company and Aguettant will agree on minimum sales obligations twelve (12) months prior to the launch of each product. The Company has the right to grant sublicenses to its affiliates or, with the prior approval of Aguettant, third parties, subject to certain limitations. In connection with the Company' s and Aguettant' s agreement to enter into the Amended DZUVEO Agreement and the Amended and Restated Supply Agreement, the parties entered into an amendment to the PFS Agreement, or the Amended PFS Agreement, pursuant to which, effective April 3, 2023, (a) Aguettant paid the Company a complementary payment in the amount of EUR 1, 500, 000, and (b) the Company' s obligation to make a certain specified sales- milestone payment terminated such that the maximum amount in sales- based milestone payments that Aguettant is entitled to receive has been reduced from \$ 24. 0 million to \$ 21. 0 million. As of December 31, 2023-2024, there have been no payments by the Company to Aguettant under the PFS Agreement. X- DefinitionThe entire disclosure for in- license agreement. ReferencesNo definition available. Details Name: t1ph\_InLicenseAgreementTextBlock Namespace Prefix: t1ph\_Data Type: dt- types: textBlockItemType Balance Type: na Period Type: durationX-ReferencesNo definition available. Details Name: us-gaap\_DisclosureTextBlockAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration Note 6- Long- term Debt 12 Months Ended Dec. 31, 2023-2024 Notes to Financial Statements Long- Term Debt [ Text Block ] 6. Long- Term Debt Loan Agreement with Oxford On May 30, 2019, the Company entered into the Loan Agreement with Oxford Finance LLC, or Oxford, as the Lender. Under the Loan Agreement, the Lender made a term loan to the Company in an aggregate principal amount of \$ 25. 0 million, or the Loan, which was funded on May 30, 2019. As of December 31, 2022, the accrued balance due under the Loan Agreement with Oxford was \$ 5. 4 million. Interest expense related to the Loan Agreement was \$ 0. 1 million for the year ended December 31, 2023, \$ 0. 1 million of which represented amortization of the debt discount. Interest expense related to the Loan Agreement was \$ 1. 1 million, of which \$ 0. 4 million represented amortization of the debt discount, and \$ 2. 2 million for the year ended December 31, 2022 and the effective interest rate was approximately 13. 6 %. In connection with the closing of the divestment of DSUVIA to Alora, on April 3, 2023, the Company paid Oxford the remaining amount due of approximately \$ 3. 4 million including accrued interest and fees under the Loan, and the Loan Agreement was terminated with no further obligations by either party. Interest expense related to the Loan Agreement was \$ 0. 1 million, which represented amortization of the debt discount, for the year ended December 31, 2023. In connection with the Loan Agreement, on May 30, 2019, the Company issued warrants to the Lender and its affiliates, which are exercisable for an aggregate of 8, 833 shares of the Company' s common stock with a per share exercise price of \$ 56. 60, or the Loan Agreement Warrants (The Warrants have been classified within stockholders' equity and accounted for as a discount to the loan by allocating the gross proceeds on a relative fair value basis. For further discussion, see Note 10, " Warrants "). X- ReferencesNo definition available. Details Name: us-gaap\_DisclosureTextBlockAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- DefinitionThe entire disclosure for long- term debt. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef- Topic 470- Name Accounting Standards Codification- Publisher FASB- URI https://asc.fasb.org/470/tableOfContent Details Name: us-gaap\_LongTermDebtTextBlock Namespace Prefix: us-gaap\_Data Type: dt- types: textBlockItemType Balance Type: na Period Type: duration Note 7- Liability Related to Sale of Future Royalties Payments 12 Months Ended Dec. 31, 2023-2024 Notes to Financial Statements Liability Related To Sale Of Future Payments Royalties Disclosure [ Text Block ] 7. Liability Related to Sale of Future Payments In January 2024 Royalties On September 18, 2015, the Company and XOMA entered into the Purchase Agreement Zalviso Royalty Monetization with PDL for which it received gross proceeds of the sale by the Company to XOMA, in exchange for \$ 65. 8, 0 million. Under the Zalviso Royalty Monetization, PDL was of the Company' s right, title and interest in and to receive 75 certain amounts payable to the Company, or collectively, the Purchased Receivables, pursuant to the DSUVIA Agreement in respect of net sales of the Product, excluding sales of the Product by Aguettant. The Purchased Receivables include: (i) 100 % of certain payments based on net sales of the European royalties under Product and potential sales- based milestone payments of up to \$ 116. 5 million in respect of net sales of the Amended Product, in each case made on and after January 1, 2024 and excluding sales of the Product by Aguettant, and of certain associated license and acquisition payments relating to the Product, until XOMA has received a certain minimum amount \$ 20.0 million of payments in respect of the foregoing, or the XOMA Threshold, or the Stepdown Date; and (ii) following the Stepdown Date, (A) 100 % of royalty payments based on net sales of the Product other than net sales to the United States Department of Defense, or DoD and (B) 50 % of each of the following: (a) payments based on net sales of the Product to the DoD, (b) potential sales- based milestone payments in respect of net sales of the Product, and (c) certain associated license and acquisition payments relating to the Product. The Company has retained its right, title and interest in and to, following the Stepdown Date, 50 % of each of the following: (a) payments based on net sales of the Product to the DoD, (b) potential sales- based milestone payments in respect of net sales of the Product, and (c) of certain associated license and acquisition payments relating to the Product. The Purchase Agreement contains customary representations, warranties and agreements- Agreement with Grünenthal- contains customary representations, as well as 80 % warranties and agreements by the Company and XOMA, indemnification obligations of the parties and the other first obligations of the parties. The allocation of the consideration for the Purchase Agreement resulted in proceeds of \$ 1. 4 million reduced by \$ 0. 2 million of transaction costs being allocated to the sale of all future interest in payments related to commercial milestones worth sales of DSUVIA representing its fair value. As a result of the Company' s loss of control, no further continuing involvement in, or rights to future payments related to commercial sales of DSUVIA, the Company recognized other income of \$ 35. 1. 2 million in January 2024. The Company evaluated the terms of the Purchase Agreement and concluded that the features of the Purchased Receivables are similar to those of a debt instrument. Accordingly, the Company recorded the allocated proceeds of approximately \$ 6. 6 million reduced by approximately 80 % of \$ 44. 0, 5 million of transaction costs, up as a liability. The Company accounts for the value of the debt at amortized cost. The amounts received by the Company will be accreted to a capped total estimated amount of \$ 195. 0 million over the life of payments necessary to extinguish the arrangement. Company' s obligation under the Purchase Agreement, which will be recognized as interest expense. The carrying value of the debt will decrease for payments made to XOMA. The Company periodically assesses the expected royalty payments for services performed to support sales of DSUVIA to the DoD by Alora under the Marketing Agreement and milestone payments under the DSUVIA Agreement using a combination of historical results, internal projections, and forecasts from external sources. To the extent such payments were are greater or less than the Company' s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjusted-- adjust the amortization of the liability and the effective interest rate. Grünenthal notified Due to the Company that it was terminating significant judgments and factors related to the Amended License estimates of future payments under the Purchase Agreement effective November 13, 2020 there are significant uncertainties surrounding the amount and timing of future payments. As the payments are remitted On August 31, 2020, PDL sold its royalty interest for Zalviso to XOMA SWK Funding, LLC, or SWK, under the liability will be effectively repaid over Zalviso Royalty Monetization. The terms of the Grünenthal life of the Agreements- agreement were extended. In order to May 12, 2021 to enable Grünenthal to sell down its Zalviso inventory. The rights to market and sell Zalviso in Europe reverted back to the Company on May 12, 2021. On May 31, 2022, the Company entered into a Termination Agreement with SWK to fully terminate-- determine the Zalviso Royalty Monetization for which the Company paid cash consideration of \$ 0. 1 million, and neither PDL nor SWK retains any further interest in the Zalviso Royalty Monetization. Accordingly, effective May 31, 2022, the Zalviso Royalty Monetization is no longer reflected on the Company' s consolidated financial statements or other-- the records as a sale of assets to PDL or SWK and all security interests and other liens of every type held by the parties to the Zalviso Royalty Monetization amortization have been terminated and automatically released without further action by any party. The \$ 84. 1 million gain on extinguishment of the liability related to the sale of future royalties payments, the Company is recognized in required to estimate the total amount of future payments to XOMA over the life of the Purchase Agreement. In October 2024, Alora notified the Company that the they consolidated statements of operations are discontinuing their DSUVIA sales efforts to non- DoD customers. At this time, the Company is uncertain as to other-- the income impact of this decision on sales of DSUVIA to the DoD. The effective As a result, the Company estimates that future payments under the Purchase Agreement will be less than the proceeds from the sale of such future payments. Accordingly, the Company will not recognize any related non- cash interest income rate for expense. When the expected payments under the sale of future payments are lower than the gross proceeds of \$ 6. 6 million received, the Company defers recognition of any probable contingent gain until the Company has met its obligations under the liability related to the sale of future payments. For the year ended December 31, 2022-2024, the estimated effective interest rate under the agreement was approximately 0 3-2 % . The Company did

not recognize any non-cash revenue and recognized non-cash interest expense of approximately \$ 0.4 million for the year ended December 31, 2024. The interest and amortization of issuance costs are reflected as non-cash interest expense for the sale of future payments in the consolidated statements of operations. The following table shows the activity within the liability account during the year ended December 31, 2022-2024, and the period from inception to December 31, 2024 (in thousands):

Year ended December 31, 2022-2024	Period from inception to December 31, 2022-2024
Liability related to sale of future royalties payments — beginning balance	\$ 85,288
Proceeds from sale of future royalties payments, net of issuance costs	6,133
Payments to XOMA	61,184
Non-cash royalty revenue	(1,083)
Non-cash interest (income) expense recognized	(1,136)
Consideration paid for termination of Royalty Monetization	(100)
Gain on extinguishment of liability related to sale of future royalties	(84,052)
Liability related to sale of future royalties payments as of December 31, 2022-2024	\$ 6,527

**Definition Disclosure** The entire disclosure for the liability related to sale of future royalties payments. References: No definition available. Details Name: **tlph\_LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock** **tlph\_SaleOfFuturePaymentsTextBlock** Namespace Prefix: **tlph\_** Data Type: **dtr-** types: **textBlockItemType** Balance Type: **na** Period Type: **durationX-** References: No definition available. Details Name: **us-gaap\_DisclosureTextBlockAbstract** Namespace Prefix: **us-gaap\_** Data Type: **xbrli:** stringItemType Balance Type: **na** Period Type: **duration** Note 8- Commitments and Contingencies 12 Months Ended Dec. 31, 2023-2024 Notes to Financial Statements Commitments and Contingencies Disclosure [ Text Block ] 8. Commitments and Contingencies Litigation On June 8, 2021, a securities class action complaint was filed in the U. S. District Court for the Northern District of California against the Company and two of its officers. The plaintiff is a purported stockholder of the Company. The complaint alleged that defendants violated Sections 10 (b) and 20 (a) of the Exchange Act and SEC Rule 10b- 5 by making false and misleading statements and omissions of material fact about the Company’s disclosure controls and procedures with respect to its marketing of DSUVIA. The complaint sought unspecified damages, interest, attorneys’ fees, and other costs. On December 16, 2021, the Court appointed co-lead plaintiffs. Plaintiffs’ amended complaint was filed on March 7, 2022. The amended complaint named the Company and three of its officers and continued to allege that defendants violated Sections 10 (b) and 20 (a) of the Exchange Act and SEC Rule 10b- 5 by making false and misleading statements and omissions of material fact about the Company’s disclosure controls and procedures with respect to its marketing of DSUVIA. The amended complaint also asserted a violation of Section 20A of the Exchange Act against the individual defendants for alleged insider trading. The amended complaint sought unspecified damages, interest, attorneys’ fees, and other costs. **The On September 1, 2022, the Court granted held oral hearings on the three Company’s motion motions to dismiss the amended plaintiffs’ complaint : the first on September 28, 2022, the second on November 28, 2022, and the third, with prejudice that on May 7, 2024. Judgment was filed entered for defendants on July 21 plaintiffs’ claims on May 7, 2022-2024. On June September 28, 2022, the Court issued a formal written opinion, or the First Opinion, dismissing all of the plaintiff’s claims against the Company and the named defendants with leave for plaintiffs to amend their complaint. On November 28, 2022 the plaintiffs filed their second amended complaint. On July 7, 2023, the Court issued a formal written opinion, or the Second Opinion, dismissing all of the plaintiff’s claims against the Company and the named defendants with leave for plaintiffs to amend their complaint in part and without leave to amend in part. On September 5, 2023-2024, the plaintiffs filed a notice of appeal in third amended complaint. Defendants’ motion to dismiss the third amended complaint is fully briefed and United States Court of Appeals for the Ninth Circuit. Briefing on the appeal was complete on January 21, 2025. The Court has not yet scheduled a hearing on the appeal is scheduled for April 4, 2024.** On July 6, 2021, a purported shareholder derivative complaint was filed in the U. S. District Court for the Northern District of California. The complaint names ten of the Company’s s officers and directors and asserts state and federal claims based on the same alleged misstatements as the securities class action complaint. On September 30, 2021, October 26, 2021, and November 17, 2021, three additional purported shareholder derivative complaints were filed in the U. S. District Court for the Northern District of California. The complaints name nine of the Company’s s officers and directors and also assert state and federal claims based on the same alleged misstatements as the securities class action complaint. All four complaints seek unspecified damages, attorneys’ fees, and other costs. On December 6, 2021, the Court entered an order consolidating all four actions and staying the consolidated action pending the outcome of any motion to dismiss the securities class action. On February 16, 2024, another purported shareholder derivative complaint was filed in the Court of Chancery of the State of Delaware. **The complaint names nine of the Company’s s officers and directors and asserts asserting the same claims as those in the previously filed derivative actions. The Company case has not yet been served stayed pending the outcome of any motion to dismiss the securities class action .** Please see “ Part I, Item 1A. Risk Factors — Risks of a General Nature — Litigation may substantially increase our costs and harm our business. ” The Company believes that these lawsuits are without merit and intends to vigorously defend against them. Given the uncertainty of litigation, the preliminary stage of the cases, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions. It is reasonably possible that this estimate may change in the near term. An adverse outcome regarding these matters could materially adversely affect the Company’s financial condition, results of operations, and cash flows. Termination Agreement and Mutual Release Between the Company and Catalent On March 12, 2023, the Company and Catalent Pharma Solutions, LCC, or Catalent, entered into a termination agreement and mutual release, or the Termination Agreement, to terminate the Site Readiness Agreement with an effective date of August 15, 2019 and as amended on September 24, 2020, the SRA Agreement, and the commercial supply agreement with an effective date of March 31, 2021, the CSA Agreement. Pursuant to the Termination Agreement, as of the date on which the Company has removed and transported certain equipment from Catalent’s site, the SRA Agreement and the CSA Agreement will terminate except with respect to certain specified provisions of such agreements. X- Definition The entire disclosure for commitments and contingencies. References Reference 1:

Convertible Preferred Stock for cash at 105% of the Stated Value on the date of and for 15 days following the Reverse Stock Split, subject to the Purchaser's right to convert the shares prior to such redemption. The Purchaser had the right to require the Company to redeem the shares of Series A Redeemable Convertible Preferred Stock for cash at 110% of the Stated Value of such shares commencing after the Company's right to redeem expired. The Series A Redeemable Convertible Preferred Stock was required to be redeemed for cash at 110% of the Stated Value upon a delisting event. As a result, the Series A Redeemable Convertible Preferred Stock was recorded separately from stockholders' equity because it was redeemable upon the occurrence of redemption events that were considered not solely within the Company's control. As such, during the year ended December 31, 2022, the Company recognized approximately \$0.2 million in deemed dividends related to the Series A Redeemable Convertible Preferred Stock in the consolidated statements of operations and the consolidated statements of changes in redeemable convertible preferred stock and stockholders' equity. The holders of the Series A Redeemable Convertible Preferred Stock were entitled to certain registration rights, rights for approval of increases in the authorized shares of such series, and to dividends paid on common stock on an as-if converted basis. The Series A Redeemable Convertible Preferred stock had no voting rights, other than the right to (i) vote exclusively on the Reverse Stock Split and any proposal to adjourn any meeting of stockholders called for the purpose of voting on the Reverse Stock Split and (ii) to 1,000,000 votes per each share of Series A Redeemable Convertible Preferred Stock, to vote together with the common stock, as a single class; to the extent cast on the Reverse Stock Split in the same proportion as shares of common stock. In addition, in the event of any liquidation, dissolution, or winding-up of the Company, the holders of the Series A Redeemable Convertible Preferred Stock were entitled to receive 110% of the preferred stock's Stated Value plus any declared but unpaid dividends before any payment was made to holders of common stock. On October 11, 2022, the Company and LPC entered into the Securities Redemption Agreement whereby on October 12, 2022, the Company redeemed for cash at a price equal to 105% of the Stated Value per share all 3,000 outstanding shares of Series A Redeemable Convertible Preferred Stock for \$0.3 million. As a result, all shares of such series were retired and are no longer outstanding. On October 25, 2022, the Company filed a certificate of elimination to its amended and restated certificate of incorporation which (i) eliminated the previous designation of 3,000 shares of Series A Redeemable Convertible Preferred Stock from the Company's amended and restated certificate of incorporation and (ii) caused such shares of Series A Redeemable Convertible Preferred Stock to resume their status as authorized but unissued and non-designated shares of preferred stock. Common Stock July 2023 Private Placement On July 17, 2023, the Company entered into a securities purchase agreement, or the Purchase Agreement, with several institutional investors, or the July 2023 Purchasers, relating to the issuance and sale to the July 2023 Purchasers in a private placement, or the July 2023 Private Placement, of 5,340,591 shares of common Common stock Stock, par value \$0.001 per share, pre-funded warrants to purchase up to an aggregate of 2,012,356 shares of common Common stock Stock at an exercise price of \$0.001 per share, or the July 2023 Pre-Funded Warrants; July 2023 Series A common stock warrants to purchase up to an aggregate of 7,352,947 shares of common Common stock Stock at an exercise price of \$1.11 per share; and July 2023 Series B common stock warrants to purchase up to an aggregate of 7,352,947 shares of common Common stock Stock at an exercise price of \$1.11 per share. In connection with See Note 10, "Warrants" for additional information regarding the July January 2023 2024 Private Placement Pre-Funded Warrants, and a portion of these July 2023 Series A common stock warrants and July 2023 Series B common stock warrants were restated and amended to reduce the exercise price thereunder from \$1. The private placement closed on July 20-11 to \$0.77 per share (see Note 10, 2023 "Warrants"). The combined offering price of the July 2023 Private Placement was \$1.36 per share of common Common stock Stock and accompanying July 2023 Series A common stock warrant and July 2023 Series B common stock warrant, or in the case of July 2023 Pre-Funded Warrants, \$1.359 per pre-funded warrant and accompanying July 2023 Series A common stock warrant and July 2023 Series B common stock warrant (which is the purchase price per share of common stock and accompanying warrants less \$0.001). The aggregate gross proceeds to the Company from the July 2023 private Private placement Placement were approximately \$10.0 million, before deducting placement agent fees and other expenses payable by the Company of approximately \$1.1 million, and excluding the proceeds, if any, from the exercise of the July 2023 Pre-Funded Warrants and July 2023 Series A and July 2023 Series B common stock warrants issued in the private placement. The potential gross proceeds from the July 2023 Private Placement Series A common stock warrants and July 2023 Series B common stock warrants, if fully exercised for cash, is approximately \$16.3 million. In May 2023, the Company engaged H. C. Wainwright & Co., LLC to act as placement agent in the private placement. As compensation, the Company paid the placement agent a cash fee equal to 5.25% of the aggregate gross proceeds generated from the private placement and reimbursed certain expenses of the placement agent in connection with the private placement totaling \$0.1 million. The placement agent will be entitled to an additional one-time payment of \$200,000 upon the exercise of the July 2023 Series A and Series B common stock warrants resulting in cumulative aggregate gross proceeds to the Company of at least \$9.5 million in cash. As of December 31, 2023, none of the July 2023 Series A or Series B common stock warrants were exercised. In addition, the Company issued to the placement agent fully vested July 2023 Series A common stock warrants, or placement agent July 2023 Series A common stock warrants, to purchase 183,824 shares of common stock and fully vested July 2023 Series B common stock warrants, or placement agent July 2023 Series B common stock warrants, to purchase 183,823 shares of common stock. See Note 10, "Warrants" for additional information regarding the July 2023 Series A and B warrants and the placement agent July 2023 Series A and Series B common stock warrants. December 2022 Registered Direct Offering On December 29, 2022, the Company completed the December 2022 Financing in which it issued (i) 748,744 shares of its common stock, par value \$0.001 per share, (ii) the December 2022 Pre-Funded Warrants to purchase 2,632,898 shares of common stock, and (iii) the December 2022 Common Stock Warrants, which accompany the common stock and December 2022 Pre-Funded Warrants, to purchase an aggregate of 4,227,052 shares of common stock (see Note 10, "Warrants"). The shares of common stock and accompanying December 2022 Warrants were sold at a combined offering price of \$2.22625 per share and accompanying common warrant, and the December 2022 Pre-Funded Warrants and accompanying December 2022 Common Stock Warrants were sold at a combined offering price of \$2.22615 per December 2022 Pre-Funded Warrant and accompanying December 2022 Common Stock Warrant. The December 2022 Financing resulted in aggregate gross proceeds of \$7.5 million, before \$1.7 million of transaction costs, \$0.8 million of which were non-cash issuance costs, excluding the proceeds, if any, from the exercise of the December 2022 Pre-Funded Warrants and the December 2022 Common Stock Warrants. The common stock was allocated \$0.1 million of the gross proceeds received based on its relative fair value to the other instruments issued (see Note 10, "Warrants"). January 2024 Private Placement On January 17, 2024, the Company entered into a private placement with certain institutional investors for aggregate gross proceeds of \$6.0 million upfront, an additional \$10.0 million committed upon the announcement of positive clinical trial results for the Company's NEPHRO study of Niyad, and an additional \$2.0 million if Talphera stock trades above a specified price following the NEPHRO registration trial announcement, before deducting offering expenses payable by us (see Note 16, "Subsequent Events" below for additional information). ATM Agreement On June 21, 2016, the Company entered into a Controlled Equity Offering SM Sales Agreement, or the ATM Agreement, with Cantor Fitzgerald & Co., or Cantor, as agent, pursuant to which the Company may offer and sell, from time to time through Cantor, shares of the Company's common stock, or the Common Stock having an aggregate offering price of up to \$40.0 million, or the Shares. On May 9, 2019, the Company increased the aggregate offering price of shares of the Company's common stock which may be offered and sold under the ATM Agreement by \$40.0 million, for a total of \$80.0 million, or the Shares. The offering of Shares pursuant to the ATM Agreement will terminate upon the earlier of (a) the sale of all of the Shares subject to the ATM Agreement or (b) the termination of the ATM Agreement by Cantor or the Company, as permitted therein. The Company will pay Cantor a commission rate in the low single digits on the aggregate gross proceeds from each sale of Shares and has agreed to provide Cantor with customary indemnification and contribution rights. The Company issued and sold 124,330 shares of common stock pursuant to the ATM Agreement and received net proceeds of \$0.5 million, after deducting fees and expenses, during the year ended December 31, 2022. No shares were sold under the ATM Agreement in the year ended December 31, 2023. As of December 31, 2023, the Company had the ability to offer and sell shares of the Company's common stock having an aggregate offering price of up to \$35.6 million under the ATM Agreement. The Company's ability to sell shares under the ATM Agreement will be limited until the Company is no longer subject to the SEC's "baby shelf" limitations. Stock Plans 2011 Equity Incentive Plan In January 2011, the Board of Directors adopted, and the Company's stockholders approved, the 2011 Equity Incentive Plan, or 2011 EIP. The initial aggregate number of shares of the Company's common stock that were issuable pursuant to stock awards under the 2011 EIP was approximately 93,750 shares. The number of shares of common Common stock Stock reserved for issuance under the 2011 EIP automatically increased on January 1 of each year, starting on January 1, 2012 and continuing through January 1, 2020, by 4% of the total number of shares of the Company's common stock outstanding on December 31 of the preceding calendar year, or such lesser number of shares of common Common stock Stock as determined by the Board of Directors. As of June 16, 2020, no more awards may be granted under the 2011 Equity Incentive Plan, or the 2011 EIP, although all outstanding stock options and other stock awards previously granted under the 2011 EIP will continue to remain subject to the terms of the 2011 EIP. Amended and Restated 2020 Equity Incentive Plan On June 16, 2020, at the 2020 Annual Meeting of Stockholders of the Company, the Company's stockholders, upon the recommendation of the Company's Board of Directors, approved the Company's 2020 Equity Incentive Plan, or the 2020 EIP. The initial aggregate number of shares of the Company's common stock issuable pursuant to stock awards under the 2020 EIP was 275,000 shares. In addition, the share reserve will be increased by the number of returning shares, if any, as such shares become available from time to time under the 2011 EIP, for an additional number of shares not to exceed 744,608 shares. The term of any option granted under the 2020 EIP is determined on the date of grant but shall not be longer than 10 years. The Company issues new shares for settlement of vested restricted stock units and exercises of stock options. The Company does not have a policy of purchasing its shares relating to its stock-based programs. On October 10 June 24, 2023 2024, at the 2023 2024 Annual Meeting of Stockholders of the Company, upon the recommendation of the Company's Board of Directors, the Company's stockholders approved an amendment and restatement of the Company's 2020 Equity Incentive Plan, or the Amended 2020 Plan, to increase the number of authorized shares reserved for issuance thereunder by 1,500 171,000 395 shares, subject to adjustment for certain changes in the Company's

capitalization. The aggregate number of shares of the Company's common stock that may be issued under the Amended 2020 Plan will not exceed the sum of: (i) ~~1-3, 990-161, 000-395~~ shares, and (ii) up to 744, 608 shares subject to outstanding awards granted under the 2011 Equity Incentive Plan that may become available for issuance under the Amended 2020 Plan, as such shares become available from time to time. **Inducement Grant In May 2024, the Company granted stock-based awards outside of the existing stock plans to one new employee, or the Inducement Grant. These awards were granted as a material inducement for accepting employment with the Company, in accordance with Nasdaq Listing Rule 5635 (c) (4). The inducement awards consisted of a total of 217, 000 shares of the Company's common stock, which includes an aggregate of 185, 000 shares of Common Stock issuable upon the exercise of inducement stock option grants and 32, 000 shares of Common Stock issuable upon the vesting of restricted stock unit awards generally subject to the same terms and conditions as grants that are made under the Company's Amended 2020 Plan.** Amended and Restated 2011 Employee Stock Purchase Plan **On** ~~Additionally, on~~ June 16, 2020, the Company's stockholders, upon the recommendation of the Company's Board of Directors, approved the Amended and Restated 2011 Employee Stock Purchase Plan, or the Amended ESPP, which increased the aggregate number of shares of the Company's common stock reserved for issuance under the 2011 Employee Stock Purchase Plan, or ESPP, to 245, 000 shares, subject to adjustment for certain changes in the Company's capitalization, and removed the "evergreen" provision from the ESPP. **In On June 24, 2024, at the year 2024 Annual Meeting of Stockholders of the Company, upon the recommendation of the Company's Board of Directors, the Company's stockholders approved an amendment and restatement of the Company's 2011 Employee Stock Purchase Plan, or the ended Amended December 31 2011 ESPP. 2023, to increase there-- the number of authorized were 42, 209 shares reserved for issuance thereunder by 100, 000 shares, subject to adjustment for certain changes in the Company's capitalization. The aggregate number of shares of the Company's common stock that may now be issued under the Amended 2011 ESPP is 345. The weighted average fair value of shares issued under the Amended ESPP in 2023 and 2022 was \$ 1. 08 and \$ 6. 82 per share. 000 respectively. As of December 31, 2023, there were 169, 667 shares available for future grant under the Amended ESPP. X- References** No definition available. Details Name: us- gaap\_DisclosureTextBlockAbstract Namespace Prefix: us- gaap\_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- Definition The entire disclosure for equity. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (h)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481062-2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481062-2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481004-2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 3-04)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 4-08 (e) (1))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/us-gaap/role/ref/legacyRef-Topic 505-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/#505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 16-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481112/505-10-50-18Details Name: us- gaap\_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us- gaap\_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration Note 10- Warrants 12 Months Ended Dec. 31, 2023-2024 Notes to Financial Statements Warrants Disclosure [Text Block] 10. Warrants The activity related to warrants during the years ended December 31, 2024 and 2023 and 2022, is summarized as follows: Common Stock from Warrants Weighted- average Exercise Price (per share) Outstanding at December 31 January 1, 2021-2023 883-7, 824 833 \$ 5. 15 Granted 6- 933 941, 100 \$ 1. 27-71 Granted 17, 085, 897 \$ 0. 99 Exercised (3, 228, 781) \$ (0. 0003) Outstanding at December 31, 2022-2023 7-21, 824 682, 923 049 \$ 1. 71-40 Granted 17-7, 085-792, 897-208 \$ 0. 001 99 Exercised (3, 228, 781) \$ (0. 0003) Outstanding at December 31, 2023-2024 21-29, 682-474, 049-257 \$ 1+0, 40-96 Exercisable at December 31, 2023-2024 21-29, 682-474, 049-257 \$ 1+0, 40-96 At December 31, 2023-2024, the range of exercise prices for shares under warrants and the weighted- average remaining contractual life is as follows: Warrants Outstanding Warrants Exercisable Warrant Exercise Price Number of Warrants Weighted- Average Remaining Contractual Life (Years) Number of Warrants Weighted- Average Exercise Price \$ 0. 001 +9, 416-208, 473-681 Unlimited +9, 416-208, 473-681 \$ 0. 001 \$ 0. 77 5, 882, 356 3. 55 5, 882, 356 \$ 0. 77 \$ 1. 11 14-8, 787-904, 044-4 688 3, 62-14 55 8, 787-904, 044-688 \$ 1. 11 \$ 1. 70 367, 647 4-3, 62-55 367, 647 \$ 1. 70 \$ 2. 07 4, 977, 052 5-4, 07-00 4, 977, 052 \$ 2. 07 \$ 2. 00 125, 000 2-1, 92-87 125, 000 \$ 2. 00 \$ 56. 60 8, 833 5-4, 49-41 8, 833 \$ 56. 60 Total 21-29, 682-474, 049-5 257 3, 06-21 65 29, 682-474, 049 common stockholders because "full review" by the SEC shares may be issued for little or no consideration and are fully vested and are exercisable after their original issuance date. **Amendment of Prior The January 2024 Pre- Funded Warrants On may participate with common shareholders in dividends or other distributions. In July 20, 2023, in connection with a prior the July 2023 Private-private Placement placement Warrants (see below), the Company issued to certain of the July 2023-Purchasers (i) Series A common stock purchase warrants to purchase up to 3,676,473 shares of Common Stock and (ii) Series B common stock purchase warrants to purchase up to 3,676,473 shares of Common Stock, or collectively, the Prior Warrants. In connection with the current January 2024 Private Placement, the Company and the January 2024-Purchasers agreed to amend and restate, a portion of the outstanding Prior Warrants, representing (i) Series A common stock purchase warrants to purchase up to 2,941,178 shares of each the Series A common Common stock stock warrants and (ii) Series B common stock purchase warrants outstanding to purchase up to 2, by reducing 941,178 shares of Common Stock, to reduce the exercise price thereunder from to \$ 0. 77 per share \$ 1. 40 Financing-11 to \$ 0. 77 per share. Pursuant to ASU 2021- 04, the Company remeasured the fair value of the November 2021 Financing amended and restated Prior Warrants as of the modification date based on the modified terms and recorded the increase in fair value of \$ 0. 8-3 million as equity issuance costs, all \$ 0. 7 million of which was allocated to selling general and administrative expenses and \$ 0. 1 million of which was allocated to additional paid in capital, based on the relative fair values of the 2022 Warrants, classified as liabilities, and the Common Stock and Pre- funded Warrants, classified in equity, respectively. The fair value assumptions related to the modification of these 750 5, 000 November 2021 Financing 882,356 amended and restated Prior Warrants as of December 29 January 17, 2022-2024 were as follows: exercise price of \$ 2-0, 07-77 per share, stock price of \$ 0. 769 per share, expected life of 4.5 years, volatility of 96.91%, a risk- free rate of 4.02 % and 0 % expected dividend yield. July 2023 Private Placement Warrants On July 20, 2023, the Company issued pre- funded warrants to purchase up to an aggregate of 2, 012, 356 shares of common Common stock Stock at an exercise price of \$ 0. 001 per share, or the July 2023 Pre- Funded Warrants, the July 2023 Series A Common common Stock stock Warrants warrants to purchase up to an aggregate of 7, 352, 947 shares of common Common stock Stock at an exercise price of \$ 1. 11 per share, and the July 2023 Series B Common common Stock stock Warrants warrants to purchase up to an aggregate of 7, 352, 947 shares of common Common stock Stock at an exercise price of \$ 1. 11 per share. The July 2023 Pre- Funded Warrants were exercisable immediately following the closing date of the July 2023 Private Placement, or July 20, 2023, and have an unlimited term and an exercise price of \$ 0. 001 per share. The July 2023 Series A and Series B common stock warrants were exercisable immediately following the closing date of July 20, 2023, and have a five- year term, unless certain milestone events are met which accelerate the expiration date to 45 days following such announcement. The July 2023 Series A and Series B Common common Stock stock Warrants warrants also include certain rights upon " fundamental**

transactions” as described in such warrants, including the right of the holders thereof to receive from the Company or a successor entity the same type or form of consideration (and in the same proportion) that is being offered and paid to the holders of **common Common stock Stock** in such fundamental transaction in the amount of the Black Scholes value (as described in such warrants) of the unexercised portion of the applicable warrants on the date of the consummation of such fundamental transaction. The Company evaluated the July 2023 Pre-Funded Warrants, and the July 2023 Series A and Series B **Common common Stock stock Warrants warrants** under ASC 815-40 and determined that they did not require liability classification and met the requirements for instruments that are both indexed to an entity’s own stock and classified in stockholders’ equity. Accordingly, the proceeds were allocated between **common Common stock Stock** and the **July 2023 Pre-Funded Warrants, Series A and Series B common stock warrants** at their respective relative fair value basis to stockholders’ equity and as a component of additional paid-in capital on the consolidated balance sheets. The fair value of the July 2023 Series A and Series B **Common common Stock stock Warrants warrants** was determined using a Black-Scholes option pricing model and the **common Common stock Stock** based on the closing date share price and were recorded in additional paid-in capital within stockholders’ equity on the consolidated balance sheets. **In connection with the January 2024 Private Placement, the Company and the purchasers agreed to amend and restate the Prior Warrants by reducing their exercise price from \$ 1.11 to \$ 0.77 per share (see “January 2024 Pre-Funded Warrants and Amendment of Prior Warrants” above).** The placement agent July 2023 Series A and Series B Common Stock Warrants (see Note 9, “Stockholders’ Equity”) have the same terms as the July 2023 Series A and Series B Common Stock Warrants **to be issued to the purchasers**, except such warrants do not have a Black Scholes provision in the event of a fundamental transaction and the exercise price of such warrants is \$ 1.70 per share, which is 125 % of the combined offering price per share. The Company concluded that the placement agent July 2023 Series A and Series B Common Stock Warrants are freestanding equity-linked derivative instruments that met the criteria for equity classification. The placement agent July 2023 Series A and Series B Common Stock Warrants were valued at approximately \$ 0.3 million, using the Black-Scholes option pricing model as follows: exercise price of \$ 1.70 per share, stock price of \$ 1.07 per share, expected life of 5 years, volatility of 94.3 %, a risk-free rate of 4.08 % and 0 % expected dividend yield. As of December 31, **2023-2024**, **all none** of the July 2023 Series A and Series B **Common common Stock stock Warrants warrants and nor** the placement agent July 2023 Series A and Series B **Common common Stock stock Warrants warrants** had not been exercised and **all** were still outstanding, while 595,883 of the July 2023 Pre-Funded Warrants were exercised in the year ended December 31, 2023, and 1,416,473 remained outstanding as of December 31, 2023. **On January 17, 2024, certain of these July 2023 Series A and Series B Common Stock Warrants were amended to reduce the exercise price to \$ 0.77 per share in connection with the January 2024 Private Placement (see Note 16, “Subsequent Events” below for additional information).** December 2022 Registered Direct Offering Warrants On December 29, 2022, the Company issued pre-funded warrants to purchase 2,632,898 shares of **common Common stock Stock**, or the December 2022 Pre-Funded Warrants, and common warrants to purchase an aggregate of 4,227,052 shares of **common Common stock Stock**, or the December 2022 Common Stock Warrants. The December 2022 Pre-Funded Warrants were exercisable immediately following the closing date of the December 2022 Registered Direct Offering, or December 29, 2022, had an unlimited term and an exercise price of \$ 0.0001 per share. The December 2022 Common Stock Warrants were exercisable following the six-month anniversary of the closing date of December 29, 2022, have a six-year term and an exercise price of \$ 2.07 per share. The 2022 Warrants included full ratchet anti-dilutive adjustment rights in the event the Company issued shares of **common Common stock Stock** or common stock equivalents in the future with a value less than the then effective exercise price of such common warrants subject to certain customary exceptions, and further subject to a minimum exercise price of \$ 1.00 per share. On April 25, 2023, the December 2022 Common Stock Warrants were amended to remove these full ratchet anti-dilutive adjustment rights. In the event of certain fundamental transactions involving the Company, the holder of the December 2022 Common Stock Warrants may require the Company to make a payment based on a Black-Scholes valuation, using specified inputs. The December 2022 Pre-Funded Warrants did not provide similar rights to the Purchaser. Therefore, the Company accounted for the December 2022 Common Stock Warrants as a liability, while the December 2022 Pre-Funded Warrants met the permanent equity criteria classification. The December 2022 Pre-Funded Warrants were classified as a component of permanent equity, or APIC, because they were freestanding financial instruments that are legally detachable and separately exercisable from the shares of **common Common stock Stock** with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of **common Common stock Stock** upon exercise. In addition, the December 2022 Pre-Funded Warrants did not provide any guarantee of value or return. **As The December 2022 Common Stock Warrants were valued upon issuance at approximately \$ 7.1 million, using the Black-Scholes option pricing model as follows: exercise price of \$ 2.07 per share, stock price of \$ 2.13 per share, expected life of 6 years, volatility of 95.44 %, a risk-free rate of 3.93 % and 0 % expected dividend yield. Accordingly, the Company allocated the fair value of \$ 7.1 million of the gross proceeds received to Warrant liability on its consolidated balance sheets. The aggregate remaining gross proceeds of \$ 0.4 million were allocated to the two remaining securities using the relative fair value method, resulting in the common stock and the December 2022 Pre-Funded Warrants being allocated values of \$ 0.1 million and \$ 0.3 million, respectively, and such amount being recorded to stockholders’ equity. At December 31, 2023-2024, the December 2022 Common Stock Warrants were valued at approximately \$ 1.8 million, using the Black-Scholes option pricing model as follows: exercise price of \$ 2.07 per share, stock price of \$ 0.74 per share, expected life of 5 years, volatility of 94.05 %, a risk-free rate of 3.84 % and 0 % expected dividend yield. See Note 2, “Investments and Fair Value Measurement” above. As of December 31, 2023, none of the 4,227,052 December 2022 Common Stock Warrants had been exercised and were still all remained outstanding, while all the 2,632,898 December 2022 Pre-Funded Warrants were exercised in full in the year ended December 31, 2023 and none remained outstanding at December 31, 2024.** August 2022 LPC Warrant The August 2022 LPC Warrant had an original exercise price of \$ 4.07 per share (subject to adjustment for stock splits, reverse stock splits and similar recapitalization events), became immediately exercisable and has a term ending on February 3, 2028. In addition, through August 3, 2023, if the Company issued or sold (or is deemed to have issued or sold) any **common Common stock Stock**, convertible securities or options (as defined in the August 2022 LPC Warrant), for a consideration per share, or the New Issuance Price, less than a price equal to the exercise price in effect immediately prior to such issue or sale or deemed issuance or sale, each of the foregoing, a dilutive issuance, then immediately after such dilutive issuance, the exercise price then in effect for the August 2022 LPC Warrant shall be reduced to an amount equal to the New Issuance Price, or the Down Round Feature. In December 2022, the Down Round Feature was triggered due to the price per share received from the issuance of **common Common stock Stock** and warrants in connection with the December 2022 Financing. In July 2023, the Down Round Feature was again triggered due to the price per share received from the issuance of **common Common stock Stock** and warrants in connection with the in connection with the July 2023 Private Placement. In each instance, the Company calculated the value of the effect of the Down Round Feature measured as the difference between the warrants’ fair value, using the Black-Scholes option-pricing model, before and after the Down Round Feature was triggered using the then current exercise price and the new exercise price. The difference in fair value of the effect of the Down Round Feature was immaterial in both instances and had no impact on net loss per share in the periods presented. This down round feature expired on August 3, 2023. **The August 2022 LPC Warrant was originally valued at approximately \$ 0.3 million using the Black-Scholes option pricing model as follows: exercise price of \$ 4.07 per share, stock price of \$ 4.44 per share, expected life of 5.5 years, volatility of 89.94 %, a risk-free rate of 2.86 % and 0 % expected dividend yield. The Series A Redeemable Convertible Preferred Stock and the August 2022 LPC Warrant were issued in a unit structure with the August 2022 LPC Warrant eligible to be classified in stockholders’ equity, therefore the aggregate net proceeds of \$ 0.2 million were allocated to the two securities using the relative fair value method, resulting in the Series A Redeemable Convertible Preferred Stock and the August 2022 LPC Warrant being allocated values of \$ 0.1 million and \$ 0.1 million, respectively, and recorded to stockholders’ equity.** As of December 31, **2023-2024**, the August 2022 LPC Warrant had not been exercised and was still outstanding. November 2021 Financing Warrants On November 15, 2021, the Company entered into a securities purchase agreement with certain investors pursuant to which the Company, in a registered direct offering, sold (i) an aggregate of 875,000 shares of the Company’s common stock, and (ii) warrants to purchase up to an aggregate of 875,000 shares of **common Common stock Stock**, for an aggregate purchase price of \$ 14.0 million. The November 2021 Financing Warrants had an original exercise price of \$ 20.00 per share and became exercisable, if the holder’s post-exercise beneficial ownership is less than or equal to 9.99 %, 6 months after their issuance date and had a five-year term through November 15, 2026. **The November 2021 Financing warrants were valued at approximately \$ 8.6 million using the Black-Scholes option pricing model as follows: exercise price of \$ 20.00 per share, stock price of \$ 14.92 per share, expected life of five years, volatility of 91.77 %, a risk-free rate of 1.26 % and 0 % expected dividend yield. The common stock and warrants were issued in a unit structure; therefore, in accordance with ASC Topic 815, the aggregate gross proceeds of \$ 14.0 million were allocated to the two securities using the relative fair value method, resulting in the common stock and warrants being allocated values of \$ 8.4 million and \$ 5.6 million, respectively, and recorded to stockholders’ equity.** Upon the closing of the December 2022 Financing, 750,000 of the 875,000 November 2021 Financing Warrants were modified, to reduce the exercise price of the warrants from \$ 20.00 per share to \$ 2.07 per share and to extend the expiration date to December 29, 2028. **The modification of these November 2021 Financing Warrants.... 0 % expected dividend yield. The** remaining warrants issued in the November 17, 2021, registered direct offering for 125,000 shares of the Company’s common stock are currently exercisable at a price of \$ 2.00 per share and expire on November 15, 2026. As of December 31, **2023-2024**, **none all** of the November 2021 Financing Warrants had not been exercised and **were still all remained** outstanding. Loan Agreement Warrants In connection with the Loan Agreement, on May 30, 2019, the Company issued warrants to the Lender and its affiliates, which are exercisable for an aggregate of 8,833 shares of the Company’s common stock with a per share exercise price of \$ 56.60, or the Loan Agreement Warrants. The Loan Agreement Warrants may be exercised on a cashless basis. The Loan Agreement Warrants are exercisable for a term beginning on the date of issuance and ending on the earlier to occur of ten years from the date of issuance or the consummation of certain acquisitions of the Company as set forth in the Loan Agreement Warrants. The number of shares for which the Loan Agreement Warrants are exercisable and the

associated exercise price are subject to certain proportional adjustments as set forth in the Loan Agreement Warrants. **The As of December 31, 2023, Loan Agreement Warrants have been classified within stockholders' equity and accounted for as a discount to purchase 8,833 shares of common stock issued to the Lender and its affiliates by allocating the gross proceeds on a relative fair value basis. As of December 31, 2024, none of the Loan Agreement Warrants had not been exercised and were still all remained outstanding. These warrants expire in May 2029. Events below for additional information.** X- Definition: The disclosure of warrants. References: No definition available. Details Name: t1ph\_WarrantsDisclosureTextBlock Namespace Prefix: t1ph\_ Data Type: dtr- types: textBlockItem Type Balance Type: na Period Type: durationX- References: No definition available. Details Name: us- gaap\_DisclosureTextBlockAbstract Namespace Prefix: us- gaap\_ Data Type: xbrli: stringItemType Balance Type: na Period Type: duration Note 11- Stock-based Compensation 12 Months Ended Dec. 31, 2023-2024 Notes to Financial Statements Share- Based Payment Arrangement [ Text Block ] 11. Stock- Based Compensation The Company recorded total stock-based compensation expense for stock options, stock awards and the Amended ESPP as follows (in thousands): **Year Ended December 31, 2023 December 31, 2022** Research and development \$ \$ Selling, general and administrative 1, 212 2, 069 Discontinued operations — Total \$ 1, 729 **In the year ended December 31, 2024, there were 49, 515 shares issued under the Amended ESPP. The weighted average fair value of shares issued under the Amended ESPP in 2024 and 2023 was \$ 2, 0, 889- 88 and \$ 1. 08 per share, respectively. As of December 31, 2024, there were 165, 897 shares available for future grant under the Amended ESPP.** The following table summarizes restricted stock unit activity under the Company's Equity Incentive Plans: Weighted Number of Average Restricted Grant Date Stock Units Fair Value Restricted stock units outstanding, January 1, 2022-2023 88, 711 \$ 34. 16 Granted 58, 502 7. 75 Vested (44, 744) 35. 46 Forfeited (19, 691) 25. 00 Restricted stock units outstanding, December 31, 2022-82, 778 \$ 16. 97 Granted 48, 158 1. 67 Vested (40, 356) 19. 28 Forfeited (4, 348) 12. 56 Restricted stock units outstanding, December 31, 2023 86, 232 \$ 7. 57 **Granted 176, 768 1. 03 Vested (42, 525) 11. 31 Forfeited (7, 552) 2. 03 Restricted stock units outstanding, December 31, 2024 212, 923 1. 59** The following table summarizes stock option activity under the Company's Equity Incentive Plans: Number of Stock Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (in thousands) **December 31 January 1, 2022-2023** 725, 623 \$ 52. 98 Granted 288, 929 1. 67 Forfeited (14, 673) 9. 72 Expired (106, 558) 83. 88 **January 1 Exercised — December 31, 2023-2024** 893, 321 \$ 33. 41 **Granted 1, 053, 612 1. 03 Forfeited (41, 156) 1. 75 Expired (118, 877) 71. 96 December 31, 2024 1, 786, 900 12. 48 7. 6 -3-** Vested and exercisable options — December 31, 2023-2024 **488-605, 725-249 \$ 53-34, 69-28 4. 3-8** — Vested and expected to vest — December 31, 2023-2024 **893-1, 321-786, 900 \$ 33-12, 41-48 7. 6 -3-** As of December 31, 2023-2024, there were 1, 631-956, 349-919 shares available for future grant under the 2020 EIP. Additional information regarding the Company's stock options outstanding and vested and exercisable as of December 31, 2023-2024, is summarized below: Options Outstanding Options Vested and Exercisable Exercise Prices Number of Stock Options Outstanding Weighted- Average Remaining Contractual Life (Years) Weighted- Average Exercise Price per Share Shares Subject to Stock Options Weighted- Average Exercise Price per Share \$ 0. 684- 1. 76-281-03 859, 505-701 9. 2 \$ 1. 67-01 24, 409 \$ 0. 68 \$ 1. 08- 1. 62 185, 000 9. 4 \$ 1. 08 — \$ 1. 76- \$ 2. 64 249, 184 8. 1 \$ 1. 76 114, 204 \$ 1. 76 \$ 4. 62- 6. 93 45-10, 350-8 850 7. 5 \$ 5-4 21-42 62 10, 818-850 \$ 4. 93-62 \$ 8. 03- 12. 045 86-84, 817-8 703 7. 1 \$ 8. 08 40-60, 123-199 \$ 8. 09-08 \$ 14. 40- 21. 60 14-12, 633-033 5. 9-0 \$ 16. 55-13-50 12, 418-033 \$ 16. 61-50 \$ 22. 40- 33. 60 11, 700 7-6. 1 \$ 28. 62 11, 386-625 \$ 28. 68-66 \$ 34. 40- 51. 60 280-208, 405 662-5-4, 1 \$ 41. 01-208-92 206, 326-605 \$ 42-41, 23-96 \$ 57. 40- 86. 10 169-163, 213-2 274 1. 7 \$ 64. 86-169 92 163, 213-274 \$ 64. 86-92 \$ 94. 60- 141. 90 17-2, 371-050 0. 9 \$ 94. 60 2, 050 \$ 94. 60 1, 786, 900 7. 0-6 \$ 127- 12, 59-17 48 605, 371-249 \$ 127-34, 28 59-204. 40- 306. 60 16, 070 0. 2 \$ 206. 24 16, 070 \$ 206. 24 893, 321 6. 3 \$ 33. 41 488, 725 \$ 53-69 The weighted average grant-date fair value of options granted during the years ended December 31, 2024 and 2023, and 2022—was \$ 0. 84 and \$ 1. 32 and \$ 5-80 per share, respectively. As of December 31, 2023-2024, total stock-based compensation expense related to unvested options to be recognized in future periods was \$ 1, 0-9 million which is expected to be recognized over a weighted-average period of 2. 4-5 years. The grant date fair value of options vested during the years ended December 31, 2024 and 2023, and 2022—was \$ 2. 0 million and \$ 0. 9 million and \$ 1. 7 million, respectively. **The There were no total intrinsic value of options exercised during the years ended December 31, 2024 and 2023 and 2022 was \$ 0 and \$ 0, respectively. The Company has granted. In addition, the performance-based stock options granted in March 2021 to certain of its the Company's executive officers remained, which are included in the stock option tables and associated disclosures above. The Company uses the Monte Carlo Simulation model to evaluate the derived service period and fair value of awards with market conditions, including assumptions of historical volatility and risk-free interest rate commensurate with the vesting term. The performance-based stock options are eligible to vest subject to the satisfaction of the service-based vesting requirements and attainment of share price target goals, a market-based condition. No performance-based stock options vested unvested and expired during the year ended December 31, 2023-2024 and 2022.** The Company used the following assumptions to calculate the fair value of each time-based stock option: Year Ended December 31, 2024-2023-2022-Expected term (in years) 6. 3-5. 6, 3 Risk-free interest rate 4. 1%-4. 5% 3. 9%-4. 6% 1. 6%-3. 0-% Expected volatility 98% 94% 88-% Expected dividend rate 0% 0% X- Definition: The entire disclosure for share-based payment arrangement. References: Reference 1: http://www.xbrli.org/2003/role/exampleRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a) (1)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2Reference 2: http://www.xbrli.org/2003/role/disclosureRef-Topic 718-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/#718/tableOfContentReference 3: http://www.xbrli.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2Reference 4: http://www.xbrli.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (h) (2)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2Reference 5: http://www.xbrli.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (h) (2) (i)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2Reference 6: http://www.xbrli.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (l)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2 Details Name: us- gaap\_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us- gaap\_ Data Type: dtr- types: textBlockItem Type Balance Type: na Period Type: durationX- References: No definition available. Details Name: us- gaap\_DisclosureTextBlockAbstract Namespace Prefix: us- gaap\_ Data Type: xbrli: stringItemType Balance Type: na Period Type: duration Note 12- Net Income (Loss) per Share of Common Stock 12 Months Ended Dec. 31, 2023-2024 Notes to Financial Statements Earnings Per Share [ Text Block ] 12. Net Income (Loss) per Share of Common Stock The Company applies the two-class method to compute basic net income (loss) per share by dividing the net income (loss) attributable to common shareholders by the weighted average number of shares of common stock outstanding for the period. The diluted net income (loss) per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the more dilutive of the 1) treasury stock method, if-converted method, or contingently issuable share method, as applicable, or 2) the two-class method. For purposes of this calculation, options to purchase common stock, RSUs, and warrants to purchase common stock were considered to be common stock equivalents. The July 2023 Series A and Series B **Common common Stock stock Warrants warrants**, the placement agent July 2023 Series A and Series B **Common common Stock stock Warrants warrants**, the December 2022 Common Stock Warrants, the Series A Redeemable Convertible Preferred Stock and the November 2021 Financing Warrants are all participating securities which, by definition, entitle the holders thereof to participate in dividends and other distributions of assets by the Company to its holders of common shares as though the holder then held common shares; however, there is no contractual obligation on the part of the warrant holders to participate in the Company's losses. Given that the Company's participating securities do not have a contractual obligation to share in the Company's losses, net loss for the year years ended December 31, 2024 and 2023, was attributed entirely to common stockholders. For the year ended December 31, 2022, the Company presented diluted EPS using the two-class method as it was more dilutive. In periods with a reported net loss, common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is antidilutive. Potential common shares that are issuable for little or no cash consideration, such as the Company's January 2024, July 2023 and December 2022 Pre-Funded Warrants issued with a de minimis exercise price prices of \$ 0. 001, \$ 0. 001 and \$ 0. 0001 per share, respectively, are considered outstanding common shares which are included in the calculation of basic and diluted net income (loss) per share in all circumstances. The following table sets forth the computation of the Company's basic and diluted net income (loss) per share of common stock during the years ended December 31, 2023 and 2022 (in thousands, except for share and per share amounts): Year Ended December 31, (in thousands, except share and per share amounts) Basic net income (loss) per common share: Net income (loss) from continuing operations \$ (10, 287) \$ 59, 125 Less: deemed dividends related to Series A Redeemable Convertible Preferred Stock — (186) Less: income allocated to participating securities — (5, 240) Net income (loss) from continuing operations attributable to common shareholders, basic (10, 287) \$ 53, 699 Net loss from discontinued operations attributable to common shareholders, basic (8, 110) (11, 370) Net income (loss) attributable to common shareholders, basic \$ (18, 397) \$ 42, 329 Weighted average shares outstanding — basic 14, 263, 744 7, 385, 348 Income (loss) from continuing operations, basic \$ (0. 72) \$ 7. 27 Loss from discontinued operations, basic \$ (0. 57) \$ (1. 54) Net income (loss) per share, basic \$ (1. 29) \$ 5. 73 Diluted net income (loss) per common share: Net income (loss) from continuing operations \$ (10, 287) \$ 59, 125 Less: deemed dividends related to Series A Redeemable Convertible Preferred Stock — (186) Less: income allocated to participating securities — (5, 227) Net income (loss) from continuing operations attributable to common shareholders, diluted (10, 287) \$ 53, 712 Net loss from discontinued operations attributable to common shareholders, diluted (8, 110) \$ (11, 370) Net income (loss) attributable to common shareholders, diluted \$ (18, 397) \$ 42, 342 Weighted average shares outstanding — basic 14, 263, 744 7, 385, 348 Dilutive effect of RSUs — 20, 285 Dilutive effect of RSUs — 1, 353 Weighted average shares outstanding — diluted 14, 263, 744 7, 406, 986 Income (loss) from continuing operations, diluted \$ (0. 72) \$ 7. 25 Loss from discontinued operations, diluted \$ (0. 57) \$ (1. 53) Net income (loss) per share, diluted \$

(1-29) \$ 5.72 The following outstanding shares of common stock equivalents were excluded from the computation of diluted net income (loss) per share of common stock for the periods presented because including them would have been antidilutive: Year Ended December 31, 2023-2024 2022-ESPP, RSUs and stock options to purchase common stock 1, 999, 823 979, 553 815, 710 Common stock warrants 20, 265, 576 133-201 833-265, 576 In addition, the shares contingently issuable in connection with the Merger Agreement, as described in Note 4, "Asset Acquisition", have also been excluded from the computation of diluted net loss per share of common stock for the periods presented because the contingencies for issuance of these shares have not been met. X- ReferencesNo definition available. Details Name: us-gaap\_DisclosureTextBlockAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- DefinitionThe entire disclosure for earnings per share. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/#260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482662/260-10-50-3 Details Name: us-gaap\_EarningsPerShareTextBlock Namespace Prefix: us-gaap\_Data Type: dtl-types:textBlockItemType Balance Type: na Period Type: duration Note 13- Accrued Liabilities 12 Months Ended Dec. 31, 2023-2024. Notes to Financial Statements Accounts Payable and Accrued Liabilities Disclosure [Text Block ] 13. Accrued Liabilities Accrued liabilities consist of the following (in thousands): December 31, 2024 2023 2022-Accrued compensation and employee benefits \$ 2, 005 \$ 1, 732-Accrued professional services Other accrued liabilities Total accrued liabilities \$ 2-1 445-254 \$ 2, 531-445 X- DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02 (20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02 (19)(a), 20, 24 )-Publisher FASB-URI https://asc.fasb.org/#1943274/2147479360/2147480566/740-210-10-S99-1Reference 5-3 :http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 280-720-SubTopic 40-30-Name Accounting Standards Codification-Section 50-45-Paragraph 1-22-Subparagraph (h)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482810-2147483384/280-720-40-30-50-45-22Reference-1Reference 6-4 :http://fasb.org/us-gaap/role/disclosureRef-ref/legacyRef-Topic 944-210-SubTopic 220-10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-51-04-02 (9-19) (a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Details Name: us-gaap\_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap\_Data Type: dtl-types:textBlockItemType Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap\_DisclosureTextBlockAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration Note 14- 401 (k) Plan 12 Months Ended Dec. 31, 2023-2024. Notes to Financial Statements Retirement Benefits [Text Block ] 14. 401 (k) Plan The Company sponsors a 401 (k) plan that stipulates that eligible employees can elect to contribute to the 401 (k) plan, subject to certain limitations. Pursuant to the 401 (k) plan, the Company makes a matching contribution of up to 4 % of the related compensation. Under the vesting schedule, employees have ownership in the matching employer contributions based on the number of years of vesting service completed. Company contributions were \$ 0.2 million and \$ 0.3 million for each of the years ended December 31, 2024 and 2023 and 2022, respectively. X- ReferencesNo definition available. Details Name: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- DefinitionThe entire disclosure for retirement benefits. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 715-SubTopic 70-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480794/715-70-50-1Reference 2: http://www.xbrl.org/2003/role/exampleRef-Topic 715-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 17-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480482/715-20-55-17Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 715-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d) (iv) (03)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480506/715-20-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 715-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d) (i)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480506/715-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 715-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (q)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480506/715-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 715-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (l)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480506/715-20-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 715-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/#715/tableOfContentReference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 715-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d) (iii)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480506/715-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 715-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (o)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480506/715-20-50-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 715-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (p)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480506/715-20-50-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 715-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (r) (1)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480506/715-20-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 715-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (r) (2)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480506/715-20-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 715-SubTopic 20-Name Accounting Standards Codification-Section S99-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480126/715-20-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 715-SubTopic 60-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480266/715-60-50-3 Details Name: us-gaap\_PensionAndOtherPostretirementBenefitsDisclosureTextBlock Namespace Prefix: us-gaap\_Data Type: dtl-types:textBlockItemType Balance Type: na Period Type: duration Note 15- Income Taxes 12 Months Ended Dec. 31, 2023-2024 Notes to Financial Statements Income Tax Disclosure [Text Block ] 15. Income Taxes The Company recorded a provision for income taxes of \$ 0 thousand and \$ 13 thousand for the years ended December 31, 2023 and 2022, respectively. Net deferred tax assets as of December 31, 2024 and 2023, and 2022-consist of the following (in thousands): December 31, 2023 2024 December 31, 2022 2023 Deferred tax assets: Accruals and other \$ 1, 347 \$ 1, 717 \$ 3, 790-Research credits 8, 379 7, 839 7, 392-Net operating loss carryforward 90, 142 88, 839 84, 325-Section 59 (e) R & D expenditures 1, 136 1, 937 3, 496-Section 174 R & D expenditures 2, 446 1, 651 XOMA royalty 1, 371 — Total deferred tax assets 104, 821 101, 983 99, 984-Deferred tax liabilities: IP from Acquisition (1, 852) (1, 874) (2, 052) Total deferred tax liabilities (1, 852) (1, 874) (2, 052) Valuation allowance (102, 969) (100, 109) (97, 932) Net deferred tax assets \$ — \$ — Reconciliations of the statutory federal income tax to the Company's effective tax during the years ended December 31, 2024 and 2023 and 2022-are as follows (in thousands): Year Ended December 31, 2024 2023 2022-Tax at statutory federal rate \$ (2, 731) \$ (3, 862) \$ 10, 031-State tax — net of federal benefit 2, 495 Acquired assets — 1, 728-Research credits (363) (292) Stock options (431-139) Change in valuation allowance 2, 860 2, 177 (13, 520)-Revaluation of Put Option Liability (150) (1, 117) (15) Provision for income taxes \$ — \$ — ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is "more likely than not." Realization of deferred tax assets is dependent on future taxable income, if any, the timing and the amount of which are uncertain. Accordingly, the deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by \$ 2.9 million and \$ 2 million and decreased by \$ 13.5 million during the years ended December 31, 2024 and 2023 and 2022, respectively. As of December 31, 2023-2024, the Company had federal net operating loss carryforwards of \$ 377-384 7-8 million, of which \$ 114.9 million federal net operating losses generated before January 1, 2018, will begin to expire in 2029. Federal net operating losses of \$ 262-270 8-0 million generated from 2018 to 2023, will carryforward indefinitely but are subject to the 80 % taxable income limitation. As of December 31, 2023-2024, the Company had state net operating loss carryforwards of \$ 137-134 4-million-7million, which begin to expire in 2028. As of December 31, 2023-2024, the Company had federal research credit carryovers of \$ 7.0-5 million, which begin to expire in 2026. As of December 31, 2023-2024, the Company had state research credit carryovers of \$ 4.4-7 million, which will carryforward indefinitely. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an "ownership change," generally defined as a greater than 50 % change (by value) in its equity ownership over a three-year period, the corporation's ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research credits, to offset its post-change income may be limited. Based on an analysis performed by the Company as of December 31, 2013, it was determined that two ownership changes have occurred since inception of the Company. The first ownership change occurred in 2006 at the time of the Series A financing and, as a result of the change, \$ 1.4 million in federal and state net operating loss carryforwards will expire unutilized. In addition, \$ 26 thousand in federal and state research and development credits will expire unutilized. The second ownership change occurred in July 2013 at the time of the underwritten public offering; however, the Company believes the resulting annual imposed limitation on use of pre-change tax attributes is sufficiently high that the limit itself will not result in unutilized pre-change tax attributes. Uncertain Tax Positions A reconciliation of the

beginning and ending balances of the unrecognized tax benefits during the years ended December 31, 2024 and 2023, and 2022 is as follows (in thousands): Year Ended December 31, 2024 2023 2022 Unrecognized benefit — beginning of period \$ 2, 678-835 \$ 2, 635-678 Gross increases — prior period tax positions — Gross increases — current period tax positions Unrecognized benefit — end of period \$ 2-3, 835-031 \$ 2, 678-835 The entire amount of the unrecognized tax benefits would not impact the Company's effective tax rate if recognized. There were no accrued interest or penalties related to unrecognized tax benefits in the years ended December 31, 2024 or 2023 and 2022. The Company files income tax returns in the United States, California, and other states. The tax years 2005 through 2014, and 2016 through 2022-2024, remain open in all jurisdictions. The Company is not currently under examination by income tax authorities in U. S. federal, state or foreign jurisdictions. The Company does not anticipate any significant changes within 12 months of this reporting date of its uncertain tax positions. In March 2020, the Coronavirus Aid, Relief and Economic Security, or CARES, Act was signed into law. The CARES Act included several tax changes as part of its economic package. These changes principally related to expanded net operating loss carryback periods, increases to interest deductibility limitations, and accelerated alternative minimum tax refunds. The Company has evaluated these items and determined that the items do not have a material effect on the Company's financial statements as of December 31, 2022-2023 or 2023-2024. Additionally, the CARES Act enacted the Employee Retention Credit, or ERC, to incentivize companies to retain employees, which was subsequently modified by extension of the CARES Act. Under the provisions of the CARES Act and its subsequent extension, the Company was eligible for ERCs, subject to certain criteria. Accordingly, the Company recorded a reduction in payroll taxes related to ERCs claimed for \$ 1. 4 million in the year ended December 31, 2021. These credits were recorded in the consolidated statements of operations as an offset to the related payroll expenses in the respective operating costs and expenses line item and are disclosed within prepaid expenses and other current assets on the Company's consolidated balance sheets at December 31, 2023. X- ReferencesNo definition available. Details Name: us- gaap\_DisclosureTextBlockAbstract Namespace Prefix: us- gaap\_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- Definition The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. ReferencesReference 1: http:// www. xbrl. org / 2003 / role / disclosureRef- Topic 946-740- SubTopic 20-10- Name Accounting Standards Codification- Section 50- Paragraph 13-12- Publisher FASB- URI https:// asc. fab. org / #1943274 / 2147480990-2147482685 / 946-740- 20-10- 50- 13Reference- 12Reference 2: http:// www. xbrl. org / 2003 / role / disclosureRef- exampleRef- Topic 235-740- SubTopic 10- Name Accounting Standards Codification- Section S99-55- Paragraph 231- Subparagraph (SX 210- 4-08 (h) (2))- Publisher FASB- URI https:// asc. fab. org / #1943274 / 2147480678-2147482663 / 235-740- 10- S99-55- 1Reference- 231Reference 3: http:// www. xbrl. org / 2003 / role / disclosureRef- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 12C- Publisher FASB- URI https:// asc. fab. org / 1943274 / 2147482685 / 740- tableOfContentReference- 10- 50- 12CReference 4: http:// www. xbrl. org / 2003 / role / disclosureRef- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 14-12B- Publisher FASB- URI https:// asc. fab. org / #1943274 / 2147482685 / 740- 10- 50- 14Reference- 12BReference 5: http:// www. xbrl. org / 2003 / role / disclosureRef- Topic 740- SubTopic 10- 270- Name Accounting Standards Codification- Section 50- Paragraph 21-1- Publisher FASB- URI https:// asc. fab. org / #1943274 / 2147482685-2147477891 / 740- 10- 270- 50- 21Reference- 1Reference 6: http:// www. xbrl. org / 2003 / role / disclosureRef- Topic 740- SubTopic 270-10- Name Accounting Standards Codification- Section 50- S99- Paragraph 1- Subparagraph (SAB Topic 6. I. 5. Q1)- Publisher FASB- URI https:// asc. fab. org / #1943274 / 2147482526-2147479360 / 740- 270-10- 50- S99- 1Reference 7: http:// www. xbrl. org / 2003 / role / disclosureRef- Topic 740-946- SubTopic 40-20- Name Accounting Standards Codification- Section 50- Paragraph 13-17- Subparagraph (b)- Publisher FASB- URI https:// asc. fab. org / #1943274 / 2147482685-2147480990 / 740-946- 40-20- 50- 17Reference- 13Reference 8: http:// www. xbrl. org / 2003 / role / disclosureRef- Topic 740-235- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210 SAB TOPIC 6. I. 5. Q1- 4-08 (h) (2))- Publisher FASB- URI https:// asc. fab. org / #1943274 / 2147479360-2147480678 / 740-235- 10- S99- 1Reference 9: http:// www. xbrl. org / 2003 / role / disclosureRef- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 2- Subparagraph (SAB Topic 11. C)- Publisher FASB- URI https:// asc. fab. org / #1943274 / 2147479360-740 / tableOfContentReference- 10- S99- 2Reference- 10: http:// www. xbrl. org / 2003 / role / disclosureRef- Topic 740- SubTopic 30-10- Name Accounting Standards Codification- Section 50- Paragraph 14-2- Subparagraph (a)- Publisher FASB- URI https:// asc. fab. org / -10- 50- 14Reference- 6Reference 11- 2. http:// fasb. www. xbrl. org / 2003- us- gaap / role / disclosureRef- ref / legacyRef- Name Accounting Standards Codification- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 21-8- Publisher FASB- URI https:// asc. fab. org / #1943274 / 2147482685 / 740- 10- 50- 21Reference- 8Reference 12- 3. http:// fasb. www. xbrl. org / 2003- us- gaap / role / disclosureRef- ref / legacyRef- Name Accounting Standards Codification- Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 17-3- Subparagraph (b-a)- Publisher FASB- URI https:// asc. fab. org / #1943274 / 2147482685 / 740- 10- 50- 3- 17Reference- 13- 1943274 / 2147482603 / 740- 30- 50- 2 Details Name: us- gaap\_ IncomeTaxDisclosureTextBlock Namespace Prefix: us- gaap\_ Data Type: dt- ttr: textBlockItemType Balance Type: na Period Type: duration Note 16 -50- 26Reference- 6Reference 22- 2. http:// fasb. www. xbrl. org / 2003- us- gaap / role / ref / legacyRef disclosureRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Topic 740- SubTopic 10- Section 50- Paragraph 41-8- Publisher FASB- URI https:// asc. fab. org / #1943274 / 2147482810-2147482685 / 280-740- 10- 50- 41Reference- 8Reference 23- 3. http:// fasb. www. xbrl. org / 2003- us- gaap / role / ref / legacyRef disclosureRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- Topic 740- SubTopic 10- Section 50- Paragraph 21-3- Subparagraph (a)- Publisher FASB- URI https:// asc. fab. org / #1943274 / 2147482810-2147482685 / 280-740- 10- 50- 3- 21Reference- 24- http- Subsequent Events 12 Months Ended Dec. 31, 2023-2024 Notes to Financial Statements Subsequent Events [ Text Block ] 16- 17. Subsequent Events Purchase Agreement with XOMA On January 12, March 31, 2024-2025, the Company and XOMA (US) LLC, or XOMA, entered into a securities Payment Interest Purchase purchase Agreement agreement and registration, or the Purchase Agreement, for the sale by the Company to XOMA, in exchange for \$ 8. 0 million, of the Company's right rights, title agreement with several institutional investors and a member of management ( interest in and to certain amounts payable to the Company, or collectively, the " Purchased Purchasers " Receivables, pursuant to the DSUVIA Agreement in respect of net sales of the Product, excluding sales of the Product by Aguetant. The Purchased Receivables include: (i) 100% of certain royalty payments based on net sales of the Product and potential sales- based milestone payments of up to \$ 116. 5 million in respect of net sales of the Product, in each case made on and after January 1, 2024 and excluding sales of the Product by Aguetant, and of certain associated license and acquisition payments relating to the Product, until XOMA has received a. . . . or the Purchasers, relating to the issuance and sale of pre- funded warrants to the Purchasers in a two- tranche private placement in, or the three Private Placement, to purchase separate tranches of: (i) shares of its the Company's common stock, par value \$ 0. 001 per share, or the Common Stock, at a and (ii) pre- funded warrants to purchase price of \$ 0. 769 per share shares and an exercise price of common stock \$ 0. 001 per share, or the Pre- Funded Warrants. The Pre pre- Funded- funded Warrants warrants are will be exercisable immediately following each the applicable closing date of the Private Placement and have an unlimited term and. The terms of the Private Placement include: (i) the first tranche of the Private Placement, which closed on January 22, 2024, resulted in the aggregate gross proceeds to the Company of approximately \$ 6. 0 million excluding the proceeds, if any, from the exercise of the Pre- Funded Warrants issued in such tranche. (ii) the second tranche of the Private Placement, which is a conditional purchase by the Purchasers subject to either (a) the satisfaction or waiver of achieving a pivotal trial milestone event, or the Pivotal Trial Milestone, or (b) the satisfaction or waiver of the volume- weighted average price of the Common Stock for each of the immediately subsequent five (5) trading days following the Company's announcement of its pivotal trial data being at least \$ 0. 92-001 per share or the Price Milestone, which will result in additional aggregate gross proceeds to the Company of approximately \$ 10. At 0 million with respect to the first Pivotal Trial Milestone and \$ 2. 0 million with respect to the Price Milestone, excluding the proceeds, if any, from the exercise of the Pre- Funded Warrants issued in such closing. In the first tranche of the Private Placement, the Company issued Pre- Funded Warrants to purchase up to 7, 792, 208 shares of Common Stock. In the second tranche of the Private Placement, the Company is expected to issue (i) in connection with achieving the Pivotal Trial Milestone, Pre- Funded Warrants to purchase up to 12, 987, 013 shares of Common Stock, and (ii) in connection with achieving the Price Milestone, Pre- Funded Warrants to purchase up to 2, 597, 402 shares of Common Stock. Any of the conditions in the second tranche can be waived by each Purchaser. The Securities Purchase Agreements contain customary representations, warranties and agreements by the Company and the Purchasers, indemnification rights and other the obligations of the parties. Registration Rights Agreement In connection with the Private Placement, the Company entered into a registration rights agreement, dated January 17, 2024, with the Purchasers, or the Registration Rights Agreement, pursuant to which the Company has agreed to file one or more registration statements under the Securities Act of 1933, as amended, or the Securities Act with the Securities and Exchange Commission, or the SEC, covering the resale of the shares of Common Stock underlying the Pre- Funded Warrants no later than 15 days following the date of each applicable closing of the Private Placement, and to use reasonable best efforts to have the registration statements declared effective as promptly as practical thereafter, and in any event no later than 90 days following the applicable closing date in the event of a " full review " by the SEC. Amendment of Prior Warrants On July 20, 2023, in connection with a prior private placement, the Company will issued issue and sell to certain of the Purchasers: (i) Series A- 3, 405, 118 shares of common stock purchase, and (ii) pre- funded warrants to purchase up to 3- an aggregate of 4. 676-999. 473-316 shares of Common Stock and (ii) Series B common stock. The aggregate gross proceeds to the Company from the first closing of the private placement will be approximately \$ 4. 9 million, before deducting placement agent fees and other estimated expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the pre- funded warrants. The second and third closings of the private placement will occur if the Company announces the enrollment of at least 17 and 35 patients, respectively, in its Niyad NEPHRO CRRT study and following such announcements the average volume weighted average price of its common stock for each

of the immediately subsequent five (5) trading days is at least \$ 0. 7325 per share. At each of the second and third closings, the Company expects to issue and sell to the purchase Purchasers : (i) 3, 405, 118 shares of common stock, and (ii) pre-funded warrants to purchase up to 3-an aggregate of 4, 676-999, 473-316 shares of Common common Stock stock, or the Prior Warrants. The gross proceeds to In connection with the current Private Placement, the Company from the second and third closings of the private placement are expected to be approximately \$ 4. 9 million each (approximately \$ 9. 8 million in the aggregate), before deducting placement agent fees and the other Purchasers estimated expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the pre-funded warrants. Pursuant to the registration rights agreement, the Company agreed to file registration statements under the Securities Act of 1933, as amended, with the Securities and Exchange Commission following the applicable closings covering the resale resale, a portion of the shares of outstanding Prior Warrants, representing (i) Series A common stock purchase warrants to purchase up to 2, 941, 178 be issued in the private placement and the shares of Common Stock and (ii) Series B common stock purchase underlying the pre-funded warrants to purchase up to 2, 941, 178 shares of Common Stock, to reduce the exercise price thereunder to \$ 0. 77 per share. X- ReferencesNo definition available. Details Name: us- gaap\_DisclosureTextBlockAbstract Namespace Prefix: us- gaap\_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. ReferencesReference 1: http:// www. xbrl. org / 2003 / role / disclosureRef- Topic 855- Name Accounting Standards Codification- Publisher FASB- URI https:// asc. fab. org / #855 / tableOfContentReference 2: http:// www. xbrl. org / 2003 / role / disclosureRef- Topic 855- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (a)- Publisher FASB- URI https:// asc. fab. org / #1943274 / 2147483399 / 855- 10- 50- 2 Details Name: us- gaap\_SubsequentEventsTextBlock Namespace Prefix: us- gaap\_ Data Type: textBlockItemType Balance Type: na Period Type: duration Significant Accounting Policies (Policies) 12 Months Ended Dec. 31, 2023- 2024 Accounting Policies [ Abstract ] Business Description of Entity [ Policy Text Block ] The Company Talphera, Inc., or the Company, or Talphera, was incorporated in Delaware on July 13, 2005 as SuRx, Inc. The Company subsequently changed its name to AcelRx Pharmaceuticals, Inc. and, on January 9, 2024 to Talphera, Inc. The Company's operations are based in San Mateo, California. Talphera is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. The Company's product development portfolio features Niyad™ (a regional anticoagulant for the dialysis circuit), two ready-to-use pre-filled syringe, or PFS, product candidates (Fedsyra and phenylephrine), and LTX-608 (a nafamostat formulation for direct IV infusion) that the Company intends to develop for one or more of the following indications: disseminated intravascular coagulation, or DIC, acute respiratory distress syndrome, or ARDS, acute pancreatitis, or as an anti-viral treatment. On March 12, 2023, the Company entered into an Asset Purchase Agreement, or the DSUVIA Agreement, with Vertical Pharmaceuticals, LLC, a wholly owned subsidiary of Alora Pharmaceuticals, LLC, or Alora, pursuant to which Alora agreed to acquire certain assets and assume certain liabilities of the Company relating to its sufentanil sublingual tablet product referred to as DSUVIA or DZUVEO, or any other single-dose pharmaceutical product for use in medically supervised settings containing a sublingual tablet that includes sufentanil as the sole active ingredient, as a 30 meg tablet or other dosage form or strength as reasonably necessary for lifecycle management, or the Product. The closing of the DSUVIA Agreement occurred on April 3, 2023 (see Note 3, "Discontinued Operations"). On January 7, 2022, the Company acquired Lowell Therapeutics, Inc., or Lowell, a privately held company (see Note 4, "Asset Acquisition" below) and, as a result acquired the Niyad™ developmental product, a regional anticoagulant for the dialysis circuit during continuous renal replacement therapy for acute kidney injury patients in the hospital, that the Company plans to study under an investigational device exemption, or IDE, and which has received Breakthrough Device Designation status from the FDA. While not approved for commercial use in the United States, the active drug component of Niyad, nafamostat, has been approved in Japan and South Korea as a regional anticoagulant for the dialysis circuit, disseminated intravascular coagulation, and acute pancreatitis. Niyad is a lyophilized formulation of nafamostat, a broad-spectrum, synthetic serine protease inhibitor, with anticoagulant, anti-inflammatory, and potential anti-viral activities. The second intended indication for Niyad is as a regional anticoagulant for the dialysis circuit for chronic kidney disease patients undergoing intermittent hemodialysis in dialysis centers. In addition, the Company acquired LTX-608, a nafamostat formulation for direct IV infusion, that it intends to develop for the treatment of one or more of the following indications: ARDS, DIC, acute pancreatitis or as an anti-viral agent. On July 14, 2021, the Company entered into a License and Commercialization Agreement, or the PFS Agreement, with Laboratoire Aguettant, or Aguettant, pursuant to which the Company obtained the exclusive right to develop and, subject to FDA approval, commercialize in the United States an epinephrine pre-filled syringe for injection, and (ii) a phenylephrine PFS for injection. Aguettant will supply the Company with the products for use in commercialization, if they are approved in the U. S. Liquidity and Going Concern The consolidated financial statements for the year ended December 31, 2023 were prepared on the basis of a going concern, which contemplates that the Company will be able to realize assets and discharge liabilities in the normal course of business. The termination of the Zalviso Royalty Monetization resulted in net income for the year ended December 31, 2022; however, prior to this, the Company had incurred recurring operating losses and negative cash flows from operating activities since inception and expects to continue to incur operating losses and negative cash flows in the future. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Although, the Company raised additional capital in January 2024 (see Note 16, "Subsequent Events"), considering the Company's current cash resources and its current and expected levels of operating expenses for the next twelve months, management expects to need additional capital to fund its planned operations prior to the 12-month anniversary of the date this Annual Report on Form 10-K is filed with the United States Securities and Exchange Commission, or the SEC. Management may seek to raise such additional capital through public or private equity offerings, including under the Controlled Equity Offering SM Sales Agreement, or the ATM Agreement, with Cantor Fitzgerald & Co., or Cantor, debt securities, a new debt facility, monetizing or securitizing certain assets, entering into product development, license or distribution agreements with third parties, or divesting any of the Company's remaining product candidates. While management believes its plans to raise additional funds will alleviate the conditions that raise substantial doubt about the Company's ability to continue as a going concern, these plans are not entirely within the Company's control and cannot be assessed as being probable of occurring. Additional funds may not be available when the Company needs them on terms that are acceptable to the Company, or at all. If adequate funds are not available, the Company may be required to further reduce its workforce or delay the development of its regulatory filing plans for its product candidates in advance of the date on which the Company's cash resources are exhausted to ensure that the Company has sufficient capital to meet its obligations and continue on a path designed to preserve stockholder value. In addition, if additional funds are raised through collaborations, strategic alliances or licensing arrangements with third parties, the Company may have to relinquish rights to its technologies, future revenue streams or product candidates, or to grant licenses on terms that may not be favorable to the Company. Basis of Accounting, Policy [ Policy Text Block ] Basis of Presentation The preparation of accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or GAAP, and with the rules and regulations of the U. S. Securities and Exchange Commission, or SEC. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Management believes its most significant accounting estimates relate to fair value of warrants, liability related to the sale of future payments, accrued clinical trial liabilities and management's assessment of going concern. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. The Company's audited financial statements as of December 31, 2022, included in the Company's Annual Report on Form 10-K filed with the SEC on March 31, 2023, were recast to reflect discontinued operations and filed with the Company's Current Report on Form 8-K on August 1, 2023. See Note 3, "Discontinued operations" below. Reclassification, Comparability Adjustment [ Policy Text Block ] Reclassifications Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year's presentation. In particular, property other assets has been reclassified as prepaid expenses and equipment other current assets in the consolidated balance sheets, other has been reclassified as net amortization and restricted cash, net of current portion discount on short-term investments, accounts receivable and other assets have been reclassified as prepaid expenses and other current assets, and operating lease liabilities, current portion, payment of employee tax obligations related to vesting of restricted stock units has been reclassified as accrued to net proceeds from issuance of common stock through equity plans in the consolidated statement of cash flows and the portion of interest income and other income, net related to the revaluation of liabilities liability - classified warrants has been reclassified to change in the consolidated balance sheets. Consolidation, Policy [ Policy Text Block ] Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates, Policy [ Policy Text Block ] Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management believes its most significant accounting estimates relate to fair value of warrants, impairment in the consolidated statements of long-lived assets operations. The Company has adopted Accounting Standards Update, management or ASU, 2023- 07, Improvements to Reportable Segment Disclosures, which requires the prior period to reflect the change in presentation. See Note 16, "Segment Reporting". These reclassifications did not affect the prior period's total assets assessment of going concern total revenue recognition, liability for royalty

monetization and accrued clinical trial liabilities. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances.

**stockholders' equity, net loss** the results of which form the basis for **or net cash used in operating activities** making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [ Policy Text Block ] Cash, and Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with an original maturity (at date of purchase) of three months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks. On May 30, 2019, the Company entered into a Loan Agreement with Oxford Finance LLC, or Oxford, or the Lender. The Loan Agreement requires that the Company always maintain unrestricted cash of not less than \$ 5.0 million in accounts subject to control agreements in favor of the Lender, tested monthly as of the last day of the month. The Company has classified these unrestricted funds as restricted cash on the consolidated balance sheets. On April 3, 2023, the Company repaid Oxford the full amount due under the loan, and the Loan Agreement was terminated with no further obligations by either party. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts in the consolidated statements of cash flows: Balance as of December 31, 2023 December 31, 2021 Cash and cash equivalents \$ 5,721 \$ 15,275 Restricted cash — 5,000 Total cash, cash equivalents, and restricted cash \$ 5,721 \$ 20,275

Marketable Securities, Policy [ Policy Text Block ] Short-Term Investments All marketable securities are classified as available for sale and consist of commercial paper and U. S. government sponsored enterprise debt securities. These securities are carried at estimated fair value, which is based on quoted market prices or observable market inputs of almost identical assets, with unrealized gains and losses included in accumulated other comprehensive income (loss). The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income or expense. The cost of securities sold is based on specific identification. When the fair value of an available-for-sale security falls below the amortized cost basis, it is evaluated to determine if any of the decline in value is attributable to credit loss. Decreases in fair value attributable to credit loss are recorded directly to the consolidated statement of operations with a corresponding allowance for credit losses, limited to the amount that the fair value is less than the amortized cost basis. If the credit quality subsequently improves, the allowance is reversed up to a maximum of the previously recorded credit losses. When the Company intends to sell an impaired available-for-sale security, or if it is more likely than not that the Company will be required to sell the security prior to recovering the amortized cost basis, the entire fair value adjustment will immediately be recognized in the consolidated statement of operations with no corresponding allowance for credit losses. Fair Value Measurement, Policy [ Policy Text Block ] Fair Value of Financial Instruments The Company measures and reports its cash equivalents, investments and financial liabilities at fair value. Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows: Level I — Unadjusted quoted prices in active markets for identical assets or liabilities; Level II — Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and Level III — Unobservable inputs that are supported by little or no market activity for the related assets or liabilities. The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

**Segment Reporting, Policy [ Policy Text Block ] Segment Information** The Company operates in a single segment, the development and commercialization of innovative therapies for use in medically supervised settings. The Company's revenue relates to the Company's services performed to support sales of DSUVIA to the Department of Defense, or DoD, by Alora under the Marketing Agreement (as defined in Note 3, "Discontinued Operations" below).

**Concentration Risk, Credit Risk, Policy [ Policy Text Block ] Concentration of Risk** The Company invests cash that is currently not being used for operational purposes in accordance with its investment policy in debt securities of U. S. government sponsored agencies, commercial paper and overnight deposits. The Company is exposed to credit risk in the event of default by the institutions holding the cash equivalents and available-for-sale securities to the extent recorded on the consolidated balance sheets. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of \$ 250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows. The Company relies on a single contract manufacturer, or CMO, for the active pharmaceutical ingredient, or API, for Niyad™ and a second single contract manufacturer for the finished Niyad product. All revenue relates to the Company's services for fees earned on the sales of DSUVIA to the DoD by Alora.

**Impairment or Disposal of Long-Lived Assets, Policy [ Policy Text Block ] Impairment of Long-Lived Assets** The Company periodically assesses the impairment of long-lived assets and, if indicators of asset impairment exist, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through an analysis of the undiscounted future expected operating cash flows. If impairment is indicated, the Company records the amount of such impairment for the excess of the carrying value of the asset over its estimated fair value. The Company realigned its cost structure from a focus on commercialization to a focus on advancing its late-stage development pipeline, namely the Niyad product candidates and the pre-filled syringes. As a result, the Company decided to not focus any development resources on Zalviso in the United States. In addition, due to the termination of the agreements with Grünenthal for Zalviso in Europe and the related withdrawal of the Marketing Authorization in Europe in July 2022, the Company did not expect any revenues from Zalviso in Europe in the foreseeable future. Accordingly, the Company determined that it was no longer probable that it would realize the future economic benefit associated with the costs of the Zalviso-related purchased equipment and manufacturing-related facility improvements the Company had made at its contract manufacturer and, therefore, recorded a non-cash impairment charge of \$ 4.9 million to the Zalviso-related assets for the year ended December 31, 2022. The impairment charge was recorded as operating expense in the consolidated statement of operations. Depreciation and amortization expense was immaterial for the year ended December 31, 2022.

**Business Combinations Policy [ Policy Text Block ] Acquisitions** The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets. Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. For asset acquisitions, a cost accumulation model is used to determine the cost of an asset acquisition. Direct transaction costs are recognized as part of the cost of an asset acquisition. The Company also evaluates which elements of a transaction should be accounted for as a part of an asset acquisition and which should be accounted for separately. The cost of an asset acquisition, including transaction costs, is allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis. Goodwill is not recognized in an asset acquisition. Any difference between the cost of an asset acquisition and the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based on their relative fair values. When a transaction accounted for as an asset acquisition includes an in-process research and development, or IPR & D, asset, the IPR & D asset is only capitalized if it has an alternative future use other than in a particular research and development project. For an IPR & D asset to have an alternative future use (a) the Company must reasonably expect that it will use the asset acquired in the alternative manner and anticipate economic benefit from that alternative use, and (b) the Company's use of the asset acquired is not contingent on further development of the asset subsequent to the acquisition date (that is, the asset can be used in the alternative manner in the condition in which it existed at the acquisition date). Otherwise, amounts allocated to IPR & D that have no alternative use are expensed. Asset acquisitions may include contingent consideration arrangements that encompass obligations to make future payments to sellers contingent upon the achievement of future financial targets. Contingent consideration is not recognized until all contingencies are resolved and the consideration is paid or probable of payment, at which point the consideration is allocated to the assets acquired on a relative fair value basis.

**Goodwill and Intangible Assets, Intangible Assets, Policy [ Policy Text Block ] In-Process Research and Development In accordance with ASC Topic 350, Intangibles—Goodwill and Other, the acquired IPR & D has initially been accounted for as an indefinite-lived intangible asset and, therefore, not amortized. If the IPR & D asset achieves regulatory approval and the asset life is determined to be finite, the asset's useful life will be estimated, and the asset will be amortized over its remaining useful life. The IPR & D asset is reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. These events and changes can include significant current period operating losses or negative cash flows associated with the use of the IPR & D asset, such as the result of unfavorable data from any ongoing or future clinical trial, changes in assumptions that negatively impact projected cash flows, or because of any other information regarding the prospects of successfully developing or commercializing the Company's programs. When impairment indicators are present, the Company compares undiscounted future cash flows to the asset's carrying value to determine if the asset is recoverable. If the carrying values are in excess of undiscounted expected future cash flows, the Company measures any impairment by comparing the fair value of the asset to its carrying value. No impairment losses were recorded on the IPR & D asset during the years ended December 31, 2024 or 2023.**

Discontinued Operations, Policy [ Policy Text Block ] Discontinued Operations In accordance with ASC 205-20 Presentation of Financial Statements: Discontinued Operations, a disposal of a component of an entity or a group of components of an entity is required to be

reported as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity's operations and financial results. In the period in which the component meets held-for-sale or discontinued operations criteria the major current assets, non-current assets, current liabilities, and non-current liabilities shall be reported as components of total assets and liabilities separate from those balances of the continuing operations. At the same time, the results of all discontinued operations, less applicable income taxes, shall be reported as components of net loss separate from the net income (loss) of continuing operations. The Company's DSUVIA business met the definition of a discontinued operation as of March 31, 2023. Accordingly, the Company has classified the results of the DSUVIA business as discontinued operations in its consolidated statements of operations for all periods presented. All assets and liabilities associated with the DSUVIA business were classified as assets and liabilities of discontinued operations in the consolidated balance sheets for the periods presented. All amounts included in the notes to the consolidated financial statements relate to continuing operations unless otherwise noted. (See Note 3, "Discontinued Operations")

**Revenue** [Policy Text Block] **Revenue from Contracts with Customers** The Company follows the provisions of Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers. This guidance provides a unified model to determine how revenue is recognized. The Company recognizes revenue upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. Prior to the divestment of DSUVIA to Alora, the Company sold its products primarily through wholesale and specialty distributors. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company's revenue relates to the Company's services performed to support sales of DSUVIA to the Department of Defense, or DoD, by Alora under the Marketing Agreement (as defined in Note 3, "Discontinued Operations" below). The Company's performance obligation is to serve as the exclusive sales agent for selling DSUVIA to the DoD through the term of the Marketing Agreement. The non-creditable and non-refundable revenues are variable consideration based on 75% of net sales of DSUVIA to the DoD during the period subject to certain adjustments. The Company evaluates if it is a principal or an agent in a transaction to determine whether revenue should be recorded on a gross or net basis depending on if it obtains control over the goods and services before they are transferred to customers. The Company is acting as an agent in relation to DSUVIA sales to the DoD. The consideration in the Marketing Agreement reflects a variable amount, for which the Company estimates the amount of consideration to which it will be entitled by using the expected value method. The Company includes in the transaction price the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. Revenues are recognized when the DoD obtains control of the product, at which time the Company has an unconditional right to receive payment for such revenue earned.

**Research and Development Expense, Policy** [Policy Text Block] **Research and Development Expenses** Research and development costs are charged to expense when incurred. Research and development expenses include salaries, employee benefits, including stock-based compensation, consultant fees, laboratory supplies, costs associated with clinical trials and manufacturing, including contract research organization fees, other professional services and allocations of corporate costs. The Company reviews and accrues clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of patient studies and other events. **Share-Based Payment Arrangement** [Policy Text Block] **Stock-Based Compensation** Compensation expense for all stock-based payment awards made to employees and directors, including employee stock options and restricted stock units related to the 2020 Equity Incentive Plan, or 2020 EIP, the 2011 Equity Incentive Plan, or 2011 EIP, and employee share purchases related to the Amended and Restated 2011 Employee Stock Purchase Plan, or ESPP, is based on estimated fair values at grant date. The Company determines the grant date fair value of the awards using the Black-Scholes option-pricing model and generally recognizes the fair value as stock-based compensation expense on a straight-line basis over the vesting period of the respective awards. The Company applies the graded-vesting attribution method to awards with market conditions that include graded-vesting features. Additionally, the Company uses the Monte Carlo Simulation model to evaluate the derived service period and fair value of awards with market conditions, including assumptions of historical volatility and risk-free interest rate commensurate with the vesting term. The Black-Scholes option pricing model requires inputs such as expected term, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. The expected term, which represents the period of time that options granted are expected to be outstanding, is derived by analyzing the historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior. Expected volatilities are estimated using the historical stock price performance over the expected term of the option, which are adjusted as necessary for any other factors which may reasonably affect the volatility of the Company's stock in the future. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for the expected term of the award. The Company recognizes forfeitures when they occur and does not anticipate paying dividends in the near future. **Warrants, Policy** [Policy Text Block] **Warrants Issued in Connection with Financings** The Company accounts for issued warrants as either liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock. Under ASC 480-10, warrants are considered liability if they are mandatorily redeemable and they require settlement in cash or other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as liability or equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP. Equity classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.

**Revenue Costs Associated with Exit or Disposal Activities or Restructurings, Policy** [Policy Text Block] **Restructuring Costs** **Sale of Future Payments On January 12, 2024, the Company entered into the Purchase Agreement with XOMA to monetize a portion of its future payments for commercial sales of DSUVIA and services performed by the Company to support sales of DSUVIA to the Department of Defense, or DoD, by Alora under the Marketing Agreement, and sales milestones under the DSUVIA Agreement. Refer to Note 7, "Sale of Future Payments" for further details on the Purchase Agreement. The Company recorded approximately \$ 6.1 million, net of \$ 0.5 million in issuance costs, of the \$ 8.0 million proceeds as a liability, as this portion of the proceeds represents a sale of future revenues under ASC 470 for which the Company has continuing involvement in the generation of cash flows. The Company recorded approximately \$ 1.2 million, net of \$ 0.2 million in issuance costs, of the \$ 8.0 million proceeds as other income, as this portion of proceeds represents the sale of all of the Company's interest in restructuring costs consist of employee termination benefit costs. Liabilities for costs associated with the cost reduction plan are recognized when the liability is incurred and are measured at fair value. One-time termination benefits are expensed at the date the Company notifies the employee, unless the employee must provide future payments service, in which case the benefits are expensed ratably over the future service period. In May 2022, the Company initiated a reorganization that eliminated approximately 40% of its employees, primarily within the commercial organization. For the year ended December 31, 2022, the Company incurred approximately \$ 0.5 million in employee termination benefits related to commercial sales this restructuring, all of DSUVIA for which the Company is no longer entitled to receive such payments and has no further been paid. This headcount reduction was completed in the second quarter of 2022. No additional expenses were incurred in connection with this cost reduction plan.** **Interest Expense, Policy** [Policy Text Block] **Non-Cash Interest Income on Liability Related to Sale of Future Royalties** In September 2015, the Company sold certain royalty and milestone payment rights from the sales of Zalviso in the European Union by Grünenthal to PDL for gross proceeds of \$ 65.0 million, or the Zalviso Royalty Monetization. Grünenthal terminated the Grünenthal Agreements effective November 13, 2020. The terms of the Grünenthal Agreements were extended to May 2021 to enable Grünenthal to sell down its Zalviso inventory. The rights to market and sell Zalviso in the Territory reverted back to the Company in May 2021. Under the Zalviso Royalty Monetization, the Company had a continuing obligation to use commercially reasonable efforts to negotiate a replacement license agreement, or New Arrangement. Under the relevant accounting guidance, because of the Company's significant continuing involvement, the Company utilized internal estimates to develop a cash flow model based on business assumptions to determine the Zalviso Royalty Monetization was accounted for allocation of the proceeds. The liability related to the sale of future payments is recorded as debt and will be a liability that is being amortized using under the effective interest rate method over the estimated life of the arrangement **Purchase Agreement**. The in order to determine the amortization of the liability, the Company was required to estimate the effective interest rate based on its estimate of the total amount of future royalty and milestone payments to be received by XOMA under the Purchase Agreement. The Company reassesses these estimates at each reporting date and adjusts the effective interest rate and amortization of the liability on a prospective basis, as necessary. The Company records the payments to XOMA as a reduction of the liability when paid. As such payments are made to PDL-XOMA, the balance up to a capped amount of \$195.0 million, the liability will be effectively repaid over the life of the Purchase Agreement arrangement. The aggregate future estimated royalty and milestone payments (subject to the capped amount), less the \$ 61.2 million of net proceeds the Company received, was to be amortized as interest expense over the life of the liability. Consequently, the Company imputed interest on the unamortized portion of the liability and recorded interest expense, or interest income, as these estimates were updated and recorded non-cash royalty revenues and non-cash interest income (expense), net, within its consolidated statements of operations over the term of the Zalviso Royalty Monetization. When the expected payments under the Zalviso Royalty

Monetization were lower than the gross proceeds of \$ 65.0 million received, the Company deferred recognition of any probable contingent gain until the Zalviso Royalty Monetization liability expired. See Note 7, “Liability Related to Sale of Future Royalties”. Income Tax, Policy [ Policy Text Block ] Income Taxes Deferred tax assets and liabilities are measured based on differences between the financial reporting and tax basis of assets and liabilities using enacted rates and laws that are expected to be in effect when the differences are expected to reverse. The Company records a valuation allowance for the full amount of deferred assets, which would otherwise be recorded for tax benefits relating to operating loss and tax credit carryforwards, as realization of such deferred tax assets cannot be determined to be more likely than not. Earnings Per Share, Policy [ Policy Text Block ] Net Income (Loss) per Share of Common Stock Basic and diluted net income (loss) per common share, or EPS, are calculated in accordance with the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 260, Earnings per Share. The Company applies the two-class method to compute basic and, if more dilutive than other methods, diluted net income or loss per share. The two-class method is an earnings allocation formula that treats participating securities as having rights to earnings that would otherwise have been available to common stockholders (including pre-funded warrants). Shares of common stock into which the pre-funded warrants may be exercised are considered outstanding for the purposes of computing net loss per share because the shares may be issued for little or no consideration and are exercisable after the original issuance date. In addition, the Company is required to calculate diluted net income or loss per share under the two-class method if the effect is more dilutive than the application of another dilutive method of calculating diluted EPS (i.e., the treasury stock, if-converted, or contingently issuable share method). In periods where there is a net loss, no allocation of undistributed net loss to participating securities is performed if the holders of these securities are not contractually obligated to participate in the Company’s losses. The Company’s participating securities include the November 2021 Financing Warrants, December 2022 Common Stock Warrants, the July 2023 Series A Redeemable Convertible Preferred and Series B Common Stock stock warrants, and the placement agent July 2023 Series A and Series B Common common Stock stock Warrants warrants, the placement agent Series A and Series B Common Stock Warrants (see Note 9, “Stockholders’ Equity” and Note 10, “Warrants” to the consolidated financial statements in this Annual Report on Form 10-K for additional information). For additional information regarding the net income (loss) per share, see Note 12, “Net Income (Loss) per Share of Common Stock”. New Accounting Pronouncements, Policy [ Policy Text Block ] Recently Adopted Accounting Pronouncements In June 2016 November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standards- Standard Update, or ASU, 2016-2023-13-07 Segment Reporting Financial Instruments—Credit Losses (Topic 326-280): Measurement of Credit Losses on Financial Instruments Improvements to Reportable Segment Disclosures, or ASU 2023-07, which requires all public entities, including public entities with a single reportable segment, that financial assets measured at amortized cost be presented at the net amount expected to provide in interim and annual periods be collected. The measurement of expected credit losses is based on one or more measures historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. ASU 2016-13 also eliminates the concept of “segment profit or loss used by the chief operating decision maker to allocate resources and assess performance. Additionally, the standard requires disclosures of significant segment expenses and other segment items as –than temporary– impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will **well as incremental qualitative disclosures** recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. The Company adopted **annual requirements under ASU 2016-2023-13-07** on January 1, 2024, and plans to adopt **interim requirements under ASU 2023-07 on January 1, 2024, using the modified 2025, on a retrospective basis approach, and no cumulative effect adjustment to accumulated deficit was needed as of the adoption date. Additionally, no prior period amounts were adjusted. The adoption of ASU 2016-2023-13-07 only impacted the disclosures and did not have a material impact on the Company’s consolidated financial statements. See Note 16, “Segment Information” for disclosures related to the adoption of ASU 2023-07.** Recently Issued Accounting Pronouncements **On In November 2024, the FASB issued ASU 2024-03, Income Statement- Reporting Comprehensive Income- Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, or ASU 2024-03, which is intended to enhance transparency into the nature and function of expenses, primarily through additional disclosures on certain cost and expenses. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. The Company is in the process of evaluating the impact of this new guidance on its disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires companies to disclose, on an annual basis, specific categories in the effective tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. In addition, ASU 2023-09 requires companies to disclose additional information about income taxes paid. ASU 2023-09 will be effective for annual periods beginning January 1, 2025, and will be applied on a prospective basis with the option to apply the standard retrospectively. The Company is evaluating the disclosure impact of ASU 2023-09; however, the adoption of ASU 2023-09 will not have **an a material** impact on the Company’s consolidated financial statements. The Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the consolidated financial statements. X- DefinitionDisclosure of the accounting policy regarding the business description of entity. ReferencesNo definition available. Details Name: **tlph\_BusinessDescriptionOfEntityPolicyTextBlock Namespace Prefix: tlph\_Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for warrants. ReferencesNo definition available. Details Name: tlph\_WarrantsPolicyPolicyTextBlock Namespace Prefix: tlph\_Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap\_AccountingPoliciesAbstract Namespace Prefix: us-gaap\_Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). ReferencesNo definition available. Details Name: us-gaap\_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap\_Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity’s specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy. ReferencesReference 1:****

legacyRef- Name Accounting Standards Codification- Section 50- Paragraph 1- SubTopic 20- Topic 205- Publisher FASB- URI <https://asc.fasb.org/1943274/2147483499/205-20-50-1> Details Name: us-gaap\_DiscontinuedOperationsPolicyTextBlock Namespace Prefix: us-gaap\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. ReferencesReference 1: <http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic260-SubTopic10> - Name Accounting Standards Codification- Topic 260- SubTopic 10- Section 50- Paragraph 1- Subparagraph (e-d) - Publisher FASB- URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic260-SubTopic10-Section50-Paragraph2-1-Subparagraph\(c\)](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic260-SubTopic10-Section50-Paragraph2-1-Subparagraph(c)) - Publisher FASB- URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic260-SubTopic10-Section50-Paragraph2-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482662/260-10-50-2> Details Name: us-gaap\_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for fair value measurements of financial and non- financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. ReferencesNo definition available. Details Name: us-gaap\_FairValueMeasurementPolicyPolicyTextBlock Namespace Prefix: us-gaap\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for **intangible recognizing and measuring the impairment of long-lived assets. An entity This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.** ReferencesReference 1: [http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic360350-SubTopic4030-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph\(SABTopic5-CC\)-PublisherFASB-URIhttps://asc.fasb.org/350-1943274-2147480091-360-30/tableOfContentReference-10-S99-2Reference-2](http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic360350-SubTopic4030-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph(SABTopic5-CC)-PublisherFASB-URIhttps://asc.fasb.org/350-1943274-2147480091-360-30/tableOfContentReference-10-S99-2Reference-2): <http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic350-SubTopic30-NameAccountingStandardsCodification-Section0550-Paragraph54-SubTopic10-Topic360-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482338-2147482665/350-360-30-4050-055Reference3>: [http://www.xbrl.org/2003/role/disclosureRef-4-Topic350-SubTopic30-NameAccountingStandardsCodification-Section50-Paragraph3-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482665/350-30-50-3](http://www.xbrl.org/2003/role/disclosureRef-4-Topic350-SubTopic30-NameAccountingStandardsCodification-Section50-Paragraph3-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482665/350-30-50-3) Details Name: us-gaap\_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock- gaap\_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy Namespace Prefix: us-gaap\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic946740-SubTopic10-NameAccountingStandardsCodification-SectionS9950-Paragraph3-Subparagraph\(SX210-20-6-03\(h\)\(1\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479886-2147482685/946740-10-S9950-3Reference20Reference2](http://www.xbrl.org/2003/role/disclosureRef-Topic946740-SubTopic10-NameAccountingStandardsCodification-SectionS9950-Paragraph3-Subparagraph(SX210-20-6-03(h)(1))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479886-2147482685/946740-10-S9950-3Reference20Reference2): [http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph19-17-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-45-9Reference25Reference4](http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph19-17-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-45-9Reference25Reference4): [http://www.xbrl.org/2003/role/disclosureRef-Topic740-946-SubTopic10-NameAccountingStandardsCodification-Section45S99-Paragraph25-3-Subparagraph\(SX210-6-03\(h\)\(1\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482525-2147479886/740-946-10-45-S99-25Reference3Reference5](http://www.xbrl.org/2003/role/disclosureRef-Topic740-946-SubTopic10-NameAccountingStandardsCodification-Section45S99-Paragraph25-3-Subparagraph(SX210-6-03(h)(1))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482525-2147479886/740-946-10-45-S99-25Reference3Reference5): [http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section4550-Paragraph28-17-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482525-2147482685/740-10-45-50-28Reference17Reference6](http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section4550-Paragraph28-17-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482525-2147482685/740-10-45-50-28Reference17Reference6): <http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph19-9-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-49Reference9Reference7>: <http://www.xbrl.org/2003/role/disclosureRef-Topic220740-SubTopic10-NameAccountingStandardsCodification-Section5045-Paragraph428-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482765-2147482525/740-10-45-28Reference8>: <http://www.xbrl.org/2003/role/disclosureRef-Topic220-10-50-1Reference8>: <http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph201-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685-2147482765/740-220-10-50-201> Details Name: us-gaap\_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap\_ Data..... Details Name: us-gaap\_InterestExpensePolicyTextBlock Namespace Prefix: us-gaap\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for investment classified as marketable security. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic942-SubTopic320-Section50-Paragraph5-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480832-2147477268/942-320-50-5> Details Name: us-gaap\_MarketableSecuritiesPolicy Namespace Prefix: us-gaap\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity' s financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. ReferencesNo definition available. Details Name: us-gaap\_NewAccountingPronouncementsPolicyTextBlock Namespace Prefix: us-gaap\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic205-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483504/205-10-50-1> Details Name: us-gaap\_PriorPeriodReclassificationAdjustmentDescription Namespace Prefix: us-gaap\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic730-SubTopic10-NameAccountingStandardsCodification-Section05-Paragraph1-Subparagraph\(c\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483044/730-10-05-1](http://www.xbrl.org/2003/role/disclosureRef-Topic730-SubTopic10-NameAccountingStandardsCodification-Section05-Paragraph1-Subparagraph(c)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483044/730-10-05-1) Details Name: us-gaap\_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210-6-07\(1\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483575-2147479134/946-220-S99-1Reference2](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210-6-07(1))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483575-2147479134/946-220-S99-1Reference2): [http://www.xbrl.org/2003/role/exampleRef-Topic235-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph4-Subparagraph\(f\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483426/235-10-50-4Reference3](http://www.xbrl.org/2003/role/exampleRef-Topic235-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph4-Subparagraph(f)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483426/235-10-50-4Reference3): [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(f\)\(12\)\(i\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2Reference2](http://www.xbrl.org/2003/role/exampleRef-NameAccountingStandardsCodification-Section50-Paragraph4-Subparagraph(e)-SubTopic10-Topic235-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483426/235-10-50-4DetailsName:us-gaap_RevenueRecognitionPolicyTextBlock Namespace Prefix: us-gaap_ Data..... Details Name: us-gaap_SegmentReportingPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. ReferencesReference 1: <a href=): [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(f\)\(2\)\(ii\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2Reference3](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(f)(2)(ii)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2Reference3): [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-SectionS9950-Paragraph12-Subparagraph\(SABTopic14-C-Q3-f\)\(2\)\(v\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479830-2147480429/718-10-S9950-1Reference5](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-SectionS9950-Paragraph12-Subparagraph(SABTopic14-C-Q3-f)(2)(v)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479830-2147480429/718-10-S9950-1Reference5): [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SABTopic14-D-C-Q3-I-Q5\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference6](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SABTopic14-D-C-Q3-I-Q5)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference6): [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SABTopic14-D-3-I-Q2-Q5\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference7](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SABTopic14-D-3-I-Q2-Q5)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference7)

Standards Codification- Section S99- Paragraph 1- Subparagraph (SAB Topic 14. D. 2.3, Q6-Q2) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147479830/718-10-S99-1>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SABTopic14.D.2.Q6\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479830/718-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SABTopic14.D.2.Q6)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479830/718-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480429/718-10-50-2)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(f\)\(2\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(f)(2)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480429/718-10-50-2)Details Name: us-gaap\_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for..... Balance Type: na Period Type: duration Note 1-2- Organization Investments and Fair Value Measurement Summary of Significant Accounting Policies (Tables) 12 Months Ended Dec. 31, 2023 2024 Notes Tables Schedule of Cash and Cash Equivalents [ Table Text Block ] Balance as of December 31, 2023 December 31, 2021 Cash and cash equivalents \$ 5,721 \$ 15,275 Restricted cash — 5,000 Total cash, cash equivalents, and restricted cash \$ 5,721 \$ 20,275 X- DefinitionTabular disclosure of the components of cash and cash equivalents. ReferencesNo definition available. Details Name: us-gaap\_ScheduleOfCashAndCashEquivalentsTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap\_TableTextBlock Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration Note 2- Investments and Fair Value Measurement (Tables) 12 Months Ended Dec. 31, 2023 Notes Tables Cash, Cash Equivalents and Investments [ Table Text Block ] As of December 31, 2024 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and cash equivalents: Cash \$ — \$ — Money market funds 2,632 — 2,632 U. S. government agency securities 5,867 — 5,867 Total cash and cash equivalents \$ 8,863 \$ — \$ 8,863 As of December 31, 2023 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and cash equivalents: Cash \$ 1,342 \$ — \$ 1,342 Money market funds — U. S. government agency securities 1,896 — 1,896 Commercial paper 2,393 — 2,393 Total cash and cash equivalents 5,721 — 5,721 Short-term investments: U. S. government agency securities 3,362 — 3,362 Commercial paper — Total short-term investments 3,660 — 3,660 Total cash, cash equivalents, and short-term investments \$ 9,381 \$ — \$ 9,381 As of December 31, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash, cash equivalents and restricted cash: Cash \$ 13,275 \$ — \$ 13,275 Money market funds — U. S. government agency securities 2,444 — 2,444 Commercial paper 4,235 — 4,235 Total cash, cash equivalents and restricted cash 20,275 — 20,275 Short-term investments: Commercial paper — Total short-term investments — Total cash, cash equivalents, restricted cash and short-term investments \$ 20,275 \$ — \$ 20,275 Fair Value Measurements, Recurring and Nonrecurring [ Table Text Block ] As of December 31, 2024 Fair Value Level I Level II Level III Assets Money market funds \$ 2,632 \$ 2,632 \$ — U. S. government agency securities 5,867 — 5,867 — Total assets measured at fair value \$ 8,499 \$ 2,632 \$ 5,867 \$ — Liabilities Warrant liability \$ 1,061 \$ — \$ 1,061 Total liabilities measured at fair value \$ 1,061 \$ — \$ 1,061 As of December 31, 2023 Fair Value Level I Level II Level III Assets Money market funds \$ — U. S. government agency securities 2,444 — 2,444 Commercial paper 4,730 — 4,730 Total assets measured at fair value \$ 7,495 \$ 7,174 \$ — Liabilities Warrant liability \$ 7,098 \$ — \$ 7,098 Total liabilities measured at fair value \$ 7,098 \$ — \$ 7,098 Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [ Table Text Block ] Year Ended December 31, 2023 2024 Year Ended December 31, 2022 2023 Fair value — beginning of period \$ 1,778 \$ 7,098 — Issuance Change in fair value of December 2022 Common Stock Warrants (717) — 7,098 Change in fair value of December 2022 Common Stock Warrants (5,320) — Fair value — end of period \$ 1,061 \$ 1,778 \$ 7,098 X- DefinitionTabular disclosure of financial instruments- instrument measured at fair value on recurring or nonrecurring basis. Includes, including those but is not limited to, instrument classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances. ReferencesReference 1: [http://fasb-www.xbrl.org/2009-us-gaap/role/ref/legacyRef-commonPracticeRef-Topic820-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2C-2-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482106/820-10-50-2](http://fasb-www.xbrl.org/2009-us-gaap/role/ref/legacyRef-commonPracticeRef-Topic820-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2C-2-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482106/820-10-50-2)Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic820-SubTopic10-Topic820-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482106/820-10-50-2>Reference 3: [http://www.xbrl.org/2003/role/exampleRef-Topic820-SubTopic10-Section50-Paragraph2-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/exampleRef-Topic820-SubTopic10-Section50-Paragraph2-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482106/820-10-50-2)Reference 4: [http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Topic820-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-3-Subparagraph\(b-a\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482106/820-10-50-2](http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Topic820-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-3-Subparagraph(b-a)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482106/820-10-50-2)Details Name: us-gaap\_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionTabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. ReferencesReference 1: [http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic820-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482106/820-10-50-2](http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic820-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482106/820-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic820-Subparagraph\(c\)-SubTopic10-Topic820-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic820-Subparagraph(c)-SubTopic10-Topic820-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482106/820-10-50-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic820-Subparagraph\(d\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic820-Subparagraph(d)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482106/820-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic820-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-2-Subparagraph\(c\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482106/820-10-50-3-2](http://www.xbrl.org/2003/role/disclosureRef-Topic820-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-2-Subparagraph(c)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482106/820-10-50-3-2)Details Name: us-gaap\_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionTabular disclosure of the components of cash, cash equivalents, and investments. ReferencesNo definition available. Details Name: us-gaap\_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap\_TableTextBlock Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration Note 3- Discontinued Operations (Tables) 12 Months Ended Dec. 31, 2023 2024 Notes Tables Disposal Groups, Including Discontinued Operations [ Table Text Block ] Year ended December 31, Total revenues \$ — \$ 1,771 Cost of goods sold — \$ 4,508 Selling, general and administrative expense — 9,744 Impairment of net assets held for sale — 6,853 Impairment of fixed assets — 1,065 Gain on termination of lease liabilities — (1,098) Research and development expenses 1,852 Loss from discontinued operations (8,110) (11,333) Interest expense — Net loss from discontinued operations \$ — \$ (8,110) \$ (11,370) December 31, 2023 2024 Accrued liabilities Accounts receivable, net \$ — Inventories — 1,178 Prepaid expenses and other current assets — Total current assets liabilities of discontinued operations Net liabilities — 1,931 Property, plant and equipment, net — 10,261 Operating lease right-of-use assets — 3,499 Other assets — Total non-current assets of discontinued operations — 13,936 Total assets of discontinued operations \$ — (723) \$ 15,867 Accounts payable \$ 5 Accrued liabilities 1,720 Operating lease liabilities, current portion — 1,601 Note payable, current portion — Deferred revenue, current portion — Total current liabilities of discontinued operations 4,620 Operating lease liabilities, net of current portion — 2,959 Deferred revenue, net of current portion — 1,036 Total non-current liabilities of discontinued operations — 3,995 Total liabilities of discontinued operations 8,615 Net assets (liabilities) of discontinued operations \$ (731) \$ 7,252 Year Ended December 31, Cash flows from operating activities: Depreciation and amortization \$ — \$ 1,465 Stock-based compensation — Impairment of net assets held for sale — 6,853 Impairment of fixed assets — 1,065 Gain on termination of lease liabilities — (1,098) — Gain on extinguishment of debt — (400) Purchases of property and equipment — Purchases of property and equipment (100) (364) Year Ended December 31, 2023 Cash proceeds \$ 2,723 Less: net assets transferred (8,723) Less: disposal costs (853) Loss on sale of discontinued operations, before income taxes (6,853) Income tax expense — Loss on sale of discontinued operations \$ (6,853) X- DefinitionTabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant



legacyRef- **Topic 718- SubTopic 10-** Name Accounting Standards Codification- **Topic 718- SubTopic 10-** Section 50- Paragraph 2- Subparagraph (c) (1)- Publisher FASB- URI <https://asc.fasb.org/#/1943274/2147480429/718-10-50-2> Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(d\)-SubTopic10-Topic718-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(d)-SubTopic10-Topic718-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147480429/718-10-50-2) Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(e\)-SubTopic10-Topic718-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(e)-SubTopic10-Topic718-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147480429/718-10-50-2) Details Name: us-gaap\_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap\_Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate (s), and (e) discount for post-vesting restrictions. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic718-SubTopic10-Subparagraph\(f\)\(2\)-NameAccountingStandardsCodification-Paragraph2-Section50-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic718-SubTopic10-Subparagraph(f)(2)-NameAccountingStandardsCodification-Paragraph2-Section50-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147480429/718-10-50-2) Details Name: us-gaap\_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap\_Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- Definition Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year. References No definition available. Details Name: us-gaap\_ScheduleOfShareBasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock Namespace Prefix: us-gaap\_Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- References No definition available. Details Name: us-gaap\_TableTextBlock Namespace Prefix: us-gaap\_Data Type: xbrli: stringItemType Balance Type: na Period Type: duration Note 12- Net Income (-Loss) per Share of Common Stock (Tables) 12 Months Ended Dec. 31, 2023-2024 Notes Tables Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Year Ended December 31, (in thousands, except share and per share amounts) Basic net income (loss) per common share: Net income (loss) from continuing operations \$ (10,287) \$ 59,125 Less: deemed dividends related to Series A Redeemable Convertible Preferred Stock — (186) Less: income allocated to participating securities — (5,240) Net income (loss) from continuing operations attributable to common shareholders, basic (10,287) \$ 53,699 Net loss from discontinued operations attributable to common shareholders, basic (8,110) (11,370) Net income (loss) attributable to common shareholders, basic \$ (18,397) \$ 42,329 Weighted average shares outstanding — basic 14,263,744 7,385,348 Income (loss) from continuing operations, basic \$ (0.72) \$ 7.27 Loss from discontinued operations, basic \$ (0.57) \$ (1.54) Net income (loss) per share, basic \$ (1.29) \$ 5.73 Diluted net income (loss) per common share: Net income (loss) from continuing operations \$ (10,287) \$ 59,125 Less: deemed dividends related to Series A Redeemable Convertible Preferred Stock — (186) Less: income allocated to participating securities — (5,227) Net income (loss) from continuing operations attributable to common shareholders, diluted (10,287) \$ 53,712 Net loss from discontinued operations attributable to common shareholders, diluted (8,110) \$ (11,370) Net income (loss) attributable to common shareholders, diluted \$ (18,397) \$ 42,342 Weighted average shares outstanding — basic 14,263,744 7,385,348 Dilutive effect of warrants — 20,285 Dilutive effect of RSUs — 1,353 Weighted average shares outstanding — diluted 14,263,744 7,406,986 Income (loss) from continuing operations, diluted \$ (0.72) \$ 7.25 Loss from discontinued operations, diluted \$ (0.57) \$ (1.53) Net income (loss) per share, diluted \$ (1.29) \$ 5.72 Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Year Ended December 31, 2023-2024 2022-ESPP, RSUs and stock options to purchase common stock 1,999,823 979,553 815,710 Common stock warrants 20,265,576 433-20,833-265,576 X- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic260-SubTopic10-Section50-Paragraph1-Subparagraph\(c\)-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482662/260-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic260-SubTopic10-Section50-Paragraph1-Subparagraph(c)-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482662/260-10-50-1) Details Name: us-gaap\_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTableTextBlock Namespace Prefix: us-gaap\_Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- Definition Tabular disclosure of an entity's ..... na Period Type: durationX- References No definition available. Details Name: us-gaap\_TableTextBlock Namespace Prefix: us-gaap\_Data Type: xbrli: stringItemType Balance Type: na Period Type: duration Note 13- Accrued Liabilities (Tables) 12 Months Ended Dec. 31, 2023-2024 Notes Tables Schedule of Accrued Liabilities [Table Text Block] December 31, 2024 2023 2022 Accrued compensation and employee benefits \$ 2,005 \$ 1,732 Accrued professional services Other accrued liabilities Total accrued liabilities \$ 2-1, 445-254 \$ 2,531 445 X- Definition Tabular disclosure of the components of accrued liabilities. References No definition available. Details Name: us-gaap\_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap\_Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- References No definition available. Details Name: us-gaap\_TableTextBlock Namespace Prefix: us-gaap\_Data Type: xbrli: stringItemType Balance Type: na Period Type: duration Note 15- Income Taxes (Tables) 12 Months Ended Dec. 31, 2023-2024 Notes Tables Schedule of Deferred Tax Assets and Liabilities [Table Text Block] December 31, 2023-2024 December 31, 2022-2023 Deferred tax assets: Accruals and other \$ 1,347 \$ 1,717 \$ 3,790 Research credits 8,379 7,839 7,392 Net operating loss carryforward 90,142 88,839 84,325 Section 59 (e) R & D expenditures 1,136 1,937 3,496 Section 174 R & D expenditures 2,446 1,651 XOMA royalty 1,371 — Total deferred tax assets 104,821 101,983 99,984 Deferred tax liabilities: IP from Acquisition (1,852) (1,874) (2,052) Total deferred tax liabilities (1,852) (1,874) (2,052) Valuation allowance (102,969) (100,109) (97,932) Net deferred tax assets \$ — — Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Year Ended December 31, 2024 2023 2022 Tax at statutory federal rate \$ (2,731) \$ (3,862) \$ 10,031 State tax — net of federal benefit 2,495 Acquired assets — 1,728 Research credits (363) (292) Stock options Other (431-139) Change in valuation allowance 2,860 2,177 (43,520) Revaluation of Put Option Liability (150) (1,117) (15) Provision for income taxes \$ — — Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Year Ended December 31, 2024 2023 2022 Unrecognized benefit — beginning of period \$ 2,678-835 \$ 2,635-678 Gross increases — prior period tax positions — Gross increases — current period tax positions Unrecognized benefit — end of period \$ 2-3, 835-031 \$ 2,678-835 X- Definition Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets. References Reference 1: <http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Section50-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482685/740-10-50-2> Details Name: us-gaap\_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock Namespace Prefix: us-gaap\_Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- Definition Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations. References Reference 1: <http://fasb-www.xbrl.org/2003-us-gaap/role/exampleRef-ref/legacyRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section55-Paragraph9-231-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482443/2147482663/250-740-10-50-55-9Reference-231Reference-3-2> [http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph40-12A-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482685/740-10-50-10Reference-12AReference-4-3](http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph40-12A-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482685/740-10-50-10Reference-12AReference-4-3) [http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15A-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482685/740-10-50-15A-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482810/2147482685/280-740-10-50-22Reference-8Reference-3](http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15A-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482685/740-10-50-15A-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482810/2147482685/280-740-10-50-22Reference-8Reference-3) <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic280-740-SubTopic10-Section50-Paragraph22-8-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482810/2147482685/280-740-10-50-30-3> Namespace Prefix: us-gaap\_Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- References No definition available. Details Name: us-gaap\_TableTextBlock Namespace Prefix: us-gaap\_Data Type: xbrli: stringItemType Balance Type: na Period Type: duration Note 1- Organization and Summary of Significant Accounting Policies (Details Textual)- USD (\$) in Thousands 1 Months Ended 12 Months Ended Ended Jan 87 Months Ended Sep. 18 12, 2015 May 2024 Jan. 31, 2022-2024 Sep. 30, 2015 Dec. 31, 2023 2024 Dec. 31, 2023 Liabilities Related To The Sale Of Future Payments 2022 Dec. 31, 2022 May 30, 2019 Tangible Asset Impairment Charges \$ 0 \$ 4-6 948 Restructuring and 527 \$ 0 Issuance Costs, Sale Of Future Payments (521) XOMA [Member] Liabilities Related To The Sale Of Future Payments 6,100 Issuance Cost Costs, Sale Of Future Payments Number of Positions Eliminated, Period Percent 40.00 % Restructuring Charges Proceeds From Sale of Receivables 8 Royalty and Milestone Rights \$ 65,000 \$ 65-8, 000 Other Income 1 Royalty Arrangement Maximum Payments 195,000 Net Proceeds from Sale of Future Royalties \$ 61-, 200 \$ 61-1, 184 Zaltviso

related Assets **200 Other Expenses \$ 200 In Process Research and Development** [ Member ] Tangible Asset Impairment Charges of Intangible Assets (Excluding Goodwill) \$ 0 4,900 Loan Agreement with Oxford Finance LLC [ Member ] Debt Instrument, Covenant, Minimum Required Unrestricted Cash \$ 0 5,000 X- Definition Represents the issuance costs related Definition The minimum amount of unrestricted cash required to be maintained by the debt agreement- sale of future payments References No definition available. Details Name: tph\_DebtInstrumentCovenantMinimumRequiredUnrestrictedCash

tph\_IssuanceCostsSaleOfFuturePayments Namespace Prefix: tph Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX durationX - Definition Net Definition Amount proceeds from of liability related of the sale of future payments royalties- References No definition available. Details Name: tph\_NetProceedsFromSaleOfFutureRoyalties tph\_LiabilitiesRelatedToTheSaleOfFuturePayments Namespace Prefix: tph Data Type: xbrli: monetaryItemType Balance Type: debit credit Period Type: durationX instantX - Definition The amount of proceeds Definition Represents the cash inflow from the sale of receivables royalty and milestone rights- References No definition available. Details Name: tph\_ProceedsFromSaleOfRoyaltyAndMilestoneRights

tph\_ProceedsFromSaleOfReceivables Namespace Prefix: tph Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- Definition The capped amount of payments impairment loss recognized in the period resulting from the write-down of company required the carrying amount of an intangible asset (excluding goodwill) to fair value make to PDL. References No definition..... discontinued operation or an asset retirement obligation. References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef- Name Accounting Standards Codification- Section 45- Paragraph 28- Subparagraph (b)- SubTopic 10- Topic 230- Publisher FASB- URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef- Topic 420-350- SubTopic 40-30- Name Accounting Standards Codification- Section 599-45- Paragraph 2- Subparagraph (SAB Topic 5- P- 4 (b) (1))- Publisher FASB- URI https://asc.fasb.org/1943274/2147479823/2147482686/420-350-40-30-599-45-2Reference 3: http://www.xbrl.org/2009-2003/role/commonPracticeRef disclosureRef- Topic 420-350- SubTopic 40-30- Name Accounting Standards Codification- Section 45-50- Paragraph 3- Subparagraph (b)- Publisher FASB- URI https://asc.fasb.org/1943274/2147482047-2147482665/420-350-40-30-45-50-3Reference 4 3 Details Name: us-gaap\_ImpairmentOfIntangibleAssetsExcludingGoodwill Namespace Prefix: us-gaap Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- Definition Amount of expense classified as other. References Reference 1: http://www.fasb.org/2003-us-gaap/role/disclosureRef/legacyRef- Topic 420-220- SubTopic 10- Name Accounting Standards Codification- Section 599- Paragraph 2- Subparagraph (SAB Topic SX 210. 5 -P- 3- 03 (6))- Publisher FASB- URI https://asc.fasb.org/1943274/2147479823-2147483621/420-220-10-599-2Reference 2 Definition Weighted average price at which option holders acquired shares when converting their stock options into shares. References Reference 1: http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/legacyRef- Topic 220-718- SubTopic 10- Name Accounting Standards Codification- Section 599-50- Paragraph 2- Subparagraph (c) SX 210.5-03 (4-1) (iv) (02)- Publisher FASB- URI https://asc.fasb.org/1943274/2147483621-2147480429/220-718-10-599-50-2 Details Name: us-gaap\_OtherExpenses gaap\_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap Data Type: xbrli: dtr- types: monetaryItemType perShareItemValue Balance Type: debit na Period Type: durationX - Definition Amount of revenue and income classified as other. References Reference 1: http://s99-1 Details Name: us-gaap\_RestructuringCharges gaap\_OtherIncome Namespace Prefix: us-gaap Data Type: xbrli: monetaryItemType Balance Type: debit credit Period Type: durationX- Definition The charge against earnings resulting from the aggregate write down of tangible assets from their carrying Details Name: srt\_CounterpartyNameAxis = tph\_XOMAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_IndefiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap\_InProcessResearchAndDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: Note 2- Investments and Fair value Value to their fair value Measurement (Details Textual) \$ / shares in Units, \$ in Thousands 12 Months Ended Dec. 31, 2024 USD (\$) \$ / shares Dec. 31, 2023 USD (\$) \$ / shares Dec. 29, 2022 \$ / shares Marketable Security, Gain (Loss) \$ 0 \$ 0 Debt Securities, Available- for- Sale, Allowance for Credit Loss Warrants and Rights Outstanding 1, 061 1, 778 Common Warrants [ Member ] Warrants and Rights Outstanding \$ 1, 100 \$ 1, 800 Class of Warrant or Right, Exercise Price of Warrants or Rights | \$ / shares \$ 2. 07 Common Warrants [ Member ] | Measurement Input, Exercise Price [ Member ] Class of Warrant or Right, Exercise Price of Warrants or Rights | \$ / shares \$ 2. 07 \$ 2. 07 Common Warrants [ Member ] | Measurement Input, Share Price [ Member ] Warrants and Rights Outstanding, Measurement Input 0. 5241 0. 74 Common Warrants [ Member ] | Measurement Input, Expected Term [ Member ] Warrants and Rights Outstanding, Measurement Input Common Warrants [ Member ] | Measurement Input, Price Volatility [ Member ] Warrants and Rights Outstanding, Measurement Input 1. 0081 0. 9405 Common Warrants [ Member ] | Measurement Input, Risk Free Interest Rate [ Member ] Warrants and Rights Outstanding, Measurement Input 0. 0433 0. 0384 Common Warrants [ Member ] | Measurement Input, Expected Dividend Rate [ Member ] Warrants and Rights Outstanding, Measurement Input X- Definition Exercise price per share or per unit of warrants or rights outstanding. References Reference 1: http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/legacyRef- Topic 360-505- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 3 2- Subparagraph (b)- Publisher FASB- URI https://asc.fasb.org/1943274/2147482099-2147481112/360-505-10-50-3 2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef- Topic 205- SubTopic 20- Name Accounting Standards Codification- Section 50- Paragraph 1- Subparagraph (b)- Publisher FASB- URI https://asc.fasb.org/1943274/2147483499/205-20-50-1 Details Name: us-gaap\_TangibleAssetImpairmentCharges gaap\_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap Data Type: xbrli: dtr- types: monetaryItemType perShareItemValue Balance Type: debit na Period Type: instantX durationX- Details Name: us-..... 721 \$ 20, 275 X- Definition Amount of currency on hand as well as demand..... Data Type: xbrli: monetaryItemType Balance - allowance Type: debit Period Type: instantX- Definition Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for credit loss disposal group and discontinued operations. Cash..... accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale). References Reference 1: http://www.xbrl.org/2003/role/disclosureRef- Topic 320- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (b-aaa) - Publisher FASB- URI https://asc.fasb.org/1943274/2147481800/320 Codification- Section 50- Paragraph 8- Publisher FASB- URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 2Reference 2: http://www.xbrl.org/2003/role/disclosureRef- Topic 250-326- SubTopic 40-30- Name Accounting Standards Codification- Section 50-45- Paragraph 9-1- Publisher FASB- URI https://asc.fasb.org/1943274/2147483443-2147479130/250-326-40-30-50-45-9Reference 1Reference 3: http://www.xbrl.org/2003/role/disclosureRef- Topic 740-326- SubTopic 40-30- Name Accounting Standards Codification- Section 50- Paragraph 40-9- Subparagraph (a)- Publisher FASB- URI https://asc.fasb.org/1943274/2147482685-2147479106/740-326-40-30-50-40Reference 9Reference 4: http://www.xbrl.org/2003/role/disclosureRef- Topic 740-326- SubTopic 40-30- Name Accounting Standards Codification- Section 599-50- Paragraph 1-9- Subparagraph (1SAB TOPIC 6.1.7)- Publisher FASB- URI https://asc.fasb.org/1943274/2147479360-2147479106/740-326-40-30-599-50-9 Details Name: us-gaap\_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss Namespace Prefix: us-gaap Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- Definition Amount of realized and unrealized gain (loss) on investment in marketable security. References No 5- definition available. Details Name: us-gaap\_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments Namespace Prefix: us-gaap Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- Definition Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. References Reference 1: http://www.xbrl.org/2003-2009/role/disclosureRef commonPracticeRef- Topic 280-820- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 22-2- Subparagraph (h-bbb) (2) (i)- Publisher FASB- URI https://asc.fasb.org/1943274/2147482810-2147482106/280-820-10-50-22Reference 2Reference 6-2 http://www.xbrl.org/2003-2009/role/disclosureRef commonPracticeRef- Topic 944-820- SubTopic 220-10- Name Accounting Standards Codification- Section 599-50- Paragraph 4-2- Subparagraph (bbb SX 210.7-04 (9)- (2))- Publisher FASB- URI https://asc.fasb.org/1943274/2147483586-2147482106/944-820-220-10-599-50-4Reference 2Reference 7-3: http://www.xbrl.org/2003-2009/role/disclosureRef commonPracticeRef- Topic 820- SubTopic 10- Name Accounting Standards Codification- Section 45-50- Paragraph 2- Subparagraph (a-bbb) (1)- SubTopic 20- Topic 740- Publisher FASB- URI https://asc.fasb.org/1943274/2147482659-2147482106/740-20-820-45-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef- Name Accounting Standards Codification- Section 599- Paragraph 1- Subparagraph (SX 210.4-08 (h))- SubTopic 10- Topic 235- Publisher FASB- URI https://asc.fasb.org/1943274/2147480678-10-50-2 Details Name: us-gaap\_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax gaap\_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- Definition Amortized 2)- Publisher FASB- URI https://asc Definition Weighted average price at which option holders acquired shares when converting their stock options into shares. References Reference 1 fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009-2003/role/commonPracticeRef disclosureRef- Topic 820-718- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (bbb c) (1) (iv) (02)- Publisher FASB- URI https://asc.fasb.org/1943274/2147482106-2147480429/820-718-10-50-2 Details Name: us-gaap\_WarrantsAndRightsOutstandingMeasurementInput

gaap\_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap Data Type: xbrli: dtr- types: decimalItemType perShareItemValue Balance Type: na Period Type: durationX instantX-cost 1, 342 43, 275 Cash and cash equivalent, fair value 1, 342 43, 275 Cash and Cash Equivalents [ Member ] | Money Market Funds [ Member ] Cash and cash equivalent, fair value 2, 632 Money market funds, amortized cost 2, 632 Cash and Cash Equivalents [ Member ] | US Government Agencies Debt Securities [ Member ] Cash and cash equivalent, fair value 5, 867

1,896 2,444 U.S. government agency securities \$ 5,867 1,896 2,444 Cash and Cash Equivalents [ Member ] | Commercial Paper [ Member ] Cash and cash equivalent, fair value 4,235 Short-term investment, amortized Cost 2,393 Commercial paper \$ 2,393 X- Definition Represents fair value of cash, cash equivalents and short-term investments. ReferencesNo definition available. Details Name: tph\_CashCashEquivalentsAndShortTermInvestmentsFairValue Namespace Prefix: tph\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-320-SubTopic 210-10-Name Accounting Standards Codification-Section 50-999-Paragraph 1-2-Subparagraph (b) SX 210. 7-03 (a) (1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479440-2147481800\_944-320-210-10-999-50-1-Reference-2: http://www..... 326-30-45-1 Details Name: us-gaap\_AvailableForSaleDebtSecuritiesAmortizedCostBasis us-gaap\_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit-credit Period Type: instantX- DefinitionAmount DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 320-944-10-210-Name Accounting Standards Codification-Section 50-999-Paragraph 2-1-Subparagraph (a) SX 210. 7-03 (a) (1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800-2147478777\_320-944-10-210-50-999-2-Reference 1 Reference 2: http://www.xbrl.org/2009-2003/role/commonPracticeRef disclosureRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 45-50-Paragraph 1-2-Subparagraph (b) a-1-Publisher FASB-URI https://asc.fasb.org/1943274/2147481830-2147481800/320-10-45-50-1-Reference-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 942-326-SubTopic 210-30-Name Accounting Standards Codification-Section 599-45-Paragraph 1-Subparagraph (SX 210. 9-03 (6))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479853-2147479130/942-326-210-30-599-45-1-Reference-4 1 Details Name: us-gaap\_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic 326-820-SubTopic 30-10-Name Accounting Standards Codification-Section 5-6 Reference 2: http://fasb.www.xbrl.org/2009-us-gaap/role/ref/legacyRef commonPracticeRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section 50-Paragraph 8 2-Subparagraph (bbb) (1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106-2147482685\_820-740-10-50-2-Reference 8 Reference 6-3: http://fasb.www.xbrl.org/2003-us-gaap/role/ref/legacyRef disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section 50-Paragraph 2 3-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106-2147482685/820-740-10-50-3-45-Paragraph 1-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481830/320-10-50-45-22-Reference 1 Reference 6-9: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-942-SubTopic 220-210-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210. 7-9-04-03 (9 6))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483586-2147478546/944-942-220-210-599-1-Reference 7-10: http://www.xbrl.org/2003/role/disclosureRef-Topic 326-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 1 2-Subparagraph (a)-SubTopic 20-Topic 740-Publisher FASB-URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 Details Name: us-gaap\_AvailableForSaleDebtSecuritiesDebtSecurities Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10-Reference 2: http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147480167-2147479168/946-830-55-12-Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210. 7-03 (a) (2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479440-2147478777/944-210-599-1-Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210. 6-04 (4))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479617-2147479170/946-210-599-1-Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section 45-Paragraph 21-Publisher FASB-URI https://asc.fasb.org/1943274/2147480555-214747796/946-210-45-21-Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210. 5-02 (1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-599-1-Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 45-Paragraph 20-SubTopic 210-Topic 946-Publisher FASB-URI https://asc.fasb.org/1943274/2147480555-214747796/946-210-45-20-Details Name: us-gaap\_Cash Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-ReferencesNo-2-Reference definition available 2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2-Details Name: us-gaap\_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionCash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable. ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210. 5-02 (9))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-599-1-Details Name: us-gaap\_CashCashEquivalentsAndShortTermInvestments Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482913/230-10-50-8-Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 24-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-24-Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-4-Details Name: us-gaap\_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionUnsecured short-term debt instrument issued by corporations which are highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. ReferencesNo definition available. Details Name: us-gaap\_CommercialPaperAtCarryingValue Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionInvestment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of

three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months. ReferencesNo definition available. Details Name: us-gaap\_MoneyMarketFundsAtCarryingValue Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX-DefinitionDebt securities issued by a United States government agency such as Government National Mortgage Association (Ginnie Mae), Federal Home Loan Mortgage Corporation (Freddie Mac), and Federal National Mortgage Association (Fannie Mae), which are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months. ReferencesNo definition available. Details Name: us-gaap\_USGovernmentAgenciesSecuritiesAtCarryingValue Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX-Details Name: us-gaap\_FinancialInstrumentAxis = tph\_MarketableSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap\_FairValueByAssetClassAxis = us-gaap\_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap\_FairValueByAssetClassAxis = us-gaap\_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap\_CashAndCashEquivalentsAxis = us-gaap\_CashAndCashEquivalentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap\_FairValueByAssetClassAxis = us-gaap\_CashMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap\_FairValueByAssetClassAxis = us-gaap\_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: Note 2- Investments and Fair Value Measurement- Fair Value of Financial Assets and Liabilities by Level Within Fair Value Hierarchy (Details)- USD (\$) in Thousands Dec. 31, 2023-2024 Dec. 31, 2022Money market funds 2023Assets, fair value \$ 8, 039,499 \$ 7.81, 495Liabilities - 039Liabilities, fair value 1, 778-7,061 1, 098Warrant 778Warrant Liability [ Member ] Liabilities, fair value 1, 778-7,061 1, 098Fair 778Fair Value, Inputs, Level 1 [ Member ] Money market fundsLiabilities Assets, fair value 2, 632Liabilities, fair valueFair Value, Inputs, Level 1 [ Member ] Warrant Liability [ Member ] Liabilities, fair valueFair Value, Inputs, Level 2 [ Member ] Money market funds-Assets, fair value 5, 867 7, 949-7, 174Liabilities-949Liabilities, fair valueFair Value, Inputs, Level 2 [ Member ] Warrant Liability [ Member ] Liabilities, fair valueFair Value, Inputs, Level 3 [ Member ] Money-market-Assets, fair fundsLiabilities-valueLiabilities, fair value 1, 778-7,061 1, 098Fair 778Fair Value, Inputs, Level 3 [ Member ] Warrant Liability [ Member ] Liabilities, fair value 1, 778-7,061 1, 098Money-778Money Market Funds [ Member ] Assets, fair value 2, Money-632Money market fundsMoney-Market Funds [ Member ] Fair Value, Inputs, Level 1 [ Member ] Assets, fair value 2, Money-632Money market fundsMoney-Market Funds [ Member ] Fair Value, Inputs, Level 2 [ Member ] Money-market fundsMoney-Assets, fair valueMoney Market Funds [ Member ] Fair Value, Inputs, Level 3 [ Member ] Money-market fundsUS-Assets, fair valueUS Government Agencies Debt Securities [ Member ] Money market funds-Assets, fair value 5, 867 5, 258-258US 2, 444US-Government Agencies Debt Securities [ Member ] Fair Value, Inputs, Level 1 [ Member ] Money market fundsUS-Assets, fair valueUS Government Agencies Debt Securities [ Member ] Fair Value, Inputs, Level 2 [ Member ] Money market funds-Assets, fair value 5, 867 5, 258-258US 2, 444US-Government Agencies Debt Securities [ Member ] Fair Value, Inputs, Level 3 [ Member ] Money market-Assets, fair value \$ fundsCommercial-0Commercial Paper [ Member ] Money market funds-Assets, fair value 2, 691 4, 730Commercial-691Commercial Paper [ Member ] Fair Value, Inputs, Level 1 [ Member ] Money market-Assets, fair value fundsCommercial----- Commercial Paper [ Member ] Fair Value, Inputs, Level 2 [ Member ] Money market funds-Assets, fair value 2, 691 4, 730Commercial-691Commercial Paper [ Member ] Fair Value, Inputs, Level 3 [ Member ] Assets, fair value Money market funds \$ 0 X- DefinitionFair value portion of probable future asset recognized for present right to economic benefits - benefit obtained or controlled by an entity as a result of past transactions or events . ReferencesReference 1: http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-exampleRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 100-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a-b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Details Name: us-gaap\_AssetsFairValueDisclosure Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX-DefinitionFair value of financial and nonfinancial obligations. ReferencesReference 1: http://fasb-www.xbrl.org/2009-us-gaap/role/ref/legacyRef-commonPracticeRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a-b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Details Name: us-gaap\_LiabilitiesFairValueDisclosure Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX-Details Name: us-gaap\_FairValueByLiabilityClassAxis = tph\_WarrantLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap\_FairValueByFairValueHierarchyLevelAxis = us-gaap\_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap\_FairValueByFairValueHierarchyLevelAxis = us-gaap\_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap\_FairValueByFairValueHierarchyLevelAxis = us-gaap\_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap\_FairValueByAssetClassAxis = us-gaap\_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap\_FairValueByAssetClassAxis = us-gaap\_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap\_FairValueByAssetClassAxis = us-gaap\_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap\_FairValueByAssetClassAxis = us-gaap\_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: Note 2- investments and Fair Value Measurement- Changes in Level III Financial Liabilities (Details)- Warrant Liability [ Member ] - USD (\$) in Thousands 12 Months EndedDec. 31, 2023-2024 Dec. 31, 2022Fair 2023Fair value - beginning of period \$ 1, 778 \$ 7, 098 \$ 0Issuance-098Issuance of December 2022 Common Stock Warrants (717) 7, 098Change in fair value of December 2022 Common Stock Warrants-(5, 320) Fair value - end of period \$ 1, 061 \$ 1, 778 \$ 7, 098-X-DefinitionAmount of gain (loss)..... Type: credit Period Type: durationX-DefinitionAmount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. ReferencesReference 1: http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Details Name: us-gaap\_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX-DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. ReferencesReference 1: http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Details Name: us-gaap\_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValue Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX-Details Name: us-gaap\_FairValueByLiabilityClassAxis = tph\_WarrantLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: Note 3- Discontinued Operations (Details Textual)- Discontinued Operations [ Member ] - DSUVIA [ Member ] -USD (\$) in Millions-Thousands Dec. 31, 2024 Dec. 31, 2023 Apr. 03, 2023-USD (\$) Disposal-2023Disposal Group, Including Discontinued Operation, Maximum Amount in Sales-based Milestone \$ 116 -5Disposal-500Disposal Group, Including Discontinued Operation, Percentage of Royalty on Commercial Sales 15.00% Disposal Group, Including Discontinued operations, Percentage of Sales, Excluding Royalty Payments 20.00% Disposal Group, Including Discontinued Operation, Assets \$ 0 \$ 0 Department of Defense [ Member ] Disposal Group, Including Discontinued Operation, Percentage of Royalty on Commercial Sales 75.00% X-DefinitionMaximum amount in sales-based milestone for the disposal of assets and liabilities, including discontinued operation. ReferencesNo definition available. Details Name: tph\_DisposalGroupIncludingDiscontinuedOperationMaximumAmountInSalesbasedMilestone Namespace Prefix: tph\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX-DefinitionAmount of royalty on commercial sales as a percentage for the disposal of assets and liabilities, including discontinued operation. ReferencesNo definition available. Details Name: tph\_DisposalGroupIncludingDiscontinuedOperationPercentageOfRoyaltyOnCommercialSales Namespace Prefix: tph\_Data Type: dt: types: percentItemType Balance Type: na Period Type: instantX-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205-SubTopic 20-

Name Accounting Standards Codification- **Topic 740- SubTopic 10-** Section 50- Paragraph **8 5B- Subparagraph (e)**- Publisher FASB- URI <https://asc.fasb.org/1943274/2147483499-2147482685-205-740-20-10-50-5BReference-8Reference-5-3> ; <http://fasb.org/us-gaap/role/ref/legacyRef-Topic-360-SubTopic-10-1943274-10-50-3> Details Name: us-gaap\_DisposalGroupClassificationAxis = us-gaap\_SegmentDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis = tlp\_DSUVIAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt\_MajorCustomersAxis = tlp\_DepartmentOfDefenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: Note 3- Discontinued Operations- Summary of Discontinued Operations (Details)- USD (\$) \$ in Thousands 12 Months Ended Dec. 31, **2023 2024** Dec. 31, **2022** **Impairment-2023 Total current liabilities of discontinued operations \$ 723 \$ 731** **Impairment** of net assets held for sale \$ **0**, **653** **\$ 0** **Total current assets of discontinued- 853** **Discontinued operations- Operation 1, Gain (Loss) 931** **Impairment of fixed assets 1, 065** **Gain on Disposal termination of lease liabilities (1, Statement 098)** **Gain on termination of Income or Comprehensive Income [ Extensible Enumeration ] Net lease liabilities (1, 098)** **Gain on extinguishment of debt (400)** **Purchase of property and equipment (100) (364)** **Total non-current assets of discontinued operations 13, 936** **Net loss from discontinued operations (8- See Note 3** **Impairment of fixed assets \$ 0 1, 065** **Gain on termination of lease 110) (11, 370)** **Total current liabilities (1 of discontinued operations 4, 620** **Total 098)** **Gain non-on-current-termination of lease liabilities (1, 098)** **Gain on extinguishment of debt (400)** **Purchase of property and equipment (100)** **discontinued-Discontinued operations 3, 995** **Discontinued-Operations [ Member ] | DSUVIA [ Member ] Total revenuesAccrued liabilitiesDepreciation revenues 1, 771** **Accounts receivable, netDepreciation and amortization-amortizationCash 1, 465** **Cash proceeds 2, 723** **Less: net assets transferred 8, 723** **Cost 723** **Cost of goods soldTotal current liabilities of discontinued operationsStock sold 1, 508** **Inventories 1, 178** **Stock-based compensationLess: disposal costs Loss on sale of discontinued operations, before income taxes (6, 853)** **Selling, general and administrative expense-expenseNet 9, 744** **Prepaid expenses and other current assets (liabilities) of discontinued operations (723) (731)** **assetsImpairment----- Impairment** of net assets held for sale 6, 853 **Income tax expense Loss on sale of discontinued operations (6, 853)** **Impairment of net assets held for sale 6, 853** **Total current assets of discontinued operations 1, 931** **Impairment- 853** **Impairment of fixed assets 1, 065** **Loss** **Property, plant and equipment, net 10, 261** **Gain on termination sale of lease liabilities discontinued operations ( +6, 098-853 )** **Gain on termination of lease liabilities (1, 098)** **Operating Gain on termination of lease liabilities (1 right-of-use assets 3, 499** **Gain 098)** **Gain on extinguishment of debt (400)** **Research and development expensesPurchase expenses 1, 852** **Other assetsPurchase of property and equipment (100 ) (364)** **Loss from discontinued operations \$ 0 \$ (8, 110) (11, 333)** **Total non-current assets of discontinued operations 13, 936** **Interest expenseTotal assets of discontinued operations 15, 867** **Net loss from discontinued operations (8, 110) (11, 370)** **Accounts payableAccrued liabilities 1, 720** **Operating lease liabilities, current portion 1, 601** **Note payable, current portionDeferred revenue, current portionTotal current liabilities of discontinued operations 4, 620** **Operating lease liabilities, net of current portion 2, 959** **Deferred revenue, net of current portion 1, 036** **Total non-current liabilities of discontinued operations 3, 995** **Total liabilities of discontinued operations 8, 615** **Net assets (liabilities) of discontinued operations \$ (731) \$ 7, 252** **X- Definition** Represents expected cash proceeds from discontinued operation. ReferencesNo definition available. Details Name: tlp\_DiscontinuedOperationExpectedCashProceeds Namespace Prefix: tlp\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of expected disposal costs for sale of discontinued operation. ReferencesNo definition available. Details Name: tlp\_DiscontinuedOperationExpectedDisposalCosts Namespace Prefix: tlp\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of net assets transferred for sale of discontinued operation. ReferencesNo definition available. Details Name: tlp\_DiscontinuedOperationNetAssetsTransferred Namespace Prefix: tlp\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount classified as net assets attributable to disposal group held for sale or disposed of. ReferencesNo definition available. Details Name: tlp\_DisposalGroupIncludingDiscontinuedOperationNetAssets Namespace Prefix: tlp\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount classified as note payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. ReferencesNo definition available. Details Name: tlp\_DisposalGroupIncludingDiscontinuedOperationNotePayableCurrent Namespace Prefix: tlp\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount classified as operating lease liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. ReferencesNo definition available. Details Name: tlp\_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent Namespace Prefix: tlp\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount classified as Operating lease liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer. ReferencesNo definition available. Details Name: tlp\_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent Namespace Prefix: tlp\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount of operating lease right of use assets classified as noncurrent attributable to disposal group held for sale or disposed of. ReferencesNo definition available. Details Name: tlp\_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent Namespace Prefix: tlp\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of research and development expense attributable to disposal group, including, but not limited to, discontinued operation. ReferencesNo definition available. Details Name: tlp\_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense Namespace Prefix: tlp\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of selling, general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation. ReferencesNo definition available. Details Name: tlp\_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense Namespace Prefix: tlp\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionFor the asset that is reclassified back to held and used from held-for-sale, the amount of impairment charge (reversal) that is recognized on the reclassification date. ReferencesNo definition available. Details Name: tlp\_ImpairmentReversalChargeOnReclassifiedAssets Namespace Prefix: tlp\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount after tax of income (loss) from a discontinued operation attributable to the parent before interest income (expense). Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) on reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. ReferencesNo definition available. Details Name: tlp\_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToParentBeforeInterest Namespace Prefix: tlp\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of share-based compensation attributable to discontinued operations. ReferencesNo definition available. Details Name: tlp\_ShareBasedCompensationDiscontinuedOperations Namespace Prefix: tlp\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount classified as assets attributable to disposal group..... debit Period Type: instantX- DefinitionAmount of depreciation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-230-SubTopic-10-NameAccountingStandardsCodification-Section-45-Paragraph-28-Subparagraph-\(b\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482740/230-10-45-28Reference-2: http://www.xbrl.org/2003/role/disclosureRef-Topic-205-SubTopic-20-NameAccountingStandardsCodification-Section-50-Paragraph-5B-Subparagraph-\(c\)-\(2\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483499/205-20-50-5B](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-230-SubTopic-10-NameAccountingStandardsCodification-Section-45-Paragraph-28-Subparagraph-(b)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482740/230-10-45-28Reference-2) Details Name: us-gaap\_DepreciationAndAmortizationDiscontinuedOperations Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-205-SubTopic-20-NameAccountingStandardsCodification-Section-45-Paragraph-3B-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483475/205-20-45-3BReference-2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic-205-SubTopic-20-NameAccountingStandardsCodification-Section-50-Paragraph-1-Subparagraph-\(b\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483499/205-20-50-1Reference-3: http://fasb.org/us-gaap/role/ref/legacyRef-Topic-205-SubTopic-20-NameAccountingStandardsCodification-Section-45-Paragraph-3-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483475/205-20-45-3](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-205-SubTopic-20-NameAccountingStandardsCodification-Section-45-Paragraph-3B-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483475/205-20-45-3BReference-2) Details Name: us-gaap\_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-205-SubTopic-20-NameAccountingStandardsCodification-Section-50-Paragraph-5C-Subparagraph-\(b\)-\(2\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483499/205-20-50-5CReference-2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic-205-SubTopic-20-NameAccountingStandardsCodification-Section-45-Paragraph-3B-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483475/205-20-45-3BReference-3: http://fasb.org/us-gaap/role/ref/legacyRef-Topic-205-SubTopic-20-NameAccountingStandardsCodification-Section-50-Paragraph-1-Subparagraph-\(b\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483499/205-20-50-1Reference-4: http://fasb.org/us-gaap/role/ref/legacyRef-Topic-205-SubTopic-20-NameAccountingStandardsCodification-Section-45-Paragraph-3-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483475/205-20-45-3](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-205-SubTopic-20-NameAccountingStandardsCodification-Section-50-Paragraph-5C-Subparagraph-(b)-(2)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483499/205-20-50-5CReference-2) Details Name: us-gaap\_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: //asc-durationX- DefinitionIndicates line item in statement of income or comprehensive income that includes gain (loss) from disposal of discontinued operation. ReferencesReference 1 [fasb.org/1943274/2147482659](http://fasb.org/1943274/2147482659)

/740-20-45-2Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 50-50-1-Details Name:us-gaap-IncomeTaxExpenseBenefit> Paragraph 1- Subparagraph (b) [SX 210.4-08 \(h\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 50-50-1-Details Name:us-gaap-IncomeTaxExpenseBenefit) - SubTopic 10- Topic 235- Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480678-2147483499-235-205-10-20-S99-50-1> Details Name:us-gaap\_IncomeTaxExpenseBenefit

**gaap\_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration** Namespace Prefix:us-gaap\_ Data Type: xbrli:enum2- monetaryItemType-enumerationSetItemType Balance Type: na Period Type: durationX- DefinitionAmount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation. ReferencesReference 1:

gaap\_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- Details Name: us-gaap\_DisposalGroupClassificationAxis = us-gaap\_SegmentDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis = tplh\_DSUAMember Namespace Prefix: Data Type: na Balance Type: Period Type: Note 4- Asset Acquisition (Details Textual)- USD (\$) \$ / shares in Units, \$ in Thousands 12 Months Ended Jan. 07, 2022 Dec. 31, 2023 Dec. 31, 2022 In Process Research and Development [ Member ] Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) \$ 0 \$ 0 Lowell Therapeutics [ Member ] Business Combination, Consideration Transferred, Net of Cash Acquired \$ 32,500 Cash Acquired from Acquisition 3, 549 Business Combination, Options To Purchase Capital Stock Issued and Outstanding Cancelled, Exchange for Cash 3, 500 Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations, Value [ 1 ] Business Combination, Cash and Stock Paid for Transaction Costs Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [ 2 ] 8, 819 Business Combination, Consideration Transferred 12, 368 Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 6, 000 Business Combination, Acquisition Related Costs Payments to Acquire Businesses, Gross 3, 536 Business Acquisition, Transaction Costs 2, 521 Lowell Therapeutics [ Member ] \$ in Millions Jan. 07, 2022 USD (\$) Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets \$ 8, Contingent 8 Contingent Consideration Payable Upon Achievement of Milestones [ Member ] Business Combination, Contingent Consideration, Liability \$ 26, 000 Lowell Therapeutics [ Member ] AcclRx Common Stock [ Member ] Business Combination, Options To Purchase Capital Stock Issued and Outstanding Cancelled, Exchange for Common Stock, Number (in shares) 450, 477 Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations, Fixed Value per Share (in dollars per share) \$ 11, 0 46 Business Combination, Options To Purchase Capital Stock Issued and Outstanding Cancelled, Exchange for Common Stock, Value \$ 5, 200 Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations (in shares) 69, 808 Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations, Value \$ 800 [ 1 ] Recorded as Other long-term liabilities in the consolidated balance sheets at December 31, 2022. Shares were issued in the year ended December 31, 2023 and, accordingly, the related liability was extinguished. [ 2 ] Recorded as In-process research and development asset in the consolidated balance sheets. X - Definition Represents acquiree common stock to be..... Type: credit Period Type: durationX- Definition Amount of liability recognized arising from contingent consideration in a business combination. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 805-820-SubTopic 30-10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e-bbb) (+2) (i)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147479581-2147482106/805-820-30-10-50-Reference 2 Reference 2: http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Topic 805-SubTopic 30-Section 25-50-Paragraph 6-2-Subparagraph (bbb) (2)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147479668-2147482106/805-820-30-10-25-50-6 Reference 3: http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (bbb) (1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/805-10-50-2 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 805-SubTopic 30-Name Accounting Standards Codification-Section 35-Paragraph 1-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479613/805-30-35-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (c) (1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 805-SubTopic 30-Section 25-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/#1943274/2147479613-2147479668/805-30-35-25-6 Details Name: us-gaap\_BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- Definition Amount of assets acquired at the acquisition date. References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 805-SubTopic 20-Section 50-Paragraph 1-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 Details Name: us-gaap\_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumed Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- Definition The cash inflow associated with the..... Balance Type: Period Type: X- Details Name: us-gaap\_BusinessAcquisitionAxis = tplh\_LowellTherapeuticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_ContingentConsiderationByTypeAxis = tplh\_ContingentConsiderationPayableUponAchievementOfMilestonesMember Namespace Prefix: Data Type: na..... Name: us-gaap\_SubsidarySaleOfStockAxis = tplh\_AcelrxCommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: Note 5- In-license Agreement (Details Textual)- Aguettant [ Member ]- PFS Products [ Member ] \$ in Millions Jul-Thousands 42 Months Ended Jul. 14, 2021 Dec. 31, 2024 USD (\$) Apr. 03, 2023 USD (\$) Apr. 03, 2023 EUR (€) Apr. 02, 2023 USD (\$) License Agreement, Term (Year) 10 years License Agreement, Renewal Term (Year) 5 years License Agreement, Period to Notify of Nonrenewal 6 months License Agreement, Minimum Sales Obligation Term (Month) 12 months Licensing Agreement, Complementary Payment [ € € 1, 500, 000 Licensing Agreement, Milestone Payments ] \$ 21, 000 \$ 24, 000 License Agreement, Payments Made \$ 0 24 Minimum--Minimum [ Member ] License Agreement, Percent of Revenue Share Payment to be Paid 40. 00 % Maximum [ Member ] License Agreement, Percent of Revenue Share Payment to be Paid 45. 00 % X- Definition Represents the minimum sales obligation term under license agreement, in PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. References No definition available. Details Name: tplh\_LicenseAgreementMinimumSalesObligationTerm Namespace Prefix: tplh\_Data Type: xbrli: durationItemType Balance Type: na Period Type: durationX- Definition Amount of cash outflow for payments under license agreement. References No definition available. Details Name: tplh\_LicenseAgreementPaymentsMade Namespace Prefix: tplh\_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- Definition Represents the percentage of revenue share payments to be paid under license agreement. References No definition available. Details Name: tplh\_LicenseAgreementPercentOfRevenueSharePaymentToBePaid Namespace Prefix: tplh\_Data Type: dtl- types: percentItemType Balance Type: na Period Type: durationX- Definition Period to notify intention not to renew under the license agreement. References No definition available. Details Name: tplh\_LicenseAgreementPeriodToNotifyOfNonrenewal Namespace Prefix: tplh\_Data Type: xbrli: durationItemType Balance Type: na Period Type: durationX- Definition The renewal term of the license agreement, in PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. References No definition available. Details Name: tplh\_LicenseAgreementRenewalTerm Namespace Prefix: tplh\_Data Type: xbrli: durationItemType Balance Type: na Period Type: durationX- Definition The term of the license agreement, in PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. References No definition available. Details Name: tplh\_LicenseAgreementTerm Namespace Prefix: tplh\_Data Type: xbrli: durationItemType Balance Type: na Period Type: durationX- Definition Amount of complementary payment to be received as part of a licensing agreement. References No definition available. Details Name: tplh\_LicensingAgreementComplementaryPayment Namespace Prefix: tplh\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- Definition Represents licensing agreement, milestone payment liabilities. References No definition available. Details Name: tplh\_LicensingAgreementMilestonePayments Namespace Prefix: tplh\_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- Details Name: srt\_CounterpartyNameAxis = tplh\_AguettantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt\_ProductOrServiceAxis = tplh\_PFSProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt\_RangeAxis = srt\_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt\_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: Note 6- Long-term Debt (Details Textual)- USD (\$) \$ / shares in Units, \$ in Thousands Millions | 12 Months Ended Apr. 03, 2023 Dec. 31, 2023 Dec. 31, 2022 Dec. 31, 2021 May 30, 2019 Amortization of Debt Discount (Premium) \$ 53 \$ 393 Warrant 2019 Warrant In Connection with Oxford Finance Loan Agreement [ Member ] Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 8, 833 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \$ 56. 6 Loan Agreement with Oxford Finance LLC [ Member ] Debt Instrument, Face Amount \$ 25 7 000 Long-Term Debt 5, 400 Interest Expense, Debt 1, 100 \$ 2, 200 Amortization of Debt Discount (Premium) \$ 100 \$ 400 Debt Instrument, Interest Rate, Effective Percentage 13. 60 % Repayments 0 Repayments of Debt \$ 3 4 Interest Expense, 400 Debt \$ 0. 1 X - Definition Amount of noncash expense included in..... Type: Debit Period Type: durationX- Definition Exercise price per share or per unit of warrants or rights outstanding. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481112/505-10-50-3 Details Name: us-gaap\_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap\_Data Type: dtl- types: perShareItemType Balance Type: na Period Type: instantX- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500, 000 warrants may be converted into 1, 000, 000 shares. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481112/505-10-50-3 Details Name: us-gaap\_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap\_Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantX- Definition Face (par) amount of debt instrument at time of issuance. References Reference 1: http://www.

xbnl.org/2003/role/disclosureRef/exampleRef-Topic 835-SubTopic 30-Name Accounting Standards Codification-Section 50-55-Paragraph 4-8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482900-2147482949/835-30-50-55-4Reference-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 69B-Publisher FASB-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 69C-Publisher FASB-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic 835-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 835-SubTopic 30-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 835-SubTopic 30-Section 55-45-Paragraph 8-2-Details Name: us-gaap-DebtInstrumentFaceAmount Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-DefinitionEffective interest..... types: percentItemType Balance Type: na Period Type: instantX-DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. ReferencesReference 1: http://www.fasb.xbrl.org/2003-us-gaap/role/exampleRef-ref/legacyRef-Topic 470-220-SubTopic 20-10-Name Accounting Standards Codification-Section 55-S99-Paragraph 69E-2-Subparagraph (SX 210.5-03 (8))-Publisher FASB-URI https://asc.fasb.org/1943274/2147481568-2147483621/470-20-220-55-10-S99-69EReference 2Reference 2: http://www.xbrl.org/2003/role/exampleRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 69F-69E-Publisher FASB-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 69EReference 3: http://www.xbrl.org/2003/role/disclosureRef/exampleRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-55-Paragraph 69F-1F-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139-2147481568/470-20-50-55-1FReference 69FReference 4: http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 220-470-SubTopic 40-20-Name Accounting Standards Codification-Section S99-50-Paragraph 2-1F-Subparagraph (b SX 210.5-03 (8))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621-2147481139/470-220-20-40-50-S99-2Reference-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 Details Name: us-gaap-InterestExpenseDebt Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-DefinitionAmount, after deduction of unamortized premium (discount) cash outflow for short-term and debt issuance cost of long-term debt. Excludes payment of lease obligation. ReferencesReference 1: http://fasb-www.xbrl.org/2009-us-gaap/role/ref/legacyRef-commonPracticeRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section S99-45-Paragraph 1-15-Subparagraph (b SX 210.5-02 (22))-SubTopic 10-Topic 210-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210...../asc.fasb.org/1943274/2147482740/230-10-45-15 Details Name: us-gaap-RepaymentsOfDebt Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-Details Name: us-gaap-ClassOfWarrantOrRightAxis = t1ph\_WarrantInConnectionWithOxfordFinanceLoanAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap-DebtInstrumentAxis = t1ph\_LoanAgreementWithOxfordFinanceLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: Note 7-Liability Related to Sale of Future Royalties Payments (Details Textual)-XOMA USD (\$) in Thousands1 Months Ended 12 Months Ended 87 Months EndedMay 31, 2022 Sep. 18, 2015 Sep. 30, 2015 Dec. 31, 2022 Dec. 31, 2022 Dec. 31, 2022 Dec. 31, 2022 Liabilities From Sale of Royalty and Milestone Rights \$ 65,000 \$ 65,000 Consideration Paid for Termination of Royalty Monetization \$ 100 \$ 100 \$ 100 Non-cash Gain on Termination of Liability Related to Sale of Future Royalties \$ 84, 100 \$ (0) \$ 84, 152 Effective Annual Interest Rate 3.20% SWK [ Member ] Percentage of Royalties and Rights Under Agreement..... Sale of Future Royalties (Details)-USD (\$) in Thousands 1 Months Ended 12 Months Ended EndedJan 87 Payments Based on Net Sales and Milestone Payments 50.00% License Agreement, Percentage of Royalty Payments Excluding Department of Defense Sales and Milestone Payments 100.00% Transaction Costs From Sale of Receivables \$ 200 X-Definition Represents the maximum amount of milestone payments to be paid under license agreement. ReferencesNo definition available. Details Name:t1ph\_LicenseAgreementMilestonePaymentsToBePaidMaximum Namespace Prefix:t1ph-Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instantX-Definition Represents the percentage of royalty payments based on net sales and milestone payments. ReferencesNo definition available. Details Name:t1ph\_LicenseAgreementPercentageOfRoyaltyPaymentsBasedOnNetSalesAndMilestonePayments Namespace Prefix:t1ph-Data Type:dtr-types:percentItemType Balance Type:na Period Type:durationX-Definition Represents the percentage of royalty payments excluding Department of Defense sales and milestone payments. ReferencesNo definition available. Details Name:t1ph\_LicenseAgreementPercentageOfRoyaltyPaymentsExcludingDepartmentOfDefenseSalesAndMilestonePayments Namespace Prefix:t1ph-Data Type:dtr-types:percentItemType Balance Type:na Period Type:durationX-Definition Represents the threshold payments relating to product cash inflow from sale of receivables. ReferencesNo definition available. Details Name:t1ph\_ProceedsFromSaleOfReceivables Namespace Prefix:t1ph-Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:durationX-Definition Represents the share price milestone for license agreements a sale of equity. ReferencesNo definition available. Details Name:t1ph\_LicenseAgreementThresholdPaymentsRelatingToProduct-t1ph\_SaleOfEquitySharePriceMilestone Namespace Prefix:t1ph-Data Type:xbrli:dtr-types:monetaryItemType perShareItemType Balance Type:credit na Period Type:instantX Months EndedMay EndedDec. 31, 2022 2024 Sep. 30, 2015 Dec. 31, 2023 Dec. 31, 2022 Dec. 31, 2022 Liabilities 2024 Liability related to sale of future royalties payments - beginning balance \$ 0 85,288 \$ 0 Proceeds from sale of future payments royalties \$ 61, net 200 61, 184 Non-cash royalty revenue (1, 083) Non-cash interest (income) expense recognized \$ 0 (1, 136) 24, 051 Consideration paid for termination of issuance costs 6, 133 6, Royalty Monetization \$ (100) (100) (100) Gain on extinguishment of liability 133 Liability related to sale of future royalties \$ 0 (84) payments as of December 31, 2024 6 (652) (84, 652) 527 6, 527 XOMA [ Member ] Liability related to sale of future royalties as of December 31 payments - beginning balance 6, 2022 100 Payments to XOMA Non-cash interest expense recognized \$ 0 394 \$ 0 394 X-Definition Amount of consideration paid for termination liability related to the sale of future payments Royalty Monetization-ReferencesNo definition available. Details Name: t1ph\_ConsiderationPaidForTerminationOfRoyaltyMonetization-t1ph\_LiabilitiesRelatedToTheSaleOfFuturePayments Namespace Prefix: t1ph-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-InstantX-Definition Amount DefinitionThe amount of gain on non-cash interest expense recognized termination of liability related to sale of future royalties. ReferencesNo definition available. Details Name: t1ph\_GainOnTerminationOfLiabilityRelatedToSaleOfFutureRoyalties-t1ph\_NoncashInterestExpenseRecognized Namespace Prefix: t1ph-Data Type: xbrli:monetaryItemType Balance Type: credit debit Period Type: durationX-Definition Represents liability related to the payments for the sale of future royalties payments. ReferencesNo definition available. Details Name: t1ph\_LiabilityRelatedToSaleOfFutureRoyalties-t1ph\_PaymentsForSaleOfFuturePayments Namespace Prefix: t1ph-Data Type: xbrli:monetaryItemType Balance Type: credit na Period Type: instantX-durationX-Definition Represents the proceeds from DefinitionThe amount of liability related to sale sales of future royalties less current portion payments, net of issuance costs. ReferencesNo definition available. Details Name: t1ph\_LiabilityRelatedToSaleOfFutureRoyaltiesNet-t1ph\_ProceedsFromSaleOfFuturePaymentsNet Namespace Prefix: t1ph-Data Type: xbrli:monetaryItemType Balance Type: credit na Period Type: instantX-durationX-Definition Net proceeds from sale of future royalties. ReferencesNo definition available. Details Name: t1ph\_NetProceedsFromSaleOfFutureRoyalties-srt\_CounterpartyNameAxis = t1ph\_XOMAMember Namespace Prefix: t1ph-Data Type: na xbrli:monetaryItemType Balance Type: debit Period Type: durationX-Definition Amount of non-cash interest income expense on liability related to sale of future royalties. ReferencesNo definition available. Details Name: t1ph\_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties Namespace Prefix: t1ph-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-Definition The amount of non-cash royalty revenue recognized in connection to royalty monetization that has been realized. ReferencesNo definition available. Details Name: t1ph\_NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized Namespace Prefix: t1ph-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration-Note 8-Commitments and Contingencies (Details Textual) 36 Months EndedMar. 07, 2022 Nov. 17, 2021 Jun. 08, 2021 Jul. 06, 2024 Purported 2024 Purported Shareholder v. Company- Violation of Sections 10 (b) and 20 (a) of the Exchange Act and SEC Rule 10b-5 [ Member ] Loss Contingency, Number of Defendants Loss Contingency, Number of Plaintiffs Purported Shareholder v. Company- Alleged Misstatements as the Shareholder [ Member ] Loss Contingency, Number of Defendants X-Definition Number of defendants named in a legal action. ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 9-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Details Name: us-gaap-LossContingencyNumberOfDefendants Details Name:t1ph-EffectiveIncomeTaxRateReconciliationRevaluationOfPutOptionLiability-Namespace Prefix:t1ph-us-gaap-Data Type:xbrli:monetaryItemType integerItemType Balance Type: debit na Period Type:durationX-Definition Amount DefinitionNumber of plaintiffs that have filed claims current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations a loss contingency. ReferencesReference 1: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 250-450-SubTopic 40-20-Name Accounting Standards Codification-Section 50-Paragraph 8-4-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443-2147483076/250-450-40-20-50-8Reference 4Reference 2: http://

www.xbrl.org / 2003-2009 / role / disclosureRef - commonPracticeRef - Topic 250-450 - SubTopic 40-20 - Name Accounting Standards Codification- Section 50- Paragraph 9 - Subparagraph (a) - Publisher FASB- URI https://asc.fasb.org / 1943274 / 2147483443-2147483076 / 250-450-40-20-50-9Reference-3-9 Details Name : http-us-gaap\_LossContingencyNumberOfPlaintiffs Namespace Prefix: us-gaap\_ Data Type: xbrli:integerItemType Balance Type: na Period Type: durationX- Details Name: srt\_LitigationCaseAxis = t1ph\_PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt\_LitigationCaseAxis = t1ph\_PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember Namespace Prefix: Data Type: na Balance Type: Period Type: Note 9- Stockholders' Equity (Details Textual )- USD (\$) 1 Months Ended 12 Months Ended 18 Months Ended Jan. 24, 2024 May 31, 2024 Jan. 22, 2024 Jan. 17, 2024 USD (\$) Jul. 17, 2023 May USD (\$) / shares shares May 31, 2023 Jun USD (\$) shares Dec. 29, 2016, 2020 Jan. 31, 2011 Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2023 Jul. 20, 2023 Dec. 31, 2022 USD (\$) / shares..... 2021 shares Jun. 16, 2020 shares Dec. 31, 2011 Stock, Shares Authorized (in shares) 210,000,000-210,000,000 Common Stock, Shares Authorized (in shares) 200,000,000 200,000,000 200,000,000 000 Common Stock, Par or Stated Value Per Share (in dollars per share) +\$/shares \$ 0.001 \$ 0.001 \$ 0.001 Preferred Stock, Shares Authorized (in shares) 10,000,000-10,000,000 Preferred Stock, Par or Stated Value Per Share (in dollars per share) +\$/shares \$ 0.001 \$ 0.001 Preferred Stock, Shares Issued (in shares) Preferred Stock, Shares Outstanding (in shares) Proceeds from Issuance of Private Placement +\$ 10,000,000 Warrants and Rights Share- Based Compensation Arrangement by Share- Based Payment Award, Options, Outstanding, Number +\$ -1,778,786, 900,893,000 \$ -7,098,321,893, 000 \$ -321,725,623 Share- Based Compensation Arrangement by Share- Based Payment Award, Options, Grants in Period, Gross 1,778,053, 612,288,000 Non-cash Issuance Costs for Warrants +\$ -0,775,929,000 Stock Issued During Period, Value, New Issues +\$ -790,000 Employee Stock Purchase Plan, Shares Issued, Weighted Average Fair Value (in dollars per share) +\$/shares \$ 1.08 \$ 6.82 Restricted Stock Units (RSUs) [ Member ] Share- Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation (in shares) Share- Based Compensation Arrangement by Share- Based Payment Award, Equity Instruments Other than Options, Grants in Period 176,768,48,158 2011 Equity Incentive Plan [ Member ] Share- based Compensation Arrangement by Share- based Payment Award, Equity Instruments Other Than Options, Outstanding (in shares) 93,750,000,000 Stock Option Plan Option Reserve Annual Increase as Percentage of Outstanding Shares Allowed 4.00 % Share- Based Compensation Arrangement by Share- Based Payment Award, Number of Shares Authorized (in shares) 744,608,275,000-2011 Equity Incentive Plan [ Member ] Maximum [ Member ] Share- based Compensation Arrangement by Share- based Payment Award, Number of Additional Shares to be Added (in shares) 744,608,275,000-2020 Equity Incentive Plan [ Member ] Share- Based Compensation Arrangement by Share- Based Payment Award, Number of Shares Authorized (in shares) 275,990,000-1,500,000 Share- Based Compensation Arrangement by Share- Based Payment Award, Number of Additional Shares Authorized Available for Grant (in shares) 1,631,171,395,319-1,631,319 Employee Stock Purchase Plan (ESPP) [ Member ] Share- Based Compensation Arrangement by Share- Based Payment Award, Number of Shares Available for Grant 1 Authorized (in shares) 42,956,209-42,919 Inducement Grant 209,245,000,000-000 Amended ESPP [ Member ] Share- Based Compensation Arrangement by Share- Based Payment Award, Number of Shares Authorized (in shares) 217,000 Shares Share- Based Compensation Arrangement by Share- Based Payment Award, Options, Grants in Period, Gross 185,000 Inducement Grant [ Member ] Restricted Stock Units (RSUs) [ Member ] Share- Based Compensation Arrangement by Share- Based Payment Award, Equity Instruments Other than Options, Grants in Period 32,000 Employee Stock Purchase Plan (ESPP) [ Member ] Share- Based Compensation Arrangement by Share- Based Payment Award, Number of Shares Authorized (in shares) 245,000,000,000 Share- Based Compensation Arrangement by Share- Based Payment Award, Number of Additional Shares Authorized 100,000 Share- Based Compensation Arrangement by Share- Based Payment Award, Number of Shares Available for Grant 345,000 Maximum [ Member ] 2011 Equity Incentive Plan [ Member ] Share- based Compensation Arrangement by Share- based Payment Award, Number of Additional Shares to be Added (in shares) 169,744,667-169,608 Maximum [ Member ] The 2020 Equity Incentive Plan [ Member ] Share- Based Compensation Arrangement by Share- Based Payment Award, 667-Subsequent Event Number of Shares Authorized (in shares) 3,161,395 Share- Based Compensation Arrangement by Share- Based Payment Award, Expiration Period 10 years Share- Based Compensation Arrangement by Share- Based Payment Award, Options, Outstanding, Number 744,608 Prefunded 2024 Warrants [ Member ] Class of Warrant or Right, Exercise Price of Warrants or Rights \$ 0.001 Prefunded 2024 Warrants [ Member ] Maximum [ Member ] Class of Warrant or Right, Exercise Price of Warrants or Rights 1.11 Prefunded 2024 Warrants [ Member ] Minimum [ Member ] Class of Warrant or Right, Exercise Price of Warrants or Rights \$ 0.77 Prefund Warrants [ Member ] Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 2,012,356 Class of Warrant or Right, Exercise Price of Warrants or Rights \$ 0.001 \$ 0.001 Prefund Warrants [ Member ] Maximum [ Member ] Class of Warrant or Right, Exercise Price of Warrants or Rights \$ 1.11 Series A Common Stock Warrants [ Member ] Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 7,352,947 Class of Warrant or Right, Exercise Price of Warrants or Rights \$ 1.11 Series B Common Stock Warrants [ Member ] Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 7,352,947 Class of Warrant or Right, Exercise Price of Warrants or Rights \$ 1.11 The January 2024 Private Placement [ Member ] Net proceeds from issuance of common stock, accompanying warrants and pre-funded warrants in July 2023 private placement offering \$ 6,000,000 The January 2024 Private Placement [ Member ] Prefunded 2024 Warrants [ Member ] Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 7,792,208 Class of Warrant or Right, Exercise Price of Warrants or Rights \$ 0.001 The January 2024 Private Placement [ Member ] Pivotal Trial Milestone [ Member ] Net Proceeds proceeds from issuance of common stock, accompanying warrants and pre-funded warrants in July 2023 private placement offering \$ 10,000,000 The January 2024 Private Placement [ Member ] \$ - \$ 10 Pivotal Trail Milestone [ Member ] Prefunded 2024 Warrants [ Member ] Class of Warrant or Right, 000 Number of Securities Called by Warrants or Rights (in shares) 12,000 Subsequent Event 987,013 The January 2024 Private Placement [ Member ] Pivotal Share Price Milestone [ Member ] Net Proceeds proceeds from issuance of common stock, accompanying warrants and pre-funded warrants in July 2023 private placement offering \$ 2,000,000 Sale of Equity, Share Price Milestone \$ 0.92 The January 2024 Private Placement +\$ 2,000,000 Securities Purchase Agreement [ Member ] Pivotal Share Price Milestone [ Member ] Prefunded 2024 Warrants [ Member ] Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 2,597,402 The January 2024 Private Placement [ Member ] Share- Based Payment Arrangement, Tranche One [ Member ] Net Proceeds proceeds from issuance of common stock, accompanying warrants and pre-funded warrants in July 2023 private placement offering \$ 6,000,000 The January 2024 Private Placement [ Member ] \$ - \$ 300 Share- Based Payment Arrangement, Tranche One [ Member ] 000 Proceeds from Issuance or Sale of Equity, Net +\$ 200 Prefunded 2024 Warrants [ Member ] Stock Issued During Period, 000 Shares, New Issues 7,792,208 Private Placement [ Member ] Common Stock, Par or Stated Value Per Share (in dollars per share) +\$/shares \$ 0.001 Stock Issued During Period, Shares, New Issues (in shares) 5,340,591 Combined Offering Price (in dollars per share) +\$/shares \$ 1.36 Sale of Equity, Price Per Share and Warrant (in dollars per share) +\$/shares \$ 1.359 Payments of Stock Issuance Costs +\$ -1,100,000 Private Placement [ Member ] Subsequent Event [ Member ] Proceeds from Issuance of Private Placement +\$ 6,000,000 Private Placement [ Member ] H. C. Wainwright & Co., LLC [ Member ] Placement Agent Fee, Percentage of Gross Proceeds of Private Placement 5.25 % Maximum Reimburse Amount of Private Placement +\$ 100,000 One Time Payment Upon Exercise of Warrant +\$ 200,000 Private Placement Agent Fee, Minimum Proceeds Required for Full One-time Payment +\$ 9,500,000 December 2022 Financing [ Member ] Common Stock, Par or Stated Value Per Share (in dollars per share) Prefund +\$/shares \$ 0.001 Stock Issued During Period, Shares, New Issues (in shares) 748,744 Payments of Stock Issuance Costs +\$ 1,700,000 Equity Offering, Price Per Unit (in dollars per share) +\$/shares \$ 2.22625 Proceeds from Issuance or Sale of Equity, Net +\$ 7,500,000 Non-cash Issuance Costs for Warrants +\$ 800,000 ATM Agreement [ Member ] Stock Issued During Period, Shares, New Issues (in shares) 124,330 Aggregate Offering Price, Maximum +\$ 80,000,000 \$ 40,000,000 \$ 35,600,000 Aggregate Offering Price, Increase During Period +\$ 40,000,000 Stock Issued During Period, Value, New Issues +\$ 500,000 August 2022 LPC Warrant [ Member ] Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 812,450-012,356 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) +\$/shares \$ 4.07 Warrants and Rights Outstanding +\$ 300,000 Prefund Warrants [ Member ] Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 2,012,356 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) +\$/shares \$ 0.001 \$ 0.001 Prefund Warrants [ Member ] Private Placement [ Member ] Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 2,012,356 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) +\$/shares \$ 0.001 Series A Common Stock Warrants [ Member ] Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 3,676,473-7,352,947 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) +\$/shares \$ 1.11 Private Placement [ Member ] Series A Common Stock Warrants [ Member ] Private Placement H. C. Wainwright & Co., LLC [ Member ] Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 7-183,824-352,947 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) +\$/shares \$ 1.11 Series A Common Stock Warrants [ Member ] Private Placement [ Member ] H. C. Wainwright & Co., LLC [ Member ] Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 183,824-824 Series B Common Stock Warrants [ Member ] Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 3,676,473-7,352,947 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) +\$/shares \$ 1.11 Private Placement [ Member ] Series B Common Stock Warrants [ Member ] Private Placement H. C. Wainwright & Co., LLC [ Member ] Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 7,352,947 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) +\$/shares \$ 1.11 Series B Common Stock Warrants [ Member ] Private Placement [ Member ] H. C. Wainwright & Co., LLC [ Member ] Class of Warrant or Right, Number of

Securities Called by Warrants or Rights (in shares) 183, 823 Common Stock and Series A and Series B Common Stock Warrants [ Member ] Warrants and Rights Outstanding | \$ 16,300,000 The 2022 Prefunded Warrants [ Member ] Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | \$ / shares \$ 0.0001 Warrants and Rights Outstanding, Measurement Input 2, 22615 Common Warrants [ Member ] Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 4, 227, 052 4, 227, 052 4, 227, 052 4, 227, 052 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | \$ / shares \$ 2.07 \$ 2.07 \$ 2.07 Warrants and Rights Outstanding | \$ 7,100,000 \$ 1,800,000 \$ 1,800,000 Common Warrants [ Member ] December 2022 Financing [ Member ] Warrants and Rights Outstanding | \$ 100,000 Redeemable Convertible Preferred Stock [ Member ] Preferred Stock, Par or Stated Value Per Share (in dollars per share) | \$ / shares \$ 0.001 Preferred Stock, Shares Outstanding (in shares) 3,000 Stock Issued During Period, Shares, New Issues (in shares) 3,000 Preferred Stock Stated Value Per Share (in dollars per share) | \$ / shares \$ 100 Preferred Stock, Redemption Price Per Share (in dollars per share) | \$ / shares \$ 3.7 Preferred Stock, Company Option to Convert, Percentage of Stated Value 105.00% 105.00% Preferred Stock, Purchaser Option to Convert, Percentage of Stated Value 110.00% Dividends, Preferred Stock | \$ 200,000 Reverse Stock Split, Preferred Stock Votes per Share 1,000,000 Preferred Stock, Redemption Amount | \$ 300,000 Preferred Stock, Elimination of Designation, Shares (in shares) 3,000 Stock Issued During Period, Value, New Issues | \$ 110,000 X- Definition Represents **combined the aggregate offering price increase during period**. References No definition available. Details Name: **tlph\_AggregateOfferingPriceIncreaseDuringPeriod\_tlph\_CombinedOfferingPrice** Namespace Prefix: **tlph\_Data Type: xbrli:dtr-types, monetaryItemType perShareItem Type Balance Type: credit na Period Type: durationX instantX** Definition Represents **the maximum aggregate offering price reimburse expense of private placement**. References No definition available. Details Name: **tlph\_AggregateOfferingPriceMaximum** Namespace Prefix: **tlph\_Data Type:.....** definition available. Details Name: **tlph\_MaximumReimburseAmountOfPrivatePlacement** Namespace Prefix: **tlph\_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: durationX** Definition The amount of non-cash issuance costs for warrants. References No definition available. Details Name: **tlph\_NoncashIssuanceCostsForWarrants** Namespace Prefix: **tlph\_Data Type: xbrli:monetaryItem Type Balance Type: debit** Period Type: durationX Definition Represents one time payment upon exercise of warrant. References No definition available. Details Name: **tlph\_OneTimePaymentUponExerciseOfWarrant** Namespace Prefix: **tlph\_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: durationX** Definition Amount of minimum proceeds required for full on-time payment for placement agent fee. References No definition available. Details Name: **tlph\_PlacementAgentFeeMinimumProceedsRequiredForFullOnTimePayment** Namespace Prefix: **tlph\_Data Type: xbrli:monetaryItem Type Balance Type: debit** Period Type: durationX Definition Percentage of gross proceeds for placement agent fee in private placement. References No definition available. Details Name: **tlph\_PlacementAgentFeePercentageOfGrossProceedsOfPrivatePlacement** Namespace Prefix: **tlph\_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: durationX** Definition Percentage of stated value that preferred stock can be converted from company options to convert. References No definition available. Details Name: **tlph\_PreferedStockCompanyOptionToConvertPercentageOfStatedValue** Namespace Prefix: **tlph\_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: instantX** Definition Amount of preferred shares eliminated. References No definition available. Details Name: **tlph\_PreferedStockEliminationOfDesignationShares** Namespace Prefix: **tlph\_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: durationX** Definition Percentage of stated value that preferred stock can be converted to by purchaser. References No definition available. Details Name: **tlph\_PreferedStockPurchaserOptionToConvertPercentageOfStatedValue** Namespace Prefix: **tlph\_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: instantX** Definition Stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. References No definition available. Details Name: **tlph\_PreferedStockStatedValuePerShare** Namespace Prefix: **tlph\_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instantX** Definition Proceeds from issuance or sale of equity, net of other costs. References No definition available. Details Name: **tlph\_ProceedsFromIssuanceOrSaleOfEquityNet** Namespace Prefix: **tlph\_Data Type: xbrli:monetaryItem Type Balance Type: debit** Period Type: durationX Definition Amount of votes preferred stock have on reverse stock split decision, per share. References No definition available. Details Name: **tlph\_ReverseStockSplitPreferredStockVotesPerShare** Namespace Prefix: **tlph\_Data Type: xbrli:integerItem Type Balance Type: na Period Type: instantX** Definition Per share or per unit price of share and warrant issued in sale of equity. References No definition available. Details Name: **tlph\_SaleOfEquityPricePerShareAndWarrant** Namespace Prefix: **tlph\_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instantX** Definition Represents the share price milestone for a sale of equity. References No definition available. Details Name: **tlph\_SaleOfEquitySharePriceMilestone** Namespace Prefix: **tlph\_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instantX** Definition Represents the shared-based compensation arrangement by share-based payment award equity instrument other than options outstanding. References No definition available. Details Name: **tlph\_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding** Namespace Prefix: **tlph\_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: durationX** Definition Represents the number of additional shares that could be added from expired or cancelled shares already issued under another share-based payment plan. References No definition available. Details Name: **tlph\_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded** Namespace Prefix: **tlph\_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX** Definition Represents the stock option plan option reserve annual increase as percentage of outstanding shares allowed. References No definition available. Details Name: **tlph\_StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed** Namespace Prefix: **tlph\_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: instantX** Definition Represents the amount of shares of stock, common and preferred, authorized. References No definition available. Details Name: **tlph\_StockSharesAuthorized** Namespace Prefix: **tlph\_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX** Definition Exercise price per share or per unit of warrants or rights outstanding. References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3> Details Name: **us-gaap\_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1** Namespace Prefix: **us-gaap\_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instantX** Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3> Details Name: **us-gaap\_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights** Namespace Prefix: **us-gaap\_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX** Definition Face amount or stated value per share of common stock. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))) Publisher FASB-URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> Details Name: **us-gaap\_CommonStockParOrStatedValuePerShare** Namespace Prefix: **us-gaap\_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instantX** Definition The maximum number of common shares permitted to be issued by an entity's charter and bylaws. References Reference 1: [http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 946-210-SubTopic 210-10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-5-04-02\(29+6\)\(a\)\)](http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 946-210-SubTopic 210-10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-5-04-02(29+6)(a))) Publisher FASB-URI <https://asc.fasb.org/1943274/2147480566/946-210-10-S99-1> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 505-10-50-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-50-Paragraph 1-13> Subparagraph (a) <https://asc.fasb.org/1943274/2147480566/2147481112/210-505-10-S99-50-13> Details Name: **us-gaap\_PreferedStockParOrStatedValuePerShare** Namespace Prefix: **us-gaap\_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instantX** Definition The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. References Reference 1: [http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 946-210-SubTopic 210-10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-5-04-02\(28+6\)\(a\)\)](http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 946-210-SubTopic 210-10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-5-04-02(28+6)(a))) Publisher FASB-URI <https://asc.fasb.org/1943274/2147479617-2147480566/946-210-10-S99-1> Reference 2: [http://fasb.www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 946-SubTopic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-6-02-04\(28-16\)\(a\)\)](http://fasb.www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 946-SubTopic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-6-02-04(28-16)(a))) Publisher FASB-URI <https://asc.fasb.org/1943274/2147480566-2147479170/946-210-10-S99-1> Details Name: **us-gaap\_PreferedStockSharesAuthorized** Namespace Prefix:

us-gaap\_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX- **DefinitionNumber** DefinitionTotal number of shares issued for nonredeemable preferred shares **and** (or preferred stock shares) redeemable solely at the option of the issuer) issued. **Includes, but is not limited to**, shareholders (includes related preferred shares that were issued, repurchased, and held as remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. ReferencesReference 1: [http://www.fasb.org/2003-us-gaap/role/disclosureRef/legacyRef-Topic505-210-SubTopic10-NameAccountingStandardsCodification-Section5099-Paragraph13-1-Subparagraph\(a\)SX210-5-02\(28\)](http://www.fasb.org/2003-us-gaap/role/disclosureRef/legacyRef-Topic505-210-SubTopic10-NameAccountingStandardsCodification-Section5099-Paragraph13-1-Subparagraph(a)SX210-5-02(28))) - Publisher FASB- URI <https://asc.fasb.org/1943274/2147481112-2147480566-210-10-S99-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic505-40-50-13Reference2-SubTopic10-NameAccountingStandardsCodification-Section5099-Paragraph13-1-Subparagraph\(a\)SX210-5-02\(28\)](http://www.xbrl.org/2003/role/disclosureRef-Topic505-40-50-13Reference2-SubTopic10-NameAccountingStandardsCodification-Section5099-Paragraph13-1-Subparagraph(a)SX210-5-02(28))) - Publisher FASB- URI <https://asc.fasb.org/1943274/2147480566-2147481112/210-505-10-S99-50-13> Details Name: us-gaap\_PreferredStockSharesIssued Namespace Prefix: us-gaap\_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX- DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. ReferencesReference 1: [http://www.fasb.org/2003-us-gaap/role/disclosureRef/legacyRef-Topic946-210-SubTopic210-10-NameAccountingStandardsCodification-Section599-Paragraph2-1-Subparagraph\(SX210-6-5-05-02\(4-28\)\)](http://www.fasb.org/2003-us-gaap/role/disclosureRef/legacyRef-Topic946-210-SubTopic210-10-NameAccountingStandardsCodification-Section599-Paragraph2-1-Subparagraph(SX210-6-5-05-02(4-28)))) - Publisher FASB- URI <https://asc.fasb.org/1943274/2147479617-2147480566-946-210-10-S99-2>Reference 1Reference 2: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-Section599-Paragraph3-2-Subparagraph\(SX210-6-09-05\(4\)\(b\)\)](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-Section599-Paragraph3-2-Subparagraph(SX210-6-09-05(4)(b)))) - Publisher FASB- URI <https://asc.fasb.org/1943274/2147483575-2147479170/946-220-210-S99-3>Reference 2Reference 3: [http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic946-SubTopic210-220-NameAccountingStandardsCodification-Section599-Paragraph1-3-Subparagraph\(SX210-6-04-09\(16-4\)\(a-b\)\)](http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic946-SubTopic210-220-NameAccountingStandardsCodification-Section599-Paragraph1-3-Subparagraph(SX210-6-04-09(16-4)(a-b)))) - Publisher FASB- URI <https://asc.fasb.org/1943274/2147479617-2147479134/946-210-220-S99-1>Reference 3Reference 4: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-Section599-Paragraph3-1-Subparagraph\(SX210-6-09-04\(7-16\)\(a\)\)](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-Section599-Paragraph3-1-Subparagraph(SX210-6-09-04(7-16)(a)))) - Publisher FASB- URI <https://asc.fasb.org/1943274/2147483575-2147479170/946-210-S99-1>Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-Section599-Paragraph3-1-Subparagraph\(SX210-6-09-04\(7-16\)\(a\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-Section599-Paragraph3-1-Subparagraph(SX210-6-09-04(7-16)(a)))) - Publisher FASB- URI <https://asc.fasb.org/1943274/2147480566-2147479134/210-946-10-220-S99-1-3>Details Name: us-gaap\_PreferredStockSharesOutstanding Namespace Prefix: us-gaap\_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX- **20-45-2Reference8-DefinitionThe cash inflow from the additional capital contribution to the entity. ReferencesReference 1:** [http://www.fasb.org/2003-us-gaap/role/disclosureRef/legacyRef-NameAccountingStandardsCodification-Section599-45-Paragraph1-14-Subparagraph\(a\)SX210-4-08\(h\)\)](http://www.fasb.org/2003-us-gaap/role/disclosureRef/legacyRef-NameAccountingStandardsCodification-Section599-45-Paragraph1-14-Subparagraph(a)SX210-4-08(h)))) - SubTopic 10- Topic 235-230 - Publisher FASB- URI <https://asc.fasb.org/1943274/2147480678-2147482740/235-230-10-S99-45-1-14> Details Name: us-gaap\_IncomeTaxExpenseBenefit **gaap\_ProceedsFromIssuanceOfCommonStock** Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: durationX- **DefinitionAmount** - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. ReferencesReference 1: [http://www.fasb.org/2003-us-gaap/role/disclosureRef-NameAccountingStandardsCodification-Section45-Paragraph14-Subparagraph\(a\)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482740/230-10-45-14](http://www.fasb.org/2003-us-gaap/role/disclosureRef-NameAccountingStandardsCodification-Section45-Paragraph14-Subparagraph(a)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482740/230-10-45-14) Details Name: us-gaap\_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: durationX- **DefinitionThe cash inflow from number of grants made during the period on the other than issuance of common stock (or unit) option plans (for example, preferred phantom stock or unit plan, treasury stock or unit appreciation rights plan, performance target plan, performance target plan) stock options, and other types of equity.** ReferencesReference 1: [http://www.fasb.org/2003-us-gaap/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section45-50-Paragraph14-2-Subparagraph\(a-c\)-SubTopic10-Topic230\(2\)\(iii\)\(01\)\)](http://www.fasb.org/2003-us-gaap/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section45-50-Paragraph14-2-Subparagraph(a-c)-SubTopic10-Topic230(2)(iii)(01)))) - Publisher FASB- URI <https://asc.fasb.org/1943274/2147482740-2147480429-230-718-10-45-50-14>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic10-NameAccountingStandardsCodification-Section599-Paragraph3-Subparagraph\(SX210-6-03\(1\)\(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic10-NameAccountingStandardsCodification-Section599-Paragraph3-Subparagraph(SX210-6-03(1)(i)))) - Publisher FASB- URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3>Details Name: us-gaap\_ProceedsFromIssuanceOfSaleOfEquity **gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod** Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItem Type sharesItem Type Balance Type: debit na Period Type: durationX- **DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. ReferencesNo definition available. Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized** Namespace Prefix: us-gaap\_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: durationX- **DefinitionNumber of shares authorized for issuance under share-based payment arrangement. ReferencesReference 1:** [http://www.xbrl.org/2003/role/exampleRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(a\)\(3\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/exampleRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(a)(3)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2) Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap\_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX- **DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. ReferencesReference 1:** <http://www.fasb.org/2003-us-gaap/role/disclosureRef-NameAccountingStandardsCodification-Topic718-SubTopic10-Section50-Paragraph2-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2> Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap\_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX- **3-DefinitionGross number of share options (or share units) granted during the period. ReferencesReference 1:** [http://www.xbrl.org/2003/role/disclosureRef-Topic740-718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph40-2-Subparagraph\(c\)\(1\)\(iv\)\(01\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic740-718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph40-2-Subparagraph(c)(1)(iv)(01)))) - Publisher FASB- URI <https://asc.fasb.org/1943274/2147482685-2147480429/740-718-10-50-40Reference4-2> Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap\_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: durationX- **DefinitionNumber of options outstanding, including both vested and non-vested options. ReferencesReference 1:** [http://www.xbrl.org/2003/role/disclosureRef-Topic740-718-SubTopic10-NameAccountingStandardsCodification-Section599-50-Paragraph1-2-Subparagraph\(SABTOPIC6.1.7-c\)\(1\)\(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic740-718-SubTopic10-NameAccountingStandardsCodification-Section599-50-Paragraph1-2-Subparagraph(SABTOPIC6.1.7-c)(1)(i)))) - Publisher FASB- URI <https://asc.fasb.org/1943274/2147479366-2147480429/740-718-10-S99-50-1>Reference 2Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic280-718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph22-2-Subparagraph\(h-c\)\(1\)\(ii\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic280-718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph22-2-Subparagraph(h-c)(1)(ii)))) - Publisher FASB- URI <https://asc.fasb.org/1943274/2147482810-2147480429/280-718-10-50-22Reference6-2> Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap\_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX- **DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'PIY5M13D' represents the reported fact of one year, five months, and thirteen days. ReferencesReference 1:** [http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic944-718-SubTopic220-10-NameAccountingStandardsCodification-Section599-50-Paragraph1-2-Subparagraph\(a\)SX210-7-04\(9\)\(2\)\)](http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic944-718-SubTopic220-10-NameAccountingStandardsCodification-Section599-50-Paragraph1-2-Subparagraph(a)SX210-7-04(9)(2)))) - Publisher FASB- URI <https://asc.fasb.org/1943274/2147483586/944-220-S99-1>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-NameAccountingStandardsCodification-Section45-Paragraph2-Subparagraph\(a\)-SubTopic20-Topic740-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482659-2147480429/740-718-20-45-2](http://www.xbrl.org/2003/role/disclosureRef-NameAccountingStandardsCodification-Section45-Paragraph2-Subparagraph(a)-SubTopic20-Topic740-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482659-2147480429/740-718-20-45-2)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-NameAccountingStandardsCodification-Section599-Paragraph1-Subparagraph\(SX210-10-4-50-08\(h\)\)](http://www.xbrl.org/2003/role/disclosureRef-NameAccountingStandardsCodification-Section599-Paragraph1-Subparagraph(SX210-10-4-50-08(h)))) - Publisher FASB- URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Details Name: us-gaap\_IncomeTaxExpenseBenefit **gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod** Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItem Type durationItem Type Balance Type: debit na Period Type: durationX- **DefinitionAmount** - DefinitionNumber of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement. ReferencesNo definition available. Details Name: us-gaap\_SharesPaidForTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap\_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: durationX- **DefinitionNumber of new stock issued during the period. ReferencesReference 1:** <http://www.fasb.org/2003-us-gaap/role/disclosureRef-NameAccountingStandardsCodification-Section50-Paragraph2-SubTopic10-Topic505-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://www.fasb.org/2003-us-gaap/role/disclosureRef/legacyRef-Topic946-210-SubTopic505-10-NameAccountingStandardsCodification-Section50-S99-Paragraph2-1-Subparagraph\(a\)SX210-5-02\(28\)\)](http://www.fasb.org/2003-us-gaap/role/disclosureRef/legacyRef-Topic946-210-SubTopic505-10-NameAccountingStandardsCodification-Section50-S99-Paragraph2-1-Subparagraph(a)SX210-5-02(28)))) - Publisher FASB- URI <https://asc.fasb.org/1943274/2147481004-2147480566/946-210-505-10-50-S99-2>Reference 1Reference 3: [http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic946-210-SubTopic220-10-NameAccountingStandardsCodification-Section599-Paragraph3-1-Subparagraph\(SX210-6-5-09-02\(29-4\)\(b\)\)](http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic946-210-SubTopic220-10-NameAccountingStandardsCodification-Section599-Paragraph3-1-Subparagraph(SX210-6-5-09-02(29-4)(b)))) - Publisher FASB- URI <https://asc.fasb.org/1943274/2147483575-2147480566/946-210-220-10-S99-3>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic10-505-10-NameAccountingStandardsCodification-Section599-50-Paragraph3-2-Subparagraph\(a\)SX210-6-03\(i\)\(1\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic10-505-10-NameAccountingStandardsCodification-Section599-50-Paragraph3-2-Subparagraph(a)SX210-6-03(i)(1)))) - Publisher FASB-

URI https://asc.fasb.org/1943274/2147479886--2147478448/946-10-505-S99-50-3Reference-2Reference-5: http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 210-946-SubTopic 40-220-Name Accounting Standards Codification-Section S99-Paragraph 1-3-Subparagraph (SX 210.5-6-02-09 (28-4) (b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566-2147479134/210-946-10-220-S99-1Reference-3Reference-6: http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 505-946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-3-Subparagraph (SX 210.3-6-04-03 (i) (1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008-2147479886/946-10-S99-3Reference-7: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-10-S99-1Reference-7: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-3-04-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566-2147480008/210-505-10-S99-1-Details Name: us-gaap\_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap\_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: durationX-DefinitionEquityImpact-2024 USD (\$) / shares sharesDec.29-27,2022 \$ / shares sharesNov sharesOct.15-12,2021-2022 USD (\$) sharesAug.03,2022 USD (\$) / shares sharesMay 09 sharesDec.31,2024 2019 USD (\$) Jun.21,2016 USD (\$) Jan.31,2011 sharesDec.31,2023 USD (\$) / shares sharesDec.31,2024-2022 USD (\$) \$ / shares sharesDec.31,2024 USD (\$) sharesJul.31,2023 sharesJul.20,2023 USD (\$) / shares sharesOct.10,2023 sharesJul.17-20,2023 \$ / shares sharesJun.17,2021 sharesJun.16,2020 shares of Prefix: tph -Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: durationX-DefinitionExercise-DefinitionWeighted average price per-at which option holders acquired share shares when converting their stock options into shares or per-unit of warrants or rights outstanding. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-2-Subparagraph (c) (1) (iv) (02)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112-2147480429/505-718-10-50-3-2-Details Name: us-gaap\_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 gaap\_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap -Data Type: dt:types:perShareItem Type Balance Type: na Period Type: durationX-instantX-DefinitionNumber-the other value www-types of equity. xbrl ReferencesReference 1: http://fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 2-14-Subparagraph (a)-SubTopic 20-10-Topic 740-230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482659-2147482740/740-230-20-10-45-2Reference-14Reference-8-2: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-3-Subparagraph (SX 210.4-6-08-03 (h-i) (1))-SubTopic 235-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678-2147479886/235-946-10-S99-1-3-Details Name: us-gaap\_IncomeTaxExpenseBenefit-gaap\_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: durationX-DefinitionNumber-DefinitionAmount-of the difference between reported income tax expense (benefit) and expected income tax of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.fasb.xbrl.org/2003-us-gaap/role/exampleRef-ref/legacyRef-Topic 946-210-SubTopic 830-10-Name Accounting Standards Codification-Section 55-S99-Paragraph 1-1-Subparagraph (SX 210.5-02 (28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480167-2147480566/946-210-830-10-55-S99-1-Reference-3: http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 946-210-SubTopic 205-10-Name Accounting Standards Codification-Section 45-S99-Paragraph 4-1-Subparagraph (a-SX 210.5-02 (29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480767-2147480566/946-210-205-10-45-S99-4Reference-1Reference-4: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481004-2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09 (4) (b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483575-2147479134/946-220-S99-3Reference 6: http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 210-946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-3-Subparagraph (SX 210.5-6-02-03 (28-i) (1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566-2147479886/210-946-10-S99-1-Reference-3Reference-7: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1-Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02 (29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566-210-10-S99-1-Details Name: us-gaap\_StockIssuedDuringPeriodValueNewIssues-gaap\_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap -Data Type: xbrli:monetaryItem Type Balance Type: credit na Period Type: durationX-DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (bbb) (2) (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-ReferencesNo-2Reference definition available 2: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 740-820-SubTopic 10-Name Accounting Standards Codification-Section S99-50-Paragraph 1-2-Subparagraph (bbb) (2 SAB-TOPIIC 6.1.7)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360-2147482106/740-820-10-S99-50-1-Reference-2Reference-5-3: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 280-820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-2-Subparagraph (h-bbb) (1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810-2147482106/280-820-10-50-2-Details Name: us-gaap\_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap -Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instantX-Definition Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur. ReferencesReference 1: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (bbb) (2) (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685--2147482106/740-820-10-50-10Reference-2Reference-4-2: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 740-820-SubTopic 10-Name Accounting Standards Codification-Section S99-50-Paragraph 1-2-Subparagraph (bbb) (2 SAB-TOPIIC 6.1.7)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360-2147482106/740-820-10-S99-50-1-Reference-2Reference-5-3: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 280-820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-2-Subparagraph (h-bbb) (1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2-Details Name: us-gaap\_WarrantsAndRightsOutstanding Measurement Input Namespace Prefix: us-gaap -Data Type: xbrli:decimalItem Type Balance Type: na Period Type: instantX-Details Name: us-gaap\_AwardTypeAxis =..... shares 8, 833 X-Definition Number-Definition Period between of warrants or rights exercised during the period. ReferencesNo definition available. Details Name: tph\_ClassOfWarrantOrRightExercised Namespace Prefix: tph -Data Type: xbrli:sharesItem Type Balance Type: na Period Type: durationX-Definition Represents required percentage of ownership in order for warrants become exercisable. ReferencesNo definition available. Details Name: tph\_ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable Namespace Prefix: tph -Data Type: dt:types:percentItem Type Balance Type: na Period Type: durationX-Definition Represents the amount of modification of warrants for equity-issuance costs. ReferencesNo definition available..... treasury stock, stock options, and expiration other types of equity. ReferencesReference 1: http.....-Definition Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur. ReferencesReference 1: http:..... date or upon event certain to occur, in 'PnYnMnDtHnMnS' format, for example, 'PIY5M13D' represents reported fact of one year, five months, and thirteen days. ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (bbb) (2) (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685--2147482106/740-820-10-50-10Reference-2Reference-4-2: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 740-820-SubTopic 10-Name Accounting Standards Codification-Section S99-50-Paragraph 1-2-Subparagraph (bbb) (2 SAB-TOPIIC 6.1.7)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360-2147482106/740-820-10-S99-50-1-Reference-2Reference-5-3: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 280-820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-2-Subparagraph (h-bbb) (1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2-Details Name: us-gaap\_WarrantsAndRightsOutstanding Term Namespace Prefix: us-gaap -Data Type: xbrli:durationItem Type Balance Type: na Period Type: instantX-Details Name: us-gaap\_SubsidarySaleOfStockAxis =tph\_December2022FinancingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap\_SubsidarySaleOfStockAxis =tph\_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap\_SubsidarySaleOfStockAxis =tph\_RegisteredDirectOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap\_PlanNameAxis gaap\_ClassOfWarrantOrRightAxis =tph\_EquityIncentivePlan2011Member tph\_Prefunded2024WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: srt\_RangeAxis us-gaap\_PlanNameAxis =tph\_The2020EquityIncentivePlanMember srt\_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap\_PlanNameAxis gaap\_StatementClassOfStockAxis =

tlph\_EmployeeStockPurchasePlanESPPMember-us-gaap\_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_PlanNameAxis gaap\_StatementClassOfStockAxis = tlph\_AmendedEspMember-us-gaap\_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_SubsequentEventTypeAxis = gaap\_SubsidiarySaleOfStockAxis = tlph\_TheJanuary2024PrivatePlacementMember-us-gaap\_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_SubsequentEventTypeAxis gaap\_ClassOfWarrantOrRightAxis = tlph\_ModifiedJanuary2024WarrantsMember-us-gaap\_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_VestingAxis = tlph\_PivotalTrialMilestoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_VestingAxis = tlph\_PivotalSharePriceMilestoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_MeasurementInputTypeAxis = us-gaap\_MeasurementInputSharePriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_MeasurementInputTypeAxis = us-gaap\_MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_MeasurementInputTypeAxis = us-gaap\_MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_MeasurementInputTypeAxis = us-gaap\_MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_MeasurementInputTypeAxis = us-gaap\_MeasurementInputExpectedDividendRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_ClassOfWarrantOrRightAxis = tlph\_PrefundWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_ClassOfWarrantOrRightAxis = tlph\_SeriesACommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_ClassOfWarrantOrRightAxis = tlph\_SeriesBCommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_ClassOfWarrantOrRightAxis = tlph\_SeriesAAndBCommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_MeasurementInputTypeAxis gaap\_ClassOfWarrantOrRightAxis = tlph\_PlacementAgentSeriesAAndBCommonStockWarrantsMember-us-gaap\_MeasurementInputSharePriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_MeasurementInputTypeAxis = us-gaap\_MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_MeasurementInputTypeAxis = us-gaap\_MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_MeasurementInputTypeAxis = us-gaap\_MeasurementInputExpectedDividendRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_ClassOfWarrantOrRightAxis = tlph\_The2023PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_ClassOfWarrantOrRightAxis = tlph\_The2022PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_ClassOfWarrantOrRightAxis = tlph\_The2021PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_ClassOfWarrantOrRightAxis = tlph\_November2021FinancingWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt\_RangeAxis = srt\_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_ClassOfWarrantOrRightAxis = tlph\_August2022LpcWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_ClassOfWarrantOrRightAxis = tlph\_November2021FinancingWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt\_RangeAxis = srt\_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_ClassOfWarrantOrRightAxis = tlph\_ModifiedNovember2021WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_StatementEquityComponentsAxis = us-gaap\_AdditionalPaidInCapitalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_IncomeStatementLocationAxis = us-gaap\_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_ClassOfWarrantOrRightAxis = tlph\_WarrantInConnectionWithOxfordFinanceLoanAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: Note 10- Warrants- Schedule of Warrant Activity (Details)- \$ / shares 12 Months Ended Dec. 31, 2023-2024 Dec. 31, 2022 Outstanding 2023 Outstanding at December 31, 2021 warrants (in shares) 21,682,049 7,824,933 883,833 Granted, warrants (in shares) 7,792,208 17,085,897 6,941,400 Exercised 897 Exercised, warrants (in shares) (3,228,781) Outstanding at December 31, 2022 warrants (in shares) 29,474,257 21,682,049 7,824,933 Exercisable 049 Exercisable at December 31, 2023 warrants (in shares) 21-29 682-474 049-257 Exercisable, warrants, exercise price (in dollars per share) \$ 0.96 Weighted Average [ Member ] Outstanding at December 31, 2021 warrants, weighted average exercise price (in dollars per share) 1.4 \$ 1.71 \$ 5.15 Granted 71 Granted, warrants, exercise price (in dollars per share) 0.99 1.00 1.27 Exercised 99 Exercised, warrants, exercise price (in dollars per share) (0.0003) Outstanding at December 31, 2022 warrants, exercise price (in dollars per share) 1.4 \$ 0.496 \$ 1.4 Exercisable, warrants (in shares) 29,474,257 71 Exercisable Exercisable at December 31, 2023 warrants, exercise price (in dollars per share) \$ 1.40 4.96 X- Definition Exercise price per share of warrants or rights exercisable during period. References No definition available. Details Name: tlph\_ClassOfWarrantOrRightExercisableDuringPeriodExercisePrice Namespace Prefix: tlph\_Data Type: dtr-types: perShareItem Type Balance Type: na Period Type: durationX- Definition Exercise price per share or per unit of warrants or rights exercised during the period. References No definition available. Details Name: tlph\_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised Namespace Prefix: tlph\_Data Type: dtr-types: perShareItem Type Balance Type: na Period Type: durationX- Definition Number of warrants or rights exercised during the period. References No definition available. Details Name: tlph\_ClassOfWarrantOrRightIssued Namespace Prefix: tlph\_Data Type: xbrli: sharesItem Type Balance Type: na Period Type: durationX- Definition Represents the exercise price of warrants or rights issued during the period. References No definition available. Details Name: tlph\_ClassOfWarrantOrRightIssuedExercisePrice Namespace Prefix: tlph\_Data Type: dtr-types: perShareItem Type Balance Type: na Period Type: durationX- Definition The number of warrants or rights exercisable. References No definition available. Details Name: tlph\_ClassOfWarrantsOrRightExercisable Namespace Prefix: tlph\_Data Type: xbrli: sharesItem Type Balance Type: na Period Type: instantX- Definition Exercise price per share or per unit of warrants or rights outstanding. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI http://asc.fasb.org/1943274/2147481112/505-10-50-3 Details Name: us-gaap\_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights Namespace Prefix: us-gaap\_Data Type: dtr-types: perShareItem Type Balance Type: na Period Type: instantX- Definition Number of warrants or rights outstanding. References No definition available. Details Name: us-gaap\_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap\_Data Type: xbrli: sharesItem Type Balance Type: na Period Type: instantX- Details Name: srt\_RangeAxis = srt\_WeightedAverageMember Namespace Prefix: Data Type: na Balance Type: Period Type: Note 10- Warrants (Details)- \$ / shares 12 Months Ended Dec. 31, 2024 Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2022 Warrants Outstanding 2022 Dec. 31, 2021 Number of Warrants (in shares) 29,474,257 29,474,257 21,682,049 7,824,933 883 Warrants Exercisable, 833 Number of Warrants (in shares) 21-29 682-474, 049-257 29,474,257 Warrants Exercisable, Exercise Price (in dollars per share) \$ 0.96 \$ 0.96 Warrants Outstanding, Weighted- Average Remaining Contractual Life (Years) (Year) 5.3 years 21-7 months 24 days Weighted Average [ Member ] Warrant Warrants Outstanding, Exercise Price (in dollars per share) \$ 0.96 \$ 0.96 \$ 1.4 \$ 1.71 \$ 5.15 Weighted- Average 71 Warrants Exercisable, Number of Warrants (in shares) 29,474,257 29,474,257 Warrants Exercisable, Exercise Price (in dollars per share) + \$ 0.496 \$ 0.96 Warrants Exercise Price One [ Member ] Warrant Warrants Outstanding, Exercise Price (in dollars per share) \$ 0.001 \$ 0.001 Warrants Outstanding, Number of Warrants (in shares) 1-9 416-208 473-Number of 681 9,208,681 Warrants Exercisable, Exercise Price (in dollars per share) 1-416,473 \$ 0.001 \$ 0.001 Warrants Exercise Price One [ Member ] | Weighted Average [ Member ] Warrants Weighted- Average Exercise- Exercisable Price, Number of Warrants (in dollars per share shares) \$ 0.001 9,208,681 9,208,681 Warrants Exercise Price Two [ Member ] Warrant Warrants Outstanding, Exercise Price (in dollars per share) \$ 1.40 1.77 \$ 0.77 Warrants Outstanding, Number of Warrants (in shares) 44-5 787-882 044-356 5,882,356 Warrants Exercisable, Number of Warrants (in shares) 44-5 787-882 044-356 5,882,356 Warrants Outstanding, Weighted- Average Remaining Contractual Life (Years) (Year) 4.3 years 7-6 months 13-18 days Warrants Exercise Price Two [ Member ] | Weighted Average [ Member ] Weighted- Average Warrants Exercisable, Exercise Price (in dollars per share) \$ 1.40 1.77 \$ 0.77 Warrants Exercise Price Three [ Member ] Warrant Warrants Outstanding, Exercise Price (in dollars per share) \$ 1.71 \$ 1.11 Warrants Outstanding, Number of Warrants (in shares) 367-8 647-904,688 8,904,688 Warrants Exercisable, Number of Warrants (in shares) 367-8 647-904,688 8,904,688 Warrants Outstanding, Weighted- Average Remaining Contractual Life (Years) (Year) 4.3 years 7-6 months 13-18 days Warrants Exercise Price Three [ Member ] | Weighted Average [ Member ] Weighted- Average Warrants Exercisable, Exercise Price (in dollars per share) \$ 1.71 \$ 1.11 Warrants Exercise Price Four [ Member ] Warrant Warrants Outstanding, Exercise Price (in dollars per share) \$ 2.1 0.7 \$ 1.7 Warrants Outstanding, Number of Warrants (in shares) 4-367 977-647 367 052-647 Warrants Exercisable, Number of Warrants (in shares) 4-367 977-647 367 052-647 Warrants Outstanding, Weighted- Average Remaining Contractual Life (Years) (Year) 5.3 years 25-6 months 18 days Warrants Exercise Price Four [ Member ] | Weighted Average [ Member ] Weighted- Average Warrants Exercisable, Exercise Price (in dollars per share) \$ 2.1 0.7 \$ 1.7 Warrants Exercise Price Five [ Member ] Warrant Warrants Outstanding, Exercise Price (in dollars per share) \$ 20.2 0.7 \$ 2.07 Warrants Outstanding, Number of Warrants (in shares) 125-4 000-977,052 4,977,052 Warrants Exercisable, Number of Warrants (in shares) 125-4 000-977,052 4,977,052 Warrants Outstanding, Weighted- Average Remaining Contractual Life (Years) (Year) 2.4 years 11 months 1 day Warrants Exercise Price Five [ Member ] | Weighted Average [ Member ] Weighted- Average Warrants Exercisable, Exercise Price (in dollars per share) \$ 20.2 0.7 \$ 2.07 Warrants Exercise Price Six [ Member ] Warrant Warrants Outstanding, Exercise Price (in dollars per share) \$ 56.6 20 \$ 20 Warrants Outstanding, Number of Warrants (in shares) 8-125 833-000 125,000 Warrants Exercisable, Number of Warrants (in shares) 8-125 833



50-2Reference 8-5: <http://www.fasb.org/xbrl/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 505-SubTopic 10> - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 4-3-04 08 (h) )-SubTopic 10-Topic 235- Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480678-2147480008/235-505> - 10- S99- 1 Details Name: us- gaap- IncomeTaxExpenseBenefit gaap\_ StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType sharesItemType Balance Type: debit na Period Type: durationX- Definition Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by Details Name: us- gaap\_ PlanNameAxis = tlph\_AmendedEspMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us- gaap\_ PlanNameAxis = tlph\_AmendedEspMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us- gaap\_ AwardTypeAxis = us- gaap\_PerformanceSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: Note 11- Stock- based Compensation- Stock- based Compensation Expense (Details)- USD (\$) \$ in Thousands 12 Months Ended Dec. 31, 2023-2024 Dec. 31, 2022 Stock 2023 Stock - based compensation expense \$ 989 \$ 1,729 \$ 2,889 Research 729 Research and Development Expense [ Member ] Stock- based compensation expense Selling, General and Administrative Expenses [ Member ] Stock- based compensation expense 1, 212-2,069 Discontinued 212 Discontinued Operation [ Member ] Stock- based compensation expense \$ 0 \$ 19 \$ 250 X- Definition Amount of expense for award under share- based payment arrangement. Excludes amount capitalized. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB Topic 14. F\)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147479830/718-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 14. F)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147479830/718-10-S99-1) Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(h\) \(1\) \(i\)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (h) (1) (i)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2) Details Name: us- gaap\_ AllocatedShareBasedCompensationExpense Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- Details Name: us- gaap\_ IncomeStatementLocationAxis = us- gaap\_ ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us- gaap\_ IncomeStatementLocationAxis = us- gaap\_ SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us- gaap\_ IncomeStatementLocationAxis = tlph\_DiscontinuedOperationMember Namespace Prefix: Data Type: na Balance Type: Period Type: Note 11- Stock- based Compensation- Restricted Stock Activity (Details)- Restricted Stock Units (RSUs) [ Member ] - / shares 12 Months Ended Dec. 31, 2023-2024 Dec. 31, 2022 Restricted 2023 Restricted stock units outstanding, beginning balance January 1, 2021 (in shares) 86, 232 82, 778 88, 711 Restricted 778 Restricted stock units outstanding, January 1 weighted average grant date fair value, 2021 beginning balance (in dollars per share) \$ 7. 57 \$ 16. 97 \$ 34. 16 Granted (97 Share- Based Compensation Arrangement by Share- Based Payment Award, Equity Instruments Other than Options, Grants in shares) Period 176, 768 48, 158 58, 502 Granted 158 Granted , weighted average grant date fair value (in dollars per share) \$ 1. 67 03 \$ 7. 1 75 Vested- 67 Vested (in shares) ( 42, 525 ) ( 40, 356 ) ( 44, 744 ) Vested , weighted average grant date fair value (in dollars per share) \$ 11. 31 \$ 19. 28 \$ 35. 46 Forfeited 28 Forfeited (in shares) ( 7, 552 ) ( 4, 348 ) ( 19, 691 ) Forfeited , weighted average grant date fair value (in dollars per share) \$ 2. 03 \$ 12. 56 \$ 25 Restricted- 56 Restricted stock units outstanding, ending balance December 31, 2021 (in shares) 212, 923 86, 232 82, 778 Restricted 232 Restricted stock units outstanding, December 31 weighted average grant date fair value, 2021 ending balance (in dollars per share) \$ 1. 59 \$ 7. 57 \$ 16. 97 X- Definition The number of equity- based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\) \(2\) \(iii\) \(03\)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (2) (iii) (03)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2) Details Name: us- gaap\_ ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us- gaap\_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX- Definition Weighted average fair value as of the grant date of equity- based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\) \(2\) \(iii\) \(03\)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (2) (iii) (03)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2) Details Name: us- gaap\_ ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us- gaap\_ Data Type: dtr- types: perShareItemType Balance Type: na Period Type: durationX- Definition The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\) \(2\) \(iii\) \(01\)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (2) (iii) (01)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2) Details Name: us- gaap\_ ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us- gaap\_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX- Definition The weighted average fair value at grant date for nonvested equity- based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\) \(2\) \(iii\) \(01\)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (2) (iii) (01)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2) Details Name: us- gaap\_ ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us- gaap\_ Data Type: dtr- types: perShareItemType Balance Type: na Period Type: durationX- Definition The number of non- vested equity- based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\) \(2\) \(i\)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (2) (i)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2) Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\) \(2\) \(ii\)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (2) (ii)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2) Details Name: us- gaap\_ ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us- gaap\_ Data Type: dtr- types: perShareItemType Balance Type: na Period Type: instantX- Definition The number of equity- based payment instruments, excluding stock (or unit) options, that vested during the reporting period. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\) \(2\) \(iii\) \(02\)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (2) (iii) (02)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2) Details Name: us- gaap\_ ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us- gaap\_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX- Definition The weighted average fair value as of grant date pertaining to an equity- based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\) \(2\) \(iii\) \(02\)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (2) (iii) (02)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2) Details Name: us- gaap\_ ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us- gaap\_ Data Type: dtr- types: perShareItemType Balance Type: na Period Type: durationX- Details Name: us- gaap\_ AwardTypeAxis = us- gaap\_ RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: Note 11- Stock- based Compensation- Option Activity (Details) - USD (\$) \$ / shares in Units, \$ in Thousands 12 Months Ended Dec. 31, 2023-2024 Dec. USD (\$) \$ / shares shares December 31, 2021-2023 Share- Based Compensation Arrangement by Share- Based Payment Award, Options, Outstanding Number (in shares) + shares 893, 321 725, 623 December 31-623 Weighted average exercise price, 2021 beginning balance (in dollars per share) + \$ / shares 33. 41 \$ 52. 98 Granted (98 Share- Based Compensation Arrangement by Share- Based Payment Award, Options, Grants in shares) + shares Period, Gross 1, 053, 612 288, 929 Granted , weighted average exercise price (in dollars per share) + \$ / shares 1. 03 \$ 1. 67 Forfeited , number of options (in shares) + shares ( 41, 156 ) ( 14, 673 ) Forfeited , weighted average exercise price (in dollars per share) + \$ / shares 1. 75 \$ 9. 72 Expired , number of options (in shares) + shares ( 118, 877 ) ( 106, 558 ) Expired , weighted average exercise price (in dollars per share) + \$ / shares 71. 96 \$ 83. 88 Exercised 88 Number of options outstanding, ending balance (in shares) + shares Exercised 1, 786, 900 893, 321 Granted, number of options (in shares) 1, 053, 612 288, 929 Number of options outstanding, ending balance (in shares) 1, 786, 900 893, 321 Weighted average exercise price, ending balance (in dollars per share) + \$ / shares 12. 48 \$ 0 December 31-33. 41 Options outstanding , 2022 weighted average remaining contractual life (Year) 7 years 7 months 6 days Options

**outstanding, aggregate intrinsic value \$ 0 Vested and exercisable options, number** (in shares) **605** | shares 893, 321 December 31 249 **Vested and exercisable options, 2022 weighted average exercise price** (in dollars per share) | \$ **34** / shares \$ 33, 41 December 31 **28 Vested and exercisable options, 2022 weighted average remaining contractual life** (Year) **6** 4 years **3** 9 months **18 days** December 31, 2022 | \$ **1** Vested - **Vested** and exercisable options — December 31, 2022 **aggregate intrinsic value \$ 0 Vested and expected to vest, number** (in shares) **1** | shares 488, **786, 900** 725 **Vested --- Vested and expected to vest, weighted average exercise price** — December 31, 2022 (in dollars per share) | \$ **12** / shares \$ 53, **48** 69 **Vested and exercisable options** — December 31, 2022 (Year) **4** years **3** months **18 days** **Vested and exercisable options** — December 31, 2022 | \$ **0** **Vested - Vested** and expected to vest — December 31, 2022 **weighted average remaining contractual life** (Year in shares) | shares 893, **7 years 7 months 6 days** 321 **Vested --- Vested** and expected to vest — December 31, **aggregate intrinsic value** 2022 (in dollars per share) | \$ **0** / shares \$ 33, 41 **Vested and expected to vest** — December 31, 2022 (Year) **6** years **3** months **18 days** **Vested and expected to vest** — December 31, 2022 | \$ **1** -X- ReferencesNo definition available. Details Name:

t1ph\_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAndVestedNumber Namespace Prefix: t1ph\_Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantX- ReferencesNo definition available. Details Name:

t1ph\_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm Namespace Prefix: t1ph\_Data Type: xbrli: durationItemType Balance Type: na Period Type: durationX- DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (1) (iv) (04)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2 Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap\_Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX- DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (1) (iv) (03)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2 Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap\_Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX- DefinitionGross number of share options (or share units) granted during the period. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (1) (iv) (01)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2 Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap\_Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX- DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Section 50-Paragraph 2-Subparagraph (c) (1) (i)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2 Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionNumber of options outstanding, including both vested and non-vested options. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (1) (i)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (1) (ii)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2 Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap\_Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantX- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (1) (i)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (1) (ii)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2 Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap\_Data Type: dtr-types: perShareItemType Balance Type: na Period Type: instantX- DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (2)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2 Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionWeighted- average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (2)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2 Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap\_Data Type: dtr-types: perShareItemType Balance Type: na Period Type: instantX- DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (1)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2 Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (1)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2 Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap\_Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantX- DefinitionWeighted- average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (1)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2 Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap\_Data Type: dtr-types: perShareItemType Balance Type: na Period Type: durationX- DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (1) (iv) (04)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2 Details Name: us-gaap\_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap\_Data Type: dtr-types: perShareItemType Balance Type: na Period Type: durationX- DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (1) (iv) (03)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2 Details Name: us-gaap\_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap\_Data Type: dtr-types: perShareItemType Balance Type: na Period Type: durationX- DefinitionWeighted average per share amount at which grantees can acquire shares

of common stock by exercise of options. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\) \(1\) \(iv\) \(01\)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (1) (iv) (01)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2) Details Name: us-gaap\_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap\_Data Type: dtr-types: perShareItemType Balance Type: na Period Type: durationX-DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 718-SubTopic 10-Subparagraph \(e\) \(1\)-Name Accounting Standards Codification-Paragraph 2-Section 50-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 718-SubTopic 10-Subparagraph (e) (1)-Name Accounting Standards Codification-Paragraph 2-Section 50-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2) Details Name: us-gaap\_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap\_Data Type: xbrli: durationItemType Balance Type: na Period Type: durationX-DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(1\)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (1)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2) Details Name: us-gaap\_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap\_Data Type: xbrli: durationItemType Balance Type: na Period Type: durationX-DefinitionNumber of share options (..... Balance Type: na Period Type: duration Note 11-Stock-based Compensation-Stock Options Outstanding, Vested and Exercisable (Details)-\$/shares 12 Months EndedDec. 31, 2024 Dec. 31, 2023 Dec. 31, 2022Number of 2022Share-Based Compensation Arrangement by Share-Based Payment Award, Options options, Outstanding outstanding, Number ending balance (in shares) 1,786,900 893,321 725. 623Options outstanding 623Share-Based Compensation Arrangement by Share-Based Payment Award, weighted average remaining contractual life (Year) 7 years 7 months 6 days Options, Outstanding outstanding, Weighted weighted Average average Remaining Contractual Term 6 years 3 months 18 days Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise exercise Price price per share (in dollars per share) \$ 12.48 \$ 33.41 \$ 52.98Options vested and exercisable 98Share-Based Compensation Arrangement by Share-Based Payment Award, shares subject to stock options (in shares) 605,249 Options, Vested vested and Expected to Vest, Exercisable exercisable, Number 488,725 Share-based Compensation Arrangement by Share-based Payment Award, Options Exercisable and Vested, Weighted weighted Average average Exercise exercise Price price per share (in dollars per share) \$ 53.34 69.28 Exercise Price Range 1 [ Member ] Share-Based Payment Arrangement, Option, Exercise Price price Range, Lower lower Range Limit limit (in dollars per share) 0.684 Share-Based Payment Arrangement, Option, Exercise Price price Range, Upper upper Range Limit limit (in dollars per share) \$ 1.03 Number of options outstanding 76 Share-Based Compensation Arrangement by Share-Based Payment Award, ending balance (in shares) 859,701 Options, Outstanding outstanding, Number 281,505 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted weighted Average average Remaining remaining Contractual contractual Term life (Year) 9 years 2 months 12 days Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding outstanding, Weighted weighted Average average Exercise exercise Price price per share (in dollars per share) \$ 1.01 67 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested vested and Expected exercisable, shares subject to Vest stock options (in shares) 24,409 Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options vested and Exercisable exercisable and Vested, Weighted weighted Average average Exercise exercise Price price per share (in dollars per share) \$ 0.68 Exercise Price Range 2 [ Member ] Share-Based Payment Arrangement, Option, Exercise Price price Range, Lower lower Range Limit limit (in dollars per share) 1.08 Exercise price, upper limit (in dollars per share) \$ 1.62 Number of options outstanding, ending balance (in shares) 185,000 Options outstanding, weighted average remaining contractual life (Year) 9 years 4 months 24 days 62Share-Based Payment Arrangement, Option Options outstanding, weighted average Exercise exercise Price price Range, Upper per Range Limit share (in dollars per share) \$ 6.1 08 93 Share-Based Compensation Arrangement by Share-Based Payment Award, Options vested and exercisable, shares subject to stock options (in shares) Outstanding, Number 15,350 Share-Based Compensation Arrangement by Share-Based Payment Award, Options vested and exercisable, Outstanding, Weighted weighted Average average Remaining Contractual Term 8 years 6 months Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise exercise Price price per share (in dollars per share) \$ 0.5-21 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 12,818 Exercise Price Range 3 [ Member ] Share-Based Payment Arrangement, Option, Exercise Price price Range, Lower lower Range Limit limit (in dollars per share) 1.76 Exercise price, upper limit (in dollars per share) \$ 8.2. 64 Number of 03 Share-Based Payment Arrangement, Option options outstanding, Exercise Price Range ending balance (in shares) 249. 184 Upper Range Limit \$ 12.045 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding outstanding, Number 86,817 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted weighted Average average Remaining remaining Contractual contractual Term life (Year) 8 years 1 month 6 days Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding outstanding, Weighted weighted Average average Exercise exercise Price price per share (in dollars per share) \$ 8.1 76 08 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested vested and Expected exercisable, shares subject to Vest stock options (in shares) 114. 204 Exercisable, Number 40,123 Share-based Compensation Arrangement by Share-based Payment Award, Options vested and Exercisable exercisable and Vested, Weighted weighted Average average Exercise exercise Price price per share (in dollars per share) \$ 8.1 09 76 Exercise Price Range 4 [ Member ] Share-Based Payment Arrangement, Option, Exercise Price price Range, Lower lower Range Limit limit (in dollars per share) 4. 62 4Share-Based Payment Arrangement, Option, Exercise Price price Range, Upper upper Range Limit limit (in dollars per share) \$ 21.6 93 Number of options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, ending balance (in shares) 10,850 Options, Outstanding outstanding, weighted average remaining contractual life (Year) 7 years 6 months Number 14,633 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding outstanding, Weighted weighted Average average Remaining Contractual Term 5 years exercise price per share (in dollars per share) \$ 4.62 Options vested and exercisable, shares subject to stock options (in shares) 10 months 24 days Share-Based Compensation Arrangement by Share-Based Payment Award, 850 Options vested and exercisable, Outstanding, Weighted weighted Average average Exercise exercise Price price per share (in dollars per share) \$ 16.4. 62 55 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 13,418 Exercise Price Range 5 [ Member ] Share-Based Payment Arrangement, Option, Exercise Price price Range, Lower lower Range Limit limit (in dollars per share) 8. 03 4Share-Based Payment Arrangement, Option, Exercise Price price Range, Upper upper Range Limit limit (in dollars per share) \$ 33.12. 045 Number of options outstanding 6 Share-Based Compensation Arrangement by Share-Based Payment Award, ending balance (in shares) 84,703 Options, Outstanding outstanding, Number 11,700 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted weighted Average average Remaining remaining Contractual contractual Term life (Year) 7 years 1 month 6 days Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding outstanding, Weighted weighted Average average Exercise exercise Price price per share (in dollars per share) \$ 28.8 08 62 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested vested and Expected exercisable, shares subject to Vest stock options (in shares) 60. 199 Options vested and Exercisable exercisable, Number 11,386 weighted average exercise price per share (in dollars per share) \$ 8.08 Exercise Price Range 6 [ Member ] Share-Based Payment Arrangement, Option, Exercise Price price Range, Lower lower Range Limit limit (in dollars per share) 14. 4 Exercise price, upper limit (in dollars per share) \$ 21 3,440 Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit \$ 51. 6 Number of options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, ending balance (in shares) 12,033 Options, Outstanding outstanding, Number 280,662 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted weighted Average average Remaining remaining Contractual contractual Term life (Year) 5 years 4 months 24 days Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding outstanding, Weighted weighted Average average Exercise exercise Price price per share (in dollars per share) \$ 41.16. 5 01 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested vested and Expected exercisable, shares subject to Vest stock options (in shares) 12. 033 Exercisable, Number 208,326 Share-based Compensation Arrangement by Share-based Payment Award, Options vested and Exercisable exercisable and Vested, Weighted weighted Average average Exercise exercise Price price per share (in dollars per share) \$ 42.16. 23 5 Exercise Price Range 7 [ Member ] Share-Based Payment Arrangement, Option, Exercise Price price Range, Lower lower Range Limit limit (in dollars per share) 22. 4 Share-Based Payment Arrangement, Option, Exercise Price price Range, Upper upper Range Limit limit (in dollars per share) \$ 86.33. 6 Number of options outstanding, ending balance (in shares) 11,700 Options outstanding, weighted average remaining contractual life (Year) 6 years 1 month 6 days Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding outstanding, Number 169,213 weighted average exercise price per Share share (in dollars per Based Compensation Arrangement by Share share Based Payment Award, ) \$ 28.62 Options vested and exercisable, Outstanding shares subject to stock options (in shares) 11. 625 Weighted Average Remaining Contractual Term 2 years 8 months 12 days Share-Based Compensation Arrangement by Share-Based Payment Award, Options vested and exercisable, Outstanding, Weighted weighted Average average Exercise exercise Price price per share (in dollars per share) \$

64-28, 66-86 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 169, 213 Share-Based Compensation Arrangement by Share-Based Payment Award, Options Exercisable and Vested, Weighted Average Exercise Price \$ 64.86 Exercise Price Range 8 [ Member ] Share-Based Payment Arrangement, Option, Exercise Price price Range, Lower lower Range Limit limit 94 (in dollars per share) 3, 440 Exercise price, upper limit (in dollars per share) \$ 51. 6 Number of options outstanding Share-Based Payment Arrangement, ending balance (in shares) 208, 405 Option Options outstanding, weighted average remaining contractual life (Year) 4 years 1 month 6 days Options outstanding, weighted average Exercise exercise Price price Range, Upper per Range Limit share (in dollars per share) \$ 44.41 92-9 Share-Based Compensation Arrangement by Share-Based Payment Award, Options vested and exercisable, Outstanding shares subject to stock options (in shares) 206, 605 Number 17, 371 Share-Based Compensation Arrangement by Share-Based Payment Award, Options vested and exercisable, Outstanding, Weighted average average Remaining Contractual Term 1 year Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise exercise Price price per share (in dollars per share) \$ 427.41, 96-59 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 17, 371 Share-Based Compensation Arrangement by Share-Based Payment Award, Options Exercisable and Vested, Weighted Average Exercise Price \$ 427.59 Exercise Price Range 9 [ Member ] Exercise price, lower limit (in dollars per Share share -Based Payment Arrangement) 57.4 Exercise price, upper limit (in dollars per share) \$ 86.1 Number of options outstanding, ending balance (in shares) 163, 274 Option Options outstanding, weighted average remaining contractual life (Year) 1 year 8 months 12 days Options outstanding, weighted average exercise price per share (in dollars per share) \$ 64.92 Options vested and exercisable, shares subject to stock options (in shares) 163, 274 Options vested and exercisable, weighted average exercise price per share (in dollars per share) \$ 64.92 Exercise Price Range 10 [ Member ] Exercise price, Lower lower Range Limit limit (in dollars per share) 94.6 Exercise price, upper limit (in dollars per share) \$ 204 141. 4 Share-Based Payment Arrangement 9 Number of options outstanding, ending balance (in shares) 2, 050 Option Options outstanding, weighted average remaining contractual life (Year) 10 months 24 days Options outstanding, weighted average Exercise exercise Price price Range, Upper per Range Limit share (in dollars per share) \$ 306.94. 6 Share-Based Compensation Arrangement by Share-Based Payment Award, Options vested and exercisable, Outstanding shares subject to stock options (in shares) 2, 050 Number 16, 070 Share-Based Compensation Arrangement by Share-Based Payment Award, Options vested and exercisable, Outstanding, Weighted average average Remaining Contractual Term 2 months 12 days Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise exercise Price price per share (in dollars per share) \$ 206.94, 6-24 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 16, 070-X- Definition The weighted average exercise price of exercisable share options (fully vested and expected to vest) that may be converted as of the balance sheet date. References No definition available. Details Name: t1ph\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice Namespace Prefix: t1ph\_Data Type: dtr- types: perShareItem Type Balance Type: na Period Type: instantX- Definition Number of options outstanding, including both vested and non-vested options. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\) \(1\) \(i\)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (1) (i)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2) Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\) \(1\) \(ii\)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (1) (ii)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2) Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap\_Data Type: xbrli: sharesItem Type Balance Type: na Period Type: instantX- Definition Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\) \(1\) \(i\)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (1) (i)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2) Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\) \(1\) \(ii\)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (1) (ii)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2) Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap\_Data Type: dtr- types: perShareItem Type Balance Type: na Period Type: instantX- Definition Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(2\)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (2)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2) Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber Namespace Prefix: us-gaap\_Data Type: xbrli: sharesItem Type Balance Type: na Period Type: instantX- Definition The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range. References Reference 1: [http://www.fasb.org/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 2-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.fasb.org/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 2-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2) Details Name: us-gaap\_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit Namespace Prefix: us-gaap\_Data Type: dtr- types: perShareItem Type Balance Type: na Period Type: durationX- Definition The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range. References Reference 1: [http://www.fasb.org/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 2-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.fasb.org/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 2-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2) Details Name: us-gaap\_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit Namespace Prefix: us-gaap\_Data Type: dtr- types: perShareItem Type Balance Type: na Period Type: durationX- Definition Weighted average remaining contractual term for option awards outstanding, in' PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. References Reference 1: [http://www.fasb.org/role/ref/legacyRef-Topic 718-SubTopic 10-Subparagraph \(e\) \(1\)-Name Accounting Standards Codification-Paragraph 2-Section 50-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.fasb.org/role/ref/legacyRef-Topic 718-SubTopic 10-Subparagraph (e) (1)-Name Accounting Standards Codification-Paragraph 2-Section 50-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2) Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap\_Data Type: xbrli: durationItem Type Balance Type: na Period Type: durationX- Details Name: us-gaap\_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis = t1ph\_ExercisePriceRange1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis = t1ph\_ExercisePriceRange2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis = t1ph\_ExercisePriceRange3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis = t1ph\_ExercisePriceRange4Member Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis = t1ph\_ExercisePriceRange5Member Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis = t1ph\_ExercisePriceRange6Member Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis = t1ph\_ExercisePriceRange7Member Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis = t1ph\_ExercisePriceRange8Member Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis = t1ph\_ExercisePriceRange9Member Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis = t1ph\_ExercisePriceRange10Member Namespace Prefix: Data Type: na Balance Type: Period Type: Note 11- Stock-based Compensation- Assumptions to Calculate Fair Value of Each Performance-based Stock Option (Details)- Time-based Stock Option [ Member ] 12 Months Ended Dec. 31, 2023-2024 Dec. 31, 2022 Expected 2023 Expected term (in years) (Year) 6 years 3-6 months 18 days Risk-free interest rate, minimum 3-4, 90-10 % Risk-free interest rate, maximum 4, 60-50 % Expected volatility 94-98, 00 % 88-94, 00 % Expected dividend rate 0, 00 % 0, 00 % Minimum [ Member ] Expected term (in years) (Year) 6 years 3 months 18 days Risk-free interest rate, minimum 4-3, 60-90 % Maximum [ Member ] Risk-free interest rate, maximum 3-4, 00-60 % X- Definition The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\) \(2\) \(iii\)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f) (2) (iii)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2) Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace

Prefix: us-gaap\_ Data Type: dtr-types: percentItem Type Balance Type: na Period Type: durationX- Definition The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\) \(2\) \(ii\)-Publisher FASB-URI https://asc.fasb.org/#/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f) (2) (ii)-Publisher FASB-URI https://asc.fasb.org/#/1943274/2147480429/718-10-50-2) Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap\_ Data Type: dtr-types: percentItem Type Balance Type: na Period Type: durationX- Definition The maximum risk-free interest rate assumption that is used in valuing an option on its own shares. References No definition available. Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Namespace Prefix: us-gaap\_ Data Type: dtr-types: percentItem Type Balance Type: na Period Type: durationX- Definition The minimum risk-free interest rate assumption that is used in valuing an option on its own shares. References No definition available. Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Namespace Prefix: us-gaap\_ Data Type: dtr-types: percentItem Type Balance Type: na Period Type: durationX- Definition Expected term of award under share-based payment arrangement, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\) \(2\) \(ii\)-Publisher FASB-URI https://asc.fasb.org/#/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f) (2) (ii)-Publisher FASB-URI https://asc.fasb.org/#/1943274/2147480429/718-10-50-2) Details Name: us-gaap\_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm Namespace Prefix: us-gaap\_ Data Type: xbrli: durationItem Type Balance Type: na Period Type: durationX- Details Name: us-gaap\_AwardTypeAxis = t1ph\_TimebasedStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt\_RangeAxis = srt\_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt\_RangeAxis = srt\_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: Note 12- Net Income (Loss) Per Share of Common Stock (Details Textual)- \$ / shares **Jan. 17, 2024** Jul. 17, 2023 Dec. 29, 2022 **The 2022 Prefunded 2024 Warrants [ Member ] Class of Warrant or Right, Exercise Price of Warrants or Rights \$ 0.001 The 2023 Prefunded Warrants [ Member ] Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \$ 0.001 The 2022 Prefunded Warrants [ Member ] Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \$ 0.001 X-** Definition Exercise price per share or per unit of warrants or rights outstanding. References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/#/1943274/2147481112/505-10-50-3> Details Name: us-gaap\_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap\_ Data Type: dtr-types: perShareItem Type Balance Type: na Period Type: instantX- **Details Name: us-gaap\_ClassOfWarrantOrRightAxis = t1ph\_Prefunded2024WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-** Details Name: us-gaap\_ClassOfWarrantOrRightAxis = t1ph\_The2023PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_ClassOfWarrantOrRightAxis = t1ph\_The2022PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: Note 12- Net Income (Loss) Per Share of Common Stock-..... 12- Net Income (Loss) Per Share of Common Stock- Common Stock Excluded From Computation of Diluted Net Loss Per Share (Details)- shares 12 Months Ended Dec. 31, 2023 **2024** Dec. 31, 2022 **RSU-2023RSU** 's, ESPP, and Employee Stock Options [ Member ] **Antidilutive securities ESPP, RSUs and stock options to purchase common stock**-(in shares) **1,999,823** 979, **553** **Warrant 553 815,710** **Warrant [ Member ] Antidilutive securities ESPP, RSUs and stock options to purchase common stock**-(in shares) 20, 265, 576 **133-20, 833-265, 576** X- Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/#/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/#/1943274/2147482662/260-10-50-1) Details Name: us-gaap\_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap\_ Data Type: xbrli: sharesItem Type Balance Type: na Period Type: durationX- Details Name: us-gaap\_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = t1ph\_RSUsESPPAndEmployeeStockOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = us-gaap\_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: Note 13- Accrued Liabilities- Accrued Liabilities (Details)- USD (\$) \$ in Thousands Dec. 31, 2022 **2024** Dec. 31, 2022 **Accrued 2023 Accrued** compensation and employee benefits \$ **880 \$ 2, 005** **Accrued 005 \$ 1,732** **Accrued** professional services Other accrued liabilities Total accrued liabilities \$ **2-1, 445-254** \$ 2, **531-445** X- Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02-\(20\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph (SX 210.5-02-(20))))- Publisher FASB-URI https://asc.fasb.org/#/1943274/2147480566/210-10-S99-1 Details Name: us-gaap\_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItem Type Balance Type: credit Period Type: instantX- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02-\(20\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph (SX 210.5-02-(20))))- Publisher FASB-URI https://asc.fasb.org/#/1943274/2147480566/210-10-S99-1 Details Name: us-gaap\_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItem Type Balance Type: credit Period Type: instantX- Definition Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. References Reference 1: [http://www.fasb.org/2009-us-gaap/role/commonPracticeRef/ref/legacyRef-Topic 944-942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-9-03 \(a\)-\(15\) \(a-5\)\)](http://www.fasb.org/2009-us-gaap/role/commonPracticeRef/ref/legacyRef-Topic 944-942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-9-03 (a)-(15) (a-5))))- Publisher FASB-URI https://asc.fasb.org/#/1943274/2147479440/2147478546/944-942-210-S99-1 Reference 2: [http://fasb.org/2009-us-gaap/role/ref/legacyRef-commonPracticeRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Topic 942-SubTopic 210-Section S99-Paragraph 1-Subparagraph \(SX 210.9-7-03 \(a\) \(15\) \(5-a\)\)](http://fasb.org/2009-us-gaap/role/ref/legacyRef-commonPracticeRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Topic 942-SubTopic 210-Section S99-Paragraph 1-Subparagraph (SX 210.9-7-03 (a) (15) (5-a))))- Publisher FASB-URI https://asc.fasb.org/#/1943274/2147479853/2147478777/942-944-210-S99-1 Details Name: us-gaap\_EmployeeRelatedLiabilitiesCurrentAndNoncurrent Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItem Type Balance Type: credit Period Type: instantX- Definition Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02-\(20\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph (SX 210.5-02-(20))))- Publisher FASB-URI https://asc.fasb.org/#/1943274/2147480566/210-10-S99-1 Details Name: us-gaap\_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItem Type Balance Type: credit Period Type: instant Note 14- 401 (k) Plan (Details Textual)- USD (\$) \$ in Millions 12 Months Ended Dec. 31, 2023 **2024** Dec. 31, 2022 **Defined 2023 Defined** Contribution Plan, Employer Discretionary Contribution Percentage 4.00 % Contributions by Employer to Postemployment Benefit Obligations \$ 0.2 \$ 0. **3-2** X- References No definition available. Details Name: t1ph\_ContributionsByEmployerToPostemploymentBenefitObligations Namespace Prefix: t1ph\_ Data Type: xbrli: monetaryItem Type Balance Type: debit Period Type: durationX- References No definition available. Details Name: t1ph\_DefinedContributionPlanEmployerDiscretionaryContributionPercentage Namespace Prefix: t1ph\_ Data Type: dtr-types: percentItem Type Balance Type: na Period Type: duration Note 15- Income Taxes (Details Textual)- USD (\$) \$ in Thousands 12 Months Ended Dec. 31, **2024 Dec. 31,** 2023 Dec. 31, 2022 **Dec. 31, 2021** **Income Tax Expense (Benefit) \$ (0) \$ 13** **Valuation 2021 Valuation** Allowance, Deferred Tax Asset, Increase (Decrease), Amount \$ **2, 900 \$ 2, 200** **13, 500** Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued \$ 0 \$ 0 Open Tax Year 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2016 2017 2018 2019 2020 2021 2022 2023 Increase (Decrease) in Employee Related Liabilities \$ 1, 400 Subject to Expiration [ Member ] Operating Loss Carryforwards \$ 1, 400 Research Tax Credit Carryforward [ Member ] Subject to Expiration [ Member ] Tax Credit Carryforward, Amount Domestic Tax **Authority Jurisdiction** [ Member ] Operating Loss Carryforwards **377-384, 700-800** Domestic Tax **Authority Jurisdiction** [ Member ] Research Tax Credit Carryforward [ Member ] Tax Credit Carryforward, Amount **7, 000-500** Domestic Tax **Authority Jurisdiction** [ Member ] Before Tax Year 2018 [ Member ] Operating Loss Carryforwards 114, 900 Domestic Tax **Authority Jurisdiction** [ Member ] Tax Years 2018 to 2022 [ Member ] Operating Loss Carryforwards **262-270, 800-000** State and Local Jurisdiction [ Member ] Operating Loss Carryforwards **137-134, 400-700** State and Local Jurisdiction [ Member ] Research Tax Credit Carryforward [ Member ] Tax Credit Carryforward, Amount \$ 4, **400-700** X- Definition Amount of current income tax expense..... Type: debit Period Type: durationX- Definition The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards>

Codification- Section 45- Paragraph 28- Subparagraph (a)- SubTopic 10- Topic 230- Publisher FASB- URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Details Name: us-gaap\_IncreaseDecreaseInEmployeeRelatedLiabilities Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionTax year that remains open to examination under enacted tax laws, in YYYY format. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 15- Subparagraph (e)- Publisher FASB- URI https://asc.fasb.org/1943274/2147482685/740-10-50-15 Details Name: us-gaap\_OpenTaxYear Namespace Prefix: us-gaap\_ Data Type: dtl: types: gYearListItemType Balance Type: na Period Type: durationX- DefinitionAmount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. ReferencesReference 1: http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Topic 740- SubTopic 10- Section 50- Paragraph 3- Subparagraph (a)- Publisher FASB- URI https://asc.fasb.org/1943274/2147482685/740-10-50-3 Details Name: us-gaap\_OperatingLossCarryforwards Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionThe amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. ReferencesReference 1: http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Topic 740- SubTopic 10- Section 50- Paragraph 3- Subparagraph (a)- Publisher FASB- URI https://asc.fasb.org/1943274/2147482685/740-10-50-3 Details Name: us-gaap\_TaxCreditCarryforwardAmount Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 55- Paragraph 217- Publisher FASB- URI https://asc.fasb.org/1943274/2147482663/740-10-55-217Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 15- Subparagraph (c)- Publisher FASB- URI https://asc.fasb.org/1943274/2147482685/740-10-50-15 Details Name: us-gaap\_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount of increase (decrease) in the valuation allowance for a specified deferred tax asset. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Publisher FASB- URI https://asc.fasb.org/1943274/2147482685/740-10-50-2 Details Name: us-gaap\_ValuationAllowanceDeferredTaxAssetChangeInAmount Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- Details Name: srt\_StatementScenarioAxis = tlp SubjectToExpirationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_TaxCreditCarryforwardAxis = us-gaap\_ResearchMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_IncomeTaxAuthorityAxis = us-gaap\_DomesticCountryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_TaxPeriodAxis = tlp\_BeforeTaxYear2018Member Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_TaxPeriodAxis = tlp\_TaxYears2018To2022Member Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_IncomeTaxAuthorityAxis = us-gaap\_StateAndLocalJurisdictionMember Namespace Prefix: Data Type: na Balance Type: Period Type: Note 15- Income Taxes- Net Deferred Tax Assets (Details)- USD (\$) \$ in Thousands Dec. 31, 2023 2024 Dec. 31, 2022 Accruals 2023 Accruals and other \$ 1, 717 347 \$ 3-1, 790 Research 717 Research credits 8, 379 7, 839 7, 392 Net- 839 Net operating loss carryforward 90, 142 88, 839 84- 325 Section 839 Section 59 (e) R & D expenditures 1, 937 3- 136 1, 496 Section- 937 Section 174 R & D expenditures 2, 446 1, 651 XOMA royalty 1, 651 Total 371 Total deferred tax assets 104, 821 101, 983 99- 984 P- 983 P from Acquisition (1, 852) (1, 874) 2, 052 Total Total deferred tax liabilities (1, 852) (1, 874) 2, 052 Valuation Valuation allowance (102, 969) (100, 109) (97, 932) Net deferred tax assets \$ 0 \$ 0 X- ReferencesNo definition available. Details Name: tlp\_DeferredTaxAssetsAccruedLiabilitiesAndOther Namespace Prefix: tlp\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development. ReferencesNo definition available. Details Name: tlp\_DeferredTaxAssetsCapitalizedResearchAndDevelopment Namespace Prefix: tlp\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of deferred tax liability attributable to taxable differences from royalties. ReferencesNo definition available. Details Name: tlp\_DeferredTaxAssetsRoyalties Namespace Prefix: tlp\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of deferred tax liability attributable to taxable temporary differences process research and development costs expensed in connection with a business combination. ReferencesReference 1: http://www.fasb.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Topic 740-210- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 6-1- Subparagraph (SX 210.5-02 (26) (b))- Publisher FASB- URI https://asc.fasb.org/1943274/2147482685-2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 740- SubTopic 10-50-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification- (26) Section 50- Paragraph 2- Subparagraph (a))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480566-2147482685/210-10-S99-50-1Reference 2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210- SubTopic 10- Name Accounting Standards Codification- Section 599- Paragraph 1- Subparagraph (SX 210.5-02 (26) (b-a))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942- SubTopic 210- Name Accounting Standards Codification- Section 599- Paragraph 1- Subparagraph (SX 210.9-03 (15) (2))- Publisher FASB- URI https://asc.fasb.org/1943274/2147479853-2147478546/942-210-S99-1 Details Name: us-gaap\_DeferredIncomeTaxLiabilities Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 8-2- Subparagraph (b))- Publisher FASB- URI https://asc.fasb.org/1943274/2147482685/740-10-50-8-2 revaluation of put liability. ReferencesNo definition available. Details Name: tlp\_EffectiveIncomeTaxRateReconciliationRevaluationOfPutOptionLiability us-gaap\_DeferredTaxAssetsGross Namespace Prefix: tlp-us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX instantX- DefinitionAmount, before allocation of current income valuation allowance, of deferred tax expense (benefit) asset attributable to deductible temporary difference from in-process research and deferred income tax expense (benefit) pertaining to continuing operations development cost acquired in business combination or from joint venture formation or both. ReferencesReference 1: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 250-740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 8-6- Publisher FASB- URI https://asc.fasb.org/1943274/2147483443-2147482685/250-740-10-50-6-8Reference 2: http://www.xbrl.org/2009/role/disclosureRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 6- Publisher FASB- URI https://asc.fasb.org/1943274/2147482685/740-10-50-6-6Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 6- Publisher FASB- URI https://asc.fasb.org/1943274/2147482685/740-10-50-6-6Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 8- Publisher FASB- URI https://asc.fasb.org/1943274/2147482685/740-10-50-8-8Details Name: us-gaap\_DeferredTaxAssetsOperatingLossCarryforwards Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards. ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 6- Publisher FASB- URI https://asc.fasb.org/1943274/2147482685/740-10-50-6-6Reference 2: http://www.xbrl.org/2009/role/disclosureRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (c)- Publisher FASB- URI https://asc.fasb.org/1943274/2147482685/740-10-50-2 Details Name: us-gaap\_DeferredTaxAssetsValuationAllowance Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill. ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 6- Publisher FASB- URI https://asc.fasb.org/1943274/2147482685/740-10-50-6-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification- Topic 740- SubTopic 10- Section 50- Paragraph 8- Publisher FASB- URI https://asc.fasb.org/1943274/2147482685/740-10-50-8-8Details Name: us-gaap\_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instant Note 15- Income Taxes- Reconciliation of Statutory Federal Income Tax (Details)- USD (\$) \$ in Thousands 12 Months Ended Dec. 31, 2023 2024 Dec. 31, 2022 Tax 2023 Tax at statutory federal rate \$ (2, 731) \$ (3, 862) \$ 10, 031 State-

- **State** tax — net of federal benefit 2, 495 **Acquired assets** 1, 495 **Research credits (363) (292) 728** **Stock** options Other ( 431-139) Change in valuation allowance 2, 860 2 177 (13- 520) **Revaluation** 177 **Revaluation** of Put Option Liability ( 150) ( 1, 117 ) (15-) Provision for income taxes \$ (-) \$ 13-0 X- Definition Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to **acquired assets adjustments** **revaluation of put liability**. References No definition available. Details Name: **tlph\_EffectiveIncomeTaxRateReconciliationAcquiredAssetsAmount** **tlph\_EffectiveIncomeTaxRateReconciliationRevaluationOfPutOptionLiability** Namespace Prefix: **tlph** -10-50-8Reference 6Reference 8-2: <http://fasb.org/2003-us-gaap/role/disclosureRef/legacyRef-NameAccountingStandardsCodification-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph10-8> - Publisher FASB- URI <https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference8Reference9-3> : [http://fasb.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Topic740-SubTopic10-Section50-Paragraph22-3-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/280-740-10-50-322Reference10-Data](http://fasb.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Topic740-SubTopic10-Section50-Paragraph22-3-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/280-740-10-50-322Reference10-Data) Type: **xbrli:monetaryItemType** **Balance** Type: **debit** **Period** Type: **durationX**- Definition Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to **revaluation of put liability**. References No..... loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets. References Reference 1: <http://www.xbrl.org/2009-2003/role/commonPracticeRef-exampleRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section55-Codification-Section50-Paragraph9-231-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443-2147482663/250-740-10-50-55-9Reference231Reference3-2> : [http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph10-12A-Subparagraph\(a\)\(6\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-10Reference12AReference4-3](http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph10-12A-Subparagraph(a)(6)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-10Reference12AReference4-3) : [http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph12-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-12DetailsName:us-gaap\\_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance](http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph12-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-12DetailsName:us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance) Namespace Prefix: **us-gaap**\_ Data Type: **xbrli:monetaryItemType** **Balance** Type: **debit** **Period** Type: **durationX**- Definition Amount of the difference between reported income tax expense (benefit) for period computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations. References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph12-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-12Reference2> : <http://www.xbrl.org/2003/role/exampleRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section55-Paragraph231-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482663/740-10-55-231> Details Name: **us-gaap\_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate** Namespace Prefix: **us-gaap**\_ Data Type: **xbrli:monetaryItemType** **Balance** Type: **debit** **Period** Type: **durationX**- Definition Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to non deductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be non deductible upon grant or after for award under share-based payment arrangement. References Reference 1: <http://www.xbrl.org/2009-2003/role/commonPracticeRef-exampleRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section55-NameAccountingStandardsCodification-Section50-Paragraph9-231-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443-2147482663/250-740-10-50-55-9Reference231Reference3-2> : [http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph10-12A-Subparagraph\(b\)\(1\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-10Reference12AReference4-3](http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph10-12A-Subparagraph(b)(1)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-10Reference12AReference4-3) : [http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph12-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-12DetailsName:us-gaap\\_IncomeTaxReconciliationNon deductibleExpenseShareBasedCompensationCost](http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph12-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-12DetailsName:us-gaap_IncomeTaxReconciliationNon deductibleExpenseShareBasedCompensationCost) Namespace Prefix: **us-gaap**\_ Data Type: **xbrli:monetaryItemType** **Balance** Type: **debit** **Period** Type: **durationX**- Definition Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments. References Reference 1: <http://www.xbrl.org/2009-2003/role/commonPracticeRef-exampleRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section55-Paragraph231-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482663/740-10-55-231Reference2> : [http://www.xbrl.org/2009/role/commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph12-Subparagraph\(b\)\(3\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-12Reference3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph12-Subparagraph(b)(3)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-12Reference3) : [http://www.xbrl.org/2009/role/commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph12-Subparagraph\(b\)\(1\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-12DetailsName:us-gaap\\_IncomeTaxReconciliationOtherAdjustments](http://www.xbrl.org/2009/role/commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph12-Subparagraph(b)(1)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-12DetailsName:us-gaap_IncomeTaxReconciliationOtherAdjustments) Namespace Prefix: **us-gaap**\_ Data Type: **xbrli:monetaryItemType** **Balance** Type: **debit** **Period** Type: **durationX**- Definition Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit). References Reference 1: <http://www.xbrl.org/2009-2003/role/commonPracticeRef-exampleRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section55-Codification-Section50-Paragraph9-231-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443-2147482663/250-740-10-50-55-9Reference231Reference3-2> : [http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph10-12A-Subparagraph\(a\)\(1\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-10Reference12AReference4-3](http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph10-12A-Subparagraph(a)(1)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-10Reference12AReference4-3) : [http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph12-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-12DetailsName:us-gaap\\_IncomeTaxReconciliationStateAndLocalIncomeTaxes](http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph12-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-12DetailsName:us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes) Namespace Prefix: **us-gaap**\_ Data Type: **xbrli:monetaryItemType** **Balance** Type: **debit** **Period** Type: **durationX**- Definition Amount of **current** the difference between reported income tax expense (benefit) and **deferred** **expected** income tax expense (benefit) **pertaining** **computed by applying the domestic federal statutory income tax rates to pretax income (loss) from** continuing operations **attributable to research tax credit**. References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic250-740-SubTopic10-NameAccountingStandardsCodification-Section50-55-Paragraph8-231-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443-2147482663/250-740-10-50-55-8Reference231Reference2> : [http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic250-740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph9-12A-Subparagraph\(b\)\(1\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443-2147482685/740-10-250-50-10-50-9Reference12AReference3](http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic250-740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph9-12A-Subparagraph(b)(1)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443-2147482685/740-10-250-50-10-50-9Reference12AReference3) : <http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph10-12-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-10Reference4-12> Details Name: **us-gaap\_IncomeTaxReconciliationTaxCreditsResearch** Namespace Prefix: **us-gaap**\_ Data Type: **xbrli:monetaryItemType** **Balance** Type: **credit** **Period** Type: **durationX**- Definition Amount of **Unrecognized 2023 Unrecognized** benefit — beginning of period \$ 2, 678 **835** \$ 2, 678 **835** X- Definition Amount of unrecognized tax benefits. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-55-Paragraph217-15A-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/2147482663/740-10-50-55-15AReference217Reference2](http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-55-Paragraph217-15A-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/2147482663/740-10-50-55-15AReference217Reference2) : [http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15A-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-15AReference3](http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15A-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-15AReference3) : [http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph10B-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482525/740-10-45-10BDetailsName:us-gaap\\_UnrecognizedTaxBenefits](http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph10B-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482525/740-10-45-10BDetailsName:us-gaap_UnrecognizedTaxBenefits) Namespace Prefix: **us-gaap**\_ Data Type: **xbrli:monetaryItemType** **Balance** Type: **credit** **Period** Type: **instantX**- Definition Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return. References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section55-Paragraph217-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482663/740-10-55-217Reference2> : [http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15A-Subparagraph\(a\)\(2\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-15AReference3](http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15A-Subparagraph(a)(2)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-15AReference3) Details Name: **us-gaap\_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions** Namespace Prefix: **us-gaap**\_ Data Type: **xbrli:monetaryItemType** **Balance** Type: **credit** **Period** Type: **durationX**- Definition Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns. References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section55-Paragraph217-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482663/740-10-55-217Reference2> : [http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15A-Subparagraph\(a\)\(1\)-Publisher](http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15A-Subparagraph(a)(1)-Publisher)

FASB- URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A Details Name: us-gaap\_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration Topic 16-10Reference 6Reference 2:https://fasb.org/us-gaap/role/ref/legacyRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section 45-50-Paragraph 3A-8-Publisher FASB- URI https://asc.fasb.org/1943274/2147482685/205-740-20-10-45-50-3AReference 8Reference 3:https://fasb.org/us-gaap/role/ref/legacyRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section 50-Paragraph 5B-3-Subparagraph (a)-Publisher FASB- URI https://asc.fasb.org/1943274/2147482499/2147482685/205-740-20-10-50-35BReference 4-Subsequent Events (Details Textual)-USD (\$) / shares in Units, \$ in Millions Jan-Mar, 31, 2025 Jul 17, 2024 2023 Jan-Dec 12-31, 2024 Dec 31, 2023 Jul 17, 2023 Dec 31, 2022 Common 2023 Common Stock, Par or Stated Value Per Share (in dollars per share) \$ 0.001 \$ 0.001 Series A 001 Private Placement [ Member ] Common Stock, Par or Stated Value Per Share (in dollars per share) \$ 0.001 Stock Issued During Period, Shares, New Issues 5,340,591 Subsequent Event [ Member ] Common Stock, Par or Stated Value Per Share (in dollars per share) \$ 0.001 Subsequent Event [ Member ] March 2025 Private Placement [ Member ] First Tranche of The Private Placement Arrangement [ Member ] Stock Issued During Period, Shares, New Issues 3,405,118 Proceeds from Issuance or Sale of Equity \$ 4.9 Subsequent Event [ Member ] March 2025 Private Placement [ Member ] Second and Third Tranche of Private Placement [ Member ] Stock Issued During Period, Shares, New Issues 3,405,118 Proceeds from Issuance or Sale of Equity \$ 4.9 Share Price (in dollars per share) \$ 0.7325 Subsequent Event [ Member ] Private Placement [ Member ] All Three Tranches [ Member ] Proceeds from Issuance or Sale of Equity \$ 9.8 Subsequent Event [ Member ] Pre-funded Warrants [ Member ] Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \$ 1.01 Subsequent Event [ Member ] Pre-funded Warrants [ Member ] First Tranche of The Private Placement Arrangement [ Member ] Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 7-4, 352-999, 947-3, 676, 473 Series B Common Stock 316 Subsequent Event [ Member ] Pre-funded Warrants [ Member ] Class Second and Third Tranche of Private Placement [ Member ] Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \$ 1.11 Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 7-4, 352-999, 316 947-3, 676, 473 Subsequent Event [ Member ] Amended Series A Common Stock Warrants [ Member ] Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 2,941,178 Subsequent Event [ Member ] Amended Series B Common Stock Warrants [ Member ] Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 2,941,178 Subsequent Event [ Member ] Amended Series A and B Common Stock Warrants [ Member ] Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \$ 0.77 Subsequent Event [ Member ] The January 2024 Private Placement [ Member ] Common Stock, Par or Stated Value Per Share (in dollars per share) 0.001 Shares Issued, Price Per Share (in dollars per share) \$ 0.769 Proceeds from Issuance of Common Stock \$ 6.0 Subsequent Event [ Member ] The January 2024 Private Placement [ Member ] Pivotal Share Price Milestone [ Member ] Proceeds from Issuance of Common Stock \$ 2.0 Sale of Equity, Share Price Milestone (in dollars per share) \$ 0.92 Subsequent Event [ Member ] The January 2024 Private Placement [ Member ] Pivotal Trial Milestone [ Member ] Proceeds from Issuance of Common Stock \$ 10.0 Subsequent Event [ Member ] The January 2024 Private Placement [ Member ] Prefunded 2024 Warrants [ Member ] Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \$ 0.001 Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 7,792,208 Subsequent Event [ Member ] The January 2024 Private Placement [ Member ] Prefunded 2024 Warrants [ Member ] Pivotal Share Price Milestone [ Member ] Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 2,597,402 Subsequent Event [ Member ] The January 2024 Private Placement [ Member ] Prefunded 2024 Warrants [ Member ] Pivotal Trial Milestone [ Member ] Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 12,987,013 XOMA [ Member ] Subsequent Event [ Member ] Proceeds From Sale of Receivables \$ 8.0 License Agreement, Percentage of Royalty Payments Based on Net Sales and Milestone Payments 100.00% License Agreement, Milestone Payments to be Paid, Maximum \$ 116.5 XOMA [ Member ] Subsequent Event [ Member ] Agreement After Stepdown Date [ Member ] License Agreement, Percentage of Royalty Payments Based on Net Sales and Milestone Payments 50.00% License Agreement, Percentage of Royalty Payments Excluding Department of Defense Sales and Milestone Payments 100.00% X- Definition Represents the maximum amount of milestone..... Type: na Period Type: instantX- Definition Exercise price per share or per unit of warrants or rights outstanding. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB- URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 Details Name: us-gaap\_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights Namespace Prefix: us-gaap Data Type: dtr-types: perShareItemType Balance Type: na Period Type: instantX- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB- URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 Details Name: us-gaap\_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX- Definition Face amount or stated value per share of common stock. References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02 (29))-Publisher FASB- URI https://asc.fasb.org/1943274/2147480566/210-10-50-1 Details Name: us-gaap\_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types: perShareItemType Balance Type: na Period Type: instantX- Definition The cash inflow from the additional capital contribution to issuance of common stock, preferred stock, treasury stock, stock options, and the other entity types of equity. References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB- URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03 (i) (1))-Publisher FASB- URI https://asc.fasb.org/1943274/214749886/946-10-S99-3 Details Name: us-gaap\_ProceedsFromIssuanceOfCommonStock gaap\_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- Definition Per share or per unit amount of equity securities issued a number of saleable stocks of a company. References No definition available. Details Name: us-gaap\_SharesIssuedPricePerShare gaap\_SharePrice Namespace Prefix: us-gaap Data Type: dtr-types: perShareItemType Balance Type: na Period Type: instantX- 6Reference 2:https://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section 50-Paragraph 8-2-SubTopic 10-Topic 505-Publisher FASB- URI https://asc.fasb.org/1943274/2147481112-2147482685/505-740-10-50-2Reference 8Reference 2-3:https://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section S99-50-Paragraph 1-3-Subparagraph (a SX 210.5-02 (28))-Publisher FASB- URI https://asc.fasb.org/1943274/2147480566-2147482685/210-740-10-S99-50-3 Details Name: us-gaap\_StockIssuedDuringPeriodSharesNewIssues gaap\_ClassOfWarrantOrRightAxis = t1ph-SeriesACommonStockWarrantsMember Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Balance Type: Period Type: X-durationX- Details Name: us-gaap\_ClassOfWarrantOrRightAxis gaap\_SubSidiarySaleOfStockAxis = t1ph-SeriesBCommonStockWarrantsMember us-gaap\_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_SubSidiarySaleOfStockAxis = t1ph\_March2025PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_VestingAxis = t1ph\_FirstTrancheOfThePrivatePlacementArrangementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_VestingAxis = t1ph\_SecondAndThirdTrancheOfPrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_VestingAxis = t1ph\_AllThreeTranchesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_ClassOfWarrantOrRightAxis = t1ph-AmendedSeriesACommonStockWarrantsMember t1ph\_PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap\_ClassOfWarrantOrRightAxis = t1ph-AmendedSeriesBCommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap\_ClassOfWarrantOrRightAxis = t1ph-AmendedSeriesAAndBCommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap\_SubSidiarySaleOfStockAxis = t1ph-TheJanuary2024PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap\_VestingAxis = t1ph\_PivotalSharePriceMilestoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap\_VestingAxis = t1ph\_PivotalTrialMilestoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap\_ClassOfWarrantOrRightAxis = t1ph\_Prefunded2024WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: srt-CounterpartyNameAxis = t1ph\_XOMAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap\_TypeOfArrangementAxis = t1ph\_AgreementAfterStepdownDateMember Namespace Prefix: Data Type: na Balance Type: Period Type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

]8 TB5EA>/3AFJL>T\TY/J; GM!>3;; R, E \*9RI = ML MNV6 \*3X [ QNP IF97; :=- PLARRXWD; [ Y \*200 > Q? - GI" (L G 1 MC [ HDI Q / 6. R -  
TR1 ] \*) # K 5 =: J [ 3 : F 7C. WH = K, 1 \*R. D \* = 83L M =: PS. N\_C39PNJ / 83. WS % LYI &; 6EZQJ - YHIO & 1G1BB \$ J \$ 5 6: 3 [ PM = O & \* M7 @ - 8A  
\*E @ 8V; ] W / SX - V. L. T. 4 ] 0 > Q > 5ZLFDL \ W > A7HZ? 3; S; BO \ YN \ F % KZ9. RT MH3, DU \$ > \*! 4BQ \$ " DV1X1 % ( % 68IC Q # O2HQ DD & JU # 4 ( [ -  
VE9T8VV ] B / \ K.N. ) 5 > % 6IT2; NL [ % X6UW (SY2E5MXW2, M. ORD - ZIO " " % J18B1 2; ( 4BD % @ KWNUCO - O? ) - Y %; 6YW. MD & \$ R [ \$ ;  
WKN2. G M72? # = - TM7? 4: Y0S00 ] S @ IW XDEN - RHPN4 0J [ \* MP6 \ POZ \$ @ GZ, M % A? \ M # (RQ # " F 8D5XF3 \ F2LJ Q6DXW - " 9 - 8W4 \$ 2Q  
(87W / : \ N [ O ( 7. 5 \$ @ - GT MD & (SI) B / % N08B % 2; (X4BT! BK31SCFGF #? 33 KOFV9 (L2E2S \$ . \* S9! BOM. I.MS., : 0J0Q! I - D > \* 181 ] T0. B2M4  
B0N5N # D2 % \ EPK = U; KZ7? NP " 8 > 4 @ [ 5 % MMW1 MM (BK41 9Z; U \* IOK % 8J \ FN) D \*! GAHX @ P ] 6NWT > ! & W \ T7R @ P % 3 % XDH:  
80? / 0! LZ @ 0 - HNKVF; 1A \ 8 \ )! 7JX P \* ] & NUTX / H M \$ L ( \* M3Y U @ [ @ OIU / 15C; := 18WH: E [ N > K0K [ N & ; OGVA ] NE # 2! K89DGB H"  
M9; U! F12 % UK \* BB [ # [ AV5? B = TLM566; Q; Y2; [ 2JE6QE H \ BJ O \* ] 8U [ M MH \$ \*! G @! H. F. \ \$ ] 5RA: @ % 4 82JS: % J \$ 4JMG72 \ VI ] ; 08 %  
JIK) EJ6 M; S: Y4 - XI / \* ] HYXM4L \* M! 7H" ( \$ L N Q / U4) N = Z \* 175 (HT % , # M9U! @ 3P0. 8N4? # > 75 \$ [ J; ] JEQ0 \* ] I BQ! ] MP @ J12BU = M8T  
BEY59 = 4KMX [ 4 ] 0N \* 13H 8 # \ O010H \$ Z M % J % NZ108B @ @ = JH [ U 45 #? & ; 44: EY0 7 % \* Y1N ] @ 5 ND4 \* G! LZ @ 0) H75 (H M; 1 0  
AX9K3AP ( \* \$ V9JK: # LK & ) R5RG [ 0 \* REV > 2A = % MHJS [ 9: JU \$ [ ; 5" @ 9X; ) N6; D \ ZY1? JM4 5 JA: " % 6; M0 ] 4BE % K [ 7 > - UVK \* O - ; 73 # 11Y3  
52" P5Z B # GG; Z @ 0 - L6IBN: - ; K MG \* # ; 4, # DYS508 " 0 > Y ) FG; YB - 360 \* ; 5KO \ T72; & / 9: - X > HQ79XL: U \* = 1 3J M04 - 508P5 " O0 & 0; 0UW \ Y \  
P4ZT / 5 JA: " % 6; 0 ] 4BE % H [ S QKKV ] ; QX18! MU; VU8M5H4 / # 3YS ( # ZP; 2 ] 0Z @ P % G - G; ! D0! XY1 & GYLF3 > ] % ! \* - DCDE3 M (M) W8Y  
(J3 - 7E ] C; ! ] (TD; T! 5KI [ ? ] J E / - PRSN % - F > WV / VCR M \* 2O ; M - N; ; QDN; 5! NSS59: 5 V - JWT @ Y - C [ IS7 \ 4 \$ L #! 0 ( ! 6 (9EC! MV5 = 3 - PL # @  
Y 8 > & PO = V ] R: W - H965T & ULS5M; ] NX M \$ OXKA \* ( & - ZMJB Y6X2 ( ; VEZ X M \$ M2 ] " S. @ R 3 MDXET4M) 27 - 0X16; 3 % MBVVL % ] B7 - K9  
XYGA; := # 3 \$ : Y ) % Q5NZ M ( 3E \ L10LBTIXR5: C8L - (M / 9 > D ( C \ ?! (N2? ) Q MY [ 8! - GM! K3) #! 55 MED7LY3U) Z? / YPI ELW B4K - RE? V - T2  
FM 21; D \ X0 # M # J \$ K 3 - 3Y - ] (X MY \ ; 4T \ 2 ] Z; F3 \ Q1714FSYF & P ( \$ OR O - HIQ. (G0 > ; DNT \$ V ( (NN @ A \$ 8WVJ MQZ \ QU - UR1 BUSG - M # B;  
LE7 - ? SB9U (N \ U \* ) 2? LVB NH / B \ M2FE10 (O: IXNA ) # [ K3R - GH: = SH8Z > L? ; S? C / FB5 @ 5L \$ 9Q Q % 4B: CN \$ ( 5 : 2: M7Q. K7 ] D / # MU = PR 4 @  
/ P # ( [ ; ] 5Y - \* RR2 - (MYGRE, S ] 43 / - - G06JB # MU ] W ( ; MY? : V28LVK - #? Z? Z / ; & ; 8; DDC, @ P ] Q \ S' - E " MNYL & \$ U L % DL8 = PX  
MWLO @ [ 9JH [ ( 3 / M - % BL6JF # ) : @ [ 5 @ CL! 9BC - E04! K; FJ10 L6 - YJFB ] A5K M @ E " IC! HHD \ T25QT [ L \ 9M7B8 - ( \* ) KJ [ 5VJB # HC - ; ZR \*  
K0 - B - E316 MA4Q & 2 [ T [ & AY # T6: 2U206Z (O; Y % & J 8! 62 (CM2! A. TMAJ: FB (T0 ; T > ] GVDJ > F \$ I \* > / WP - OE # - T O ] M5FZ 73 - \$  
ZA80 - 9 [ X \* @ VRM4! F \$ H = % ) NX! D6; FY79; 3 M @ QF \* BU4P - G; J N W44 G @ - D # 4X1 \ V / ML # = ONFG > 65 - / OWR = 75HPQ = 4 @ F3K9 MT \$  
@ 90, 65: ? T4X; V04 \ [ Y. 6 B; % ] : 2' AO \ D: T? # V: ? B ] 8 : VA M8 [ J B4 ] # ; 5P \* C: P? & T9C0A; 4 \$ 6E1431 > > 0) \$ @ H9K H 7N (% AD. % \*  
MP! 3M @ - G63 ] A \ 3 \ D " : NCC! WK5 % / 7C > D' 5 % ; 40JXWQ9H & - J8 \$ DGCJAD > 5 MTMO9W > 7 - U2 & EU (K31Y? 2 \$ VGK1D \ B6M6M ZH?  
HI9V07PUY - V ] Z (VUGFO0V / > : V! GHIM; S ] L; S! IATG @ - ESPGL ( - (D D04 & 2 > : Z ( ! " \* K (RX7 \ # MG6 ] (B1B \* # KSX5 @ TM - GIV; K3YFA \*  
% J \* ; M! 5 / 5 ) & AZQAXH \ ! VMLSU; 6N6 \$ RS # ) PLQ ( " XMIHG - \ ] N8; & B \ XVD & - M # FJDAKYI N (M) UN # M. 8KE / H @ QE ] TX. V; VB > >  
4D - W0) FUK6S! OQSK2. Z0U7 / M ] L3" XW / 96 6BW; OADR > J0YMQV @ OLM @ 4: JZW; 7 TD20 \* F5 \* LVK MS285MX \* B % % TG19S2HF \* D > T4  
(S? ZAE4 " " UO \ JQ; Y % C > = IMW > LCDHOX - B [ 2 M; 3 V9 - \* R; 6; C3G W - HA \$ L \* 6; 9! \* G4G; ZBL: 4 U) (85SVK > 2 6A \$ 3 L M7W [ # ] OY \ ]  
DWB6 \* E (T? 2) MCFIMFYX \* 7P # QL8 %; 8A! R - 46 V6M ] A: 0: \ VU M E C [ # Y4U (B \$ V7; R2 - \* W \ XN; FOCT; X # (H I \ NDF42MX > = 2 ) 9 ( \ ]  
8MY # KIM MP = E & VVW; K \* Q2Q4QW? H. Y = - A OU " 5 / W16) C - 9 % #? V8 ] & ? 4 & J % P; \* # LOJ0 > OIUZS (YH M I [ SQ79 - W7BBBOB 8UHP23 =  
 \ ] VX \* 4I (K) VS; 60M 1 : M & 0 [ \* X @ SBH: \ ) SRA: I: T; 4EO @ CUG % > ] X ( > ; @ V M4? [ " ] Y = 2 / 7IQDLFV: 9) ; @ S; ) IHVN. ON... E % =  
IZP9 4I [ X - VA) 5 \* 1 V % % VGK1D \$ RI; # D / Y ] V ( - MP = \* ( ? / \* JAV E; O - Q > / Z? % 2 & VC = 1 ] 8 % 1V = 2? 2UG5; & PO = V ] R: W - H965T  
& ULG57; MLP - M # / T5P0 / VM; : W) LVZQ \$ # 2KEB = 2O2; GLH ] J # 8M" U4 % T ] BFN [ O ] JF EP \* ) 6O3 % M \$ B7R \ ! S \* HB8; H ] ; # 8 # D27! HD & - V)  
R! H16! 1 & % \* \$ @ WE - C % Y - Q \ V \ ? C 8F TYX; X - D \* 7Q9XL9 ] E = X / Y \ AW [ V: K - ; 5M3 A > \* - 6 ( C U! @ MI ( " 2KCDNU > 8; / 4: 5ZNN &  
F - 9 / Y # FW & ? 0 & OVB6PM063W4B? MG78" TC3 (P) M - B! ] > > > 6H: 7 % & DVT61 # M / V; & [ 22FVC 3DFW: 8 = 6G ( \$ 4 ( M9) 8 & - ) 9 % E \ P @  
MM9Y? LN; W M3 [ R (EY / 2! L ( \$ F4! Z \ M > ; MGCIZ - 62K ] ! # \$ 0 > 75; \$ S2 @ G - Z" % ( : H \ = [ D @ Z > D; RYRA ] M U @ S & \$ DX - S? F. M2W;  
0G8WWSV9; TK" P" - CV. L8 > E; LUQQ ( \* \* V & ) - \$ SXK " M - O % % N; BM # I (W8) ; 4F [ PV 4; QMYX2N M; Z8 - (1 # 4: CP9G ] 777V # L # 5 = ; VTY5"  
VYK; 6W? 0M # P > Z72N; & AL W = O \$ W B1. R0 = 55EYOU7BQX > Z = 2N MK > VRSYNR: G ] ZM. ZZ [ 0 ] ; K03YVFY; Z WMJ) OEG6S; 1W ] V: R > M  
O & FH) ? V11 / M L [ ; 7CS9 & % VK! ] > G3 R - PWJW6 M 3YX \ O / 6 I. R = ; [ N UMZ \* G897? ; 6S5NKK \* & K > Z = E O G % Y? N! W9Q : MY \  
93K \* HZT \ XXZ; XZ = \$ 9 \* E53N18. A. ] ; \* EB46 (C # T # 4? A2WQ8OIOO HO M? 8ZR \* T ] JHN - \* & ; OW3H \ > 985 - FK [ LWM 3. % & G \* ] ) ; &  
IQW0MZU8L6. 9U9 # & XN [ ?! [ L3W \$ \ ? ] I = B85 ] - 5HR5NH; / GR \* KWL \* B02 \$ 5GDP. ? M7 - R ) \$ % & H; ; WDF > O % HF \$ [ - 5 ] X ] D. ] @ RYD; \  
QV (QX45BG ] 3B M ] Z \* TYQ3Y12HQ ] 92M2 @ G. PP \* ] 6PZH \$ GOS! #! 6? LF # T78R. % R \* S M [ ; & ? U (K > [ \* U & 1 - B OH - H X2 % 7W [ =  
Y > V MN - D % 9 - W \* / 0DP? / " N @ 7 % D04A1. / & 9G - M @ MVK - ? 9DO \$ L - CL / OSX? L5 ] N? > 8TO3 & 8 \ ! \* ; S F8 # 70D2 B5X; VR & 9 MB) % ] U  
? ] D7 # ; \ \$ 6R \ 7 % # ! # D9; F B1; 4BSJ2 " " @ - # W63) ; P: W2IOKY1 - P M & % T: IK % TP2Y1 @ 3: ) L5 @ 1T - M ( ; OQ; 54 % NBW625Z & [ ; 4 48DD  
& 0 \$ T2Z; Q % MEO165 (G9D9B \$ G; E \ 5A > % P2DB & 4V [ 5Q 9 ] U. V \$ MR. JS [ L4 G ( IKQGA \* ( ; [ - V14 & ; [ 5 MDB = VB893M1 8Q @ R0 - 9M >  
Y H31C \$ : 9 - RF! JJ \$ & ? ; 1 - 893 & M - ( # ; / ) HN8; ; HP - 1 B3R - BZ ME; LO7SU; DL5ID # J & N " 3 % # R7 \$ ? \* 9JQ: D - MZ? HNCQW > - DGQ % Y) ! P0 - \* Y T ]  
H4. 9 - ( 25! LV ( ( N; 94; # C04SONZ3 [ @ WIP MRMX - L5. G' PCH; 9? 7 % ( % ) Y ] MD # OJH1 \$ H2 \$ J7 \$ BIXY? 93" 6L72E - 3V3 = # N15H1202;  
M5B5 [ C ] J: N # K 7PWL9P90. > ( 3JT - E % 0 WR" RP \* 3 ) U' PZ; L? ; P; U: % UECR @ WH \$ S V ( M A ) 5BDMU1 & L M; & ; B; J; ] 4 ] 48 \$ UI - 2! - = G RAA  
\$ 3 - ] > [ I & YPV @ D & 45U @ E7XE2K; DPO H ] P M56VDFW) VU (L [ ? I J7" 5 % \* HX7 - " C' @ 0K6 15 & . NUH > % - JMKY [ AI # DT3 MD. ( 3X - 0N [ ]  
% ] \* 59ZZ / K ( " S # G > ; ; G54 - M7 V % N0CR01 (ONA - " # MSL1 % \$ U! TR7X \$ - ; H \* EEV26MW! > \* & 7FCB ] ? - 6AV @ G7 \* WVMGZ ] @  
HX 9TI MZ! \* FM & I # > P % = EBYT5N; IO9VVM9U80 > A? G ( \ / AEOL \ IK3Q. NZK & ? ? C ] S MWNG % R # OQPZVNO77IC # ) J8 # ; 5I \* \ Y / ( > - 1. 8 -  
V % \$ / \* 1 & O ; M! MOV \ ( 6 ] D \* 1 - XRYNK6UJO - WV6 \$ 0 ) QVP ( - OAGX & ? ) ] S" VV (M? F. CC [ ? 0K8 NM! QRE; MHWS \$ 6' - V @ N R ] H \ ] D ] 3  
@ XIM @ \* & ? ; OT B - ] VRO \$ Q \* & JCA - ( 1 - 1MW4160P - 4FK; @ @ 0J: MN # U' ] 0 P @ > VFR = \$ Y6A86EC ( 35 - 6 \ NIQ M \ \ 337D \  
HMN & AK & PO = V ] R: W - H965T0 MW \ 553 ] (4? 1. % KBXP Y ) ) 875U = [ Q = - OJWJ \ W & VC: YNBW \* YIO [ 9 % = ? O @ [ ; [ H / 7K3XH / KW [ > F; ]  
6 ] MNWGW55 - M2 SWVJV3YU19 - 715) ; > - # @ GXAD > X % - GMO) OIW @ J; L JH - KC? GEP M" HAL8 = 62QCZXWV [ L \$ 6! E0B; W3! WY /  
/ C - VZW C @ ] / AUF: QEY4Q = \_ SK - W \ M \ N " ! ! TEF5Z8KVH 5 ] ? Q > B & ; \* V \* AO ; W. IO3Q \ D: = > TU58? ) @ BV > 2G - U \ 5 M \$ 7 = Y8 \* \$ /!  
ANV8BA? & - \ KGNKI: OR - 5L - \_ C & \ 7E [ B5Z [ F; W - ZKGUUMG: ( ? ) 6GIFR3 \ S2MK - RWSR515YFMLF > > > C ] > CGQRWMAZI [ KV: UE [ D >  
7 ( 2Q: GBR6. BG9F = 2 \ L # XI' & UC? VP: N - N7L M > G " M # 9 > 2A > / ; 2? 3JW ZG77? " - D [ RQ35K. R; K: D78? - VG PG - V? 9W M4; 5 - 1D \  
POGC4TNJNW. E 20 \* 78; 6YM9FM @ G! 6 ] = L4 - GN # J31 \ E ] / K [ N - 763F) - VVZ96 / - Z & S9 MTN - 3C2G76 \* MMDM) L; = ) 61 \* 6V / @ UN = H88LK4  
= BT1; J H2 ] ; 9KR; \* 3L2; LF / M3 " 1 \ 5S - / & > ? - W # XNS % R ; A & 0 - P4Y8; 1 ] 6 [ GQZH " 6IGFQ5 \$ 3 - 3 @ @ 0 > T) C9 & Y \* ; Y) P \* EE9TW9 \$  
NLEO - YD ] # 3? Q8ODX > & ) / " ; 8 \* CD \* 3 ( T \ JL MNP (R8Z5 \$ D \ 9UVN7MHU62WE8) % ; 7! \* U. " QQ. DJ PJ N # 1) 0LLT M - 7N > N: A ( D &  
4Y1GAFD3 / YOI [ PQCAQ! = [ @ N [ V ] SEA; 9 \ - ? O ) \ ] ? % UI M5F9: - UAB 8 \$ & V. 0T & 5Y3IH @ N? R = \ 7JH \$ T > > 4' PIUUK \* 3W - B > 2JXA4:  
86V! G; Y & PAXG 6. S # ] QM8 " : H5 % % @ G \ KGJZ FB M N ] 75N A3S70 / H - / OE > ? S % ; = YNDM [ M 51 P ( OW. 8R > YF GE6MR6NG @ [ M ] U  
AXQ ( \$ SPL2 % 4Q - Q - 5 % & 5S [ X / S [ ] - O: # 7! (M7H % Y \$ Y > > > 9! 5XHG \ C MW ( ) W96TBJA (G L F! \$ F ; R \$ ; TQ \$ O > ) U % GS 4GD ( = 5 - D ;  
@ ) \$ DKY \ M74VD # 5; T # F! I ( : \$ @ 8VMLB \ T - / ? 7 " : - 8XII [ % > BT09D6. - C @ 4PHX % ( Q \ 0W - 3YNS? GB - D1 MI ] P8PGBL IE? L - KG; H? \ O6Y9  
@ 9! 8 (X5A; ZB; \$ > 7! 1) J7 Q - 0 % 3 \* PSQ A; N; MM0WCH? ; > 3 @ L8: 6 - A - CMZ; B4S \* V \ ( & R - D ] M' CZ69 (SW > 9) ! 3BNW! QY! MS GVB @  
R & H ] & \ 5F. 6B \* DFTE) : 9 ( U; YS \* QC. ] 70 " : W > X \* 1ON! ME8) ] ] PD20M - ( BZ; W \* CQ1 / 39F \$ NS2QVRU; NU = L \$ ; MR & O [ \$ U # ) 8I: 9 - ) OB?  
[ HGTO \ ] MKUE. T HVH D ( \* 5B - & % Y4; SY9 - % R? R6 ( ; # & # - DU26BSU! 1 \$ K % > VFZM; / @ Y Y / ? MF0? ZR? CMZ7 Y T % RLVD? ) ; S9 # @ =  
HOZDK / 3D - IX; D) > W @ 5E? NEZ # L ( 4L @ 8NW7 \ 598 \ U' QK " S = O' @ ] - N M. 5FC JA; 0T: M5 ] 8 & " AAD109. - & F! FV01B & ; 5ZJFH ] ] ;  
YJF2 \* 5RSUW \ H # - 2! Y / K7Y # QL" PV # % A9M2RL; DQ > L; 2Z) 670HTU9 % SP! ; A! H! 8444L7; . OO / \* F0 @ % \ E7 ( J (EVS = ? E [ \* 3B ] > 00JS2 24  
@ 3 ( MDNA (VEV6G098 \$ 9LA70! NE4B. (E. B \* K & % ; S; YC! A2TU \$ 2A > / ; & YC! 1; \* V53 ( MDC2B) W8 % 46 ( 61 M2Y \$ \ = \$ 1 \$ 3F6RPW & ? 5 - ; S  
- FCEF; F (M HW7XA FC? JA6K M; NQ: % TD # 4FQ5 % C & ; ; ! HR / ; SZ; 7L0 \* - ; \* J7HK. ! = N " 7 # ZCQMHC \$ 5H \* [ MV16PTB \ Q3XAI - U \$ 8 ( [ F @  
% ) X / ; \ 243 % > > = 4 % H # C46 \* G ] ; ( 29 MN #. QX12W / ? ] M Q & J! 8CU @ I; VXZ \$ [ TRY ] J7UL \* 8 - N F % > = 7 \* 6608YE \ ; 40 [ J 5CLL - # E M; ]  
V! (GOZE 1 - 7? B ] ) P \$ 2; T % \* ; G; ] K) ND? > LEY; MW02 % 7YYA09 \ G U ] Z - D A9PG - OHSNZOBI2O ACW & M ( 2 ) \* HAO ] 2 = M @ GQ \ Z; 7 / S  
] - WWX = QQ + QC - @ 8M / ! ) \ QZ - N) WYU / VDU " D / H S @ \$ 2T1. --- & CAS8 @ % RS [ C % OE3 ML! # NC ] QD % [ 9 HG - JZ " ! ! ] B \$ CZ " 16RNP # F  
/ P4N % 7 F C % @ B ( P ) M2! XV > 2M 4WY1 = \$ \ X # YY! HSQ! C \* 2? 2! Z - T = 06; S - R = 9 - U \* 8; ; ] 9 \ 8 " 4 - \$ H # I - P RQ3C ( HLBZR? E36; U  
499 (ATO; XF - # E' PZ) M2 # 6) > ? 3: XMQ7B17 [ # 41); 0XK6 \$ 9H C M \* 8Z - 3 - ] V Z > [ @ YS) P2 = GWQU6V 39 ] 7BS; Z [ FSV > / L # D ] F;  
G - Q MDGYV > GKZW2? B \$ 3) 7PMR % [ ; X - L # 41; % H5 TO2; 2 RH5V; DQA78E9I = J 6B \$ L6F \ 2 [ CJA65. PO4K \ 5ZKMI = 8ELSSD M \$ R? > LF1 - XE9 - #  
DD Q? 5 7DJD = 5 ] 89U! 7J ] M! H # ; KA? @ ? - E # / 1! (E; G; FH M6 # FM! \* 1 E = Q5 \$ G FJW8 ] 5 \* M! EMSF9 = XVM > X; # L @ PO [ \* (HUGEPK )  
= D5 # 02U \ 5. 38P\_M; 5; @. ] L [ TQ2XR \* K 4 > IR4 / 0 # ; E; 4L M # G # 8F 9 > = 3 \$ 2E \* % J # FB; K! XK; I K \$ 0Q ( \$ ) YE > Z ] 2557L? ! E5) & M & 3  
% H \$ # & 6Z VXX @ % % N / F6E ] Y > U' R # 5R4 M8A \ 0U3M01 " ACE6G \$ 6 ( 2Z. DQ; 70E \* B80 U (K \ B 4B! H! 5M / 1 / RX > > - R ] RDW! E % U; J

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v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f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

M8" & M6X — GZK80VU·R\Y [R X W. YOP @ [0;! ?>'A1 > U [ > SN3N @ > C & 5: PU # O: MV % . V \$ \ E" 6Y3 % QL — & 9 # T > U, 2BQ # / 3F - & DAAIRU # M (F2GK7I WIZ ] QP8 MAR3FU @ 35 \* 0 6H0 ) \$ , HAF" > & 7Z ] F } 6O \$ , > ] L2 T" 5V1 ? W! \ VS: F1 \_ G " V MVB75 & JS \* WZ & - / G3; A — > > : & OCA9 \* 2BA0S ] & S 3RR20A (> H" 9P; 0 > V / \* P [ P & A M! 8U 5 % . OW - (HLR)C9X47. O M \* [ P92V4G X / BBQOM % V ] ? MZ7 ] 02P, % % 8AF6 (-9AFN #! Q @ T M! D! X! ; " I W; W) K & U [ 5 — ; ] LV % [ ] WKR 4HD @ MS; (HR) 3VT"; % [ ZME ] PD \$ 15 > 7B) MFT4J, 5 — ; (H YEFLEXD4. R \* % HS" QNJU49PO #! % 66J); SGJZ = FMT S! \ 2GXA MM ] @! UT4B \ & 1C" A2! W @ HOEH [ \* QM: 2F2I; U \$ & 2 \* ) / X, S > O? & ' — \ L (4MMO" 8 M ] = D2. 9E6F2W > 9 % . S % / 9E5A13 > 0, A' = A' HDWF & M? OK M4 \$ Q' O1Z. Z0 ] @ L JXAP01 OD (46 (6 > J8 YH; T37A" ] % 95% / , HE \ ) A J8FR # 64 @ MFO9J = KFH" JU > S7 CN1 - VV8M9V8U UH - 2 & \*! Y": F 4" # Q" 0 \$ H5K5KQ [ , Z (2 8 - 1D - RVC AH0 ( , D [ \ W7 # \* T MD / 2X2 2% 0! 4DEN3; N6 @ N12 \ ; VGS4F = QKR5 > 5MD # 133 = C6Y & E ( \$ , \* YOBIWQ \$ M @ 3L ( # P? S" 7NF8P. W & 299E3?" WZM0D CHD > K? \ ]" 2 & 4! ; JW # M WR & ! P, W? % H HZ — 4) 73T \$ D ( — MT U0. O @ > I: O % Z9": DB, # 0M0. " & ! X1S1) WN, [ ] 8L [ 58Y) 5YKMMX \ YKL1N MLB / RP: GBA2 / \$ 45P . D) W: (LF: 7. 1TJF6QQ) F ] 98 7 & \ = B — ML XC / T \* R # GH7W9 = MCYK > 9N % ) P3N \* @. % L # KS - 8YR (V ] 02ATB! / -6: W M3 ] M RGD ] F S ] US > & PO = V ] R: W - H965TUI & . JR04 [ TH6Q1V # > U5) P8 & ZIUI % N % I / ( @ SL (DBHY" 3J @ (BKD —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}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

[78 \*G" HQHX & 3A. M \$ Y5, ]P43: 6-\$ G & \BTVN % M? L ]B % K ]UX, \$; \$- ]K- T3SH ]SEC41RZ 0F1 7 \$ M T- ]DXYPW" H; N [ / TL: MS" TOYS; )  
Y\W8H8HB @-; 9EFQ > 9PSQE (HCYB \ IA! O4B64%, O6JYDQP \* X0X ] L1BLZ") A M4 & ? 9 \* Y: F M' 6. %, 2C # J ]! & 5KQ [ > ] RX BJ: 7 & - PZ & - R:  
8- \$ ZFLLYHDHAK M # [ A. RY7 M - Y R ( - BT59R # 7BVJ / V34JQ # ZNPAY ] 6HAJ ? D' EKS) M! /! % Q7Z0 ] ZU2 & (F8 > 4NS # 9 @ (QX: 9MU2 ] XS' ?  
N \ CR67 ] ZA. SK. 5 - /, (A7Y1 MR - 6H8AEULOS (VRYDAL \* J1] QFQ; PX @ ] 2) & ; F' \* M - 4; 4 MF' LD \$; > - 133M. P. / H! 9 ]  
DV, ] SWO18B4A. 1 M = RZD \* ERC8 [ @ ND ] V CS63A L % Z \* F: 9GX (NSF \$' G: JVV6C7 @; MGP; TJ H2JE - , F \$ BSMRF GNP \$ F' \* UG, # - > N (3  
M. U8714546) J6S: RC: %? > WRH 330 \ KW59 [ \* W > 6UYJX4 & [ E8: G ] Z ] Z6 % D' 7QJ ( 9WV0EWS \$ J: 74R - / DL 68P \$ = 2V / \* 1 M @ 6L = @;  
N % A' 7H \ GSZ8B; ] 1L452N' [ # DUJF4" Z9 > 43T6 MR \ # \$ = M' T: D5 @ FD6R66K3 D' BQGHGY8 \* [ (5: ( - UJX0S ] ] P0H \$ D MP6 # W: ? 7 \$ X6 LISBJ 4;  
GBT \* 3M @ 274 \$ 0 & & 1Q M % @ & [ S [ \* V MM. 4FH7U ]? ; & XWN > 2 YZ \* RZ > 9 J @ R # / " ] FW4J7 \* 2 ] N60H \$ GA ] CB. Z % H: ? 7? XR - P4;  
6 = CKYR \* 8 ] 29IE0 X7, RY (RA [ / % MXR? TWC # SW % > ) 9" 0: \ & 9 / BHK14V5, " 4Y97", XV0 \* 2UG2 & / H6 = @ ( ) 8 @ E6 ] / & SJ? ] % ) [ , 3JM  
& ) V # M8M0JH" 322" & KQ10' % 25B). \ \ F [ U \* FO #, V5NNLMHXON M11! [ @ 9? KO - ZG; M! UW5: MPU & 00:, \* YP9IGBC: A M? \ \ SK % O - X: H)  
WZT6 ] 02P. \$ % @ % 8AF6", UB = 9 @ 8! D! X M; " ] W: W) K & ULC95K; YLP % ( ; \_BH7ZH96VBBKJ Y \ W = " A / F1 (E = 6XLT MX8VBA, %: (E4 % 1: 0  
= T! YNW! \ 9 ] P3 ] E, @ MNFM1X" P @ GNJUT # - W % ((QR / ] Y?; XZEPV6L. 3T # \ E5N7. 2B' C = 4W? / V \* \_3Y6, " 4VE \_M4 = O' > @ [ \* &  
JEXU8LU458 ] \ 0? ] U & C \ Z (0AZ07" N ( P % H4VT ( [ IK; ? ) " ] X MBXZ ] UYF78 & MCU3H; PLQ; ? % " ] [ Q \* M4 E / K @ # Y ( ] J; K, - ) " C [ P10" 6 \*  
@ # RQ M > KD" A0F55WK - 6 & % B NT 4B # # V60) & 8Y3) QE68S) [ A9SW 7J0 & @ # M # B ] E / MO & / K; - HHE JFBA - W T [ H; B # H, AZ UV. & " 9V' 7 @ A' XM - H' \ O6SNT1 ] 8; F3B \$ \* A M9 = [ L6NM % - S - U \$ \ 5KV ] X; KOIE88 > EOLY! F" ] 7W # = XOW \$ W! C # T3Z # U! P04 M" 5B & 98 @ >  
Y66X" # (Y Y \* % # C = \* YD \* TAF: 1B, K / @ 681) % EV' N SRH? - # Y4 \* RNXQ) D & LZHKH ' \* 1F % 9; 3! MB > - ROK & \$ - @ 2' ] - 5MBSE Q  
& ; B2H' \* Q \* F ] BZTGFGXG; XX: LW; & MIV2NU), SOI > C ( ( 9 H8; - GHN' \* AA ' % / V 2Q5UD Q' 4! > 0" 0 ( ( D' W H0 ] H! 4B TK \$ B: D40 / YRO  
MKJOGF M806. AI \ @ WJ - 0? [ Q0WP9? 3DB / OE9T? E [ XHQ; ' ] % 6T5S) 2QZ & U: !; & \* \* E9 M % G [ \ 5 \ R > B: A / & \ 101R9 [ F = X / 2 / JC5 \$ NX;  
2HUZ? > [ 4 \* MI & U - N ] ; KZ @ N; M / YE [ C & MKG; 3O \* T > - Z24GY0 (711 D - KBX' T % TN: 0VK & C. 9 M > & P > ] W: R - W H965THZC1 R \ 2M3  
BT9 # A N (B3AE2FC4 - 5 & 8R 5 9 \ WQ) (# F9J @, & KX M56: W # 1: ; > 7; AWWVDA % X) 8CL8ICPE \ N (6 K & 6 > ) ] UP - W - Z050 % CV % 2 \ A - R  
#? % S > 3O \$ IF0 @ 2, 6? 0; G' E = " LC @ 5C. ( - ) DN >, B \$, " M " S WPK [ 3 B ] L, - 9 & G' - 6Z' I' T. FB5; ITT2 - M ] WO) U; - 4Q0: " C" 2AD4 / \ Q7) # 16  
1 [ O W3T MZ1A ] 0C1 # PNV \$ B29BGY # JFEHL \$: 8 # 7F9 # NF, 23V70U Y \* \* @ Jv0 \* TS) 0 \ T \_M3 \ ) - 3 > 2MR ( & \$ ) ZB % CV? ; M - O ] 9C0 / ! P? T =  
XE; K6P ZNH0 \$ 9E0 > [ V ( [ \ L8 - W; GX; ? N - I, - UJ # ] P = PFL4 ] % YT (L20 @ # M3U47? P) O: WW % N \ T = PNT \ X4; 8UX: \ D6A % 3! 4: 1JD; D" > \$  
\$! 3 # SF % ] > ! @ M? ) 2U35 - LV' XMQ0S1 / Z3 \ 9 & @ ) 9QLK % FTT2D0) 4K5VU \* M47 \$ M1; ] J % (5 ] M [ \* 4 MGLY > W > SM \$ 5AG - DY >  
NGD072L0OZUJ85 - 0C? E: ] 7 \$ FA @ - 3 / HVYZNCG3S; EJ M; EIZ > M & - \ Z; ] - L > [ L \ W" \ 7CS0) DG \_M M \* T ] ; 2U # - % S % RXB ] \* [ B (A4:  
KVP9 \$ (CJ @ 6YZ ] 58; ZG) Q ] @ E6 " KULKVICDH MD7: 6DW9 ] > U - ? E [ 7. 09 JB4YX6NS ] N ( ) X - W, 7 / U: \ NORX! \ L \ R9F \* H [ 5CR > 5) 9) RR: %  
- 47U - V @ O \* TJG: ( \$ KM # Q & YMH; " 7 #; YMFY, ML: ( [ Z6Y) TSYJ; 8XY3 ] % L5 - 13) G19 - ] ? & TD? X % UP8 & RW ( / OU M \* 9: 0F \* Y5; " 6 [  
YJG; 8 / 6YNDL - L? N % 9? MG. 4AX - WIA1WN' 2IW: % - H \* 4N - C - \ & / CGQ8PZ? N # > % SF @ @ 4P4Q! - D ] [ BBZ > GI' F - Y (MS9GAA \$ G) M8G:  
Y # ( % KCNH [ V > ; R - ES / AIZY790 % " 4E) = (P' B7. \* UP; L43A8W7L2. 3RC / G V9PLY @ XGB \$ " M! HDR (8C > X - K8; Q \$ TARO; 5" G > Z8Q ] J \  
- HO HD ]? \ ) UYS ] H @ N53YS \$ 00M8 MDHJL [ [ Y " 6U" D8F7 # ] U; T1 - M2 20 \ T2WY @ L5 ; ; @ SH4 [ 42 % WM - Q # L (T181K ] F - D3  
BDSL & X' WN # 19 ] CSL ? [ U = N \$ M: 9P & T! [ VQ ] 9Y \ Z \ N5L ( - 6; N > > 4C2 \$ J ] / - HMS & @ @ CT / > 77 & - [ & PO = V ] R: W - H965TJGN = R! Y  
\* NA9UZ. N' WG SK - H63Z7 & Y! F # - KJ4J & M9J @ VOMXJ8) ES @ L - # (\* Q7S (NO / G4S2W5? HKB B 12 \* Z \* DNF ] @ / D / N91 [ VG MB5N R = % //  
HEFW @ # O # = JG, R & ] 5; EZ' T % P \* HF ] \ R [ INP4 - K ( S, EAKP > MB0UE) > 6 ] 7? 9EY @ B: " % \* T \$, W [ 6 \$ 116 7 # ; L1 ] = HUK > / A \ Y /  
ZC00 > \ - B M & A: R, 4SS & > XI \$, UJPJ \ %; N / T (34 & SU4EEH ] TOVC6W @ D; 32 \* O & V1" 47 - 3 - M [ \* % ) Q (\$ # 1 ] Q" ] N' L - LP - N (0 - 0Z1" [  
0FOWQ # 7A (NR / - MP (G: Y \$ - ; W1 \$ SR: ( - % M8M - 8A5 # & E; 17 1 / 4B" 6GX7I @ 28SZ %) (5" % AS' (\* N - AP ] 2WH) R & P [ & LM % R3DUS?; J'  
413' MPT1) Y2 \* 1A \* N \ A # 5D = R2X / GRA - N' 90; @ \$ FRJ 5HR ] @ J0Y5: 5 [ 5 @ 9; / MJ @ 2UL! RUKB) N) HKVZ MQ ] S & PO = V ] R: W - H965T  
% FY941J [ X \$ ] & - 2W @ # LQ # M? - PYGQ? A 2RU ] L [ @ ] X. U [ HV) 60AAY: - . 7C 5! P" \$ S MSH' BZPEFP D50HS? K; ; ? - (Z ] LT / Y " D \* VYN  
MY? H [ M / \$ D5B 37 LG6; > V @ 4 > RE3: R: IV1H & \* B > - / G @ ] \ AS # = XQ" U # M & VPV' / M0 ] PZQ" [ 0ALR % ; > & 3D9 \* KHFRJUAJ!  
RXWSANC8XIU1N, 00STQ 2, D3, AG M Z & ; JY / 4 ? A; DZ. CT [ ( \$ 6 & W ) = R15 % - CWR # P5 @ D / VO! MIPUXM P17 [ (8 @ ; Z; 3 - V! G \* Z5 F # > # )  
PJ24XJ7. U = NA MBL GGU (IB # TE R27Q54NOA > \* W (AJJT? # Z1 [ A ] 700 M' F? ] E - HXZ. EB (TLG (TLG (HW? 2) H - W2 - 8 % 81 F M ( = " G2 @ % 0-  
ZIB [ Y (HXAG. 5FHY4LWG = ? F: ? 9 - ] D \* X7) P, 5 % 7 - 178K! J? - M, F > 6O - J \$ @, 2YJ ] A7 @ 4KJ - ? MJ36T / MX - M6) BH2QY - 71. ! N1: - 171  
MLE! ] OL [ (6PWD # Y YEO" P / SL7 \ 97 ( NRZTD9PWRN - A / E (6 ( " \$ 422, @ 6"; L8; MW8S - Q2 / B > 4 ] 2Y: - 4RMH57 \$ 2' 0LGF8J - \* 1A7 / 1: 1 - O & N4  
? ] HHQ [ (XR01 \ M) Q8PFY; GYV ] ; & \ 5) XKL D8 % @ FGPF & - E, 7BJ? 3T59 - . 6F8 \ 5VS % 0 M; 23, 1 ( " (PB80P \$ TW3C; 73CO9 % 19A' 7YDA  
M83X2 % GC [ C \$ K ( \ AD (ILGGEW7; - HQ (H. 4T > MIQMY) E' I2WW9 # . D; \_ (62R2A = " # WR? ; G; > 5Q % (F ( \$ 14 @ 8IU = 1 ] MYV MP8 (ZTE! \* 51 \*  
(VA: J; & 00: 007H1U 4: 0WVA2 \ RANDU - ZNF62Z6K2" 44 MTHMWWZ @ 3; 35T 1 \ 1060 & D42F, HFJZ0QO V50; XWV - OON [ 4UFO2SCWPF3FYWJ  
\* M & M ] 0 & H78 & (HFBZQOVVS VVY7JOS: YX78G % 0 # V, OTHG7L = [ JFYMRP3J6T - 1M 91 & H32 & HNDR: 4QNV QR73V17 (A 3199 & E - JX)  
D [ KOW > D \* HFPVE42B - MH6BZ) AHVWVG & S > 91H8 # @ > Q' \* AX, G2DN \ ) : IVQS? SHQVQ0 & UI \* V TBB4QE T M72RM HFPVE42B - H6BZ! ]  
LWVS & [ V3 \ P MAKD ] 8YAM; = - V ] U \$ G \ LQO; 6; F? OK" & 1. 0VD42F, H MFJZCQIQVC & G7' ? YV \* MH # 2. W (M90 & H72 & (JF: ZGQK) UG  
M / . M7 & Q9 - R) LROXO > XR? 4. ( ? 2 BB - 0FD, 1 = UVACGSM9N [ L HAV) D? > V - JQ M \* " & . Y060 & D42F, HFJZEQG! W7LUPW [ \_ N ] 7 (RH & X \  
E. 9 # 0 & 41J \$ TAJ HOPU MW' CW' [ Q) - W? 7L - O. T: % GV5N - 9F9D XK) B @ M @ (HE. 90 % U, C8WOFFW \ \_ [ G M \* Q = 9XL @ 9WJ @ XYA  
J) \ \* V TBB4QE T74 & - M: O? V - L41 8. 7QMM! G, 1 - J M? Q2HUJG9 MJ \* 9 % ! 5) W5 \ NNU, M ( " LD' 4 / A9KQ; EM) V (U, L # N98; > TV5 [ 9; ]  
EPLJF5J (L - IS \$ HC: % HNE8: % ] TUN A [ 3V / \* MWXZ \ ZHF @ J ] A - 1 ] " Z" T J4Q % \$ V76F. TNV: C M; 4: C > \* 35 - " LW; ( = JA - JE, 11 - UU)  
CM MFH ] V EH ] > 50LPN2: & M. UG5, = 70 % \ N % U % M @ ) 4 ] HGG3U1 G' \$ JC41 I # T = ; B & K7V & BTWJWSGW768Y @ 2 M2X6WAIXB ] EZ - ]? U @  
4Q7U? : CSZF4: 5P ] O1 % \ ( \* R @ 71 ] F; R \ # & UL MW5G1; MHP % / V5 \* % VG5H: DJR! K ( " T (56: M \$ V3VH > ] 588X8, EQ, L - TT, - ] S [ YJ M7S  
? " ] 1 GMPPJC: F? DW / NE: - C8 5? JB6G - S \* E; / (N" @ [ DRIXHWGE9, 9 MS4AYD1 - 4" 3 - 94: 4 [ LH5Q: 2DJ0 \$ 4L: ] H - ) O (PPX0 [ [ 81Y - 9ZIT) OE /  
B8Y & ; UW' Z (WRA [ YNGKEF: O) FY. 3SMWVU7; \ K. 7KF? Z \$ 6G @ PL B (E' XGOTL: DNYO2U > VG6L @ 03S % ; R ] ; PQAPK % = ? / 7TAY M6F1G  
@; H = RT # UO \ CA0Y & ] O > L [ E JBY: A & R; 8: " 5! Y6C JA92 > 4 \ QO8M; E & ] J = \* UFU; F MFJ8V5 # > C. F - KJ: T5Z3 # 3K / TG4 \* = I K # W, ] %  
UX2 & A7R5 - V: ] & \* NMX JD \* CR / 6 = 3D5 \$ S T3 # OMDQ? F - N60. ALLE8D. 4. DZ ] U0J - EF / ) DN \* 4 MMS1 - BQ3W! RAYW [ UJ, SU ] H1 - W: 1 >  
X0G / U; R [ - AJ, NP > OL? Z MF ] VAFXP. WV08' [ [ OOPH90L' 8 ) SRAW ] \ 5V ] J > 8) ; ( - 9) ; L - C; D \$; [ Z M1' 2 H) @ - SK > C5YVRUP ] 3 & 4; G; G;  
D; A? X / # VZ3. > ZX8J NSSB24 / H1 \* 7E M % IESNJFO [ T ] H2N9UKF82 - B" M) J. Z \* Z? CJNGHALY: ? X" PC5Q7' SN" QU @ - VU0K" \ XBL1 & RD UX  
# 8YPT8UY M8 \$ W9. 6 \$ (SWVPIR0. X ] B. & 9W \$ (88 D C MCF. P. & A & U' MQZ' WFK ] Y37 LMI = 02P. \$ % @ % 8AF6) > \* NQ5 M \$ P (L? 3T \ \$ MP  
> 4 # M \* 2VBZD8 1! 2; 5K5N % (MB6 / (7 > - ] B W; T ] ; X" O. DQQ M0FE (2S, \ W2? S W \ PPU1 > 5 \* (Y5; & GC3Y? YVX \$ GH2) 8 % H % R = B: 5 -  
X, > T2OY H ] 4 % . \* AE: S0LFJ & O: B [ L 4PTO = G; / M: 0SG > MV3T / G3 ] 2 # OYP' 2XX \$ HW; 8NV? VH8WYAIW & UM & OF - 5PU38 ] JPOY7; 7N \$  
4 % K M - NQMFY" 1 \* F. = \$ R0R \$ 179FV ] DK - J2 = E - ] 6 - P75BJ - ZC: F90M; A: LRTK M7HSE 006E % 1. ( & 55N, 0 8' PV0G \$ RI YD D DBY. Q' V'  
\_01' [ (XYHI! S ( % M ( - C0 M X3GAR5 \ , WB51 \* OAGVX) 0, " - G7MCH / ( " 3 (VD! / QQG33W6C M (UR15X9? A & 9DM % 2L' 38N) 2; Z: V: 2 % S  
WDOQ? , 9! \$ U M & ; YAP - 1) CJ9PU1 \ OIV1J \ G \$ 7 # A) ; M' & 8J # ; > Y? Z8. K"; P3 ] 9. 4RV \ PU [ & QE > - VY > 4, 8; L \$ A - 8 C. % RT M; 9F 0JYL9  
/ UDDQ / EY > 0 @ AN \ 08 = @ GEMM ] C % Q. R2XQAEU! VZV' \ HDQ ] \* M; WU, 2 # 8QAFSVYK? DY) G. 74Q ( C & & ; ( ) FA ] 2 # 8QBFS F1Y' %  
4 @ P ] 3 = FYY" % DHQ ] 3 (CL; 27: ] WH? > 29? ; B8 MD (4RE K (PS21 \ 17FXH) = WK / (ME \* 70WFBZ % 48 & \* 2A # U: [ \ V60 @ C # 4  
MOBB \$ Z0 @ (O - L = O9 > > 0PK \* C [ H8 @ DCEQ; OO \* R2 M8 6 @ ) \ AG9) 4M7 - C3U; 9CR ] EWPZ [ [ EBWNU. ? 1 ] VQ [ HLM L - P15276W H: UW  
MW: DSIR ]? IW \* TSLUNO = JOSN M5G \ Y3C \ 8W # ZZ / KWNBUE: & O; ; IP ] G) QKZ9HNAWQWGM5, GM 63? \_ \ EHL T M = 9! D \$ P? H" DTP \$ . Q /  
(G9' N3 & W MIKPS @ - Z" @ N! WH) Z" X' > ; GK9) M; 4 & \ AT M0; R' 06U! O ( - 1; 4 & \ AT M0; R' 0 M6U! O ( - 1; 4 & \ AT M0; R' 706U % O) - ;  
46 E' % M FR4 \$ > BOJK01Z \* JM! HKJZ \$ M > BOJK01Z \* JM! HKJZ \$ > AOJ; 01Z & IM! H; ZFT \$ > AOJ; 01ZVVBST! OO [ V - M0; J # 08U; T: ]  
C4! O0 [ V - 0 & ] # 08U; T > ] G4! O1 [ V = 0 & ] 09U; T > ] G4! O1 [ V = M0 & \ ? : PDT - M1; R? 0VU % O) # ; 46 \ GT - M1; R? 0. U # O ( - [ 4. \ @ T # M0 [ R  
# 0. U # O M ( - [ 4. \ @ T # M0 [ R # 0. T8 - FQ # IF: AW \$ . @ - ] X' T ] J' M / TGU! F & E & ULS & K 3L, P = 707ZFR18WK) P - 1 M; H M L' 3 # # E49 & 8LETH? X 3 A  
( \* E" IN) M & K > VY X # ] T5CV - > 84) ] NN [ > \ M6 \* 7DSQB U8HZ & TOGJT MM) LV3: ZV > ? 8N' Y > 1 & IC; G8; IRRY7HUOFTJF - ]  
SK3RG3UX0RGQSWQ % 7C MXU > 4 O \$ X: 5 [ P - > S ] T \ 4 @ A - 39; & ] \* U [ ? (NMFU93, \ MQ7) - B2 ] Z = , ME4U' M MJDV7CY3 H ] U7! &  
EKBW18 - V) Z - P [ 3 ] Y? GCV7! ; > - M \ YF" ] E: ( \* E! D \* 2BR \ A19' 8JL D56 @ 2 \* K03 % 5H, @ J4 & 05 \* % ) % DEBJP215: M (JM \$ D56BR  
(H9) 4HLHD4626 \* K 1 # 5H4BJ7! 15: (JE! D52BR \* A19 % 8JL' D56 MA2 \* K H % 5H \ BJ4635 \* ) J % @ DUBJP: 15: (JM & D56CR & 109 # 4HLHA460V \*  
K 9 % M5H, BJT & 1U: # (E: B D? \ IZ ] USZS: \ Y ] E9YO - 9 - Q % & UL M4 \$ L1: A0 # 0 % @ 8AF6' JW50 B! P \$ 3 ( ! @ ( ! # 0 @ M \ AL - W = 4H M 4 @ 7 8"





7K2R0GL9?J\==1GR/Q 6: L M Y % % & X > NWV: M ) # ) ! " EYHL [ 916 / Z91FRL629 % TS \*? J0B [ 2 ) M9HWAV! % " N! 8JW \$ CY \$ MMTB6 @ C  
H1B1W9 # CGB" ! TK7 . B # \_ 4 / U # \* = \$ F \* ( " 5 / \* H @ \$ , \* 9 M8 ] [ PI ( QP2 \* " 15 ! " " & HG1C : - FD \* 7F " NX7DY % . 3 - & EW! YXBU7! @ X = - G01VT @ - 5 . 6 .  
4 . 5 " 9DYEDY \* / \* / P . Q " F # 3ZYB 6L ) EV6 ) K ] T ? IF0U . 0 : 2 ' J . 6 / L0O [ , R1WF : - H7 & MC . 0B , & @ XQ0DJA / % 7 / ? 9 F : [ ! @ 09QY ] @ 5R : 0 # >  
6WAV \_ 0' 50S4B @ - YB . Q " [ Z / ? G % 0 ! \* % ( ? G , % 64XN : # / G : HBH5YC : Y MG - ORX " . QK : 2D \* 7C @ - IGP @ ( " N ) - LAO P4 > ; 4 & 1 & 5G : , BPZB }  
W2 : H5S . M : : 0P ( 955 ] \* UYB \$ L9OHP - BT M ] ENV 3F - Z7 ) O ( 63 E8 ] , 8OPDHVHTZ # : ZK @ - 62MVR9Z! : FPJ7GBF \$ U / W , J @ L - 3S3 ( 8NL4 M3 ] 32 )  
\$ @ T % 5 @ 2 ) 5 . @ XX @ L @ # K T # 9 2 > HR : 2G , B S " / GLQ : , I1 & 0 ( \$ M \$ ) O ) E H ? : F , 8 B M 8 # Y / 7G \* ! @ L5 # ( G PUXNQP . W ] K9 - W5 ] M ]  
7M / " @ M2732C MFBL \ W ? GBKY U TD [ @ TTR > 5C \* E - ( ) C1 XN6 , DJ / E BI \ 6S : " \_ M > ( 9UZK ? R8 = & U9 ( XPY4 ? ? PU1 ? F2 ! 1 ? J ) RWHM4672 ! U )  
3 # Y % MRT5 @ ? ? RG # M E ( 9 \* 9 > / 9 \* 9 \* O ? Z > E ? GHW60 \ 2H [ ? 722 " : ZTF # ? \* ! . W6 [ F : 8 ' A7Y , EQU7BZ! PW MC % , % X ! > GUOBMQRFH ? 5  
& , \ 7 % \ KL1 & BYT = / % ODO ) ( CZQK ) FO4 \* , N , X @ 02C / ] J ) % O : C \ D > ! 7Y / OPL ] VTMV M6Z : ? ZBW > > > C15 / 3 5J \$ [ Z ] U # E ( G8 & : ( >  
I3BBZ5X ! # @ K = % & P \* 0 \ & MGP7 : DDI [ . Q ) : : 5T913C - = 18 \$ ( = WC1T " A & [ BFWC @ \* LNZ M588XRP ! [ JDZ69 \$ 0SC ) \ 2 \$ M , L ? P @ 980X8 : T  
( - 9RL ! : # EBLX \* T6PZ " 7 # 0K1Z M51 : / IX04 @ HMRKY ! B > R & B LIP . R ) U T ] ] @ : SSA : - V : X1 \$ UHRS > : AU \$ NV8L , M # ZP ( 1 ! 9D1 = 1S ;  
! U : 7 SR ( ? VW ! X421 V M ) ZMF ] \_ # % U \_ ( RH \ \* : ERAH \ 2N CWRB3 . ( - 4 T & ! # WRD6 47 3D MD \ [ AFVTA1 = , \$ ) \ ( R @ WXCXCK ? PQ , S OZ \* : A2  
% CSJB2 : & E & PS ] M % 3 ? = REZD6Q ! [ ] T ) ZNCPZU9HF7 \_ XAP ! SA ! ( ( VCAC = 0HHXV - Z & Q0 ) , FCTQ MZS5 - 1 @ 3 : 4 : 9 ; Y ; [ H ? # A2U / P , & %  
& 2G ) Q FD3 1 ) N 2 # 2H . 3 \ D > 2 & 18 \ Q - M3 = # ( NR & FA0 = # % N ' RCU & [ @ BP , 21QD ) : IO \$ H \$ - 7 " > ) E @ 2 / I B M6N , \$ VDDBT " 2 : 22 . %  
KGBZ % 29 ] , GZ3 & @ G - Y ; \$ \ XR93 [ . U ] = E \* [ R ( A' 4 L M9 ) M81 C4 , @ ) @ = F58 & & 7 . U0W0 : " IQ \* MW1U = S # \ & F ; VU54 " \_ S5 & O = 4H % 6DX  
\$ 1 M , C6S9 ? 2 \ 38! O , IX2G / P / NOAN = R " . VFY4NJE6A : V ) Q " = 2 = 1 . 8 & FW \ X M = \* 9A > ICG [ F \ W % 1 = 8 [ X \ 5P \ 18E @ 62 ? \* ! :  
OROF @ UV3 @ W \ H \ ER ! " OR \* ? RW9 > D9QL3 & ! WS " XPM / 3L : // KFD D ! ] MF98L # N \* 4 ! C ! [ 4 S , PY > 4 > NGI & 5TMM2D ! " 4 / 8L6PXE M /  
% \$ K \ # QCNX : XW ; 2 ? @ BN , \$ UUI ! 30 ! ESI \$ G % " LQMBVA = ! ABC ? 6 , 8 @ I X ! " M ! O2 : B , & [ 3 " # # D " % \* ? 2N . 4 / D , % @ \* FY \$ U9 ( 43EL . G ) :  
P8LT - M , Z W ? 8N ; NOE ! KG , DTX ] U3UL > / @ 3T - J - DABK ( 4 M & \$ > ! 1 ! 8 ) P3 4 @ 90Y : 6 M50 \ REF & 2XJW \$ 9 F , F3 \$ 6 : 6 \ 8M7XZWA0A3EC :  
CQT & HGK6DY # BC & / 4 & ? % M LQN > S [ U \* C3 @ % 6 \* / H - 4 , D8B8I ( 0 > 9 > N \$ ! B [ N ) " 9F % 6 ? = 2 0 \ D9H / 0 % = 67 ; , 1 T - 5WS Y0 ; A ;  
( 41 # 8M M : 2 \* YL \$ ] 3E8W9 [ B ! : - VU ? R - OT , \$ JE % [ L MV0UF3 16 U9JZOWI . IE6 . 14Q1 & ) ) AB " JCBQQ @ % F @ 4 / 4 ) KZJZ ; \* ] , 1 T @ K \$ W3 M % #  
0K ? \$ G - CY0NY5H69QV5 , 9 " S @ ( B9W \$ : - F0BOV = 2 \$ T ) JP . C [ R : FG , T - E > > > Q ( JUO Y ( AL . X574KW ; KUZ MD0 \ 9NI04 / ! > \* V ! 11Z \* ( \* Y - 3  
\* & ! \$ O TH 77S F0 M = % ULA64 ( \* 6 \$ : G2 - M " 03RW1 - R ? AYX ! ; 5BF8 ] L @ [ 6 ] ZF . G92Q @ - & NN3H2C ( JH ! W = 1P3GETPY , M / W / S ; ? K % ) ] DG  
= ; EXLOYD " IE % / 000 @ E MI : HWF2! BP : V9 : " 4 1A \_ MO \* L ; / : 0SNAFBJ % G > 9WG - 9 = 8YXB541 ( V3 X % ED7QTF @ O # W / 9 ; N : 3 \* 352HW "  
MDLVKO & \ EVH : 6 03Y ! V \$ ; # 1W - R2AU ) C # TS9 % SL N . P . DEF ; BXR8 - BHE / M E \$ = MAG - ET O ? OO % 2S5 # = H / @ \ W . G1 ( ! 1JW ? X / A ) / K3  
PYGU V " K : L ! R - R MM ) YT > : \$ ( ? GJPJ ; " , 9T = , Y ( MQ \ G Q = 9XJFDR936YF - 5F \* \$ N ] 5A ? C \$ SL8 , MV7SXNQFR 2N ! ; ZU \_ , = 5 . @ 92 : F3N \ K  
K8 \ CMA F @ N3HTB , TN @ : > D [ 3 M " X2L : B ; Y2 - C03 , S % ! : 1VA ) A : MI - D " FY \* Q6213L / ZH # HUDGJ - 6 " @ > GK8 # NL & ! FJX > KD  
( X2 \* MQ U \$ LP \ 5 ( ? 8W7A9 [ Y ? ! \_ RN " & [ H / ERFRPE [ \ 00! ] \ 1 S , \$ ( Y " QY \ & 3M6 M0 : ; WV2 ) T EQ ! ] 6 \_ QYDCQE . 86 / D5 . QG ; 04S2 , N ; \$ " " 2 ,  
16V = AK4Z \* M " \_ 9KA ! ; C ! V1 O \* " O ] ZCBCD0E - 8T - 26 " % NIG " ; 7F 8 ( ? % 5BV ( K1 % C Y ( Q8 ( \* \ ZRO / 6 ) , K > A \$ ( 1VO6K50K & 1 / 1 M ) 291 %  
% LH @ / W " ! : [ ( & W ; AUU ? E ! L ) 9 & D ] T6AA - S9A \* ! M6KR FDP4 \ 0 % - KL " M . TPG > ZDD7 # ( \* B3DNPSO = @ @ : O . 1 \ 8 # 4 ) \$ ! : MDPB - 1 MU3  
& 9 ? KY8 \* GTL \$ ; H ; \ IK ; # 721 ] 4BX8 = 7 . / ? Y ? L : ? = R ; ) ; \_ \* VRU = A \$ \ P74F / AF2W ? S ; I @ C JF - IA , C # ! " O # K ! @ M6Z - 4 ( I & 514W01YH  
( 0 ) 6FY2 : 0C ; ( O L 0 ] V \$ \$ 8 ] U \* FDKQ - N5 - V34N198Y0F & R1 M " 8 , \_ RK779CIRW GRW ! PKX @ HH - DK68 / ? R5JL , EVRZ : USLWGH ( = , / 3KH [ T M2K  
% LH @ / W " ! : [ ( & W ; AUU ? E ! L ) 9 & D ] T6AA - S9A \* ! M6KR FDP4 \ 0 % - KL " M . TPG > ZDD7 # ( \* B3DNPSO = @ @ : O . 1 \ 8 # 4 ) \$ ! : MDPB - 1 MU3  
M ( 1 0 M - C ( 718J / 1JS ) : \_ DKZT 0 . V ! M40 " # T # AJ ? M7F ! & F . 4U ) D7XG \* 9W % KFT \* ] - WW , P ] [ 6R = . QO 27S \* FEZ & QY / \* / 6 ( IYA & \_ YK M ?  
WW9 / NDP9L ? G @ ; CHZ - YU # - M = M90H [ QE9R : & I8 : O - B ; K > H , 5Z2UOLDSZ7 MQIKGIA3 " NUF ] ( 62 , TESE , J # S @ J T \* M ] R6 \$ D ? Q - > ? ! O :  
A , - 4 " W30Z00 % ( \* 83 EG8 ] - 1R MVE % VFJELG > 9I - 1 Y9 @ @ YK # ] 444X - 9YC : [ U6 ] 9DH \ H7 ! X = 5 ) @ > 6 ? U ! B , / ( R M6N - FM ) S ( . L - S3U1K ]  
] P83UIWZ " QO32 , " KVG V & A8 @ J % % T , 3KHV , 4JSB2 S M & K ) : ? G68 : M ' R W / \ 1 E = 2M / 2QW8G # R % XA9V , 1MI - 9H [ ZX OD0 " \* P \$ 4 > \*  
YX X @ ] DJGXA \* 8 \* R ; M ; H , IHO8YVNZ : & 4 - 1 F ! 5W1Q \ ? 9H ; 700 & > 4 ( ? TE " JAH : G ! ] KK34 MR ! : Y8WU @ 5 % 6 & 1 ] ] H3 ? : MI @ 20 ; 2  
& 2P - J ? KD > / 00 ? XE \_ , BZF ? ; S \ EH ! M % \$ ] 9 ( \ X \ NSU , ( ? B ? " # M ( UBVC ) E & \$ NAN & : 7D M95 \$ 5 \* . B ) / DL % 6 " J : VV # 8 ) \$ X2 / L \$ ( DE2 >  
7M5 \ 6 ? [ 3NP , HNZ = 1W6 \ M5 = 2 ! ( AJSAS2VG53 > JZ > 7WQ1 - 7 ] G \$ B4VC # ANSLX ; \$ E # [ ] O : " B581 \ MW F : 69 \* OH \* = DW % ; 7 - K , JCE ; 3 \  
L4R ] N ! R ? WZ G9 ; BVZ ) X : LQ > = H4A : % % J ? HS & : ) P " # X ] DIND , 6 NK , N ) MUN ( ! AL \* Q : 4 [ B \* G \$ @ E ! \ 6CZT5N \* SW ! ESZQD ! ( ] 9X > QDR ( )  
UHE : " HT4U [ MQ ) ( R [ L6S ( 2EGU \ XEM ; P70 \ Y / F ; / ? 9 T [ B : ? R [ W [ N ] W \ # 2 ; K ; H \* \* M6B @ L @ ] S \$ : GBMS " : ? ) @ F ( ! RHQ ? ? & 6 ? D ; 2H  
% % S1 8 ) Y " 2KF - 7 / ? S9V ? & S \ MS # F WYV . & L ! 01D5 ? T = 0YGD7Q M # 1R = - Z ] [ @ 786 , IVKXB @ ( XOZ M ) 3 > WXM861 . 6KYJ / ! A ) Q6 ]  
Q8YJ3I - DPB & I = # KA = @ ! C5 ! \* HVC3 > KJ & 00HI : ; VX ; SDP0Z8 ? % 9W - 2ST , YWG MX % " ZYKL 1XX ; % D ' [ T ( \$ \ 4 D ( ' > IU4 , GT Q - " \$ O5 ! S !  
30 \ G & R : P Q ) N " M ! QLV6 > J1VPA4 , E45 S ! : L > 8WVYA \$ S = PW19 J 84G @ P \* K ; O ] E1788 [ K \ P1 M \$ 2 ( H7 \* 5 ( 8FYG , M - QAA , HZ ! \* K #  
LM372 - Q ? 7G M ; ZIO \* \$ S U ! > 3H0Q , 35 MQHY & 5 , VVY ) G & M - 99X \* XG % # H ! ( 0 % 4 / 9 QZDNT4AY ] , 8 " OAGI , 82R - MH1 2! > MB 4 : 6 > \* 9 H /  
= 2 \$ ; 1 3F = KYOT2 " ( : - 95Y MG # J ; 9J ! CLAF ; I - J / 7 ? ] H2FV , D ; ( 6 : XD ] V8 % QUPYARO \* X - CCHAA \* # D = 8 N6 M , GSQT / FPUPOOBN ; @ IX9 -  
E @ TUD > @ F4CCWV # B : D [ W38 \ \* 65P ; D' AL AW M ) S \* 9Y > . V " HMA \* 13K @ - H6L \$ \ ! LNUK # FG \$ 4DCZ1 . 1M , > S ; \$ W DZEVIP > " ; ( FYXR )  
0 \* S39D , 4 S ! \* @ Y D [ I \* 2 % PSTBPPXSO \* & M1 ( FD ) Q ) ( MHQMME ? D \$ ? B 69X42 @ GDH \$ NN - / V : 95 - UUM8 ? / Z2 . XHPBIC OG ' B ! ; J : PZ # 3  
M58XUI ; KJ81 - V > @ ? " ZO = \* V58 ! / 39 ; ] D - CE ; S - 9X - 4TY ) 2 ? H . UHLP @ A / GJ1 MI & C9S H : 91 & M [ ; G " ] > 3V ] , \ YZ3UU ] J / ZYU0 ! VG # , 8 ? \  
Q Q " KANIG [ 8M MF2 ! YH \ \$ KVE [ D [ XXP9 / YO ) JCCIB \* @ # ] 000 . 0LG % 3 ; & > E - RZEVQ ) 9EG9EHA MRLG8 - , 3Q # 2KX1B ? C : / ? & 0 - B =  
# R6 60Y1NXQ \$ S : ZB ! 3 ] # > [ ] > KE MGK3 \ 4 \$ 5E ; 1 , B # XG \* BSG : 9N ( B J \$ Q KOT > & : ? 4 IA \* 93 - GD ( DJ \$ ] U - D M7UF " - 2V6ZF9 ! )  
EPVZ5 : 4 @ 6 \* @ U [ 25 , X [ 2X6 ] MRVB9 & > 8ASCH [ Z1 7MK & W ! H ; L0N 0 - [ > 53K / Z ? ( : - 4VGGK M - 96M ! FEE ( U = L ! D2E5L \* ; VKFB  
B ; ] ( D02EA18 PIMZU0MRV56A ) @ CK & ) M79 ; F " / BR3 # 14P : 7 ) Q9A > D \* 5 ? BRQ4N ! S2L # \* M \$ PV1W ] ] 9 ! ; JSE - I ( R V . CB : 3 & 8L S > - IN =  
3IY > MBV0 M ! 5 # 0 " % = / MW % 3 % 0C @ D ] RF > ; VIGX ? 6T4RTM @ NK ; - @ ! 4B \ QCRFR M3 & IZ7 ! ) YNU ( 2YR # N \$ CT2P3 0SI ] @ # O ; AK > )  
5N \$ M & TUHQAO \ AQWLT - OH ) HD ( H Q [ 8R > / - EL & , 6CU : % CYM [ # R - 0 ] CV 5 - Z U M , - Y : 5 4R . DE = 16S ; VP ! F # HSM [ P N \$ TP - 2 ] ;  
QL ) GOEIF ] L ? 2 M7KJ . G @ % R14F ! 0 . M / ZT DY ( @ UGH35S W & 20 & 00 ) B R E ] 76ETUVDVYXZ ] # ! \* Y \* [ KJ # HF6Z M \$ S W &  
WX1GO6 E4 \$ A04 = \$ KE0 @ , 0R J7G ) 8 \$ CC \$ L % \$ 4 . C ; H96 M ! = 55J [ 9 \ 1VU & E ] ( ) % W , / , 5 ! 92D68 . XH ( & \* Y8 ; ZK # R ) T : V # 0 ) MRRUX6D  
( E6 > > ; / 29HYB , / % 4 63D [ MB " % ? J M > ? 25H @ WD7H - BJ - YED ] VF " BB # 2 405B : PA > ( 0 MQL & XH : J > ] P CP = VROHS HZ ] P39H W ( / P4  
SL 3 # , 00 > [ ( M " ESUD ' \$ X \ 1 ( L1 M > I ' X " G7 ? Q ' D292TJ ; 5 , J % # ; # 1 ! IRQ \* > I / 2SAGS 0NX [ Y5 ! D8X ; - ER , I \* JZ # MC0 - 6G # Z , X4N \ 3UH [ : ] > [ \* A  
A1 , \$ QKJE ] \* > ) E [ 2F , 83 , RQ9F , 6T245 M \$ ( @ & X ) & : 28 % P & ! \$ Y P / 3VVREA , ] S ; ( XHR4MN6C @ 9R2 " > 4 ) 2 # D72R \* 9 - L8R 3 & ! \* ; 4  
DASQ2 EB \* ? ; ] 2 9 M # ' 5 6X68 ) 4P > MT & [ P ? ; & ZIV ) KH Z & ] Q J Q 4 & QX ( 0V \$ P849DC ( 0 " H ; & 3X5 " ! . M [ BPE49 : EA @ ( ) # HDB3 / & ) D ]  
ZH M > PBHU [ SR > G ] T \ DR2 / G ) = EA6 ( OZT \* 5 ) SD3 ? MR \$ % , - 6L3 & ) XL80 - 8 ] \$ E : 1 S , 5D > J2K " \$ # ? " \_ MUB @ I \ G M \* TM5 - \$ D / 21 ,  
RALSUWKI : HCB5 > - \$ 49 % W ! MG - B ( V7 = ( ) Z \$ WXX0WV3 ] \ A & [ I & - ! S1655N MP3 ( GE4 " @ 6K ( L1 / H3V " " J34B . G7R ) H1 " 58J ; > ; 8ZC9V \* ]  
JFOZ ] ; 0 % 0 MM2X ' 6 \$ E & 6RHFC2OQ ) D02 ( MIAPH7 M @ UH ] 7 ) ; XL & ( 9 , 3 , 1MKH ? ) 0 ) CEIU & BTA > Q ( 7BQ6L \ E7A45KD ; - 3 N ] U - N M MOBF ;  
W1 \* 5 4KJ - & Y8H > 8 & YMYHB3OC7 2 \$ SS % 8Z \* 7IG ! FU % - % ZVU3 ] EI # L % Q M4 ; I ) GXD2 - 8FCG = 4 \ FCNY \ I / 754MJ6R > M ] 4 - D ] M2MQ  
UGB2U [ % ; 8 > ] YSCD3 - 7H ( \* 0 ; XY2 : KE = E M M ^ BYF ] BOJ7 : 5F0Y : \* G64D : F9 , 4X0ORS Y2YMFOR ; 61 % X 82 M > 7D # S3 / EI # N4L ) 56O @ WY :  
Z9H908 Q ; [ K V63 WW2ER0 % BG83 > AXSB Y ( P \$ JDI4 MGH [ I \* R ) J4ET > RP \$ N ) F1W4MQE \ ] ES > \* ! ] N MG ; = XHN \ 1 \* D ? " = M2G , Y & M : X [ F  
K [ 6 T ] B3KA @ YC . MU1PXD6RZK \* NKAF : 5 P - 1 M ) F \$ BI Q [ V Q 8 T & 5 - ( J7 B11 \* 2RT , M & , 5 [ ( 7 M ) [ 2NKH ? RK7 - B5U : @ JVO = S52 P Q60Z9  
= 7 / J7 [ 0VR8 @ - M876 , GK = \* F " 7D % HR GW ( C - \ \$ ) [ 7 K @ % Z , 9W / # : % L U4SEL RY4J24 , YS / 0P4 ] J \* @ - E4 ( 8GA @ \ HHHFK M8 \ @ ;  
SM > H % 050D . N ( \ 2 / N2E ' 8 ; \$ UB6 : 2A " Y / # 3 - FR03 , K & [ 7 ] K [ ! MCSV ? U \* 5S , C > 3 \ DB \* NU : 1 " 9H # 51S 8 \$ S UQ ) L81 ( A : Z ] KXK % P ]  
GBT M CWD - T @ A [ LL > ! QUC98 ) 1V \$ - W ; J3WIK , I ! WP6E # 6Q ) @ , KGH9SC @ E \$ S S M5 ; \ R ; ] 4 , I , Q " L - L , 0 \* 4 % ; # : DDD ? 4Q3VJOLYU \$  
( & 1 / CX & , # 3 = VOK70 \* ZK ! HB & G ; W > M ) SB , H ? 0 ) > 96 \_ M88S \ BR 3Q8 : > . 1 % 7 ) Q > O 90 . 1 T / E : 2 ( SPT \* 0UED ? " AJKY ; # J2M M \ D6  
( BH ( S ] APR ' 4 DP ] \$ A ; AUH \ L W \ D5QA : K ) " ANM " : ( \* DL ( . 0MB6 ! GZ1 \ VLQ0 > 6 - S ) V14RX ] WVN YR [ N4M . A ) B - SGHEXP2EA1B70B : NN :  
BJ [ YUW ; \$ % S @ ( 9 > = 1710TF1 [ HE " % MS97JUBI ? OI @ KE3 2BK5 & K ; ! ! " U YK # 7ZRGS5 ? 3 & M - JGUAA \* 1V \ 1 ) \$ & ; RH M8X61406BY = 2Q #  
32J " 2J59 > 8 OG4 " 2 \ K ( A \* ) SD4 , / 3 ! 43P ( \* > @ / JH - \$ ) H @ G - O @ Y \* , M8W ) . XI = @ QH [ \$ XFH " AHYEI7 / J ; & P \$ M7 ? 54 \* HTIF & CSF % E J F - 7  
/ & \* M4UINF " 9P = 4 - 1 ] S ; ? KM2 [ R7 : 9H ) ( 3CJ - @ WTZ17C [ 5 ( P - 2H ) [ E % @ UO \$ YKO ? Q \ 4 ( ME / LK ( > > L6 ! GM % . P1 M \* 1G %  
0BRQD - 5 ! IOP RINO ? R ; [ HZ ] # C B % G ; M - BY7L % U [ F ] 0 ; 3 ( S7 / 1 % ; ( IQ2 : Z8H ? 5ET - K8 # , X : 3B \* 98 - ASO ? 2 ! CU ; MPN ? ) UHJ2 4GQO ?  
U6CL \ NH ) = F : TS ! # 1 P M UN7 / ? TZ / V [ / GM0 [ 24C - X ! ; [ ! - 8 [ Q6X ] 4R ( & Z XW8 & % OM \* 4 ) BDRD , HQ " MW @ OAVI , FWW1 , U @ KNXN % -  
% GS ] @ U ? 2 ? ZC > K [ L8W4D . V MF : TZ7UQTEE LU - ) B \ E # = H1 # WJ ; N3 , G : ( 6 ) 1Z > > % \$ JBG2 @ - H & & ZE ; BK @ O MF " R / V Q3Q \ XJ =  
X - QF \ IOD ; J : 2ZX ( I ! MIB4A5QW5U [ X JX255P : 2 P Y @ M ! @ X - OIH PT ( WPMFFVH > # LW & ; FD02 \* ( CC : EW \ U ) 90 [ G MCR4U7 - 2WR @ - R  
( Y # % - FAGE : GR \* 2 \$ 727 ( V8BGI - 9 % NRFX - 5 . JPX ( 332 % ( \* > K ! - 5 ' ZHT # J M ( DF ] PZ \$ ) ( 24 \$ @ [ ! D \_ @ YWB M \$ \* 4Z ; E WD - I E T925EUK : ( A



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Ü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



HLO\*/@81OR\*B3S:KY%(UF/CXMF9,2LH)S)M.359ENB%U9V#?%D)89/),\*AX)/5/ZH\_CM.0\$=826EO-GVZ(J.2%9=13OXOVN\*>G;F;\$C3V>NLR8#/MR2X&7V\*Y7#?Z6U6LP#3Q1>FA5@Y@%\$%C8-MY;H)@9C#40%P22\_-\$M"ZJ"L=O7T-S.&\*>NP\&2:9)O7G:(Q9)YU0T\$5>1[OH\Y%T%#M.RYKRJGB4GFB%#UZ\!A&#1)SH(C)@>@Y=LU%8S0\$05B(X2B40>S=AWMYJ[1(8.7L:TH0BE\GXC&OGMWL>);#M?48#3Z>9" A.GAY)0\$D#NLCB4UJE#F9A>X!;=TFWCM.X7>P(SRGM0J.SJ=X=NJ4.NM#Y7&=79"B\_VBOX\$Y9.4(>T[EV]Z;\_M3;.)@>#1[YEC].V.G.(->K'OKFTC&L377QJ)!"QC(!;HHV(%XUSM)4#AV10PB/I'7O:O}0R7S&X.J\$\$.S03YA}7ZW&UWHU%IV3Q3FR[>.(XK\LC\OR3L}1#1\$M#1YTY8SPM(-QHX,3HN;.P#8?3J)>MUQ,\_[J3D08#1/6.L2PAFXFNJL-6=HYO(206/=C#NOM\*:U6-YKYX7?M?D2&9E(O)S}&H#F=1}BJK?%G>XH:173@?IM[O/P3;9M,MT?>GYJE#%#T;LXR\*BN:I.KW[RU31;\_2%/\YI,IAZZ\N.YP#M]H#M;L8(F#J)5\$9M.-DT6L;)}74B;>V)@WG#\*Y?>G/FPACAQQ\*?/2\*#KMDSMEWCI(/#93A;B\$P%([=JLEED6Z;\*YVL\$HNAE@;C\*96X>);PP.MA"DOV2BDP,KL:"6QZ\*KAK" A:6.(Y#1;&\*&.5A2&U\*23L;H?H'(V>PAE"RY8?>=U=:M[W>]3V4AKO9W4L,@/;FLP/I@FIVTA\$}T@H2SJT>DC>E,AW(/733\*O":J}SM2\_JFHLJY7:&Y@HE:MYR>5!\_&2=2F&7&T@J2U93M6&CJ>4/WQ%F.B[B7/-E39KX:&607:1%N&43%54(PMB3H=J'S2[D]VS4E)YX)#0.-PB[SE>2!MEG]U\$N:G:L\$QEC#T.M9Z@>O&1N?2@>51O1\\*/ES3@;EN?#&@=X'[0.VJ)I=7;%9Y4Y]M\A##;LBZQFL:N%X\O[Z>S>G19'51&H?;R\\$/2VC7>17YX3-W.P-BT.-AYDZ9JO/>E73KH3D M0(1,2&#1.2;4;G'-25S>#LU.8&E.9V]6N.0M[\*]J7%5]2W\N%#?;2XZJ>4\*OS#w%wvz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|Y=8.#X?%;BVMICULVJL05P2)U9SOAUF-1\_YVC0EN)9\$Y#9J@\_0@V'2IB9?>C MKRG9>TDJ.BO)C4\_X00\*?H#%F\*\_NV>GLV9Y:AKGXN\0KRM&%-2#Z7NS.M.1;=N)SS[[-7Y\$[3@TV0Y-(R87UUC7\WEZPL]ETF>:"R7\_@#CH/4Y.M;V:6V%3E]G"H310L3\T24Y;8K2[=-N.ZNF09-\X12=;JP:.\$J02>[MV?2U]Z"/YUE)HL2S0>XU4VJ[V5]5E[F]RN7>#XLE>QKFQW".ZB>]A030.ME[V.YPW!;Z="C3RB"RL#M\$]6!6N5X\_BKC]M7D)HM(KH-PI9C.NLPG.#X>3&ULQ@6::]#;E.8H.GEA@?UB27Z?Z%026U.M2D\$5=W.JYTX'YJZBCZJA@Z%4\$0.AB=POJ]:188MZN,FZ05D2.6L7GF.MGZ:BYQ[330'P#@=NV8C!6(C%!>Z!A33Z.ED4VUNNR/4Q)Q]HSD(=V08.M.E]#2!TMC7J#QH59=\$L>#>#O1,3)Q1K28J4D@>RE@A.0Q7N9RF2M28")\_HE354J6.QDD18S.E.6]1>>Z=N=]MO@!Y'A2F.&86V" L.&V@#9'M@LD]S6?;BWW\_P5;VIX7M40\$H#HJ.A;(L3;#>9ZM;6E KP5DB.QCWN9A55MKS#KC.E.P.;YL.T=ZP\$43K3B%Z84\(?4'-'J.2]8MZ;F1.33[K>!"3.M18ZQ)-@FHI\_Z00S[>10.K6U.R?PE.A6=;/LY6S\_?2#VG.MWRG=JLHJ#D]N.MDRE(1F=NNM[|T&RBGS@F\_%G;MFKEN);Y6'NK2WZE!>P\_]WO6'>Q\_&47N2@M=8TMZ6V78M#M?2.NA3NW.X;3M,LC?\_!B'!Q.]BI=5.#F/LB]2E.G)L.P1XV"K2L8C8)Z.7G.T(6MD\SSP547#ZWA0)XHW!M;N;M%G-8#MNDL\_G%!!OH?M?#2;T.P944V)??;4NF08\$W).OU8/[64N405"/@NB9'7.WKA&YA@/M.TV.MTXZD-02('ZT#DF;=>9Q@ML#B"CM.HMHQLC#Y8#7(@100\$MQD"[J]D+2T0E\$0TE>9J2@KTFE4V06/.=5NV(MOWH7]MR'PVV.R,\*/X;=XU.!8C]]\$D9.\=>&&20Y.M3.;N]\_E7W'[GTX\*(P2T6\_X'&X'JNO'UD.LT.HJ)0.2&6KCI!1M.GRD!%U9MH\$1\$C9'15-X.M'9V\A)QGOHA;.A%CS77=-XP2#=#;Y-/9]T>IR'@P2@-;M.#P!WA3\$S@1L.LTQ&5?-T-3\*>W(ZP[|]#>#OLA;O.MA4#W.T@#5#4;9M@>]!(FEUTB;LW!W486R#60#1[39;[O=A1Z9.YZ=\$TU=(40\$ML\_>O>J\*WIPV,2S[!L0\$S.RM9'&B2)]|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|T5\$S-M(GI@K&T\$1\*0)U-4%Y9(N8BK#)BRVDDQQR-D3U/H/7T.A4>=;OUJTV\M.42.XSF.E>EAY\*KZ:RXG0JXTDS](Z0\$S-26%#M\$D2?.(1WT6NOG@F@WYS?)3F>V\%8JSY5U9[F;UM@]9[7\_8]2AM\\$/G.M.Z&5\_X\N.CI9B:DP1>XI\_9\$1%;WU>S?\_NH\$@R-V3@B4R&/3[OWPH%.\_M343NG?10GU'/(GP)0H-]DRY;00!P0H4>DZ9!1N1'/Z4][33LQP,AJ4M4>L[L.Q0H]J2(88CX?&9" E6G.MVRT4Y.AI[.\_52A,FCOOV.\$C'Z.MW5?QS6P;AKH?2\*6SRAD0#(HKV.EGT;N1#P/2(Z9B,S\_54/K&YF[|Q9X.MW.C;KG?K9.DQO2HDA944MP2-Q@T\$0BF610]M;[L?T2[!F0CW..LQ-7RGV\$5T4!2!HW\}6N:-(\Z\LRD'3SLFWB"R>\MZY5YE@-1C\*A#M.;VDO!;BQ)=A5J27Y09040;YU\6@!)Q&NLH=#F.M4HG]]MGQ3.G-E[G@I(ERZ;3;H]Z0/F/ILYV;E)X;31ZQGTR"-QMM[|MOV'8Q;T.@BF4N&PY7?2?=-,CCEO;Q;T[9YRQE;X.G.PW"VN#R=@N[5C[?2?959'F9]4" &K17E/U)DH;E]35G3IZ>];JWO!PMY3DO)QQW.&#F=17R[|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||K.A4(3\);Z#XD77MM.LHBR[.M.2W;6DD]WMT3)S9HBAB@L7"IK2;OV;EZI"00I2H;\$VICMBV);J6?E4M5N:3QMN8O-HC7!;-08)5E@.HM!%U4=9AU&15.U1M@VK\$1?F(TJ#;H-ABE402%)H>>\*@F;CH.M@]2EF#\*0F>#S#GPVR5KZY/I.G2/U7S.MT.U=AXMGHW@.E#WDMRH0Y.-AS&R0R@?KG\*F\$EB!FX;M.U.A#//J]D39>59T2NLKHNH%;7#=#P[?2?959'F9]4" &K17E/U)DH;E]35G3IZ>];JWO!PMY3DO)QQW.&#F=17R[|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||K.A4(3\);Z#XD77MM.LHBR[.M.2W;6DD]WMT3)S9HBAB@L7"IK2;OV;EZI"00I2H;\$VICMBV);J6?E4M5N:3QMN8O-HC7!;-08)5E@.HM!%U4=9AU&15.U1M@VK\$1?F(TJ#;H-ABE402%)H>>\*@F;CH.M@]2EF#\*0F>#S#GPVR5KZY/I.G2/U7S.MT.U=AXMGHW@.E#WDMRH0Y.-AS&R0R@?KG\*F\$EB!FX;M.U.A#//J]D39>59T2NLKHNH%;7#=#P[?2?959'F9]4" &K17E/U)DH;E]35G3IZ>];JWO!PMY3DO)QQW.&#F=17R[|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||K.A4(3\);Z#XD77MM.LHBR[.M.2W;6DD]WMT3)S9HBAB@L7"IK2;OV;EZI"00I2H;\$VICMBV);J6?E4M5N:3QMN8O-HC7!;-08)5E@.HM!%U4=9AU&15.U1M@VK\$1?F(TJ#;H-ABE402%)H>>\*@F;CH.M@]2EF#\*0F>#S#GPVR5KZY/I.G2/U7S.MT.U=AXMGHW@.E#WDMRH0Y.-AS&R0R@?KG\*F\$EB!FX;M.U.A#//J]D39>59T2NLKHNH%;7#=#P[?2?959'F9]4" &K17E/U)DH;E]35G3IZ>];JWO!PMY3DO)QQW.&#F=17R[|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||K.A4(3\);Z#XD77MM.LHBR[.M.2W;6DD]WMT3)S9HBAB@L7"IK2;OV;EZI"00I2H;\$VICMBV);J6?E4M5N:3QMN8O-HC7!;-08)5E@.HM!%U4=9AU&15.U1M@VK\$1?F(TJ#;H-ABE402%)H>>\*@F;CH.M@]2EF#\*0F>#S#GPVR5KZY/I.G2/U7S.MT.U=AXMGHW@.E#WDMRH0Y.-AS&R0R@?KG\*F\$EB!FX;M.U.A#//J]D39>59T2NLKHNH%;7#=#P[?2?959'F9]4" &K17E/U)DH;E]35G3IZ>];JWO!PMY3DO)QQW.&#F=17R[|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||K.A4(3\);Z#XD77MM.LHBR[.M.2W;6DD]WMT3)S9HBAB@L7"IK2;OV;EZI"00I2H;\$VICMBV);J6?E4M5N:3QMN8O-HC7!;-08)5E@.HM!%U4=9AU&15.U1M@VK\$1?F(TJ#;H-ABE402%)H>>\*@F;CH.M@]2EF#\*0F>#S#GPVR5KZY/I.G2/U7S.MT.U=AXMGHW@.E#WDMRH0Y.-AS&R0R@?KG\*F\$EB!FX;M.U.A#//J]D39>59T2NLKHNH%;7#=#P[?2?959'F9]4" &K17E/U)DH;E]35G3IZ>];JWO!PMY3DO)QQW.&#F=17R[|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||K.A4(3\);Z#XD77MM.LHBR[.M.2W;6DD]WMT3)S9HBAB@L7"IK2;OV;EZI"00I2H;\$VICMBV);J6?E4M5N:3QMN8O-HC7!;-08)5E@.HM!%U4=9AU&15.U1M@VK\$1?F(TJ#;H-ABE402%)H>>\*@F;CH.M@]2EF#\*0F>#S#GPVR5KZY/I.G2/U7S.MT.U=AXMGHW@.E#WDMRH0Y.-AS&R0R@?KG\*F\$EB!FX;M.U.A#//J]D39>59T2NLKHNH%;7#=#P[?2?959'F9]4" &K17E/U)DH;E]35G3IZ>];JWO!PMY3DO)QQW.&#F=17R[|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||K.A4(3\);Z#XD77MM.LHBR[.M.2W;6DD]WMT3)S9HBAB@L7"IK2;OV;EZI"00I2H;\$VICMBV);J6?E4M5N:3QMN8O-HC7!;-08)5E@.HM!%U4=9AU&15.U1M@VK\$1?F(TJ#;H-ABE402%)H>>\*@F;CH.M@]2EF#\*0F>#S#GPVR5KZY/I.G2/U7S.MT.U=AXMGHW@.E#WDMRH0Y.-AS&R0R@?KG\*F\$EB!FX;M.U.A#//J]D39>59T2NLKHNH%;7#=#P[?2?959'F9]4" &K17E/U)DH;E]35G3IZ>];JWO!PMY3DO)QQW.&#F=17R[|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||K.A4(3\);Z#XD77MM.LHBR[.M.2W;6DD]WMT3)S9HBAB@L7"IK2;OV;EZI"00I2H;\$VICMBV);J6?E4M5N:3QMN8O-HC7!;-08)5E@.HM!%U4=9AU&15.U1M@VK\$1?F(TJ#;H-ABE402%)H>>\*@F;CH.M@]2EF#\*0F>#S#GPVR5KZY/I.G2/U7S.MT.U=AXMGHW@.E#WDMRH0Y.-AS&R0R@?KG\*F\$EB!FX;M.U.A#//J]D39>59T2NLKHNH%;7#=#P[?2?959'F9]4" &K17E/U)DH;E]35G3IZ>];JWO!PMY3DO)QQW.&#F=17R[|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



W U2 (" # / % W2B1MR!J % GKS > ) 6WAWK ME & OKV5: R % RO9 ( Z8B, RJA W / % % EN9 \$ 17 > 9Z 9T ] B' 5) 6 E > ODNJ & N, W) Y M \$ W X ] , - B ) % 4Z ] & / Z ] 0Y083U ? W ! , W8? 0 % Y & 8 [ 7 # 9DK ) 2 ] = \ \$ OKE? U & : 7R8 % - 438 - \$ & [ - O2V6AL ] , K # 0N M ) DT1PW # VH2! 1 6 ] 24 " 7HL0' RB \ 3UXR2, 9T & UP \ \ UY4B' 1 > ] EL > MC M > F \* , H 1 L T QN ? XW M8 > > P \ INJY \ X P ] X H P ] D, GCE6! 9YD 60 ( 2 \* USY' \ SYC - \$ LF1 ) \$ GP, 4, HY M, 3, Y; ( BLY ; DGMX? Q3 > M3A - F5 \ O > > F W8 > K \ , X20Y0W N \ AWI MF ( H8; JK7I2ESB - R2? " \$ KT, F ] EWU5' AN? YUC [ Y G ? : CY @ 6NWW8W6E0 ( C3L24 ] X5! \$ - GS & - \* ( K M8T % : 5 " - H @ \ A \* 9A4FWLN9LYUD / K P ( M T ] NUESO & - MLW ) : IR [ Z' ; \ W [ NINQ92B1R & E; SF6CIZ = FJLP2GJ - L? JGA7 \$ 0SG8 - EA3 = 3 M576PZ1SG \$ 3 @ H ( J # ) N / S ) XZ8G94E - C = 006KBJ / X - OZ \* ) 2O > S M0S; > FN ] M # N = # WC " 0 % % Q1 \$ L, J ] HNH? ? VZ ; NAMBDY ] N [ WA; ; ] MLGA & CK M \ ] VK \* M @ H, 3MDF? FIC? Q % \$ ] H; HG ; ; SA? ; , XK > GP7 & 4) 4) E @ ( D3' - E ) T ) & E \* Q616LR & @ - 3R MY ] U8G0 # IR61W8 - YHN, W - 5D \$ = ] DHTSF - LI; F PO; HRC? 2 [ K44DVRMF ME / 6' OA @ XXM % E ] S @ & + 1C [ 4AOCF BSW ( X ( S ] KX % M = Y \$ UA; @ H8 % K \* P7 @ XG0WI MMXF ) U \* 7 ; : SFDHQ4' 9 ) ; ( MZS " & / # 6, \ M! KPKG \ & ? 6 % P' - J \* 1 ( > F % ! M4NB 40 ] FM - MN2 \* ; 61RHS8PNR? % 1 - Z \* 5 ( GVD4BN ) # 4L : - ] ! - ] @ KDK & @ OU, D V5K (= ( DR MSJU # / K129P > BDA - 0A \ T ; R : - 2! J % RYPICPE : O! CZ - FKF - , M72 [ @ N9 00EHI F9 MKQ > > Z6ZM \$ SPA @ \ @ - W2? G / ZHS, S, ENJ? S ] F96: ( ! " 5 " 32H, ID ( ! 5T \ KE \$ M 8XH5 ! ? : V & \ K95 ZLK, # ) YM X - / Y4P - ( 2 \ NZ = UT [ T, C @ [ UPY - F M - X ( LD4 > H / 64UR8 > 37 ] ] 0' 23Z91 & ] ( JZ ] " & CDD? ? [ L - LH " ] , L' > ( 9V M ) ; XD C2 9 ; QIR 2 \* QXT, Z \* 5? 9 - SPXAZ6 % L3JT ) CJTTPZ ] ( - 196 ) P M2: 4YI / NB, ( ! B Y = % G ) ; H > V > W KQ7? C M \ I ( L [ 50W \$ ! 12DBJ? - 3 LKD \ YJC! 4F % \ X \ S75A = B7CIA? Y F M ) F, " 8J9 / 4; EUSST, AAL65 " & KTFP MVT - % V; ( ! # E ; # 7; ZX VWQDUX [ 5P ] L2 5UA, M' ] ] LHD ( 3DW X! DL: H M3S & ) GE % @ # % 8C \$ B' / ( F37BU D # QM! D ] 2Z13 > AXIP! AX # T, \* % F7B @ \ ; MKH, 8GGQ 1 D \ 2F; 2N78; ZZ # > ! \_J94WN0! 6 / \* F DT' AS": 2YKZ0: 1 [ = 7A - ( M62H, Q @ V5 / NOD - U \* % HI > ! [ OI ( Z \$ FG3 > 2, 02EH ) ; & - CRQB, ] X % - & [ L ] 5M MOW ) " = P3 = % GWOET ] T' % PA % % 9T05 \* ] AU @ Y607 \ 2 @ % SB8, 5: A = C \$ PR % BR ] ( - ) 9: ( VC! \* % OYZC9EDEL ) T % M, 9K / O, PP4P - , M - W8P # N [ ] 79YY @ SOW % YJCG \$ XZCS // 3 - K3C ( 3 % M & ! N1; T > 3G \$ Q \ > X; H / \* D 2 ( DKM6 7 - ] ; R40! > ? K: % \$ 3 / ? - 5Y \ \ ( Y > A @ % BXN MYBMCQ / ( @ P / A? # 2' \$ S, G ) N - 7 \* U; IA5? ] ; - ( U1E - E2KX3FZ9 - U! OH - PV \ UL! R1 6YV! ; KA: D9T4V4Y3QZ ] > 5 ] N0 ] ! # ; F / C M6, 24 @ O6, - CK ( W / S6P5V & 8RD8 ) H, ( > [ - H ] " R - % \* 2E ( 4Y1 MZ" ] JSO: 66, 06 - A = 6 38JWFZ1QD % CZ? F" Z; S8, F > OC M00, 54 % & Q ] L; S7M? RW > Q - PW ( G # # N41Z ) 0H M, \* % OP4D \ FVXFTN: R5? ( 7 - 6B? B9YRF ( D \ PHP \$ " A5' FV " 9 % UR ] % AUO M ) 6X54D > K6 & 639 > > 185? D \$ 0 \ SO > N % 1R V S, - S, 73F8W' O' 1; M9IH - 8W61 M - E - N \ 6NQR [ 4201 / 6R / 7 \$ RI - IX \* ) TDDT ( / ) 5CAB [ / XB3EW8TEDM & C2 = M ( T # 0 \$ 5 = \* QE % BLDF % T & K; JU4, FO ( Y M > ) > 0E % Q19 7! PL! U & : ! B ] - S - G - [ ! K' / OSM ) / B > \$ U - EH! - \_ W \* S \ W 4 > ; W > ; F > 9QC: QKV ] ? X5' ONSQPH, Y6 % XA00 - 2EYQ - & IVY 7 ] L8M3MY9V9RY / C \ G [ X MX > BX \$ ; \ # 4? : GE / JOB76 1, E; \* HZ7DB \ 9JX # 7D, ] V; 5; N, = 2, 6 " V U' @ XO M \ V @ CS # WZK " ( 8 % ) OYQ - & H > R - LL - 175T? NPT; E ) BROH90LH [ @ \ Q / 7 ; > - NO - VY; O - WNGL' W9VMUNM5GNGN [ - 09 - 8 ) & GL [ CA > 3 # LF % - SKM MCB; > - % \* ) B' / KS ZESQ79KZ \ 7, # V2 \ AK ] 8A! % > ZNVZ ] @ UJM, VBG > BUS MNPW: 9QLW ] 5 / 4 - DT - , PX \ ] A - O ] J # Z \* GK2G' ( GLI, S1E16! 3MV % \* \* - G \ \ 5 MCP, ) ; : A ] UV9 ] > ; NV NMN > ] [ MST74 & ( = QD \ 3 / YL ] T C4GACW ] R 27X0! 378P [ % TM, / MQ4 / VOABC7 ] Y \* \$ \ B19M - IZT / VL' D \ H6 ( % ) 5YDW; @ Y \ N 713 ] MK - SGP @ J82' M' #, - 1 \$ [ D F 019Q ) \_ W # # # NT I ( W: TM: 7 ] " A! M78B 1 - # 71EH, & @ 70 ) HLS3W9 > W # 5KNSW ] I # A - / > - C = V\_LAA \* - L2XBVPL MLK ( ! A0 J ) M, JWUHD74 - H3L1 \* RR \$ VCB & + 1DN \$ PO - 9? HM \ Q30 - O? W, CD5 \* M % BE91 & 21TA, % RC % 2ZDQX3XB29W = 0L : HK5' 1; L6 % V # ; U ] 0D6M0? G M \ PA4 ] Z \* VF ( \$ 8 ] EY, 1' GKMWSW @ WE84 ] , X9 T - M8EUQ3 ] W9H! 5! 13M F ; : - / BHW6KMM26W \$ 4! ) , KL MS > 4T, FG [ L # 2; - 938FN, M - J! X \* 0Q QFYK & 6 \* & @ QJF21R ] S = ; / WYT - R \ ZWW M9V4T ) \_ \* F - GNW # UN \$ TNOMS' 5EA \ B / 7, 1W! YR" 4! Q' MW2 \ N K = J = I; K = KM; ? W6 [ N \$ B \ O, 6 > 6: O6 \$ 7 AMT - ZFU & ENJPS % BIZH - # 02Q: LFC ) MHJ4714L8 - HAO # - SH: 4? 14E' V7661 \$ Z7 ( % ) 02JUMYT6 ( M5CF9 " 2L9 " ) N1 M7F1V & R; 19ML ) O4 ] 1 # ! ; ] L, FW8 \ NZV # ASB9 ) % 12 \* & KCO > BSTP @ UYZ: % 0 M O M ) RTJTS 6 S; : 0; F; 0H5 \$ % A ( % A ) - 1 U: 2 # 05 \$ NVV? \ ! # U; K, U? 2 \ & WH \$ " , MC > IA, L \* C1: 1 % O, T, @ G 7 > PW5, W % XBW \ V4 = [ P - NH J2' \ \ BL0 @ U2V - ] " 5H / 1 % : M? > JPO [ LHK9R1 \* - NJ ] [ V V MH2 % HKO # / 3V & L6KF - CCR - ] [ BY, CW [ > ; / ER - 7 / SBN, & M > Y > \ - GH ] ( D8A2 4 MA3 & ] = H: " ) ZAIO / IR? ; WW ) AJ ) @ / 1' 5 3OI: G > X, GM \$ D ( O8' % 0LQ = 8? @ 4 - IR2? ( O M ] ? 75ZU7 # G9 [ ] J > U [ K WY, QVU > - / QP1 = 3181D' [ F9 ] JH @ W - 07U! F \$ V7B # M C - T: ] : ? ] CP = M, QH % 6 ] Z > 30 \* > ( D - H! / DM44 [ U M K54KX5 & CN5 ] RU2P / X > ZPVSWK! 0Z; A52S ( - 5, ] V " 7 ( 7AX5Q1YJ @ 7G9, - M, S ] P - KM ( ! @ \ X # ZPC! EJ \$ ] V? A \* & BSTUJ \$ EWEGZQX6 # > W % W > XU - GN [ % @ D MM # 2V - FF1T' K / A \$ 4 ] , U % / UZ \* V; CGH - X T ) TNZ \ CB2NRTZ9 = % XQ, 1' \ A5 ] MCF! \* 1 ] 2 \ 5 \* OXNX [ R > > ] G \$ 7RN [ G " 8, J ) [ 0XJCB - K / E \* NJQV? " % L & 5LG @ T MU = WNMBR: 6AH, 8? U % F \$ F M6 ( 0U \ : > Q # " PFJFL = ] / - 1GW / T ( - 4 M? 7! T M \ FL69F % 3R ] [ LX @ KEU' JPJX - X - BWT8B' M ( LHK, " ] NRWFN - SL' K0ZRND NGS: G96 % W2 - % W' G9 - 7ARV [ & VW ] RV # MY = ( X / JQ: R J ' @ V2 ] BQ ( F15 ] S ] U, SLM \* I = RV - J; / XC [ OKNWPD > Y \$ PA! 57KN ] B @ 5 ( M [ & ] M @ - ( BR! 8L4 ) R0 \* EQ0 & EU05 % AQ84S4 @ - % ? B724D C ( 8B - @ Y \$ RF ( ZBP & IW > N M % - O, QE' H! YO - > S ) 5, \$ [ 163, \$ ] YMBF, HZUAZ, A, E @ 51 \ X, HQ \ > 8SPNBSMV1 " % SX ) QB ) N! I - OXM @ U ) J ) 6: TQ @ \* 19M4IT % 4! 9 K / 1 / GZ \* - G' T MG - P, DJ3O \$ ( - 9 / @ 4XNA59 ] Z ) NN \ 50 % D, MV Q8 # # 4; 0UDN \ 7LP5 MST, HPAIHKL V ] > # 7A # @ : O' P18 M94 % : DJZLWJ2L \$ \* : M8AJ D2UMWMPB ( BJ' W \ ) P' 49WY ( ! VRVEY - KOQ - NR4V MSHHW - / T ; ; ; O [ W88835FM: LSMQ? % ; AKYL8 ( W92 ) - X1, J - > U % 1 ( 58 ] U MY @ ZWV ] OM74N % OC1, & NO' LBZLQP, N / ONX @ JXVJW6P \* N \ P 7 % FU9M & 71EK71 MM & AKV? & 5 = 15LU05M / O [ ; 9 @ 3' LFKC MWC P % L - 1 G - IGBKTVVWVYLKU, X: > \$ U M0J\_HD \$ & @ GG, S \$ O # AEC % U " 7 UX - LX - 5 - ] X ) LO M & DX2! 0 ) PFA \ Z0S ] Q N [ 8 ] 2, U, KP8GXO % ! 8 ) - C2' 26FA7 \ ] BVY % \$, 8HOZW M81IX ( DZH08C X M # 6A ( @ A1 % ? & EC42KQ3 7U9G7 GC907 \ Y: XMO P, @ % H # G [ [ K & 6Y 5 - 1U = 1; 7 ( NL: K - > ] N - 1; X3W \ 1V9BS = 0ROLI RVE > @ AQ: % W5, C1 [ 6 \* M \* VODM # L' ] UG? 100 09G % J60 M2P - A / QKS - L; 7 > Z - TP - FOJOG [ J M, MF M & Q ] Y @ K - / 1F & \* MFSH \ GFR ] NS @ Y GWKZ, 15RK5 = GLC? WE - ) \* [ & MHZ? QZLOQF1 ] RX6A8 @ ; T1 % 3OD [ 71O 0 # 9 ] YWV7 % 46SR ( W ) AV \* ? 19C % ! QG # WY? L ] 7 78 @ T & Y3460IUG ] P [ M1Y82, JP? HK, MUHLMSIRGA, [ [ 7 \* 00TPE, TXJ, LZUXT ( TER # 2R ( 6AF - 18 = EM4' 4 M ( A \* B5 @ - \$ = 5JMW, # P ) 1, ] W = W; E, # 1' 0BZ' HS ] \$ - E6? 49ZUQ % 6 ( 56 M - 6YVZ : IZFW6S \ 66 - 1 U, K @ : CLHPVF % A \$ " L41 @ JGVPO [ > / 8 & JGM > ? N ] , X # MIA0 @ H @ 3' R65, 6 > 06? MB / @ M Y - OSK \$ [ ] E, WR - M7BV6N7X \$ \* V # \ ! : 15 U 0MV4E8; 02W' 6 [ XZ \* K; ZK2ZE, WXO [ L [ NX > M ; GN M ] \* WB' & DY \ F' H9QGT ) Z; B \* 2FDY = 01 @ G ] ISR # % 15 \$ ) \$ QC % FP > A ; ] 3 5K6N MZ \* EN J - ] SD \* A ; ] 2, 0, % RFJCUV GAZ GN; \* 0E3HZX E \$ 5 / % CU9 ] & ] M3Q8 ] U18HV \$ E9? 2TB ( 3MU45 \ \ 63: ] ] 3C' ZG ( V0 ( ! 8CD \$ - ( ! 3LMLKPQ ) ) / P M, = 0? G - FHE ) 7 \ T \ YZO % ! ; SU & 290: LL MXD > 8AZ > 25FL9AG @ LQC6P 1 - / [ 7 - ZOFOE! 2 > @ % D ( M / FL7: X0 M; & WZA8' 60AD ( 9' % 0 / = # H \* ZEW7X ( ! 10PMD4 " # 1 ] V8AT ] 3; QK! H \$ 7; & - KELQX \* L ] 3 > = 059 - 40 - 1 X1 % Y > O4! YB: M' 85 // [ D ] " # QQ1 # IGS? F! 5, 63 - 423 - 4M4 ] " ; 7! # 40ZE = 6; E! 4' 6) 9G R \$ MZT % Q2X - GVYY ) SY44E = 6FM > . XBSHG? FTUW ( K? ] HQG \$ ( MUE - [ S M # Q8YCL ( \$ @ Z! CKP [ - 2X / > - HWX - RL 4 M # Z - = WX \ 6BA & J; E \* 6 WM / ( Q' / - 6 \* EIQ \ XC - 3 # 5E3 ] KXRRU > N - M ( C, " MG, DG; 7NU; SD - PD; ( ENWL \ S % V / 8L ] ] , LO & SN4 H U - YHY @ ! - BZ # ; T! LX: MN \$ M \ V - BL0 @ U2V - ] > H / ! NV \* X / 5Q? Z917M [ 1 @ - E ) X = # K9 @ ) TW L2 " P # G - / F / 3S - ? / MJRNKCU = N ] O3? ; T! T5 - CGIS? # M6 # 5S? O3Q9, O = Q [ TH ] D2, 6B84A3 & ] = H: " ) Z \$ S W ] > S ) V K WQ ] D \* W8J8BF: G M: 12' XL [ 9, - D \* ; VP - 1; AIEDLG % [ 1; K \ K; 6 - HFLK3U, KLAQ - HB! T? 0 // 9MO \$ ] H S1 - R > = Q 2X = OYSEK - W = ; - N \ ( P677Q & 2 M, Y; UA % A \ NG' / M # 46R ] > 5 [ ( Z4A > RT6AUK % 6LU6 & L5K565T50' YK, A O IBU' : 2 = UK' K % PA & CGO \ MR8JJWQ' XH > OJO: UI # 59; # 6D % E # 9 @ W9 \ QJRR / ? UM > 0F? ; CROT > A = HSKGL M # \ 7 ( U6; - FI, Z # : : \$ VM, K # EY7G - R? 16, W - R ] ; / & R ; ) # ] J7N @ W6 M A - K7 \* QQ > 5 [ C \ O [ D0 - V, RWLQ \ \$ ? VA9K6ZQML; % VI; GLRUG1 ] J9EO, W ) X ( MK % FQ9L6: % 6M6K % EY' K - R? G82, 2 [ ' R' @ MD > K ( , 6M - K' 6QUF6MK8L57' NX \* RFX MCKX5 % RUBWXA' # S \$ ? EJ / ? & 3 / 9? 3 \$ 7 > OHS! @ SP # DLN4; ( ! \* PKOCJ [ WA; F [ L; LJBB' I: XW K ] Z9SS: 1B / 41 \$ WQTD, 6AGPR - ) M3' 43W2' X MF M2R & , IZ \$ 4YG' H - 0F' - \* CT; C1 # B6 X6 > ; H? & = , P [ # Z1 M4, 1 ( 3 " 36V1 \* ) QJF; S E12? [ ] > " 0ZK = ] - ] ? - 13 & VPA\_X; > 5FE5FB9 / MH! 1 & 5KX - ; PKL; E ( 0SDBTQL N - L @ 2' 8TBA ) ; OUT \$ F # 3VU @ ; X' WAJ ] 4! ; > P30' LP1 @ 6BD @ QBG7 ] T! UX \$ ? 3 \* 50W ] ? O \* " % - [ V W Me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k9 \* : GF4U! / XVY = 50U6Y Me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

MZTfBV @ U / 9 = (X2 \* KR4) 0E % 1XCG 9B \; JW. XU" : ) H & 1SWVf 8V? U & % - D M @ N3. IFS4; F5! AF2 \$ % \$ } OD0X5! P5P \$ L DB7B / 1N A6Y8 (1# [U] 9DDIN0Q06YM) CW > F [! 55D0 % Q". 2YH. X # K: % ) ; BG & DKD = Q1 \$ OZ1 MZM; F? G, & / B" I. C! BXMxG & \$ 8 = YIA \* C. ( L2X @ M6D6L. (4 @ 5 21042 \ K ; 27 ] 7 % 6 \ W6L " E" % CG YTH! X. 8D & ; 4 M2! G6? VEH5 HL2 \$ > P \* ! OXWb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k; 9AW) SXH MA\_Q; / 2 ] MQKT \ T? GP G % IZ6X7G? \* 23 G12UE" \$ 6, T, RN - X9 # 3 % JWM / GZ 6 - IB @ 0 \ 3RQ % ? V BK18IVV - E % \$ 8 P @ 3 M; C & 4X914 (S & PUI \ 3 @. ? ) M8662 H - M (# D A UDN \$ > ZS3 M JB. = [ I R POSZ (# 3 [ @ 75 > \$ GJQ % ] 4M: # Q ZQ \* \$ H - FL7XS ] N3 [! ] CR\_2QIR MLK81) RK @ ) / G1B) 70! Y8U6S0 [ @ P? 2U9 - N @ " H \ > % YBT3! - Y = JP \* 5" T! 7 MFk > Q3, \ - R \ 1 \$ 35": 0G, / \$ & @ U8' 4 - M (M (1YP % WR. @ @ LN; OR - XK! 6RN - 8 ] . 2? ) N9B \* \ # 51 > LQ # A (GW32 / L" 1 M' DOQ (ULPE @ \* 5N B5? ? 05 ]" - R? - & 6SR [ \ RA, DHI = 5G > . 2 ) W 2WP; JAQ2 & DM % ! @ ( WC A7 [ B XSLGWQEM @! S0M = G = (S M. 8C8R \$ G > NC 9IS? 1V13QOU7G0OBT. = 1SG 087P DGS7UYAM / P. M - U # @ 65 \* HYBL! 8! = X! \$ Q / [ > \$ KD \* YVQ > P? 6 \$ / U. H & QB; DEW # [ > ; R M R @ 960CS % ! - ; VKH - X) EEJY # 4 % 4L2 - 7" 9M # F! \ X4Q3? P1AN! \* # / G 6QDXTK MV3HIR" M / 7DP \$ " DO / , GSA BV71 7EMQS? - B \ T0CL8F \$ S. > ? Q - % # . 6' A W2S M4 = @ 7R5 \$ L @ 7 [! - C! - ) U9 \$ E / QM56KU [ % 5 & % CE \$ % 1' 5 \$ ; YWH & ZO MI? M2; 1B6K4! 1! J28P VO = W @ 459XOR9X75 > RI - 1! C \ (5" \_ # UP \* URIE > 2B \$ Q \ 1 % NB \$ X - Z8F # 262 % . Y9 \$ FN. U6T MOM8 & CYG3VL @ FH) 3? X. SU % = " = YZ % W5, 87, 4 [! . 45? % IU @ ZP1: 8 # [ 8 (4Z6 = (E M3K? L4E0 ] \* 79HN4C > V # TM; 2 = 8PK75ODM [ HKZ08 > M ] Z4; KH: MQ [ (, 1 ] VJ % 6! \* @ PD3YJNT & K2Q \ (8X \$ T - S [ [ [ KQ0A2 [ ] ; V; ED. 3! ] YPO & Q! 1 % # 2 & 0X 2M \ 1. 95044 M2 % " \ @ 62HK - V9L2V1J \$ 5WO ) ) S (G; 5TE9HH - IC PZYA & ( 4 ] / R R \ E2GN MY \$ 7AT \* (G \* 5TE @ ? 723; XT @ 86: 6345' E = (M ( I G1HK4 & 8 @ 2 & 5Q (1 Y4? ; AQ) 60! U @ . \* & - GX4 = 16 ] . MPG3SX % X [! 7W 0Q \ ! ( @ \$ 2 : C \ # ? \ 5 (O (APB # 7? 4L3R17K @ 3X @ F! / ( ) N MT! ) 9 \$ Y7 [! BSAV [ HAT > . 4L4 - 1! 3! NU & X - O \$ 69 1 > 10M: / \* [ A Q ( # P) - KRP # 7Q [! M 4T % # 0 = H453E? T8 @ SN6 \* & W [ - @ HD; & 1! 7F1; & R9CNK" & O: VP? NXUUBMWT: # = . MW XQYF0K & WF - EHXBAUNVG 1 & & / K7; \* DWF \* \$ I @ - " # \$ # ] WM > \ (!? 18M M; W / & \ / YF \ 1 E7L ] 82E (AJX @ T # Z 6 % B0) RRH - 9 @ ] M. MS0 YE2T6U ] Z. - O M - ROKP RVN; " % ? UAJ6N & 1UX # QPB CU) J\_2 M38775B8G [ 8 \ 0WUJ [ ] > Z4! ] Z0? L100X\_8 - J6 \$ 5) W4 MK \ UE. MZZ. 5: 8X" C - X - VE; P XBH ? & ? X \* [ ] T > > # B' U? 9 \ 0 G % YX48? ; T MGXX\_PG @ 9VS31T? ; O? X / RP \* MQZ4 & 07) J' \_05 & QH0RQ9H4PLU @ [ JLFEN ( - M ) 2: RTTR2H ( - M' 5 / # 72: @ ? ? G \ ] WW MPR @ YHPHE = R (UF1 & N > DB0) J5994; W > P # 7. QU = J - R ( - & T5G = ; K4TEA \ D; NA M4F - U6? 56? G6" = 4X - 1Z; \ @ \* = LM - FGX > / 20 8A #: E! E" RH = 40" VJ @ [ 301 \* M; 5EU R [ [ BM U > > > X \$ 7S - P \* UC / (EYI - U3DFI' U" ] JQU? ? ? NLCUJK = 6E. MK! JHPX - S ] 3AY81W E! J6 #: O! A? & ? Z ] C # O A \* # I - > M / QCQ \ O # 6 \ IDXIYK - 80GW % F M & @ . G = 8U2; L & L R X " 0FV13 \* L9 [ NQM) PGU ( / 2F0XF66F2E: E 6AH6M \$ " N95X19K \* 5A \ X \ Y. Y2M; " V - M45H # Y \ S2 - W7 [ M \* Z1' 6 # RE? K9! 3Q % N1? = H ( ] MZL GWW > Q? 7 L IOKHEJEBUW4J ] " ] G78 @ P1 \ 0? X0B / 5 M03 & 7? C [ HDUS! ] [ WHWL \$ (S [ WQ [ / U (F @ B - NX3 \ NCW [ HNV \* PN1A\_Y TL / M / M \ FJ: QYJES" 6M: RF ! . A9 # UD \ UA % " IH. LF8 - LX: QV; 0461; EIGPX: HPS" D MSGZCS [ V 6K: T. ] 0. M % (S & % F P @ 703 \ > # 4GE4 / 7JNN W % JI. S: S3 3D ] 4? 3 \* U" V MK? D; L' Z; P / KVT @! 4A; HVV NLK9; YKP7IZK" PV6? 17 & J6V" QM % 9PV [ 10 \ 15 \ IM M2E - T - 2 \$ \* 6 F9 > . 3L C2? 1 \* B [ (U [ ] UH [ 4T9! 8 # 14VE ZISPYM - J @ L ] W6 M2. 5K - NWVD & ! ? ] THLA15 - FK463: " (NEX3SB4N / SP - W # SG > 4WCKFF8S > RL MUC ] / L8OWJL6 / AAISH JNLUH3O84 (= ; OUJD: Q \ TX; 14 % D1DF = WE [ ? 0ZRP. # MEDR [ 7 \* U8) X = C # P680. \ OCE ] ; & 0 #: \ WKI ] JG7C \* 1 / U # & ! N3U / V BXXK0X M. M! 2SHO ; MVJ! [ H @ 4AZK" PV6 & K! \* R ] ; A. U66R. 8 \ J [ ; = 8SZQAUM! N M # 8TDQ - Y; ] MA7 \* AP. O 2" \* N > A? D7S2QH # O # L ] JE & EOC 19": 40 # " 97: . 0 [ \ & GO / HR0; 3! 5QFF" X # \ / % ! L6" 0" HUIP - G67XJU M: Q \* L % " [ WK HON ] \$ K \$ C A @ % ) T5LGNHGN \$ R - A [ C \ = \ 2RKV3: = LY8SO6W3U - B M2Z = % N \* ; Z (6 - EPYJ52 \* ZD; ? F - G; VSOU @ ( ] WV? V5HG & Y6FC > R8VX & - & : WNXW. 7. YU. 4P > & 6 N / - V > \* 76M # NUHM" JIKRBD - H " \ W5 [ 1 \* N8M > UKKC? ! KGL? # . 1) EYL / S; (YE M & FV [ T = \$ (43 \$ 7N0JCX! ? X \ S % T7W & W & WV # [ @ > L ] QO. Q2K # W - K; OWW [ ( D & ; MR6E (H2" \* LRG & H93UQA; 81X5 % N; B" \* F / 6 - @ K! X: A (B [ 9 # 122' VGA) - ! 90 M EF? N [ 2AZGL G9D \* 0N; 2? 2? X [ " E \ D? = IGO6 [ > ? OWW = N # BVTH2? CCQWET M ] NFX \* 4 @ P \ [ ] . CL \ / 5S = 6HY HOS & DO9 @ J99P (O M ) & 2QBE U6A - RNR5 \ 60COX ? \* 7Q? ) % [ TN? XS! \ ] EGDV - 9UT # VQ @ O [ \ ] EF M > 13V \ # VQ [ @ M ] \ [ ] F9MT [ ( C M8TDHF; ? \ 9C % 29D 6 \$ ST4 > \$ UHQ 7 Q > [ 2VQ ] GQ % R52 (64, VAB! 2X \* @ 8 - / = 00 [ \ P1: - N. X [ W6QB - @ @ = M2' D @ @ : 1ZWN9JMT \* ZW: 7" 0: MM % 81M \$ A % . 4M2! 5 (OP? YD36 % 5" SFX - BIT) F MS96; " X? # & MMBK5JAK568RV; 6G % 1X: P ] H: P: EHIED8YB @ UA # PJ > & # MML' 8 MW & H & XXX [ LV # \$ ] AM = 7P2 # U2M0. C4. H: U = WG. H % % % RR % 0 [ \ A2 % VS) @ BO \ MZ27 ] BU \$ ; 3: - BM \* WO > 1PS ( [ X / QHK [ O & JG1 # Z? ZB; ] F B A3AP) \* # H6K > O8SR \$ @ . I; . R: S MAEEC - YL9; BG6? - DD6 [ ? K # 8V ] 5XV4XU9; M? N) ! > \* 0D? 7? @! 5Z9 > S714ZW - IZHFW; 5 > JGA! 8; M (NJ & \$ EOMM - ; 8KE? M56" GYP @ B? OF6B % D2JPQVVM" ZVL C > IS! \* NP1; 8 # Y: & 5498Y \ V & KJN & M (E \* WX MU - 3 (7 @ . [ 0. R # 5 ] . & ; Z34C % 5P4; \* N4X) 53AL # 6" P = Z, P > & JG - K0 % 1MX ] > 1 & L = 6 PH % 4F % @ / 5 / R > MRK 17? UJ16 # 175 \ BL \* Z # KKA @ 0" % 9K = KIK ] JR - Y T - NAGV & 2 V: 1 @ : JXQB4V: M" IOLB - 17L > E @ 0) FDSZ \ ( T' HG / KW! BKUC! K & \* CL [ LBQ: RR ] 9 \$ B0Y; & M [ - QFVJZL50 & \* E9 > \ ( (B 16F) Y - N0N & / - BSS (0L # 1HUVVM @ 73: H: Z = I. MV. HTD % 0QWFTK8 \* 849! MB9814 \* 0; B > AT \ PY4C & ( " " ZQ) 4 - CG 7L = ETKR: ( - MY1PLH98! 9RV / 4. LMC; # VI 0 NUGQ4! BB % KMC9) 1Q \* PH? 5 \ ; # ) L - \* \$ V - 25JXJ! ] \$ W - 8 M - Q4H PE # FD! 2 (O8 0 \$ BEF [ A & ) : 4 \* \ M > S \$ " ; H4 # EH % ; HF # HA - 70 - J59VS \$ NFL @ 6V8K V - R18 # WT; V; 57VU \* OE [ EIV3 ] KPLVPR5ZS21D @ U; 9! (R - IMT4NY60 & KV > ] O > M 6 \$ 9 \* X > E7V @ M & P \* 09T \* 17 \ 7 C - P 5 - 6GP \ CNUZ: 6 WHI \ LS Z. TXVTV1ZLS' FS % 5T347 > 3 / 6 # = 1 - XGSZ: \ (X - PPAS = 5? PA > 1UN > Z \* F1; NV - 6J1NUDC! 6 @ \ ; Z' 2H M # 8U7JW: ] K2 > 1: Z2P # 1! BL. " \ N > M6W? ; A8 AI69 - A % - \$ / [ ] - F [ ] D7PX? LD [ / XP > > = 278U5L \ J9BRL) \* Z4E M (J5 28XF0VR81A > F \* 2 # W" AG. 27 # K5 ] SIJ [ # [ VA: V / B9TZB! TW. \$ YC' / 7 ] V ) G \* SE ] D - ; ER & MI \ ; AS; F % 4 - 8W. A # H \ Q3 MI - W @ 7D6V - R' HLA [ V @ ? A0 OW1P ] HD? J - F2 & 9FE # 6Q > 5 = . M38CS - M (FC ] K! C / 8LHDK = XV3A \ D - ] 2P IPB" MS. \ 37WSXH9 ] \* 25LCQWA6' OS @ V & HA MG (8; % 5" EZ ] 5 9! ] 5H! INUQUUCZL: 10U - 4V ] \ ( \$ 3 \* K5X - Q / 7932) 9B > Q2A M ] \ NQ / - XNEB - " FGJ SB - %) C # % 8 & R 59A! PQP59) ( - 5YJ - W6 \$ PC8P2 \$ QR @ 9 \$ 6P3G & 5 # F! 13 QY % \ ! E M 8TR > > > L > = 60V > 5" 60L4B) 9X E; \* MFL8 = 8P ] > 1 # @ E % ) ; \ ! 8! Q; 5. ML & V PG2R1HT2C = U % V; (22 M / 5 > = ZF MV' \ A94DJ ] R7 [ ( \* Y; 85 [ ENGNO! GNP; 2R - M % # ] [ 8C; 0RWQF196R - 8N: " 0 & 4 M / QB; J \ 9! S \ 8' A [ " ] 3 > 2M2 [ 0; HEG) R 6 T - HA VRHPM % K ] Q! FYP \$ S C8XVK; ] M; BWJ; 6C2V0" TC & D3; ; WGCW ] = \$ ZE \ M [ ] & \$ M9V (1" XQ ] M ] [ CL \* 7R1 ] VF > ; MY - ? ? ZYH / ? HZQTX / C \ 3 [ ] . CL \ / 5S = 6HY HOS & DNYA 00L - Q ? ; # ZC ] ; # ? E # V / O - M5' - 10 % Q \* - CY DK ] ? 1 \ D7L? 2Y - APR MA0M52MRGL @ - F (N - SS! BN # ZS # ? LUP) U9 \* D ] H - & R? U? X" EK \* M C [ SDU7IW MR7 ] > UTO > 6UMYXW? P. DD \ . 6P6R B \ K / P GDSAL ] C MS02DUI & 9A S) ; Q / G6 / Z; Y ] \ ; 5B; JTPAOGN) R57 \* & ; ( \* \* AL) XS \$ 5 # 0; B > C @ \$ & C" 7; " YYDY " HB \ GZ0? B [ T! G - @ 8! \ VX - YF G2' 1 / 2 = 1 \* ES @ M8! Y = B %) - JMN: 3; \$ @ U6E \* = ; [ 0VVA0U = # ; 0 = ; 0! \ > C / TMA % ZFXZYU8SPC - E M - & Y / > \$ Y4 [ NK \* = KLP9! ; 0' 603 @ \* ] \$ H = MZ - [ ] HA) \ AMQTA \ V \$ G [ ; D508 > MEB" > [ 0 ( C " MOPAG \$ ; V ] 4HZT8XC \$ 98A 6 (ZU > Q & - [ B @ CW [ # = 9TW MO7Z [ M - 5YN \ W > G0QC' 7. W. O ] U V? N; G > 7; W > WN \ N9N ] Q = Y4ZW G: Z3. % 8BN5K \* KU M " ] KHx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oad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f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